haloperidol has been researched along with Psychotic Disorders in 728 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Psychotic Disorders: Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Acutely agitated patients with schizophrenia or schizoaffective disorder (n = 67) were randomized to receive 10 mg IM olanzapine (n = 37) or 5 mg IM haloperidol plus 2 mg IM lorazepam (n = 30)." | 9.20 | Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial. ( Chen, HH; Chen, YH; Hsieh, MH; Huang, CL; Huang, GH; Hwang, TJ; Hwu, HG, 2015) |
| "Oral haloperidol, risperidone, and olanzapine seem to be suitable for treating acute severe psychotic agitation in schizophrenia spectrum disorders." | 9.19 | Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. ( Abderhalden, C; Horn, H; Maier, N; Moggi, F; Moskvitin, K; Müller, TJ; Strik, W; Walther, S, 2014) |
| "In this 8-week, multicenter, randomized, parallel-group, open-label, flexible-dose study, patients diagnosed with schizophrenia or schizoaffective disorder were randomized to aripiprazole 15-30 mg/day or haloperidol 10-15 mg/day." | 9.14 | Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol. ( Bueno, JR; Campos, JA; Chaves, A; de Abreu, PB; de Matos E Souza, FG; de Oliveira, IR; de Sena, EP; E Silva, JA; Elkis, H; Gattaz, WF; Louzã, MR, 2009) |
| "To better understand the efficacy and tolerability of atypical antipsychotics among racial groups, we reviewed data from four short-term (4-6 weeks), fixed-dose, placebo-controlled trials of ziprasidone for black, white, and overall populations of patients with schizophrenia." | 9.14 | Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies. ( Herman, BK; Lawson, WB; Lazariciu, I; Loebel, A; Malik, M, 2009) |
| "A total of 572 inpatients diagnosed with DSM-IV schizophrenia or schizoaffective disorder were the subjects in a randomized, rater-blinded, 6-week, open-label study comparing sequential intramuscular and oral ziprasidone with haloperidol." | 9.12 | Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data. ( Brook, S; Citrome, L; Czobor, P; Loebel, A; Mandel, FS; Volavka, J, 2006) |
| "This double-blind, placebo-controlled study investigated the efficacy and safety of intramuscular (IM) aripiprazole and IM haloperidol for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder." | 9.12 | Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. ( Andrezina, R; Carson, WH; Iwamoto, T; Josiassen, RC; Manos, G; Marcus, RN; Oren, DA; Stock, E, 2006) |
| "Patients with DSM-IV-diagnosed schizophrenia or schizoaffective disorder requiring long-term antipsychotic treatment were randomly assigned to open-label oral quetiapine or intramuscular haloperidol decanoate for 48 weeks." | 9.11 | Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. ( Glick, ID; Marder, SR, 2005) |
| "Aripiprazole is an investigational agent for treating schizophrenia that has a novel pharmacologic profile." | 9.10 | Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL, 2002) |
| "The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder." | 9.10 | Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "Newer antipsychotic drugs have shown promise in ameliorating neurocognitive deficits in patients with schizophrenia, but few studies have compared newer antipsychotic drugs with both clozapine and conventional agents, particularly in patients who have had suboptimal response to prior treatments." | 9.10 | Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. ( Bilder, RM; Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Goldman, RS; Hoptman, M; Horowitz, TL; Kunz, M; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2002) |
| "Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapine for up to 3 years, and comparisons were made to patients treated with haloperidol." | 9.09 | Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. ( Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD, 2001) |
| "Despite the demonstrated efficacy of clozapine in severely refractory schizophrenia, questions remain regarding its efficacy for primary negative symptoms, comparison with a moderate dose of a first-generation antipsychotic, and adverse effects during a longer-term trial." | 9.09 | Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. ( Baker, RW; Borenstein, M; Ganguli, R; Kane, JM; Marder, SR; McMeniman, M; Safferman, A; Schooler, NR; Umbricht, D; Wirshing, DA; Wirshing, WC, 2001) |
| "A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial." | 9.09 | Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2001) |
| "Plasma haloperidol levels between 5 and 11 ng/mL may be clinically optimal for acutely exacerbated schizophrenia, but the evidence for this therapeutic window has been inconsistent." | 9.08 | Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. ( Cooper, TB; Czobor, P; Meisner, M; Volavka, J, 1995) |
| "After individual determination of neuroleptic threshold (NT) doses of haloperidol, 106 patients with schizophrenia or schizoaffective disorder (Research Diagnostic Criteria) were treated openly at such doses (mean, 3." | 9.07 | Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. ( Hogarty, GE; McEvoy, JP; Steingard, S, 1991) |
| "Seventy-one patients were entered into a multicentre, double-blind randomized study to compare the efficacy and safety of remoxipride with those of haloperidol in the acute treatment of schizophrenia or schizophreniform disorder." | 9.06 | A double-blind comparative study of remoxipride and haloperidol in acute schizophrenia. ( den Boer, JA; Huisman, J; Ohrvik, J; Ravelli, DP; Verhoeven, WM; Westenberg, HG, 1990) |
| " However, its being well-tolerated and effective on chronic psychotic patients, coupled to the "bonus" of a single daily dose, turns BP into a suitable alternative drug for Haloperidol when dealing with schizophrenia, and delusions with no deficitary evolution." | 9.06 | [Clinical experience with bromperidol in chronic psychoses]. ( Bellomo, LE; Forconesi, N; Rosset, N; Tellarini, L, 1988) |
| "In order to evaluate the efficacy and tolerance to Haloperidol Decanoate, 26 patients with different psychotic disorders were included in a six month's clinical study." | 9.06 | [Open clinical trial with haloperidol decanoate in patients with psychotic disorders]. ( Ellerman, LA, 1987) |
| "Haloperidol used alone is recommended to help calm situations of aggression or agitation for people with psychosis." | 8.95 | Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Brooke-Powney, MJ; Li, X; Ostinelli, EG, 2017) |
| "To examine whether haloperidol plus promethazine is an effective treatment for psychosis-induced aggression." | 8.93 | Haloperidol plus promethazine for psychosis-induced aggression. ( Alexander, J; Allen, MH; Gandhi, P; Huf, G, 2016) |
| "To examine whether haloperidol alone, administered orally, intramuscularly or intravenously, is an effective treatment for long-term/persistent aggression in psychosis." | 8.93 | Haloperidol for long-term aggression in psychosis. ( Khushu, A; Powney, MJ, 2016) |
| "To compare the efficacy, acceptability, and tolerability of haloperidol with other first-generation antipsychotics in schizophrenia and schizophrenia-like psychosis." | 8.91 | Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. ( Dold, M; Leucht, S; Li, C; Samara, MT; Tardy, M, 2015) |
| "To estimate the clinical effects of zuclopenthixol acetate for the management of acute aggression or violence thought to be due to serious mental illnesses, in comparison to other drugs used to treat similar conditions." | 8.88 | Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. ( Gibson, RC; Gunadasa, S; Jayakody, K; Kumar, A, 2012) |
| "Haloperidol, used alone is recommended to help calm situations of aggression with people with psychosis." | 8.88 | Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Jones, H; Powney, MJ, 2012) |
| "The objective of this article is to assess the clinical characteristics of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder receiving aripiprazole, haloperidol, olanzapine, or placebo." | 8.86 | Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. ( Assunção-Talbott, S; Barnes, TR; Buckley, P; Correll, CU; Eudicone, J; Kane, JM; McQuade, R; Pikalov, A; Sachs, G; Tran, QV, 2010) |
| "To examine the effects of oral or intramuscular chlorpromazine for psychosis induced agitation or aggression." | 8.86 | Chlorpromazine for psychosis induced aggression or agitation. ( Adams, CE; Ahmed, U; Jones, H, 2010) |
| "Pooled data were analyzed from 5 short-term, double-blind, multicenter studies (published between 1997 and 2007) involving patients hospitalized with acute exacerbation of schizophrenia (5 studies) or schizoaffective disorder (2 studies) and randomly assigned to aripiprazole (N = 875), haloperidol (N = 193), risperidone (N = 95), or placebo (N = 406)." | 8.85 | The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. ( Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD, 2009) |
| "To examine whether haloperidol plus promethazine is an effective treatment for psychosis induced agitation/aggression." | 8.85 | Haloperidol plus promethazine for psychosis-induced aggression. ( Alexander, J; Allen, MH; Huf, G; Raveendran, NS, 2009) |
| "The frequency of neuroleptic malignant syndrome (NMS) after clozapine or olanzapine is low and often of non-serious nature." | 8.82 | [Life threatening neuroleptic malignant syndrome due to olanzapine]. ( Becker, T; Kopf, A; Köster, J; Krömker, H; Schulz, A, 2003) |
| "To examine whether haloperidol plus promethazine is an effective treatment for psychosis induced agitation/aggression." | 8.82 | Haloperidol plus promethazine for psychosis induced aggression. ( Alexander, J; Allen, MH; Huf, G, 2005) |
| "A total of 1476 patients diagnosed with DSM-IV schizophrenia or schizoaffective disorder were the subjects in 5 short-term, double-blind studies comparing aripiprazole with placebo; 3 of these studies also included a comparison with haloperidol." | 8.82 | Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. ( Carson, WH; Citrome, L; Czobor, P; Hardy, S; Kostic, D; Marcus, R; McQuade, RD; Volavka, J, 2005) |
| " Some dimensions of the schizophrenia syndrome in man can be mimicked in animals by the amphetamine (AMPH)-sensitization-induced psychosis model." | 7.88 | Schizophrenia dimension-specific antipsychotic drug action and failure in amphetamine-sensitized psychotic-like rats. ( Dere, E; Grömer, TW; Kornhuber, J; Müller, CP; Schindehütte, M; Uzuneser, TC; von Hörsten, S, 2018) |
| "In this study, we investigated whether minocycline, a second-generation tetracycline proposed as an add-on to antipsychotics in treatment-resistant schizophrenia (TRS), may affect the expression of Homer and Arc postsynaptic density (PSD) transcripts, implicated in synaptic regulation." | 7.85 | Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia. ( Avvisati, L; Buonaguro, EF; Chiodini, P; de Bartolomeis, A; Iasevoli, F; Latte, G; Marmo, F; Rossi, R; Tomasetti, C, 2017) |
| "The aim of this study was to compare serum amino acid patterns in patients on long-term clozapine treatment with long-term conventional antipsychotic treatment, and their relationships to insulin resistance and antipsychotic serum concentrations." | 7.81 | Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. ( Hall, K; Lewitt, M; Melkersson, K, 2015) |
| "Bromperidol is a close structural analogue of haloperidol." | 7.76 | Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses. ( Benfield, P; Clark, BG; Jue, SG; Ward, A, 1988) |
| "Three studies compared olanzapine and haloperidol given orally in maintenance therapy for schizophrenia and related psychoses." | 7.70 | Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. ( Beasley, CM; Dellva, MA; Tollefson, GD; Tran, PV; Wentley, AL, 1998) |
| " A 13-year-old female patient developed hyperprolactinemia with galactorrhea and amenorrhea while receiving thioridazine 300 mg daily." | 7.69 | Attenuation of antipsychotic-induced hyperprolactinemia with clozapine. ( Bunker, MT; Marken, PA; Ruehter, VL; Schneiderhan, ME, 1997) |
| "A case of haloperidol-induced bronchospasm is described, and possible etiologies are suggested." | 7.68 | Haloperidol-induced bronchospasm. ( Notkin, R; Sethna, R, 1991) |
| "A 31-year-old man with psychosis and neuroleptic-induced tardive dystonia developed neuroleptic malignant syndrome (NMS) while taking haloperidol." | 7.67 | Neuroleptic malignant syndrome responsive to carbidopa/levodopa: support for a dopaminergic pathogenesis. ( Harris, M; Nora, L; Tanner, CM, 1987) |
| " The patient had unusual, life-threatening complications, consisting of cardiac arrhythmia, followed by cardiac arrest, dysphagia persisting for eight weeks and leading to aspiration pneumonia, seizures, and myoclonus following treatment with haloperidol." | 7.66 | Neuroleptic malignant syndrome after haloperidol therapy. ( Cruz, FG; Harney, JH; Thiagarajan, D, 1983) |
| "Co-occurring substance use disorders, mostly involving alcohol, cannabis or cocaine, occur commonly in patients with schizophrenia and are associated with increased morbidity and mortality." | 6.71 | First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. ( Clark, WS; Glick, I; Green, AI; Hamer, RM; Lieberman, JA; Strakowski, SM; Tohen, MF, 2004) |
| "Haloperidol was associated with a sustained hyperprolactinemia, unlike ziprasidone, where only transient elevations in prolactin that returned to normal within the dosing interval were observed." | 6.69 | An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. ( Goff, DC; Herz, L; Kletti, N; Ko, GN; Lapierre, K; Law, CG; Posever, T; Simmons, J; Wilner, KD, 1998) |
| " A simulation of this dependence of clinical improvement on serum levels, mediated by the variable dose design, can be excluded because of the results of a retrospective analysis of dosing behavior." | 6.69 | Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. ( Braun, V; Meyer, FP; Neuhof, S; Ulrich, S, 1998) |
| "Haloperidol treated patients reported more tiredness and drowsiness than remoxipride treated patients." | 6.67 | A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. ( Beckmann, H; Bunse, J; Dittmann, V; Klieser, E; König, P; Laux, G; Schöny, HW; Schröder, HG; Schubert, H; Unterweger, B, 1990) |
| "When droperidol was compared with placebo, for the outcome of tranquillisation or asleep by 30 minutes we found evidence of a clear difference (1 RCT, N = 227, RR 1." | 6.53 | Droperidol for psychosis-induced aggression or agitation. ( Khokhar, MA; Rathbone, J, 2016) |
| "Aripiprazole is a novel antipsychotic with a unique mechanism of action." | 6.42 | Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. ( Ali, M; Iwamoto, T; Kaplita, S; Marcus, R; Marder, SR; McQuade, RD; Safferman, AZ; Saha, A; Stock, E, 2003) |
| "Haloperidol was stopped and intravenous clonazepam 5mg/kg was begun." | 5.36 | [Catatonia in a 14 year-old girl: treatment with clorazepam and carbamazepine, a 10-year follow-up]. ( Askenazy, F; Benoit, M; Dor, E; Dupuis, G; Myquel, M; Seddiki, Y; Serret, S, 2010) |
| "Haloperidol was prescribed to control psychotic symptoms." | 5.32 | Potentiation of haloperidol neurotoxicity in acute hyperthyroidism: report of a case. ( Chu, H; Hsu, YD; Lin, JC, 2004) |
| " Then, the principal pharmacokinetic data of haloperidol are exposed with a special emphasis on the lack of information about the correlations between plasma levels and clinical effects." | 5.26 | [Value of pharmacokinetic data during the treatment of psychoses with haloperidol]. ( Cottereau, MJ; Cuche, H; Deniker, P; Lôo, H; Zarifian, E, 1979) |
| " Acutely agitated patients with schizophrenia or schizoaffective disorder (n = 67) were randomized to receive 10 mg IM olanzapine (n = 37) or 5 mg IM haloperidol plus 2 mg IM lorazepam (n = 30)." | 5.20 | Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial. ( Chen, HH; Chen, YH; Hsieh, MH; Huang, CL; Huang, GH; Hwang, TJ; Hwu, HG, 2015) |
| "Oral haloperidol, risperidone, and olanzapine seem to be suitable for treating acute severe psychotic agitation in schizophrenia spectrum disorders." | 5.19 | Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. ( Abderhalden, C; Horn, H; Maier, N; Moggi, F; Moskvitin, K; Müller, TJ; Strik, W; Walther, S, 2014) |
| "A prospective, randomized, open-label study was carried out to compare the long-term neurocognitive effectiveness of haloperidol, olanzapine, and risperidone in the first episode of schizophrenia spectrum disorders." | 5.17 | Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone. ( Ayesa-Arriola, R; Crespo-Facorro, B; Martínez-García, O; Pérez-Iglesias, R; Rodríguez-Sánchez, JM; Roiz-Santiáñez, R; Sánchez-Moreno, J; Tabarés-Seisdedos, R; Vázquez-Barquero, JL, 2013) |
| "Ninety-nine physically aggressive inpatients (aged 18-60 years) with schizophrenia or schizoaffective disorder (diagnosed according to DSM-IV) who completed tests of executive function were randomly assigned in a double-blind, parallel-group, 12-week trial to clozapine (n = 32), olanzapine (n = 32), or haloperidol (n = 35)." | 5.16 | Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial. ( Czobor, P; Krakowski, MI, 2012) |
| "The ITT population included both schizoaffective and schizophrenia patients (N = 2401): n = 370, n = 494, and n = 424 for iloperidone 4-8, 10-16, and 20-24 mg/day, respectively; n = 294 for risperidone; n = 114 for haloperidol; n = 144 for ziprasidone; and n = 561 for placebo." | 5.16 | Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. ( Citrome, L; Hochfeld, M; Meng, X; Stahl, SM, 2012) |
| " The aim of our study was to assess social cognition in schizophrenia inpatients being treated with first-generation antipsychotic drugs (FGAs), n=28 (perphenazine and haloperidol, FGAs) or with second-generation antipsychotic drugs (SGAs), n=56 (olanzapine and clozapine, SGAs)." | 5.16 | Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs. ( Czernikiewicz, A; Kucharska-Pietura, K; Mortimer, A; Tylec, A, 2012) |
| "All medications produced a calming effect within one hour of administration, but only olanzapine and haloperidol reduced agitation by less than 10 points, and only olanzapine reduced aggression by less than four points in the first hour." | 5.15 | Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. ( Baldaçara, L; Cordeiro, DC; Jackoswski, AP; Sanches, M, 2011) |
| "To compare the effects of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on hostility in first-episode schizophrenia, schizoaffective disorder, or schizophreniform disorder." | 5.15 | Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). ( Bitter, I; Czobor, P; Derks, EM; Fleischhacker, WW; Kahn, RS; Libiger, J; Volavka, J, 2011) |
| "Eighty hospitalized patients suffering from Schizophrenia or Schizoaffective disorder (male 54, female 26) were first treated with Haloperidol (N=60) or Fluphenazine (N=20), and then were switched to Risperidone." | 5.15 | First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients. ( Popović, I; Popović, V; Ravanić, D; Stanojević, A; Stojanović, M; Vladejić, S, 2011) |
| "In this 8-week, multicenter, randomized, parallel-group, open-label, flexible-dose study, patients diagnosed with schizophrenia or schizoaffective disorder were randomized to aripiprazole 15-30 mg/day or haloperidol 10-15 mg/day." | 5.14 | Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol. ( Bueno, JR; Campos, JA; Chaves, A; de Abreu, PB; de Matos E Souza, FG; de Oliveira, IR; de Sena, EP; E Silva, JA; Elkis, H; Gattaz, WF; Louzã, MR, 2009) |
| "To compare the effectiveness of a switch from haloperidol (N=99), olanzapine (N=82), or risperidone (N=104) to 12 weeks of treatment with 80-160 mg/day ziprasidone in patients with stable schizophrenia or schizoaffective disorder." | 5.14 | Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. ( Akkaya, C; Alptekin, K; Brook, S; Danaci, AE; El Tallawy, H; Hafez, J; Karayal, ON; Lowe, W; Tzebelikos, E; Ucok, A, 2009) |
| "To better understand the efficacy and tolerability of atypical antipsychotics among racial groups, we reviewed data from four short-term (4-6 weeks), fixed-dose, placebo-controlled trials of ziprasidone for black, white, and overall populations of patients with schizophrenia." | 5.14 | Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies. ( Herman, BK; Lawson, WB; Lazariciu, I; Loebel, A; Malik, M, 2009) |
| "A total of 572 inpatients diagnosed with DSM-IV schizophrenia or schizoaffective disorder were the subjects in a randomized, rater-blinded, 6-week, open-label study comparing sequential intramuscular and oral ziprasidone with haloperidol." | 5.12 | Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data. ( Brook, S; Citrome, L; Czobor, P; Loebel, A; Mandel, FS; Volavka, J, 2006) |
| "Clozapine was superior to both olanzapine and haloperidol in reducing the number and severity of physical assaults as assessed by the MOAS physical aggression score and in reducing overall aggression as measured by the MOAS total score." | 5.12 | Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. ( Bark, N; Citrome, L; Cooper, TB; Czobor, P; Krakowski, MI, 2006) |
| "This double-blind, placebo-controlled study investigated the efficacy and safety of intramuscular (IM) aripiprazole and IM haloperidol for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder." | 5.12 | Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. ( Andrezina, R; Carson, WH; Iwamoto, T; Josiassen, RC; Manos, G; Marcus, RN; Oren, DA; Stock, E, 2006) |
| "Acutely agitated patients with schizophrenia or schizoaffective disorder treated with aripiprazole IM or haloperidol IM demonstrated similar effective and safe transition to their respective oral formulations." | 5.12 | Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. ( Allen, MH; Crandall, DT; Currier, GW; Daniel, DG; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL, 2007) |
| "While haloperidol is still widely used in the treatment of psychoses, the optimal daily dose remains a topic of controversy, particularly in first-episode psychosis." | 5.11 | A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. ( Emsley, R; Jadri Turner, H; Keyter, N; Oosthuizen, P, 2004) |
| "This 12-month, randomized, investigator-blinded study compared the efficacy of quetiapine (N = 22) and haloperidol (N = 23) in treating patients with DSM-IV schizophrenia or schizoaffective disorder and established tardive dyskinesia." | 5.11 | A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. ( Botha, K; Emsley, R; Oosthuizen, PP; Schronen, J; Smit, R; Turner, HJ, 2004) |
| "Adults with schizophrenia or schizoaffective disorder (N=481) were randomly assigned in a 3:1:1 ratio to receive fixed doses of investigational drug, placebo, or haloperidol for 6 weeks." | 5.11 | Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. ( Arvanitis, L; Bauer, D; Meltzer, HY; Rein, W, 2004) |
| "Patients with a first episode of schizophrenia, schizoaffective disorder, or schizophreniform disorder (N=167) were randomly assigned to double-blind treatment with olanzapine (mean modal dose= 9." | 5.11 | Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. ( Christensen, BK; Gur, RC; Hamer, RM; Keefe, RS; Lewine, RR; Lieberman, JA; Sanger, TM; Seidman, LJ; Sharma, T; Sitskoorn, MM; Tohen, M; Tollefson, GD; Yurgelun-Todd, DA, 2004) |
| "Patients with DSM-IV-diagnosed schizophrenia or schizoaffective disorder requiring long-term antipsychotic treatment were randomly assigned to open-label oral quetiapine or intramuscular haloperidol decanoate for 48 weeks." | 5.11 | Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. ( Glick, ID; Marder, SR, 2005) |
| "Cognitive assessments were conducted in 533 patients experiencing their first episode of schizophrenia or a related psychosis who had been randomly assigned to receive low doses of risperidone or haloperidol." | 5.11 | Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. ( Davidson, M; Eerdekens, M; Harvey, PD; Rabinowitz, J, 2005) |
| "Aripiprazole is an investigational agent for treating schizophrenia that has a novel pharmacologic profile." | 5.10 | Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL, 2002) |
| " Fifty subjects met the DSM-III-R criteria for schizophrenia or schizoaffective disorder, participated in a 10-week, double-blind comparison of haloperidol and clozapine and a 1-year, open-label clozapine trial, and had available serum glucose and lipid levels." | 5.10 | Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. ( Ball, P; Baymiller, SP; Buchanan, RW; McMahon, RP, 2003) |
| " The authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial." | 5.10 | Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2003) |
| "The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder." | 5.10 | Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "The effects of haloperidol, risperidone, and thioridazine on the pharmacokinetics and side-effect profile of quetiapine were investigated in 36 patients with schizophrenia, schizoaffective disorder, or bipolar disorder in a single-center, two-period, multiple-dose, open-label, randomized trial." | 5.10 | The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. ( Alva, G; Arvanitis, LA; Bera, R; Potkin, SG; Thyrum, PT; Yeh, C, 2002) |
| "Newer antipsychotic drugs have shown promise in ameliorating neurocognitive deficits in patients with schizophrenia, but few studies have compared newer antipsychotic drugs with both clozapine and conventional agents, particularly in patients who have had suboptimal response to prior treatments." | 5.10 | Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. ( Bilder, RM; Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Goldman, RS; Hoptman, M; Horowitz, TL; Kunz, M; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2002) |
| "Effects of flexible doses of risperidone and haloperidol were compared in 77 psychotic patients (83% with chronic schizophrenia) with disturbing neuroleptic-induced EPS (risperidone 40 patients, haloperidol 37)." | 5.09 | Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. ( de Groot, IW; Haffmans, PM; Heck, AH; Hoencamp, E, 2000) |
| "Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapine for up to 3 years, and comparisons were made to patients treated with haloperidol." | 5.09 | Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. ( Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD, 2001) |
| "Despite the demonstrated efficacy of clozapine in severely refractory schizophrenia, questions remain regarding its efficacy for primary negative symptoms, comparison with a moderate dose of a first-generation antipsychotic, and adverse effects during a longer-term trial." | 5.09 | Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. ( Baker, RW; Borenstein, M; Ganguli, R; Kane, JM; Marder, SR; McMeniman, M; Safferman, A; Schooler, NR; Umbricht, D; Wirshing, DA; Wirshing, WC, 2001) |
| "A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial." | 5.09 | Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2001) |
| "Plasma haloperidol levels between 5 and 11 ng/mL may be clinically optimal for acutely exacerbated schizophrenia, but the evidence for this therapeutic window has been inconsistent." | 5.08 | Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. ( Cooper, TB; Czobor, P; Meisner, M; Volavka, J, 1995) |
| "Data were analyzed from three actively controlled and blind long-term responder studies of subjects meeting DSM-III-R criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder treated with olanzapine (N = 707, up to 20 mg/day, 237 median days of exposure) or haloperidol (N = 197, up to 20 mg/day, 203 median days of exposure) who did not have evidence of tardive dyskinesia at baseline." | 5.08 | Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. ( Beasley, CM; Potvin, JH; Tamura, RN; Tollefson, GD; Tran, PV, 1997) |
| "Sixty-two first-episode psychotic patients who were neuroleptic-naive were studied to examine predictors of acute dystonia after treatment with haloperidol." | 5.07 | Predictors of acute dystonia in first-episode psychotic patients. ( Aguilar, EJ; Gómez-Beneyto, M; Hernández, J; Keshavan, MS; Martínez-Quiles, MD; Schooler, NR, 1994) |
| "In a double-blind, prospective study, 2 mg of intramuscular lorazepam and 5 mg of intramuscular haloperidol were equally effective in controlling aggression, agitation, and assaultive behavior." | 5.07 | Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. ( Flowers, E; Glassman, R; Miyawaki, E; Rood, L; Salzman, C; Solomon, D; Thayer, S, 1991) |
| "After individual determination of neuroleptic threshold (NT) doses of haloperidol, 106 patients with schizophrenia or schizoaffective disorder (Research Diagnostic Criteria) were treated openly at such doses (mean, 3." | 5.07 | Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. ( Hogarty, GE; McEvoy, JP; Steingard, S, 1991) |
| "Twenty-nine inpatients with major psychotic disorders were treated for 14 days with a clinician-determined dose of haloperidol and with either benztropine or placebo given by double-blind random assignment on days 1 through 7." | 5.07 | The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. ( Arana, GW; Dupont, R; Goff, DC; Greenblatt, DJ; Harmatz, JS; Ornsteen, M; Shader, RI, 1991) |
| "Seventy-one patients were entered into a multicentre, double-blind randomized study to compare the efficacy and safety of remoxipride with those of haloperidol in the acute treatment of schizophrenia or schizophreniform disorder." | 5.06 | A double-blind comparative study of remoxipride and haloperidol in acute schizophrenia. ( den Boer, JA; Huisman, J; Ohrvik, J; Ravelli, DP; Verhoeven, WM; Westenberg, HG, 1990) |
| "The antipsychotic effect of remoxipride was compared to that of haloperidol in a randomized double-blind study with parallel group design comprising 98 patients with schizophrenia or schizophreniform disorder according to DSM-III." | 5.06 | A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders. ( Cosyns, P; de Bleeker, E; Deleu, G; Lotstra, F; Masson, A; Mendlewicz, J; Mertens, C; Parent, M; Peuskens, J; Suy, E, 1990) |
| "Nine double-blind studies comparing remoxipride to haloperidol in the treatment of acute schizophrenia formed the basis of this analysis." | 5.06 | Clinical profile of remoxipride--a combined analysis of a comparative double-blind multicentre trial programme. ( Lewander, T; Morrison, D; Westerbergh, SE, 1990) |
| " However, its being well-tolerated and effective on chronic psychotic patients, coupled to the "bonus" of a single daily dose, turns BP into a suitable alternative drug for Haloperidol when dealing with schizophrenia, and delusions with no deficitary evolution." | 5.06 | [Clinical experience with bromperidol in chronic psychoses]. ( Bellomo, LE; Forconesi, N; Rosset, N; Tellarini, L, 1988) |
| "In order to evaluate the efficacy and tolerance to Haloperidol Decanoate, 26 patients with different psychotic disorders were included in a six month's clinical study." | 5.06 | [Open clinical trial with haloperidol decanoate in patients with psychotic disorders]. ( Ellerman, LA, 1987) |
| " Haloperidol has a relatively weak effect on aggression when given alone and can also cause side effects such as early dyskinesia and epileptic seizures." | 5.01 | The Use of Rapid Tranquilization in Aggressive Behavior. ( Hirsch, S; Steinert, T, 2019) |
| "PubMed/Medline and EBSCO databases were searched using the keywords: diabetic ketoacidosis, antipsychotics, atypical antipsychotics, second generation antipsychotics, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, paliperidone, amisulpride and haloperidol." | 4.95 | Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature. ( Baretic, M; Kuzman, MR; Osvatic, MM; Vuk, A, 2017) |
| "Haloperidol used alone is recommended to help calm situations of aggression or agitation for people with psychosis." | 4.95 | Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Brooke-Powney, MJ; Li, X; Ostinelli, EG, 2017) |
| "To examine whether haloperidol plus promethazine is an effective treatment for psychosis-induced aggression." | 4.93 | Haloperidol plus promethazine for psychosis-induced aggression. ( Alexander, J; Allen, MH; Gandhi, P; Huf, G, 2016) |
| "To examine whether haloperidol alone, administered orally, intramuscularly or intravenously, is an effective treatment for long-term/persistent aggression in psychosis." | 4.93 | Haloperidol for long-term aggression in psychosis. ( Khushu, A; Powney, MJ, 2016) |
| "To compare the efficacy, acceptability, and tolerability of haloperidol with other first-generation antipsychotics in schizophrenia and schizophrenia-like psychosis." | 4.91 | Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. ( Dold, M; Leucht, S; Li, C; Samara, MT; Tardy, M, 2015) |
| "To estimate the clinical effects of zuclopenthixol acetate for the management of acute aggression or violence thought to be due to serious mental illnesses, in comparison to other drugs used to treat similar conditions." | 4.88 | Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. ( Gibson, RC; Gunadasa, S; Jayakody, K; Kumar, A, 2012) |
| "Haloperidol, used alone is recommended to help calm situations of aggression with people with psychosis." | 4.88 | Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Jones, H; Powney, MJ, 2012) |
| "Haloperidol in combination with promethazine, and olanzapine, are effective in psychotic agitation, although haloperidol plus promethazine has a more rapid onset of effect faster; lorazepam is effective in non-psychotic agitation, aggression or excitement as well as in acute agitation of unknown origin." | 4.87 | [Rapid tranquillisation; review of the literature and recommendations]. ( Bak, M; Marcelis, M; van Os, J, 2011) |
| "The objective of this article is to assess the clinical characteristics of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder receiving aripiprazole, haloperidol, olanzapine, or placebo." | 4.86 | Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. ( Assunção-Talbott, S; Barnes, TR; Buckley, P; Correll, CU; Eudicone, J; Kane, JM; McQuade, R; Pikalov, A; Sachs, G; Tran, QV, 2010) |
| "To examine the effects of oral or intramuscular chlorpromazine for psychosis induced agitation or aggression." | 4.86 | Chlorpromazine for psychosis induced aggression or agitation. ( Adams, CE; Ahmed, U; Jones, H, 2010) |
| "Pooled data were analyzed from 5 short-term, double-blind, multicenter studies (published between 1997 and 2007) involving patients hospitalized with acute exacerbation of schizophrenia (5 studies) or schizoaffective disorder (2 studies) and randomly assigned to aripiprazole (N = 875), haloperidol (N = 193), risperidone (N = 95), or placebo (N = 406)." | 4.85 | The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. ( Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD, 2009) |
| "To examine whether haloperidol plus promethazine is an effective treatment for psychosis induced agitation/aggression." | 4.85 | Haloperidol plus promethazine for psychosis-induced aggression. ( Alexander, J; Allen, MH; Huf, G; Raveendran, NS, 2009) |
| " This study compared the use of olanzapine (10 mg/day) with haloperidol (12 mg/day) in 16 patients suffering from schizophrenia-like psychosis of epilepsy (SLPE)." | 4.84 | Interventions for psychotic symptoms concomitant with epilepsy. ( Farooq, S; Sherin, A, 2008) |
| "The frequency of neuroleptic malignant syndrome (NMS) after clozapine or olanzapine is low and often of non-serious nature." | 4.82 | [Life threatening neuroleptic malignant syndrome due to olanzapine]. ( Becker, T; Kopf, A; Köster, J; Krömker, H; Schulz, A, 2003) |
| "To examine whether haloperidol plus promethazine is an effective treatment for psychosis induced agitation/aggression." | 4.82 | Haloperidol plus promethazine for psychosis induced aggression. ( Alexander, J; Allen, MH; Huf, G, 2005) |
| "A total of 1476 patients diagnosed with DSM-IV schizophrenia or schizoaffective disorder were the subjects in 5 short-term, double-blind studies comparing aripiprazole with placebo; 3 of these studies also included a comparison with haloperidol." | 4.82 | Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. ( Carson, WH; Citrome, L; Czobor, P; Hardy, S; Kostic, D; Marcus, R; McQuade, RD; Volavka, J, 2005) |
| "Neuroleptic-induced catatonia is reported in an adolescent patient who responded successfully to lorazepam." | 4.78 | Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. ( Woodbury, MA; Woodbury, MM, 1992) |
| "Lithium carbonate is the single most important long-term treatment for recurrent affective disorders." | 4.76 | Lithium. ( DePaulo, JR, 1984) |
| "Caffeine and nicotine are widely used by schizophrenia patients and may worsen psychosis and affect antipsychotic therapies." | 3.88 | Nicotine and caffeine modulate haloperidol-induced changes in postsynaptic density transcripts expression: Translational insights in psychosis therapy and treatment resistance. ( Avvisati, L; Buonaguro, EF; de Bartolomeis, A; Iasevoli, F; Latte, G; Marmo, F; Tomasetti, C, 2018) |
| " Some dimensions of the schizophrenia syndrome in man can be mimicked in animals by the amphetamine (AMPH)-sensitization-induced psychosis model." | 3.88 | Schizophrenia dimension-specific antipsychotic drug action and failure in amphetamine-sensitized psychotic-like rats. ( Dere, E; Grömer, TW; Kornhuber, J; Müller, CP; Schindehütte, M; Uzuneser, TC; von Hörsten, S, 2018) |
| " Withdrawal of the narcolepsy treatment and initiation of haloperidol 1 mg/day (the only antipsychotic treatment she could tolerate) improved the delusions, hallucinations and dysphoria but worsened the narcolepsy symptoms." | 3.85 | Narcolepsy-cataplexy and psychosis: a case study. ( Arango-Lopez, C; Canellas-Dols, F; Delgado, C; Peraita-Adrados, R, 2017) |
| "In this study, we investigated whether minocycline, a second-generation tetracycline proposed as an add-on to antipsychotics in treatment-resistant schizophrenia (TRS), may affect the expression of Homer and Arc postsynaptic density (PSD) transcripts, implicated in synaptic regulation." | 3.85 | Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia. ( Avvisati, L; Buonaguro, EF; Chiodini, P; de Bartolomeis, A; Iasevoli, F; Latte, G; Marmo, F; Rossi, R; Tomasetti, C, 2017) |
| "The aim of this study was to compare serum amino acid patterns in patients on long-term clozapine treatment with long-term conventional antipsychotic treatment, and their relationships to insulin resistance and antipsychotic serum concentrations." | 3.81 | Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. ( Hall, K; Lewitt, M; Melkersson, K, 2015) |
| " There is a strong genetic and pharmacological evidence supporting the hypothesis that activation of D2 receptors could lead to hypothermia and that the treatment haloperidol is capable of inducing hypothermia apomorfino similarily in laboratory animals." | 3.79 | What about temperature? Haloperidol-induced hypotermia. ( Aguglia, E; Battiato, M; Nalis, F; Signorelli, MS, 2013) |
| " The syndrome resolved within a few days of stopping haloperidol and initiation of lorazepam." | 3.78 | Neuroleptic-induced catatonia in two hospitalized patients. ( Gugger, JJ; Saad, M; Smith, C, 2012) |
| "Bromperidol is a close structural analogue of haloperidol." | 3.76 | Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses. ( Benfield, P; Clark, BG; Jue, SG; Ward, A, 1988) |
| "The authors conducted a prospective observational study of women treated with an atypical antipsychotic or haloperidol during pregnancy." | 3.74 | Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. ( Beach, AJ; Calamaras, MR; DeVane, CL; Donovan, J; Gibson, BB; Knight, BT; Nemeroff, CB; Newport, DJ; Owens, MJ; Stowe, ZN; Viguera, AC; Winn, S, 2007) |
| "One hundred patients with schizophrenia or schizoaffective disorder participated in an 8 week, double-blind study of risperidone, olanzapine, and haloperidol." | 3.74 | Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. ( Braff, DL; Erhart, S; Green, MF; Kee, KS; Marder, SR; Mintz, J; Reist, C; Sergi, MJ; Widmark, C, 2007) |
| "Plasma prolactin concentration was measured in patients with schizophrenia and schizoaffective disorders receiving therapy with risperidone, olanzapine, and quetiapine and compared with the corresponding parameter in patient receiving typical neuroleptic drug haloperidol." | 3.73 | Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders. ( Gorobets, LN, 2005) |
| "Fifty-seven subjects with first-episode psychosis and a DSM-IV diagnosis of schizophreniform disorder, schizophrenia, or schizoaffective disorder were treated according to a fixed protocol with a mean dose of haloperidol of 1." | 3.72 | Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. ( Emsley, RA; Keyter, N; Maritz, JS; Oosthuizen, PP; Turner, JA, 2003) |
| " In a first genome scan on obesity under antipsychotics in SZ and BP, we analyzed 21 multigenerational kindreds (508 family members) including several patients treated for a minimum of 3 years mainly with haloperidol or chlopromazine." | 3.72 | A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. ( Bouchard, RH; Chagnon, YC; Emond, C; Maziade, M; Mérette, C; Roy, MA, 2004) |
| "Patients with a Diagnostic and Statistical Manual of Mental Disorders (third edition, revised) diagnosis of schizophrenia or psychotic disorder not otherwise specified with onset of psychosis before the age of 13 participated in 6- to 8-week open or double-blind trials of haloperidol (n = 15, mean dose 15." | 3.71 | Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. ( Alfaro, CL; Gochman, P; Lenane, M; Nicolson, R; Rapoport, JL; Sporn, A; Wudarsky, M, 2002) |
| "We examined the effect of age on psychopharmacological management in a naturalistic study of a group of 165 patients with a clinical diagnosis of schizophrenia or a related psychotic disorder (age range = 21-84 years; subjects > or = 1;45 years n = 86) treated with either haloperidol decanoate or fluphenazine decanoate." | 3.71 | The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders. ( Chengappa, KN; Jeste, DV; Mamo, DC; Reddy, RR; Sweet, RA, 2002) |
| " However, accumulating evidence suggests that these agents, particularly clozapine and olanzapine, have serious side effects of their own, including weight gain and elevated glucose and triglyceride levels." | 3.71 | The effects of novel antipsychotics on glucose and lipid levels. ( Ballon, JS; Boyd, JA; Marder, SR; Meng, LR; Wirshing, DA; Wirshing, WC, 2002) |
| "Three studies compared olanzapine and haloperidol given orally in maintenance therapy for schizophrenia and related psychoses." | 3.70 | Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. ( Beasley, CM; Dellva, MA; Tollefson, GD; Tran, PV; Wentley, AL, 1998) |
| "Elevated cerebrospinal fluid (CSF) angiotensin I-converting enzyme (ACE) levels have been evidenced in patients with schizophrenia who have been treated with antipsychotics." | 3.70 | Current antipsychotic dose correlates to mononuclear cell counts in the cerebrospinal fluid of psychotic patients. ( Ahokas, A; Nikkilä, H; Rimón, R; Wahlbeck, K, 2000) |
| " A 13-year-old female patient developed hyperprolactinemia with galactorrhea and amenorrhea while receiving thioridazine 300 mg daily." | 3.69 | Attenuation of antipsychotic-induced hyperprolactinemia with clozapine. ( Bunker, MT; Marken, PA; Ruehter, VL; Schneiderhan, ME, 1997) |
| "Eleven acutely psychotic patients with schizophrenia or schizoaffective disorder underwent a 5-7 day drug-washout period (with lorazepam allowed) prior to participating in a 6-week controlled dose haloperidol trial." | 3.68 | Haloperidol response and plasma catecholamines and their metabolites. ( Alam, MY; Boshes, RA; Fitzgibbon, ME; Green, AI; Pappalardo, KM; Schildkraut, JJ; Tsuang, MT; Waternaux, C, 1993) |
| " Thirty-six acutely psychotic patients receiving parenteral haloperidol were evaluated by the Brief Psychiatric Rating Scale, the Schedule for Affective Disorders and Schizophrenia-Change Version, and the Nurses' Observation Scale for Inpatient Evaluation, as well as by drug levels in plasma." | 3.68 | Acutely psychotic patients receiving high-dose haloperidol therapy. ( Coulter, K; Pollock, B; Reed, K; Remington, G; Voineskos, G, 1993) |
| "The use of intravenous haloperidol in five severely regressed, nonviolent, psychiatric inpatients with psychotic disorders is described." | 3.68 | Intravenous haloperidol treatment of severely regressed, nonviolent psychiatric inpatients. ( Brown, GR; Plotnick, EK, 1991) |
| "A case of haloperidol-induced bronchospasm is described, and possible etiologies are suggested." | 3.68 | Haloperidol-induced bronchospasm. ( Notkin, R; Sethna, R, 1991) |
| "Twenty recently admitted patients with mood-incongruent psychoses underwent 1) interviews with the Schedule for Affective Disorders and Schizophrenia for diagnostic evaluation and symptom profiles, 2) drug-free baseline measurements of CSF neurotensin and homovanillic acid, and 3) close monitoring of a therapeutic trial of haloperidol to determine latency of antipsychotic response." | 3.68 | Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. ( Bissette, G; Garver, DL; Nemeroff, CB; Yao, JK, 1991) |
| " Many such patients respond to a trial of lithium therapy; responders are usually better able to work or attend school and to live independently, and they less often show the degree of personality deterioration present in classical schizophrenia." | 3.67 | Acutely psychotic patients: a treatment approach. ( Cade, JR; Lippmann, S; Wagemaker, H, 1985) |
| "A 31-year-old man with psychosis and neuroleptic-induced tardive dystonia developed neuroleptic malignant syndrome (NMS) while taking haloperidol." | 3.67 | Neuroleptic malignant syndrome responsive to carbidopa/levodopa: support for a dopaminergic pathogenesis. ( Harris, M; Nora, L; Tanner, CM, 1987) |
| " In this retrospective study, 15 of 16 young adult patients treated only with haloperidol had such reactions within 60 hours of beginning the drug, while none of the seven patients treated with haloperidol plus prophylactic benztropine mesylate developed dystonia." | 3.67 | Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions. ( Bakalar, NH; Boyer, WF; Lake, CR, 1987) |
| "Combined treatment with haloperidol and lithium is a frequently employed strategy for the treatment of acute psychoses." | 3.66 | Effect of combined haloperidol-lithium treatment on vitro RBC lithium uptake in patients with affective disorders. ( Grof, P; Rotstein, E; Werner, L; Werstiuk, ES, 1983) |
| " The patient had unusual, life-threatening complications, consisting of cardiac arrhythmia, followed by cardiac arrest, dysphagia persisting for eight weeks and leading to aspiration pneumonia, seizures, and myoclonus following treatment with haloperidol." | 3.66 | Neuroleptic malignant syndrome after haloperidol therapy. ( Cruz, FG; Harney, JH; Thiagarajan, D, 1983) |
| "About 30 patients with, in some cases, recurring paranoid or paranoid-hallucinatory psychoses underwent a long-term treatment--from 2--6 years according to individual cases--with very small doses of powerful neuroleptics (Haloperidol, Triperidol, and occasionally Trisedyl)." | 3.65 | [Neuroleptic long term care with extremely low doses in psychotic syndromes of paranoid-hallucination type]. ( König, L; Rossner, M, 1975) |
| "Twenty-four patients with acute functional psychoses were treated with intramuscular haloperidol in a three-hour period." | 3.65 | Rapid treatment of acute psychosis. ( Anderson, WH; Catanzano, DM; Kuehnle, JC, 1976) |
| "A second case of severe limb malformations was observed following maternal use of haloperidol early in the first trimester of pregnancy." | 3.65 | Limb malformations following maternal use of haloperidol. ( Heggeness, L; McCullar, FW, 1975) |
| "Diagnosis, cannabis use, duration of untreated psychosis (DUP), smoking and antipsychotic class were examined as possible predictive variables." | 2.79 | Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. ( Crespo-Facorro, B; de León, J; Diaz, FJ; Pelayo-Terán, JM; Pérez-Iglesias, R; Suárez-Pinilla, P; Tabarés-Seisdedos, R, 2014) |
| "Haloperidol open treatment was efficacious, and relapse was greater on placebo than with haloperidol continuation." | 2.76 | A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. ( Cunqueiro, K; Devanand, DP; Marder, K; Pelton, GH; Sackeim, HA, 2011) |
| " Sample size was reduced from 311 to 156 patients, thereby decreasing the number of patients exposed to placebo from 54 to 30 and the number exposed to the active control with a known side effect from 126 to 60." | 2.74 | Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach. ( Baker, R; Breier, A; Dunayevich, E; Lindborg, S; Seaman, J; Spann, M, 2009) |
| "Weight gain has become one of the most common and concerning side effects of antipsychotic treatment." | 2.73 | Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. ( Amado, JA; Berja, A; Carrasco-Marín, E; Crespo-Facorro, B; Garcia-Unzueta, MT; Mata, I; Pelayo-Terán, JM; Perez-Iglesias, R; Vazquez-Barquero, JL, 2008) |
| "Aripiprazole was significantly inferior to olanzapine (SMD = 1." | 2.72 | Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis. ( Likhitsathian, S; Maneeton, B; Maneeton, N; Oon-Arom, A; Srisurapanont, M; Suradom, C; Suttajit, S, 2021) |
| "The authors conducted a multicenter, double-blind, placebo-controlled, randomized trial of flexibly dosed quetiapine and haloperidol." | 2.72 | Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. ( Copenhaver, M; Katz, IR; Mintzer, JE; Schneider, L; Street, J; Tariot, PN; Williams-Hughes, C, 2006) |
| "Olanzapine-treated patients had significantly more weight gain compared with the haloperidol and risperidone groups (p < ." | 2.72 | A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. ( Crespo-Facorro, B; Llorca, J; Luis Vázquez-Barquero, J; Martínez-García, O; Pérez-Iglesias, R; Ramirez-Bonilla, M, 2006) |
| "Olanzapine-treated patients experienced a lower rate of treatment-emergent parkinsonism and akathisia but had significantly more weight gain, compared with the haloperidol-treated patients." | 2.71 | Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. ( Green, AI; Gur, RE; Hamer, RM; Kahn, R; Lieberman, JA; McEvoy, J; Perkins, D; Sharma, T; Tohen, M; Tollefson, G; Wei, H; Zipursky, R, 2003) |
| "Co-occurring substance use disorders, mostly involving alcohol, cannabis or cocaine, occur commonly in patients with schizophrenia and are associated with increased morbidity and mortality." | 2.71 | First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. ( Clark, WS; Glick, I; Green, AI; Hamer, RM; Lieberman, JA; Strakowski, SM; Tohen, MF, 2004) |
| "Duration of untreated psychosis (DUP) may contribute to the observed heterogeneity of the treatment response in first-episode schizophrenia." | 2.71 | Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. ( Green, A; Gu, H; Gur, R; Kahn, R; Lieberman, J; McEvoy, J; Perkins, D; Sharma, T; Strakowski, S; Tohen, M; Tollefson, G; Zipursky, R, 2004) |
| "Ziprasidone induces lower D2 RO and EPS than haloperidol, which is consistent with an atypical antipsychotic profile." | 2.71 | Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. ( Aguilar, Y; Alvarez, E; Carrió, I; Catafau, AM; Corripio, I; Mena, E; Perez, V; Puigdemont, D, 2005) |
| "As treatment approaches have advanced, more attention has been given to re-integrating patients into their psychosocial environments, rather than simply monitoring psychotic symptoms." | 2.71 | Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. ( Delbello, MP; Glick, I; Green, AI; Hamer, RM; Johnson, JL; Lieberman, JA; Patel, JK; Strakowski, SM; Tohen, M, 2005) |
| " According to response, dosage was then adjusted to a maximum dosage of 20 mg daily of either drug." | 2.71 | Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis. ( Christensen, BK; Daskalakis, Z; Epstein, I; Furimsky, I; Kapur, S; Roy, P; Sanger, T; Zipursky, RB, 2005) |
| " Haloperidol blood levels may be clinically useful in identifying patients who are nonresponsive because of low drug levels and, hence, in enhancing optimal haloperidol dosing for acute mania with psychosis." | 2.70 | Haloperidol blood levels in acute mania with psychosis. ( Chou, JC; Cooper, TB; Czobor, P; Dacpano, G; Richardson, N; Trujillo, M; Tuma, I; Volavka, J, 2001) |
| "Patients with schizoaffective disorder bipolar type, characterized as currently manic, mixed, depressed, or euthymic, were assessed weekly for 6 weeks during treatment with either olanzapine or haloperidol." | 2.70 | Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. ( Breier, A; Feldman, PD; Keck, PE; Risser, RC; Tohen, M; Tran, PV; Zhang, F, 2001) |
| " A total of 123 patients (62 RIS; 61 HAL/AMI) were included; the mean daily dosage at endpoint was 6." | 2.69 | Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. ( Benkert, O; Hillert, A; Müller, MJ; Müller-Siecheneder, F; Szegedi, A; Wetzel, H, 1998) |
| "Haloperidol was associated with a sustained hyperprolactinemia, unlike ziprasidone, where only transient elevations in prolactin that returned to normal within the dosing interval were observed." | 2.69 | An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. ( Goff, DC; Herz, L; Kletti, N; Ko, GN; Lapierre, K; Law, CG; Posever, T; Simmons, J; Wilner, KD, 1998) |
| " A simulation of this dependence of clinical improvement on serum levels, mediated by the variable dose design, can be excluded because of the results of a retrospective analysis of dosing behavior." | 2.69 | Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. ( Braun, V; Meyer, FP; Neuhof, S; Ulrich, S, 1998) |
| "Haloperidol-treated first-episode patients experienced statistically significantly more extrapyramidal symptoms than haloperidol-treated multiple-episode patients." | 2.69 | Olanzapine versus haloperidol treatment in first-episode psychosis. ( Beasley, C; Grundy, S; Lieberman, JA; Sanger, TM; Tohen, M; Tollefson, GD, 1999) |
| "Haloperidol treatment did not alter glutamate concentrations." | 2.69 | Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients. ( Bardgett, M; Csernansky, JG; Faull, KF; Faustman, WO; Pfefferbaum, A, 1999) |
| "Olanzapine-treated patients achieved a statistically significant greater improvement than haloperidol treated patients on overall measures of efficacy, including clinical response." | 2.69 | Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy. ( Beasley, CM; Berg, PH; Lu, Y; Sanger, TM; Tollefson, GD; Tran, PV, 1999) |
| "Ziprasidone was associated with a lower incidence of movement disorders and a reduced requirement for anticholinergic medication during both i." | 2.69 | Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. ( Brook, S; Gunn, KP; Lucey, JV, 2000) |
| "clonazepam is an effective, safe, but slower-acting alternative to I." | 2.67 | A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. ( Annable, L; Chouinard, G; Holobow, N; Szkrumelak, N; Turnier, L, 1993) |
| " Dosage was chosen and adjusted to the individual patient's condition and response." | 2.67 | Zuclopenthixol and haloperidol in patients with acute psychotic states. A double-blind, multi-centre study. ( Eliander, H; Heikkilä, L; Pedersen, V; Turunen, M; Vartiainen, H, 1992) |
| "Haloperidol treated patients reported more tiredness and drowsiness than remoxipride treated patients." | 2.67 | A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. ( Beckmann, H; Bunse, J; Dittmann, V; Klieser, E; König, P; Laux, G; Schöny, HW; Schröder, HG; Schubert, H; Unterweger, B, 1990) |
| " Serum levels of haloperidol were determined by high performance liquid chromatography and serum concentration data obtained were submitted to pharmacokinetic analysis." | 2.66 | Pharmacokinetics of haloperidol in psychotic patients. ( Bondesson, U; Cheng, YF; Ekblom, B; Eriksson, K; Eriksson, SO; Lindberg, A; Lindström, L; Paalzow, LK, 1987) |
| "Haloperidol treatment masked withdrawal-exacerbated tardive dyskinesia more than molindone did; this difference (measured by percent change in AIMS scores) was significant (p = ." | 2.66 | Molindone and haloperidol in tardive dyskinesia. ( Benarroche, CL; Glazer, WM; Hafez, HM, 1985) |
| "Fluperlapine (NB-106-689) was tested on 26 schizophrenic patients in an open and crossover study." | 2.66 | Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol. Results of an open and crossover study. ( Bartels, M; Gärtner, HJ; Heimann, H; Mann, K; Schied, HW; Wagner, W, 1987) |
| "In a double-blind controlled study, 20 acutely psychotic inpatients were treated with different haloperidol dosage regimens." | 2.65 | Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. ( Depry, D; Janowsky, DS; Munson, E; Neborsky, RJ; Perel, JM, 1984) |
| "We studied the incidence of akathisia in two populations of newly admitted schizophrenic patients: one group was treated with haloperidol and the other group was treated with thiothixene hydrochloride." | 2.65 | Akathisia with haloperidol and thiothixene. ( Marder, SR; May, PR; Van Putten, T, 1984) |
| " Mean daily dosage was approximately 112 mg flupenthixol and 18 mg haloperidol." | 2.65 | Flupenthixol versus haloperidol in acute psychosis. ( Parent, M; Toussaint, C, 1983) |
| ", as needed over a four-hour period (total dosage ranging from 4 to 32 mg." | 2.64 | Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients. ( Stotsky, BA, 1977) |
| "Based on findings from 34 blinded, randomized controlled trials, common acute adverse effects of second-generation antipsychotics and haloperidol were headache, dizziness, insomnia, and somnolence." | 2.58 | Evidence-Based Review Of Pharmacotherapy For Acute Agitation. Part 2: Safety. ( Zun, LS, 2018) |
| "When droperidol was compared with placebo, for the outcome of tranquillisation or asleep by 30 minutes we found evidence of a clear difference (1 RCT, N = 227, RR 1." | 2.53 | Droperidol for psychosis-induced aggression or agitation. ( Khokhar, MA; Rathbone, J, 2016) |
| "When haloperidol and midazolam were compared with olanzapine, there was some evidence the combination was superior in terms of improvement, sedation and behaviour." | 2.49 | Benzodiazepines for psychosis-induced aggression or agitation. ( Beck, A; Gillies, D; Rathbone, J; Sampson, S, 2013) |
| " Antipsychotic-induced laryngeal dystonia has been reported predominantly in young males, but does not correlate to the dosage or the category of the drug." | 2.43 | Antipsychotic drug-induced acute laryngeal dystonia: two case reports and a mini review. ( Christodoulou, C; Kalaitzi, C, 2005) |
| "Aripiprazole is a novel antipsychotic with a unique mechanism of action." | 2.42 | Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. ( Ali, M; Iwamoto, T; Kaplita, S; Marcus, R; Marder, SR; McQuade, RD; Safferman, AZ; Saha, A; Stock, E, 2003) |
| "Risperidone is a relatively new antipsychotic available world-wide since the early 1990s." | 2.41 | Focus on risperidone. ( Green, B, 2000) |
| "Neuroleptic malignant syndrome is a rare but potentially fatal complication of treatment with antipsychotic medications." | 2.41 | Neuroleptic malignant syndrome in children and adolescents. ( Rothner, AD; Ty, EB, 2001) |
| "The occurrence of confusion in the elderly patient should alert the physician to the need of investigation to detect underlying severe disease without delay." | 2.39 | [Confusional states in the elderly--an underdiagnosed syndrome with a poor prognosis]. ( Pitkälä, K, 1996) |
| "The future of depot neuroleptic therapy is discussed in terms of pharmacokinetic and pharmacodynamic research opportunities." | 2.37 | Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. ( Davis, CM; Ereshefsky, L; Jann, MW; Richards, A; Saklad, SR; Seidel, DR, 1984) |
| "Haloperidol decanoate is a depot preparation of haloperidol, a commonly used butyrophenone derivative with antipsychotic activity." | 2.37 | Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. ( Beresford, R; Ward, A, 1987) |
| "Expert consensus-based clinically equivalent dose estimates and dosing recommendations can provide valuable support for the use of drugs for psychosis in clinical practice and research." | 1.91 | Second International Consensus Study of Antipsychotic Dosing (ICSAD-2). ( Baldessarini, RJ; Gardner, DM; McAdam, MK; Murphy, AL, 2023) |
| " No significant differences were found in the rate of violent behavior and antipsychotic dosage at discharge." | 1.72 | Olanzapine intramuscular shows better efficacy than zuclopenthixol acetate intramuscular in reducing the need for restraint, but not in comparison to haloperidol intramuscular. ( Bloemhof-Bris, E; Shelef, A; Sinai, O; Stryjer, R; Weizman, S, 2022) |
| " Mean endpoint LAI dosage was 65." | 1.72 | An interventional pilot of customized adherence enhancement combined with long-acting injectable antipsychotic medication (CAE-L) for poorly adherent patients with chronic psychotic disorder in Tanzania. ( Blixen, CE; Burant, CJ; Cassidy, KA; Kaaya, S; Lema, I; Levin, JB; Madundo, K; Magwiza, C; Mbwambo, J; Njiro, G; Sajatovic, M, 2022) |
| "Haloperidol-treated rats were divided into groups of DSS rats and non-DSS rats based on their voluntary locomotion data." | 1.62 | Upregulation of heat-shock protein HSP-70 and glutamate transporter-1/glutamine synthetase in the striatum and hippocampus in haloperidol-induced dopamine-supersensitivity-state rats. ( Hashimoto, K; Hirose, Y; Iyo, M; Kanahara, N; Kimura, H; Kimura, M; Niitsu, T; Oda, Y; Shirayama, Y; Yoshino, K, 2021) |
| "While the long-term administration of antipsychotics is known to cause dopamine supersensitivity psychosis (DSP), recent studies revealed that DSP helps form the foundation of treatment resistance." | 1.62 | Effects of repeated electroconvulsive shocks on dopamine supersensitivity psychosis model rats. ( Hashimoto, K; Iyo, M; Kanahara, N; Kimura, H; Kimura, M; Niitsu, T; Oda, Y; Oishi, K; Shirayama, Y; Yoshino, K, 2021) |
| "As its name suggests, delirious mania presents as a mixture of hyperactive delirium and mania; additional features may include psychosis, autonomic activation, and catatonia." | 1.62 | Pseudodelirium: Psychiatric Conditions to Consider on the Differential for Delirium. ( Ainsworth, A; Andrews, P; Ely, EW; Oldham, MA; Roy, K; Wilson, JE, 2021) |
| " The duration of each adequate antipsychotic treatment at an optimal dosage was 4 weeks or more." | 1.51 | Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study. ( Sakamoto, S; Sato, K; Takaki, M; Yamada, N; Yoshimura, B, 2019) |
| "Polydipsia was the most prevalent (24, 60." | 1.51 | Adverse drug reactions experienced by out-patients taking chlorpromazine or haloperidol at Zomba Mental Hospital, Malawi. ( Chikowe, I; Domingo, M; Kampira, E; Mafuta, C; Mwakaswaya, V; Parveen, S, 2019) |
| "Haloperidol-treated rats were divided into groups of DSP rats and non-DSP rats based on locomotion data." | 1.46 | Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats. ( Fujita, Y; Hashimoto, K; Iyo, M; Kanahara, N; Nakata, Y; Niitsu, T; Oda, Y; Oishi, K; Shirayama, Y; Takase, M, 2017) |
| "The ability of SNE to cause catalepsy in naïve mice as well as its effect on haloperidol-induced catalepsy was assessed." | 1.46 | Extract of Synedrella nodiflora (L) Gaertn exhibits antipsychotic properties in murine models of psychosis. ( Adjei, S; Amoateng, P; Bekoe, EO; Karikari, TK; Kombian, SB; Kukuia, KKE; Osei-Safo, D, 2017) |
| "Upon appropriate therapy for neurosyphilis, dramatic resolution of this brief episode ensued, prompting a literature review of psychosis associated with neurosyphilis." | 1.43 | Revisiting an old foe: The face of psychosis in neurosyphilis. ( Abdul, J; Moolla, Y, 2016) |
| "We discuss the case of a patient with Huntington's disease and psychosis and comment on the possible types of medication that should be used." | 1.42 | [Psychiatric problems in a motor disorder: psychosis in Huntington's disease]. ( Schadé, A; van der Weijde, E, 2015) |
| " The mechanism by which chronic administration of antipsychotic(s) causes DSP may be the treatment-induced up-regulation of dopamine D2 receptors (DRD2)." | 1.42 | G protein-coupled receptor kinase 6/β-arrestin 2 system in a rat model of dopamine supersensitivity psychosis. ( Hashimoto, K; Iyo, M; Kanahara, N; Oda, Y; Shirayama, Y; Tadokoro, S; Takase, M; Watanabe, H, 2015) |
| "This report attempts to highlight that use of an antipsychotic and concurrent chronic use of methamphetamine can cause drug-induced parkinsonism." | 1.42 | Drug-induced parkinsonism following chronic methamphetamine use by a patient on haloperidol decanoate. ( Gedzior, JS; Matthew, BJ, 2015) |
| "Co-morbid substance abuse was uncommon." | 1.39 | Prevalence and clinical presentation of HIV positive female psychiatric inpatients. ( Uys, H, 2013) |
| "Risperidone was started to treat psychotic symptoms." | 1.38 | Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone. ( Grohmann, R; Holl, AK; Letmaier, M; Painold, A; Vergin, H, 2012) |
| "Sertraline (10 mg/kg ip) was injected either acutely, or over 5 days of repeated treatment." | 1.38 | Effects of sertraline on experimental mouse models of psychosis. ( Bilge, U; Erol, K, 2012) |
| "Risperidone was discontinued and, owing to ongoing psychosis, olanzapine was initiated." | 1.38 | Antipsychotics leading to neuroleptic malignant syndrome in pregnancy. ( Aghajanian, P; Dossett, E; Ghaffari, N; Lee, RH, 2012) |
| " In contrast, chronic administration of ketamine not only produced significant 'hyperactivity' response but also enhanced the immobility period in animals during the forced swim test and reduced the latency period in the passive avoidance test." | 1.37 | Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis. ( Chatterjee, M; Ganguly, S; Palit, G; Srivastava, M, 2011) |
| "The dominant patient was diagnosed with schizoaffective disorder and her non-dominant sister with paranoid schizophrenia." | 1.37 | Folie à deux: double case-report of shared delusions with a fatal outcome. ( Di Cosimo, D; Girardi, N; Kotzalidis, GD; Lazanio, S; Manfredi, G; Savoja, V; Talamo, A; Tatarelli, R; Vento, A, 2011) |
| "A 64-year-old woman developed catatonia after experiencing persecutory delusions." | 1.37 | Cerebral blood flow changes in very-late-onset schizophrenia-like psychosis with catatonia before and after successful treatment. ( Ikeda, R; Katagiri, N; Mizumura, S; Mizuno, M; Nemoto, T; Shiraga, N; Tohgi, N; Tsujino, N; Yamaguchi, T, 2011) |
| "Haloperidol was stopped and intravenous clonazepam 5mg/kg was begun." | 1.36 | [Catatonia in a 14 year-old girl: treatment with clorazepam and carbamazepine, a 10-year follow-up]. ( Askenazy, F; Benoit, M; Dor, E; Dupuis, G; Myquel, M; Seddiki, Y; Serret, S, 2010) |
| "Haloperidol was discontinued, but mirtazapine was continued, and the vivid dream activity persisted; however, reality testing when awake was intact." | 1.36 | Acute psychosis associated with dissociated sleep-wakefulness state after mirtazapine treatment. ( Felthous, AR; Hoevet, R; Wenger, PJ, 2010) |
| "A large cohort of 1528 patients with parkinsonism was analyzed, gathering data on demography, motor and non-motor characteristics, as well as the final etiologic diagnoses based on established criteria." | 1.36 | The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. ( Munhoz, RP; Teive, HA; Werneck, LC, 2010) |
| "Haloperidol has been included in the World Health Organisation's list of essential medicines." | 1.35 | The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. ( Alamo, C; López-Muñoz, F, 2009) |
| "Aripiprazole was administered at fixed doses of 15 mg/day, 20 mg/day, or 30 mg/day." | 1.35 | The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. ( Assunção-Talbott, S; Eudicone, JM; Glick, ID; Mankoski, R; Marcus, RN; Tran, QV, 2009) |
| "Psychosis is linked to dysregulation of the neuromodulator dopamine and antipsychotic drugs (APDs) work by blocking dopamine receptors." | 1.34 | Linking animal models of psychosis to computational models of dopamine function. ( Becker, S; Kapur, S; Li, M; Smith, AJ, 2007) |
| "The autopsy established the diagnosis of progressive supranuclear palsy (PSP)." | 1.34 | Undiagnosed progressive supranuclear palsy in a patient with neuroleptic malignant syndrome due to use of neuroleptics: the utility of autopsy in deaths due to known drug reactions. ( Fitzgerald, J; Kemp, WL; White, CL, 2007) |
| "Schizophrenia is a neurodevelopmental disorder associated with persistent symptomatology, severe functional disability, and residual morbidity characteristic of neurodegenerative brain diseases." | 1.34 | Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. ( Jarskog, LF; Lieberman, JA; Perkins, DO, 2007) |
| "Upon treatment with diazepam and haloperidol, the psychosis subsided within three days." | 1.34 | [Postictal paranoid-hallucinatory psychosis in cryptogenic epilepsy]. ( Baum, P; Hermann, W; Kopf, A; Wagner, A, 2007) |
| "The authors use a clinical case of a paranoiac patient to highlight the role played by writing, drawing, and painting in the psychoanalytical treatment of psychosis." | 1.33 | Reading and writing: psychoanalytical treatment in a case of paranoia. ( Assadi, TC; Bueno, DS; Colucci, VL; de Cerqueira Leite, AC; Freire, JM; Pereira, ME; Portella, LB; Ribes, SI, 2005) |
| "Haloperidol was prescribed to control psychotic symptoms." | 1.32 | Potentiation of haloperidol neurotoxicity in acute hyperthyroidism: report of a case. ( Chu, H; Hsu, YD; Lin, JC, 2004) |
| "A 40-year-old woman with a schizoaffective disorder was initially treated with lithium carbonate and haloperidol decanoate, but after three years the lithium was replaced with carbamazepine." | 1.31 | [Deterioration of schizoaffective disorder due to an interaction between haloperidol and carbamazepine]. ( Cohen, D; Diemont, WL, 2002) |
| "The association between firesetting behavior and Klinefelter syndrome is reviewed, and the underlying explanatory hypothesis is discussed." | 1.31 | Fire-settng behavior associated with Klinefelter syndrome. ( Eugster, N; Eytan, A; Graf, I; Paoloni-Giacobino, A; Thorens, G, 2002) |
| "After treatment of neurosyphilis, steady improvements were noted in psychotic and cognitive symptoms." | 1.31 | Neurosyphilis presenting as schizophrenialike psychosis. ( Ballas, C; Kohler, CG; Pickholtz, J, 2000) |
| "Oral treatment with risperidone and lorazepam appears to be a tolerable and comparable alternative to intramuscular haloperidol and lorazepam for short-term treatment of agitated psychosis in patients who accept oral medications." | 1.31 | Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. ( Currier, GW; Simpson, GM, 2001) |
| "Treatment with amphetamine induced decrease of GAP-43 mRNA expression, that was detected also during recovery period, up to 14 days after the last day of 7 days treatments." | 1.31 | Differential effects of amphetamine and phencyclidine on the expression of growth-associated protein GAP-43. ( Kanazir, S; Rakic, L; Ruzdijic, S; Veskov, R; Vukosavic, S, 2001) |
| "A 36-year-old man with schizoaffective disorder was found to have a de novo 46 XY inv (9) (q31." | 1.30 | Paracentric inversion of chromosome 9 with schizoaffective disorder. ( Asaba, H; Fukushima, K; Inayama, Y; Sakai, J; Sakai, T; Yoneda, H, 1997) |
| "Very little is known about the pharmacokinetics of neuroleptic drugs in breast-feeding mothers and their infants or about possible adverse effects in the infants." | 1.30 | Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants. ( Craggs, M; Kumar, R; Smith, B; Yoshida, K, 1998) |
| "We report a patient with drug abuse who developed multiple psychotic symptoms including euphoria, excitement, hallucination and delirium during sedation with propofol under spinal anesthesia." | 1.30 | [A patient with drug abuse who developed multiple psychotic symptoms during sedation with propofol]. ( Kitajima, T; Mishio, M; Okuda, Y; Yamaguchi, S, 1998) |
| "We report five cases of neuroleptic malignant syndrome (NMS) with psychotic symptoms treated with electroconvulsive therapy (ECT)." | 1.30 | Electroconvulsive therapy for the treatment of neuroleptic malignant syndrome with psychotic symptoms: a report of five cases. ( Ishiguro, T; Nisijima, K, 1999) |
| "Post-ictal psychosis is an unusual clinical entity that is frequently recurrent and may be misdiagnosed and treated inappropriately." | 1.30 | Post-ictal psychosis: an unusual clinical entity. ( Prendergast, J; Schnieden, V; Spira, P, 1999) |
| "We report on a patient with schizoaffective disorder who developed unilateral akathisia." | 1.30 | A case of neuroleptic-induced unilateral akathisia with periodic limb movements in the opposite side during sleep. ( Horiguchi, J; Inami, Y; Kuramoto, Y; Mizuno, S; Yamashita, H; Yamawaki, S, 1999) |
| "There was a family history of alcohol dependence in (44%)." | 1.30 | A 3 year case study of alcohol related psychotic disorders at Hospital Seremban. ( Chin, CN; George, S, 1998) |
| "This form of dystonia is called tardive dystonia to distinguish it from tardive dyskinesia." | 1.29 | [Tardive dystonia. A rare neuroleptic-induced disease picture]. ( Assion, HJ; Heinemann, F, 1994) |
| "A related syndrome, Malignant Hyperthermia (MH), is sometimes associated with central core disease." | 1.29 | Hyperthermic reaction to haloperidol with rigidity, associated to central core disease. ( Calore, EE; Cavaliere, MJ; Perez, NM; Razzouk, D; Russo, DH; Wakamatsu, A, 1994) |
| "Haloperidol decanoate was initiated using the loading-dose regimen in 16 chronically ill patients." | 1.29 | A loading-dose strategy for converting from oral to depot haloperidol. ( Anderson, C; Ereshefsky, L; Saklad, SR; Seidel, D; Toney, G, 1993) |
| "The relationship between NMS and catatonia and possible therapeutic decisions are discussed." | 1.29 | Neuroleptic malignant syndrome and catatonia. A report of three cases. ( Altavista, MC; Cavallari, S; Lubich, L; Raja, M, 1994) |
| "In fact, Reyes developed neuroleptic malignant syndrome (NMS) as a direct result of the antipsychotic medications she was administered." | 1.29 | Neuroleptic malignant syndrome: liability in nursing practice. ( Blair, DT; Dauner, A, 1993) |
| "According to some authors, these psychoses could be distinct nosographic events, while others prefer to include them in psychotic disturbances which have already been classified." | 1.29 | [Postpartum psychoses. A case report]. ( Busiello, G; Cirillo, D; Musella, V; Passannanti, G; Pellicano, M; Tanzillo, M; Vitelli, R, 1996) |
| " Patients were treated with risperidone in two different dosage groups (3 mg and 8 mg) and haloperidol (10-20 mg) and compared with eight healthy control subjects." | 1.29 | Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. ( Asenbaum, S; Brücke, T; Gössler, R; Kasper, S; Küfferle, B; Podreka, I; Tauscher, J; Topitz-Schratzberger, A; Vesely, C, 1996) |
| "Risperidone was well tolerated despite this adolescent's severe cardiac and pulmonary illnesses." | 1.29 | Use of risperidone in psychotic disorder following ischemic brain damage. ( DeMaso, DR; Steingard, RJ; Zimnitzky, BM, 1996) |
| "When treated with clomipramine 100 mg daily (plasma level 85 ng/mL), obsessive-compulsive symptoms but not the hallucinations improved significantly, and racing thoughts and grandiosity developed later." | 1.29 | Differential response of psychotic and obsessive symptoms to risperidone in an adolescent. ( Dryden-Edwards, RC; Reiss, AL, 1996) |
| " HD dosage was highly correlated with both RBC H and plasma H, but RBC RH and plasma RH were not significantly related to dosage at any time point." | 1.28 | Haloperidol decanoate pharmacokinetics in red blood cells and plasma. ( Dysken, MW; Holden, L; Johnson, SB; Kim, SW; Skare, S; Thomsyck, L; Vatassery, G, 1992) |
| "Individuals with mental retardation are thought to be at greater risk, and some recommendations were offered to prevent recurrence." | 1.28 | Recurrence of neuroleptic malignant syndrome via an inadvertent rechallenge in a woman with mental retardation. ( Boyd, RD, 1992) |
| "Development of neuroleptic malignant syndrome (NMS) following discontinuation of high-dose and high-potency neuroleptic agents is described." | 1.28 | Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment. ( Hermesh, H; Munitz, H; Spivak, B; Tyano, S; Weizman, A; Wolovick, L, 1990) |
| "Fluoxetine (20 mg/day) was added for 7-10 days to stable doses of haloperidol given to eight psychotic patients." | 1.28 | Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. ( Baldessarini, RJ; Brotman, AW; Goff, DC; Midha, KK; Waites, M, 1991) |
| "Haloperidol was administered IV to 46 male psychotic inpatients and 28 male control subjects." | 1.28 | Prolactin response to low-dose haloperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects. ( Copolov, DL; Hill, C; Keks, NA; Kulkarni, J; McGorry, P; McKenzie, D; Singh, BS, 1990) |
| "Neuroleptic-induced catatonia (NIC) and milder neuroleptic malignant syndrome (NMS) share parkinsonian features, catatonic symptoms, mild fever, and have been described in patients receiving antipsychotic agents." | 1.28 | Neuroleptic-induced catatonia or a mild form of neuroleptic malignant syndrome? ( Christodoulou, GN; Kontaxakis, VP; Vaidakis, NM; Valergaki, HC, 1990) |
| " This means that it has a long half-life measurable in months rather than weeks." | 1.28 | Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. ( Cooper, TB; Levinson, DF; Lo, ES; Simpson, GM; Stephanos, MJ; Yadalam, KG, 1990) |
| "Thioridazine was the leading medication, with a consistent third of the market share, while the market share for chlorpromazine decreased from 1976 to 1985 and that for haloperidol increased for the same years." | 1.28 | Antipsychotic drug use in the United States, 1976-1985. ( Baum, C; Wysowski, DK, 1989) |
| "A case of Gilles de la Tourette syndrome in a mildly mentally retarded adult female is described." | 1.27 | Gilles de la Tourette syndrome in mental handicap. ( Reid, AH, 1984) |
| "Twenty-nine patients were treated with haloperidol decanoate, the dosage ranging from 100 to 300 mg i." | 1.27 | The use of depot neuroleptic haloperidol decanoate. ( Fernando, J; Jones, GG; Krishna Raju, R; Stanley, RO, 1984) |
| "Rhabdomyolysis is a rarely reported complication of antipsychotic drug-induced dystonia." | 1.27 | Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs. ( Cavanaugh, JJ; Finlayson, RE, 1984) |
| " In these six cases it was demonstrated that the neuroleptics dosage was inappropriate, being either too high or too low as judged from the plasma concentrations." | 1.27 | [Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring]. ( Balant-Gorgia, AE; Eisele, R; Garrone, G, 1985) |
| " Data were analyzed to determine the effect of anticholinergic prophylaxis, age, sex, and type and dosage of neuroleptic on the incidence of dystonic reactions." | 1.27 | Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study. ( Heiser, JF; Morrison, RL; Simpson, GM; Sramek, JJ, 1986) |
| "Therapeutic plasma monitoring of haloperidol, a major neuroleptic, measured by radioimmunoassay, has shown a rather good correlation between plasma level and dosage but with large interindividual variation in children as in adults; age seems not to have any effect on haloperidol metabolism." | 1.27 | [Haloperidol. Plasma monitoring and hormonal effects of treatment]. ( Debray, Q; Dugas, M; Giraud, J; Goyot, C; Grenier, J; Guay, C, 1985) |
| "Pimozide has been successfully used in the treatment of delusions of infestation; however, it is not widely available in the United States." | 1.27 | Monosymptomatic hypochondriacal psychosis manifesting as delusions of infestation: case studies of treatment with haloperidol. ( Andrews, E; Bellard, J; Walter-Ryan, WG, 1986) |
| "Treatment with thioridazine or butaperazine also tended to decrease platelet MAO activity." | 1.26 | Effects of neuroleptics on platelet monoamine oxidase activity. ( Allen, R; DeJohn, C; Ho, BT; Khan, M; Kralik, P; Schoolar, J; Smith, RC, 1982) |
| "It is the drug of choice for Tourette's syndrome, and may be useful in nonpsychotic hyperactive or aggressive children to control acute episodes, or when the stimulants normally useful in hyperactive children are ineffective." | 1.26 | Haloperidol -- its use in children. ( Serrano, AC, 1981) |
| " were in accordance with the bioavailability of haloperidol." | 1.26 | Influence of route of administration on haloperidol plasma levels in psychotic patients. ( Bianchetti, G; Deniker, P; Morselli, PL; Poirier-Littre, MF; Zarifian, E, 1980) |
| ") every 4 weeks with haloperidol decanoate using different dosage schedules which were calculated from the previously prescribed daily oral dose of haloperidol multiplied by a factor of 30, 20 or 10." | 1.26 | Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. An open multicenter study. ( Berghmans, W; Deberdt, R; Driesens, F; Elens, P; Heykants, J; Reyntjens, A; van Wijngaarden, I; Woestenborghs, R, 1980) |
| " Then, the principal pharmacokinetic data of haloperidol are exposed with a special emphasis on the lack of information about the correlations between plasma levels and clinical effects." | 1.26 | [Value of pharmacokinetic data during the treatment of psychoses with haloperidol]. ( Cottereau, MJ; Cuche, H; Deniker, P; Lôo, H; Zarifian, E, 1979) |
| "In many organic psychoses, including psychosis due to ingestion of an atropine-like drug, use of anti-psychotic drug should be avoided." | 1.25 | Psychotropic drugs in the management of psychiatric emergencies. ( Ketai, R, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 278 (38.19) | 18.7374 |
| 1990's | 147 (20.19) | 18.2507 |
| 2000's | 171 (23.49) | 29.6817 |
| 2010's | 105 (14.42) | 24.3611 |
| 2020's | 27 (3.71) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, YF | 1 |
| Paalzow, LK | 1 |
| Bondesson, U | 1 |
| Ekblom, B | 1 |
| Eriksson, K | 1 |
| Eriksson, SO | 1 |
| Lindberg, A | 1 |
| Lindström, L | 1 |
| Talaga, P | 1 |
| Matagne, A | 1 |
| Klitgaard, H | 1 |
| Kimura, M | 2 |
| Oda, Y | 4 |
| Hirose, Y | 1 |
| Kimura, H | 2 |
| Yoshino, K | 2 |
| Niitsu, T | 3 |
| Kanahara, N | 4 |
| Shirayama, Y | 4 |
| Hashimoto, K | 4 |
| Iyo, M | 4 |
| Sinai, O | 1 |
| Stryjer, R | 1 |
| Bloemhof-Bris, E | 1 |
| Weizman, S | 1 |
| Shelef, A | 1 |
| Delgado-Sallent, C | 1 |
| Nebot, P | 1 |
| Gener, T | 1 |
| Fath, AB | 1 |
| Timplalexi, M | 1 |
| Puig, MV | 1 |
| Kar, SK | 1 |
| Mbwambo, J | 1 |
| Kaaya, S | 1 |
| Lema, I | 1 |
| Burant, CJ | 1 |
| Magwiza, C | 1 |
| Madundo, K | 1 |
| Njiro, G | 1 |
| Blixen, CE | 1 |
| Cassidy, KA | 2 |
| Levin, JB | 1 |
| Sajatovic, M | 2 |
| Stetson, SR | 1 |
| Osser, DN | 2 |
| Bartolomei, G | 1 |
| Lorenzini, L | 1 |
| Martelli, M | 1 |
| Gambaro, E | 1 |
| Zeppegno, P | 1 |
| Gramaglia, C | 1 |
| Parkhomenko, AA | 1 |
| Zastrozhin, MS | 1 |
| Pozdnyakov, SA | 1 |
| Noskov, VV | 1 |
| Zaytsev, IA | 1 |
| Ivanchenko, VA | 1 |
| Denisenko, NP | 1 |
| Akmalova, KA | 1 |
| Skryabin, V | 1 |
| Bryun, EA | 1 |
| Sychev, DA | 1 |
| Collison-Ani, E | 1 |
| Faher, A | 1 |
| Au, M | 1 |
| Burrah, G | 1 |
| Ghanbarzehi, A | 1 |
| Sepehrinezhad, A | 1 |
| Hashemi, N | 1 |
| Karimi, M | 1 |
| Shahbazi, A | 1 |
| McAdam, MK | 1 |
| Baldessarini, RJ | 4 |
| Murphy, AL | 1 |
| Gardner, DM | 1 |
| Zaydlin, M | 1 |
| Bernal, JA | 1 |
| Bez, Y | 1 |
| Coffey, BJ | 2 |
| Hirsch, S | 1 |
| Steinert, T | 1 |
| Gómez-Revuelta, M | 1 |
| Pelayo-Terán, JM | 10 |
| Juncal-Ruiz, M | 2 |
| Vázquez-Bourgon, J | 1 |
| Suárez-Pinilla, P | 4 |
| Romero-Jiménez, R | 1 |
| Setién Suero, E | 1 |
| Ayesa-Arriola, R | 2 |
| Crespo-Facorro, B | 17 |
| Syamkumar, S | 1 |
| Dossetor, D | 1 |
| Herrera-Huerta, CA | 1 |
| Hernández-Salas, LP | 1 |
| Magallanes-Cano, EM | 1 |
| Dhandapani, VR | 1 |
| Ramachandran, P | 1 |
| Mohan, G | 1 |
| Chandrasekaran, S | 1 |
| Paul, V | 1 |
| Pattabiraman, R | 1 |
| Mohan, M | 1 |
| Iyer, S | 1 |
| Rangaswamy, T | 1 |
| Singh, SP | 1 |
| Miller, M | 1 |
| Barbe, N | 1 |
| Poulsen, RJ | 1 |
| Jaworowski, S | 1 |
| Weiser, M | 2 |
| Gropp, C | 1 |
| Malka, M | 1 |
| Nani, JV | 1 |
| Lee, RS | 1 |
| Yonamine, CM | 1 |
| Sant'Anna, OA | 1 |
| Juliano, MA | 1 |
| Gadelha, A | 1 |
| Mari, JJ | 1 |
| Hayashi, MAF | 1 |
| Subramanyam, AA | 1 |
| Nachane, HB | 1 |
| Mahajan, NN | 1 |
| Shinde, S | 1 |
| D Mahale, S | 1 |
| Gajbhiye, RK | 1 |
| Uzuneser, TC | 2 |
| Weiss, EM | 1 |
| Dahlmanns, J | 1 |
| Kalinichenko, LS | 1 |
| Amato, D | 1 |
| Kornhuber, J | 2 |
| Alzheimer, C | 1 |
| Hellmann, J | 1 |
| Kaindl, J | 1 |
| Hübner, H | 1 |
| Löber, S | 1 |
| Gmeiner, P | 1 |
| Grömer, TW | 2 |
| Müller, CP | 2 |
| Srisurapanont, M | 1 |
| Likhitsathian, S | 1 |
| Suttajit, S | 1 |
| Maneeton, N | 1 |
| Maneeton, B | 1 |
| Oon-Arom, A | 1 |
| Suradom, C | 1 |
| Oishi, K | 2 |
| Ostuzzi, G | 2 |
| Bertolini, F | 1 |
| Del Giovane, C | 1 |
| Tedeschi, F | 1 |
| Bovo, C | 1 |
| Gastaldon, C | 1 |
| Nosé, M | 1 |
| Ogheri, F | 1 |
| Papola, D | 1 |
| Purgato, M | 1 |
| Turrini, G | 1 |
| Correll, CU | 2 |
| Barbui, C | 2 |
| Faay, MDM | 1 |
| Sommer, IE | 1 |
| Schmack, K | 1 |
| Bosc, M | 1 |
| Ott, T | 1 |
| Sturgill, JF | 1 |
| Kepecs, A | 1 |
| Wilson, JE | 1 |
| Andrews, P | 1 |
| Ainsworth, A | 1 |
| Roy, K | 1 |
| Ely, EW | 1 |
| Oldham, MA | 1 |
| Jürgens, G | 1 |
| Bauer, JØ | 1 |
| Ramirez-Bonilla, M | 6 |
| Gomez-Arnau, J | 1 |
| Ortiz-Garcia de la Foz, V | 1 |
| Martinez-Garcia, O | 12 |
| Neergaard, KD | 1 |
| Tabares-Seisdedos, R | 5 |
| Vuk, A | 1 |
| Kuzman, MR | 1 |
| Baretic, M | 1 |
| Osvatic, MM | 1 |
| Canellas-Dols, F | 1 |
| Delgado, C | 1 |
| Arango-Lopez, C | 1 |
| Peraita-Adrados, R | 1 |
| Fujita, Y | 1 |
| Nakata, Y | 1 |
| Takase, M | 2 |
| Ostinelli, EG | 1 |
| Brooke-Powney, MJ | 1 |
| Li, X | 1 |
| Adams, CE | 3 |
| Amoateng, P | 1 |
| Adjei, S | 1 |
| Osei-Safo, D | 1 |
| Kukuia, KKE | 1 |
| Bekoe, EO | 1 |
| Karikari, TK | 1 |
| Kombian, SB | 1 |
| Taraskina, AE | 1 |
| Nasyrova, RF | 1 |
| Zabotina, AM | 1 |
| Sosin, DN | 1 |
| Sosina, КА | 1 |
| Ershov, EE | 1 |
| Grunina, MN | 1 |
| Krupitsky, EM | 1 |
| Zun, LS | 1 |
| Prakash, R | 1 |
| Aggarwal, N | 1 |
| Kataria, D | 1 |
| Prasad, S | 1 |
| de Bartolomeis, A | 2 |
| Iasevoli, F | 2 |
| Marmo, F | 2 |
| Buonaguro, EF | 2 |
| Avvisati, L | 2 |
| Latte, G | 2 |
| Tomasetti, C | 2 |
| Yoshimura, B | 1 |
| Sakamoto, S | 1 |
| Sato, K | 1 |
| Takaki, M | 1 |
| Yamada, N | 1 |
| Stiefelhagen, P | 1 |
| Schindehütte, M | 1 |
| Dere, E | 1 |
| von Hörsten, S | 1 |
| Bak, M | 3 |
| Weltens, I | 1 |
| Bervoets, C | 1 |
| De Fruyt, J | 1 |
| Samochowiec, J | 1 |
| Fiorillo, A | 1 |
| Sampogna, G | 1 |
| Bienkowski, P | 1 |
| Preuss, WU | 1 |
| Misiak, B | 1 |
| Frydecka, D | 1 |
| Samochowiec, A | 1 |
| Bak, E | 1 |
| Drukker, M | 1 |
| Dom, G | 1 |
| Gupta, S | 2 |
| De Aquino, JP | 1 |
| D'Souza, DC | 1 |
| Ranganathan, M | 1 |
| Guma, E | 1 |
| Rocchetti, J | 1 |
| Devenyi, GA | 1 |
| Tanti, A | 1 |
| Mathieu, AP | 1 |
| Lerch, JP | 1 |
| Elgbeili, G | 1 |
| Courcot, B | 1 |
| Mechawar, N | 1 |
| Chakravarty, MM | 1 |
| Giros, B | 1 |
| Chikowe, I | 1 |
| Domingo, M | 1 |
| Mwakaswaya, V | 1 |
| Parveen, S | 1 |
| Mafuta, C | 1 |
| Kampira, E | 1 |
| Elbakary, NAH | 1 |
| Ouanes, S | 1 |
| Uys, H | 1 |
| Bhojani, S | 1 |
| Aldana-Bernier, L | 1 |
| Sikder, M | 1 |
| Pawelzik, T | 1 |
| Rodríguez-Sánchez, JM | 3 |
| Pérez-Iglesias, R | 15 |
| Roiz-Santiáñez, R | 1 |
| Sánchez-Moreno, J | 1 |
| Vázquez-Barquero, JL | 12 |
| Diaz, FJ | 1 |
| de León, J | 2 |
| Emul, M | 1 |
| Sakalli, A | 1 |
| Erol, TC | 1 |
| Ertan, T | 1 |
| Gillies, D | 1 |
| Sampson, S | 1 |
| Beck, A | 1 |
| Rathbone, J | 2 |
| Vilibić, M | 1 |
| Jukić, V | 1 |
| Vidović, A | 1 |
| Brecić, P | 1 |
| Signorelli, MS | 1 |
| Nalis, F | 1 |
| Battiato, M | 1 |
| Aguglia, E | 2 |
| Pardo-Garcia, G | 3 |
| Amado, JA | 4 |
| Garcia-Unzueta, MT | 4 |
| Chandler, A | 1 |
| Freeze-Ramsey, R | 1 |
| Seupaul, RA | 1 |
| Walther, S | 1 |
| Moggi, F | 1 |
| Horn, H | 1 |
| Moskvitin, K | 1 |
| Abderhalden, C | 1 |
| Maier, N | 1 |
| Strik, W | 1 |
| Müller, TJ | 1 |
| Levin, J | 1 |
| Ramirez, LF | 1 |
| Hahn, DY | 1 |
| Tatsuoka, C | 1 |
| Bialko, CS | 1 |
| Fuentes-Casiano, E | 1 |
| Williams, TD | 1 |
| Scharfetter, J | 1 |
| Fischer, P | 1 |
| Szegő, A | 1 |
| Eleméry, M | 1 |
| Faludi, G | 1 |
| Kovács, G | 1 |
| Bianchini, O | 1 |
| Porcelli, S | 2 |
| Nespeca, C | 1 |
| Cannavò, D | 1 |
| Trappoli, A | 1 |
| De Ronchi, D | 3 |
| Serretti, A | 4 |
| Kinon, BJ | 3 |
| Kollack-Walker, S | 2 |
| Jeste, D | 1 |
| Chen, L | 1 |
| Case, M | 1 |
| Chen, J | 1 |
| Stauffer, V | 2 |
| Ramamourty, P | 1 |
| Menon, V | 1 |
| Aparna, M | 1 |
| Dold, M | 1 |
| Samara, MT | 1 |
| Li, C | 2 |
| Tardy, M | 1 |
| Leucht, S | 2 |
| Huang, CL | 1 |
| Hwang, TJ | 1 |
| Chen, YH | 1 |
| Huang, GH | 1 |
| Hsieh, MH | 1 |
| Chen, HH | 1 |
| Hwu, HG | 2 |
| van der Weijde, E | 1 |
| Schadé, A | 1 |
| Yıldızhan, E | 1 |
| Türkcan, A | 1 |
| İnan, S | 1 |
| Erenkuş, Z | 1 |
| Yalçın, Ö | 1 |
| Erdoğan, A | 1 |
| Tadokoro, S | 1 |
| Watanabe, H | 1 |
| Matthew, BJ | 1 |
| Gedzior, JS | 1 |
| Melkersson, K | 1 |
| Lewitt, M | 1 |
| Hall, K | 1 |
| McCullough, LB | 1 |
| Chervenak, FA | 1 |
| Coverdale, JH | 1 |
| Crisafulli, C | 1 |
| Calabrò, M | 1 |
| Rujescu, D | 5 |
| Rasmussen, SA | 2 |
| Rosebush, PI | 3 |
| Anglin, RE | 1 |
| Mazurek, MF | 3 |
| Rosenheck, RA | 2 |
| Leslie, DL | 1 |
| Sint, KJ | 1 |
| Lin, H | 1 |
| Li, Y | 1 |
| McEvoy, JP | 8 |
| Byerly, MJ | 1 |
| Hamer, RM | 9 |
| Swartz, MS | 1 |
| Stroup, TS | 1 |
| Chiodini, P | 1 |
| Rossi, R | 1 |
| Huf, G | 3 |
| Alexander, J | 3 |
| Gandhi, P | 1 |
| Allen, MH | 4 |
| Khushu, A | 1 |
| Powney, MJ | 2 |
| Moolla, Y | 1 |
| Abdul, J | 1 |
| Khokhar, MA | 1 |
| Dankert, ME | 1 |
| Brensinger, CM | 1 |
| Metzger, KL | 1 |
| Koleva, SG | 1 |
| Mesén, A | 1 |
| Laprade, B | 1 |
| Wiguna, T | 1 |
| Han, C | 1 |
| Farooq, S | 2 |
| Severus, WE | 1 |
| Gayares, JG | 1 |
| Langosch, JM | 2 |
| Lallart, X | 1 |
| Tateno, M | 1 |
| Mihai, A | 1 |
| Nair, SR | 1 |
| Belmaker, R | 1 |
| Rybakowski, J | 1 |
| Owe-Larsson, B | 1 |
| Kane, JM | 5 |
| Johnstone, EC | 1 |
| MacIntyre, DJ | 1 |
| Malhotra, S | 1 |
| González-Pinto, A | 1 |
| Mosquera, F | 1 |
| Babb, SM | 1 |
| Habib pour, E | 1 |
| Fatemi, SS | 1 |
| Swanson, C | 1 |
| Adler, C | 1 |
| Young, A | 1 |
| Hoeft, F | 1 |
| Sivakumar, K | 1 |
| Radoeva, PD | 1 |
| Lallart, EA | 1 |
| Bilker, WB | 1 |
| Siegel, SJ | 1 |
| Leucht, C | 1 |
| Kitzmantel, M | 1 |
| Chua, L | 1 |
| Kane, J | 1 |
| Spann, M | 1 |
| Lindborg, S | 1 |
| Seaman, J | 1 |
| Baker, R | 1 |
| Dunayevich, E | 1 |
| Breier, A | 2 |
| Sherin, A | 1 |
| Levine, SZ | 1 |
| Rabinowitz, J | 7 |
| González-Blanch, C | 2 |
| Alvarez-Jiménez, M | 1 |
| Krishnakumar, P | 1 |
| Jayakrishnan, MP | 1 |
| Beegum, MN | 1 |
| Riyaz, A | 1 |
| Emsley, R | 6 |
| Oosthuizen, P | 4 |
| Koen, L | 3 |
| Niehaus, DJ | 3 |
| Medori, R | 2 |
| López-Muñoz, F | 1 |
| Alamo, C | 1 |
| Janicak, PG | 4 |
| Glick, ID | 5 |
| Marder, SR | 9 |
| Crandall, DT | 2 |
| McQuade, RD | 4 |
| Marcus, RN | 3 |
| Eudicone, JM | 2 |
| Assunção-Talbott, S | 3 |
| Narayanan, D | 1 |
| Varghese, ST | 1 |
| Dinesh, D | 1 |
| Mankoski, R | 1 |
| Tran, QV | 2 |
| de Oliveira, IR | 1 |
| Elkis, H | 1 |
| Gattaz, WF | 1 |
| Chaves, A | 1 |
| de Sena, EP | 1 |
| de Matos E Souza, FG | 1 |
| Campos, JA | 1 |
| Bueno, JR | 1 |
| E Silva, JA | 1 |
| Louzã, MR | 1 |
| de Abreu, PB | 1 |
| Dan, A | 1 |
| Bharadwaj, R | 1 |
| Grover, S | 1 |
| Mata, I | 7 |
| Ayesa, R | 1 |
| Rajarethinam, R | 1 |
| Dziuba, J | 1 |
| Manji, S | 1 |
| Pizzuti, A | 1 |
| Lachover, L | 1 |
| Keshavan, M | 1 |
| Alptekin, K | 1 |
| Hafez, J | 1 |
| Brook, S | 3 |
| Akkaya, C | 1 |
| Tzebelikos, E | 1 |
| Ucok, A | 1 |
| El Tallawy, H | 1 |
| Danaci, AE | 1 |
| Lowe, W | 1 |
| Karayal, ON | 1 |
| Raveendran, NS | 1 |
| Lawson, WB | 1 |
| Herman, BK | 1 |
| Loebel, A | 2 |
| Lazariciu, I | 1 |
| Malik, M | 1 |
| Roman, AM | 1 |
| Hughes, J | 1 |
| Simmons, HF | 1 |
| Barnes, TR | 1 |
| Sachs, G | 1 |
| Buckley, P | 1 |
| Eudicone, J | 1 |
| McQuade, R | 2 |
| Pikalov, A | 1 |
| Miceli, JJ | 2 |
| Tensfeldt, TG | 2 |
| Shiovitz, T | 2 |
| Anziano, R | 1 |
| O'Gorman, C | 2 |
| Harrigan, RH | 2 |
| Askenazy, F | 1 |
| Dor, E | 1 |
| Benoit, M | 1 |
| Dupuis, G | 1 |
| Serret, S | 1 |
| Myquel, M | 1 |
| Seddiki, Y | 1 |
| Arad, M | 1 |
| Weiner, I | 1 |
| Zivković, M | 1 |
| Mihaljević-Peles, A | 1 |
| Sagud, M | 1 |
| Silić, A | 1 |
| Mihanović, M | 1 |
| Felthous, AR | 1 |
| Wenger, PJ | 1 |
| Hoevet, R | 1 |
| Citrome, L | 12 |
| Jaffe, A | 2 |
| Levine, J | 2 |
| Munhoz, RP | 1 |
| Werneck, LC | 1 |
| Teive, HA | 1 |
| Ahmed, U | 1 |
| Jones, H | 2 |
| Anziano, RJ | 1 |
| Hsu, WY | 1 |
| Huang, SS | 1 |
| Lee, BS | 1 |
| Chiu, NY | 1 |
| Schennach-Wolff, R | 1 |
| Seemüller, FH | 1 |
| Mayr, A | 1 |
| Maier, W | 1 |
| Klingberg, S | 1 |
| Heuser, I | 1 |
| Klosterkötter, J | 1 |
| Gastpar, M | 1 |
| Häfner, H | 1 |
| Sauer, H | 1 |
| Schneider, F | 1 |
| Gaebel, W | 1 |
| Jäger, M | 1 |
| Möller, HJ | 7 |
| Riedel, M | 1 |
| Lim, HK | 1 |
| Kim, JJ | 1 |
| Pae, CU | 1 |
| Lee, CU | 1 |
| Lee, C | 1 |
| Paik, IH | 1 |
| Milella, MS | 1 |
| Passarelli, F | 1 |
| De Carolis, L | 1 |
| Schepisi, C | 1 |
| Nativio, P | 1 |
| Scaccianoce, S | 1 |
| Nencini, P | 1 |
| Chatterjee, M | 1 |
| Ganguly, S | 1 |
| Srivastava, M | 1 |
| Palit, G | 1 |
| Preskorn, SH | 3 |
| Caseiro, O | 2 |
| Pardo, G | 1 |
| Lataster, J | 1 |
| van Os, J | 2 |
| de Haan, L | 1 |
| Thewissen, V | 1 |
| Lataster, T | 1 |
| Lardinois, M | 1 |
| Delespaul, PA | 1 |
| Myin-Germeys, I | 1 |
| Glavina, T | 1 |
| Mrass, D | 1 |
| Dodig, T | 1 |
| Glavina, G | 1 |
| Pranić, S | 1 |
| Uglešić, B | 1 |
| Talamo, A | 1 |
| Vento, A | 1 |
| Savoja, V | 1 |
| Di Cosimo, D | 1 |
| Lazanio, S | 1 |
| Kotzalidis, GD | 1 |
| Manfredi, G | 1 |
| Girardi, N | 1 |
| Tatarelli, R | 1 |
| Vasil'eva, EF | 1 |
| Koliaskina, GI | 2 |
| Brusov, OS | 1 |
| Faktor, MI | 1 |
| Kaleda, VG | 2 |
| Barkhatova, NA | 1 |
| Bogdanova, ED | 1 |
| Baldaçara, L | 1 |
| Sanches, M | 1 |
| Cordeiro, DC | 1 |
| Jackoswski, AP | 1 |
| Ortiz, V | 1 |
| Valdizan, E | 1 |
| Volavka, J | 20 |
| Czobor, P | 20 |
| Derks, EM | 1 |
| Bitter, I | 4 |
| Libiger, J | 3 |
| Kahn, RS | 4 |
| Fleischhacker, WW | 2 |
| Devanand, DP | 1 |
| Pelton, GH | 1 |
| Cunqueiro, K | 1 |
| Sackeim, HA | 1 |
| Marder, K | 1 |
| Macêdo, DS | 1 |
| Oliveira, GV | 1 |
| Gomes, PX | 1 |
| Araújo, FY | 1 |
| Souza, CM | 1 |
| Vasconcelos, SM | 1 |
| Viana, GS | 1 |
| Sousa, FC | 1 |
| Carvalho, AF | 1 |
| Marcelis, M | 1 |
| Tsujino, N | 1 |
| Nemoto, T | 1 |
| Yamaguchi, T | 1 |
| Katagiri, N | 1 |
| Tohgi, N | 1 |
| Ikeda, R | 1 |
| Shiraga, N | 1 |
| Mizumura, S | 1 |
| Mizuno, M | 1 |
| Gugger, JJ | 1 |
| Saad, M | 1 |
| Smith, C | 1 |
| Popović, I | 1 |
| Ravanić, D | 1 |
| Popović, V | 1 |
| Vladejić, S | 1 |
| Stanojević, A | 1 |
| Stojanović, M | 1 |
| Krakowski, MI | 3 |
| Meng, X | 1 |
| Hochfeld, M | 1 |
| Stahl, SM | 1 |
| Zedkova, I | 1 |
| Dudova, I | 1 |
| Urbanek, T | 1 |
| Hrdlicka, M | 1 |
| Letmaier, M | 1 |
| Painold, A | 1 |
| Holl, AK | 1 |
| Grohmann, R | 1 |
| Vergin, H | 1 |
| Bilge, U | 1 |
| Erol, K | 1 |
| Ghaffari, N | 1 |
| Dossett, E | 1 |
| Lee, RH | 1 |
| Aghajanian, P | 1 |
| Kucharska-Pietura, K | 1 |
| Mortimer, A | 1 |
| Tylec, A | 1 |
| Czernikiewicz, A | 1 |
| Jayakody, K | 1 |
| Gibson, RC | 1 |
| Kumar, A | 1 |
| Gunadasa, S | 1 |
| Joshi, M | 1 |
| Akhtar, M | 1 |
| Najmi, AK | 1 |
| Khuroo, AH | 1 |
| Goswami, D | 1 |
| Liu-Seifert, H | 1 |
| Galderisi, S | 1 |
| Mucci, A | 1 |
| Bucci, P | 1 |
| Jones, N | 1 |
| Moreno, JL | 1 |
| Holloway, T | 1 |
| Umali, A | 1 |
| Rayannavar, V | 1 |
| Sealfon, SC | 1 |
| González-Maeso, J | 1 |
| Drago, A | 2 |
| Giegling, I | 3 |
| Schäfer, M | 3 |
| Hartmann, AM | 2 |
| Friedl, M | 1 |
| Konte, B | 1 |
| Stassen, HH | 2 |
| Valdizán, EM | 1 |
| Díaz, I | 1 |
| LLerena, A | 1 |
| Berecz, R | 1 |
| de la Rubia, A | 1 |
| Dorado, P | 1 |
| Alfaro, CL | 1 |
| Wudarsky, M | 1 |
| Nicolson, R | 1 |
| Gochman, P | 1 |
| Sporn, A | 1 |
| Lenane, M | 1 |
| Rapoport, JL | 1 |
| Carson, WH | 3 |
| Saha, AR | 1 |
| Ingenito, GG | 1 |
| Zimbroff, DL | 2 |
| Ali, MW | 1 |
| Corson, PW | 1 |
| O'Leary, DS | 1 |
| Miller, DD | 2 |
| Andreasen, NC | 1 |
| Mamo, DC | 1 |
| Sweet, RA | 2 |
| Chengappa, KN | 1 |
| Reddy, RR | 1 |
| Jeste, DV | 1 |
| Cohen, D | 1 |
| Diemont, WL | 1 |
| Baymiller, SP | 1 |
| Ball, P | 1 |
| McMahon, RP | 1 |
| Buchanan, RW | 2 |
| Wirshing, DA | 2 |
| Boyd, JA | 1 |
| Meng, LR | 1 |
| Ballon, JS | 1 |
| Wirshing, WC | 2 |
| Daniel, DG | 2 |
| Lindenmayer, JP | 7 |
| Sheitman, B | 6 |
| Cooper, TB | 13 |
| Chakos, M | 4 |
| Lieberman, JA | 16 |
| Meibach, RC | 1 |
| Koyama, H | 1 |
| Mori, S | 1 |
| Sugioka, N | 1 |
| Nishihara, T | 1 |
| Nakajima, K | 1 |
| Schalekamp, T | 1 |
| Taymeeyapradit, U | 1 |
| Kuasirikul, S | 1 |
| Stock, E | 2 |
| Kaplita, S | 1 |
| Marcus, R | 2 |
| Safferman, AZ | 1 |
| Saha, A | 1 |
| Ali, M | 1 |
| Iwamoto, T | 2 |
| Bromet, EJ | 1 |
| Davidson, M | 5 |
| Eytan, A | 1 |
| Paoloni-Giacobino, A | 1 |
| Thorens, G | 1 |
| Eugster, N | 1 |
| Graf, I | 1 |
| Rosenthal, M | 1 |
| Berkman, P | 1 |
| Shapira, A | 1 |
| Gil, I | 1 |
| Abramovitz, J | 1 |
| Le Comte, M | 1 |
| Wensveen, B | 1 |
| Kreutzkamp, T | 1 |
| Kopf, A | 2 |
| Köster, J | 1 |
| Schulz, A | 1 |
| Krömker, H | 1 |
| Becker, T | 1 |
| Tollefson, G | 2 |
| Tohen, M | 8 |
| Green, AI | 5 |
| Gur, RE | 2 |
| Kahn, R | 2 |
| McEvoy, J | 5 |
| Perkins, D | 3 |
| Sharma, T | 6 |
| Zipursky, R | 2 |
| Wei, H | 1 |
| DIVRY, P | 1 |
| BOBON, J | 2 |
| COLLARD, J | 2 |
| PINCHARD, A | 3 |
| NOLS, E | 1 |
| EVRARD, E | 1 |
| MOLDERS, V | 1 |
| GIACOBINI, E | 1 |
| LASSENIUS, B | 1 |
| GUILBERT, P | 1 |
| FERON, A | 1 |
| MONCEAUX, JP | 1 |
| HARDER, A | 1 |
| DE MAIO, D | 1 |
| FAGGIOLI, L | 1 |
| CARINI, A | 1 |
| DEL GRECO, V | 1 |
| DI CRISTO, G | 1 |
| OLES, M | 1 |
| OLSSON, O | 1 |
| KRISTJANSEN, P | 1 |
| HANSEN, G | 1 |
| LINDQVIST, R | 1 |
| DELAY, J | 3 |
| PICHOT, P | 3 |
| LEMPERIERE, T | 4 |
| ELISSALDE, B | 3 |
| PEIGNE, F | 1 |
| DENBER, HC | 2 |
| RAJOTTE, P | 1 |
| KAUFFMAN, D | 1 |
| BISTER, W | 1 |
| ENTWISTLE, C | 1 |
| TAYLOR, RM | 1 |
| MACDONALD, IA | 1 |
| PALAIOLOGOS, A | 1 |
| SIGALOS, I | 1 |
| SPATHARAS, G | 1 |
| TERENTIOS, E | 1 |
| STEENFELDT-FOSS, OW | 1 |
| RAVINA, A | 1 |
| COURT, JH | 1 |
| CAMERON, IA | 1 |
| DANIK, JJ | 1 |
| GOVERDHAM, M | 1 |
| SVENDSEN, BB | 1 |
| WILLADSEN, J | 1 |
| Gerle, B | 2 |
| GALINDEZ, L | 1 |
| SANTOS, MR | 1 |
| BOREL, RO | 1 |
| FOURNY, L | 1 |
| COMBETTE, H | 1 |
| STEPHANOPOLI, J | 1 |
| VALLADE, L | 1 |
| CORSETTI, R | 1 |
| OKASHA, A | 1 |
| TEWFIK, GI | 1 |
| LEHMANN, HE | 2 |
| BAN, TA | 2 |
| KATO, G | 1 |
| GOZSY, B | 1 |
| KATO, L | 1 |
| LEONE, BN | 1 |
| BOHACEK, N | 1 |
| HAEFNER, H | 1 |
| KUTSCHER, I | 1 |
| BUIS, C | 1 |
| FLOHIL, JM | 1 |
| ROTH, M | 1 |
| HAWARD, LR | 1 |
| SUGERMAN, AA | 1 |
| WILLIAMS, BH | 1 |
| ADLERSTEIN, AM | 1 |
| KURLAND, AA | 1 |
| FERRO-DIAZ, P | 1 |
| MCCUSKER, K | 1 |
| NAYRAC, P | 2 |
| ARNOTT, G | 2 |
| MILBLED, G | 2 |
| VOLMAT, R | 1 |
| BEAUDOUIN, JL | 1 |
| COLLIN, J | 1 |
| NICOLAS-CHARLES, PJ | 1 |
| ALLERS, G | 1 |
| SCHWARZ, H | 1 |
| KRUEGER, HJ | 1 |
| JUENEMANN, HJ | 1 |
| FROGEL, M | 1 |
| LUNA, NE | 1 |
| Faurbye, A | 1 |
| Clausen, J | 1 |
| WEIDTMANN, W | 1 |
| CARDO, WN | 1 |
| DE FORTES, JR | 1 |
| DE CARVALHO, HM | 1 |
| GONCALVES, J | 1 |
| SEABRA-DINIS, J | 1 |
| MOREIRA DA SILVA, A | 1 |
| JACOB, E | 1 |
| MARIE, C | 1 |
| JENSEN, OO | 1 |
| MONNEROT, E | 1 |
| CHANCEL, M | 1 |
| DANJARD, J | 1 |
| Brieger, P | 1 |
| Reinelt, Y | 1 |
| Sikich, L | 1 |
| Bashford, RA | 1 |
| Sheitman, BB | 1 |
| Apiquian, R | 1 |
| Fresán, A | 1 |
| Herrera, K | 1 |
| Ulloa, RE | 1 |
| Lóyzaga, C | 1 |
| de la Fuente-Sandoval, C | 1 |
| Gutiérrez, D | 1 |
| Nicolini, H | 1 |
| Collins, KO | 1 |
| Comer, JB | 1 |
| Uchida, N | 1 |
| Amano, N | 1 |
| Oosthuizen, PP | 3 |
| Emsley, RA | 3 |
| Maritz, JS | 1 |
| Turner, JA | 1 |
| Keyter, N | 4 |
| Ambresin, G | 1 |
| Berney, P | 1 |
| Schulz, P | 1 |
| Bryois, C | 2 |
| Jadri Turner, H | 1 |
| Ando, N | 1 |
| Morimoto, K | 1 |
| Watanabe, T | 1 |
| Ninomiya, T | 1 |
| Suwaki, H | 1 |
| Tohen, MF | 2 |
| Strakowski, SM | 3 |
| Glick, I | 2 |
| Clark, WS | 1 |
| Turner, HJ | 2 |
| Schronen, J | 1 |
| Botha, K | 1 |
| Smit, R | 1 |
| Meltzer, HY | 3 |
| Arvanitis, L | 1 |
| Bauer, D | 1 |
| Rein, W | 1 |
| Keefe, RS | 3 |
| Seidman, LJ | 2 |
| Christensen, BK | 3 |
| Sitskoorn, MM | 2 |
| Lewine, RR | 1 |
| Yurgelun-Todd, DA | 1 |
| Gur, RC | 1 |
| Tollefson, GD | 8 |
| Sanger, TM | 4 |
| Nolan, K | 1 |
| Chagnon, YC | 1 |
| Mérette, C | 1 |
| Bouchard, RH | 1 |
| Emond, C | 1 |
| Roy, MA | 1 |
| Maziade, M | 1 |
| Lieberman, J | 1 |
| Gu, H | 1 |
| Green, A | 1 |
| Strakowski, S | 1 |
| Gur, R | 1 |
| Tebartz van Elst, L | 1 |
| Bäumer, D | 1 |
| Ebert, D | 1 |
| Trimble, MR | 2 |
| Chu, H | 1 |
| Lin, JC | 1 |
| Hsu, YD | 1 |
| Jung, IK | 1 |
| Lee, HJ | 1 |
| Cho, BH | 1 |
| Corripio, I | 1 |
| Catafau, AM | 1 |
| Perez, V | 1 |
| Puigdemont, D | 1 |
| Mena, E | 1 |
| Aguilar, Y | 1 |
| Carrió, I | 1 |
| Alvarez, E | 1 |
| Marona-Lewicka, D | 1 |
| Thisted, RA | 1 |
| Nichols, DE | 1 |
| Belgamwar, RB | 1 |
| Fenton, M | 1 |
| Conca, A | 1 |
| Waler, M | 1 |
| Walpoth, M | 1 |
| König, P | 2 |
| Hausmann, A | 1 |
| Schooler, N | 1 |
| Harvey, PD | 2 |
| Kopala, L | 1 |
| McGorry, PD | 2 |
| Van Hove, I | 1 |
| Eerdekens, M | 2 |
| Swyzen, W | 1 |
| De Smedt, G | 1 |
| Honer, WG | 1 |
| Kopala, LC | 1 |
| Christodoulou, C | 1 |
| Kalaitzi, C | 1 |
| Nolan, KA | 1 |
| Kline, L | 1 |
| Kaye, NS | 1 |
| Johnson, JL | 1 |
| Delbello, MP | 1 |
| Patel, JK | 1 |
| Dall'Igna, OP | 1 |
| Tort, AB | 1 |
| Souza, DO | 1 |
| Lara, DR | 1 |
| Ulrich, S | 2 |
| Sandmann, U | 1 |
| Genz, A | 1 |
| Zipursky, RB | 4 |
| Daskalakis, Z | 1 |
| Epstein, I | 1 |
| Roy, P | 1 |
| Furimsky, I | 1 |
| Sanger, T | 1 |
| Kapur, S | 4 |
| Rock, SL | 1 |
| Woolson, S | 2 |
| Freire, JM | 1 |
| de Cerqueira Leite, AC | 1 |
| Bueno, DS | 1 |
| Portella, LB | 1 |
| Ribes, SI | 1 |
| Assadi, TC | 1 |
| Colucci, VL | 1 |
| Pereira, ME | 1 |
| Mendhekar, DN | 1 |
| Jiloha, RC | 1 |
| Finkel, S | 1 |
| Kozma, C | 1 |
| Long, S | 1 |
| Greenspan, A | 1 |
| Mahmoud, R | 1 |
| Baser, O | 1 |
| Engelhart, L | 1 |
| Grant, MJ | 1 |
| Kostic, D | 1 |
| Hardy, S | 1 |
| Kéri, S | 1 |
| Kelemen, O | 1 |
| Janka, Z | 1 |
| Gharabawi, GM | 1 |
| Bossie, CA | 1 |
| Zhu, Y | 1 |
| Adetunji, B | 1 |
| Basil, B | 1 |
| Mathews, M | 1 |
| Williams, A | 1 |
| Osinowo, T | 1 |
| Mandel, FS | 1 |
| Smith, AJ | 1 |
| Li, M | 1 |
| Becker, S | 1 |
| Johnson, J | 1 |
| Bark, N | 2 |
| Jukić, I | 1 |
| Titlić, M | 1 |
| Tonkić, A | 1 |
| Dodig, G | 1 |
| Rogosić, V | 1 |
| Gorobets, LN | 1 |
| Gurrera, RJ | 1 |
| Zuidema, SU | 1 |
| van Iersel, MB | 1 |
| Koopmans, RT | 1 |
| Verhey, FR | 1 |
| Olde Rikkert, MG | 1 |
| Perkins, DO | 2 |
| Rothschild, AJ | 1 |
| Tariot, PN | 1 |
| Schneider, L | 1 |
| Katz, IR | 1 |
| Mintzer, JE | 1 |
| Street, J | 1 |
| Copenhaver, M | 1 |
| Williams-Hughes, C | 1 |
| Andrezina, R | 1 |
| Josiassen, RC | 2 |
| Oren, DA | 1 |
| Manos, G | 2 |
| Harms, HH | 1 |
| Llorca, J | 1 |
| Luis Vázquez-Barquero, J | 1 |
| Natesan, S | 1 |
| Reckless, GE | 1 |
| Barlow, KB | 1 |
| Nobrega, JN | 1 |
| Kidd, M | 1 |
| Kemp, WL | 1 |
| Fitzgerald, J | 1 |
| White, CL | 1 |
| Jarskog, LF | 1 |
| Chou, KL | 1 |
| Borek, LL | 1 |
| Friedman, JH | 1 |
| Currier, GW | 3 |
| Oren, D | 1 |
| Pikalov, AA | 1 |
| Buchsbaum, MS | 1 |
| Haznedar, MM | 1 |
| Aronowitz, J | 1 |
| Brickman, AM | 1 |
| Newmark, RE | 1 |
| Bloom, R | 1 |
| Brand, J | 1 |
| Goldstein, KE | 1 |
| Heath, D | 1 |
| Starson, M | 1 |
| Hazlett, EA | 1 |
| Braun, I | 1 |
| Genius, J | 1 |
| Grunze, H | 1 |
| Bender, A | 1 |
| Shim, JC | 1 |
| Choe, BM | 1 |
| Kim, JG | 1 |
| Jae, YM | 1 |
| Kim, HC | 1 |
| Kim, SG | 1 |
| Oh, MK | 1 |
| Kelly, DL | 1 |
| Conley, RR | 1 |
| Wynn, JK | 1 |
| Green, MF | 2 |
| Sprock, J | 1 |
| Light, GA | 1 |
| Widmark, C | 2 |
| Reist, C | 2 |
| Erhart, S | 2 |
| Mintz, J | 2 |
| Braff, DL | 2 |
| Newport, DJ | 1 |
| Calamaras, MR | 1 |
| DeVane, CL | 1 |
| Donovan, J | 1 |
| Beach, AJ | 1 |
| Winn, S | 1 |
| Knight, BT | 1 |
| Gibson, BB | 1 |
| Viguera, AC | 1 |
| Owens, MJ | 1 |
| Nemeroff, CB | 2 |
| Stowe, ZN | 1 |
| Archer, T | 1 |
| Fredriksson, A | 1 |
| Perlick, DA | 1 |
| Kaczynski, R | 1 |
| Bingham, S | 1 |
| Collins, J | 1 |
| Katagai, H | 1 |
| Yasui-Furukori, N | 1 |
| Kikuchi, A | 1 |
| Kaneko, S | 1 |
| Howard, JS | 1 |
| Sergi, MJ | 1 |
| Kee, KS | 1 |
| Villari, V | 1 |
| Rocca, P | 1 |
| Fonzo, V | 1 |
| Montemagni, C | 1 |
| Pandullo, P | 1 |
| Bogetto, F | 1 |
| Shingler, A | 1 |
| Ramirez-Bonilla, ML | 1 |
| Awouters, FH | 1 |
| Lewi, PJ | 1 |
| Baum, P | 1 |
| Hermann, W | 1 |
| Wagner, A | 1 |
| Carrasco-Marín, E | 2 |
| Fernandez-Prieto, L | 1 |
| Leyva-Cobián, F | 1 |
| Androsova, LV | 1 |
| Barkhatova, AN | 1 |
| Tsutsul'kovskaia, MIa | 1 |
| Martello, D | 1 |
| Allingham, B | 1 |
| Henteleff, RA | 1 |
| Zhang, W | 1 |
| Sampson, AR | 1 |
| Lewis, DA | 1 |
| Berja, A | 1 |
| Braun, GA | 1 |
| Paulonis, ME | 1 |
| Lapolla, A | 2 |
| Garver, DL | 6 |
| Hirschowitz, J | 3 |
| Fleishmann, R | 1 |
| Djuric, PE | 1 |
| Gomez, J | 1 |
| Scott, G | 1 |
| Vinar, O | 1 |
| Goode, DJ | 2 |
| Fang, VS | 1 |
| Bowers, MB | 10 |
| Heninger, GR | 1 |
| Kirkpatrick, B | 2 |
| Burnett, GB | 1 |
| Ellman, JP | 1 |
| Ho, BT | 1 |
| Smith, RC | 4 |
| Kralik, P | 1 |
| Allen, R | 2 |
| Schoolar, J | 1 |
| Khan, M | 1 |
| DeJohn, C | 1 |
| Tyrer, SP | 1 |
| Ereshefsky, L | 2 |
| Saklad, SR | 2 |
| Jann, MW | 2 |
| Davis, CM | 1 |
| Richards, A | 1 |
| Seidel, DR | 1 |
| Kucharski, LT | 1 |
| Alexander, P | 1 |
| Tune, L | 1 |
| Coyle, J | 1 |
| Neborsky, RJ | 3 |
| Janowsky, DS | 3 |
| Perel, JM | 3 |
| Munson, E | 2 |
| Depry, D | 2 |
| Resnick, M | 1 |
| Burton, BT | 1 |
| DePaulo, JR | 1 |
| Manning, AA | 1 |
| Keitner, GI | 1 |
| Rahman, S | 1 |
| Reid, AH | 1 |
| Langer, G | 2 |
| Resch, F | 2 |
| Aschauer, H | 1 |
| Keshavan, MS | 2 |
| Koinig, G | 2 |
| Schönbeck, G | 2 |
| Dittrich, R | 1 |
| Knoblich, OE | 1 |
| Witt, TN | 1 |
| Meyendorf, R | 1 |
| Spatz, R | 1 |
| Swigar, ME | 6 |
| Jatlow, PI | 7 |
| Goicoechea, N | 3 |
| Opsahl, C | 1 |
| Stilwell, AD | 1 |
| Van Putten, T | 2 |
| May, PR | 1 |
| Hershey, LA | 1 |
| Duffy, JP | 1 |
| Abernethy, DR | 1 |
| Greenblatt, DJ | 3 |
| Ropert, R | 1 |
| Leger, JM | 1 |
| Alexandre, JY | 1 |
| Clerc, G | 1 |
| Darondel, A | 1 |
| Delaunay, J | 1 |
| Delteil, P | 1 |
| Malauzat, D | 1 |
| Raynaud, J | 1 |
| Donoso, A | 1 |
| Vera, G | 1 |
| Arancibia, A | 1 |
| Díaz, E | 1 |
| Schilkrut, R | 1 |
| Miserda, R | 1 |
| Kohen, P | 1 |
| Pak, N | 1 |
| Werstiuk, ES | 1 |
| Grof, P | 1 |
| Rotstein, E | 1 |
| Werner, L | 1 |
| Bollini, P | 1 |
| Andreani, A | 1 |
| Colombo, F | 1 |
| Bellantuono, C | 1 |
| Beretta, P | 1 |
| Arduini, A | 1 |
| Galli, T | 1 |
| Tognoni, G | 1 |
| Kramer, DS | 1 |
| Drake, ME | 2 |
| Fernando, J | 1 |
| Krishna Raju, R | 1 |
| Jones, GG | 1 |
| Stanley, RO | 1 |
| Bleeker, JA | 1 |
| Dingemans, PM | 1 |
| Frohn-de Winter, ML | 1 |
| van de Slooten, EP | 1 |
| Cavanaugh, JJ | 1 |
| Finlayson, RE | 1 |
| Svestka, J | 2 |
| Náhunek, K | 1 |
| Cesková, E | 2 |
| Rysánek, R | 1 |
| Gold, BI | 1 |
| Roth, RH | 1 |
| Whalley, LJ | 1 |
| Blain, PG | 1 |
| Prime, JK | 1 |
| Parent, M | 3 |
| Toussaint, C | 2 |
| Cruz, FG | 1 |
| Thiagarajan, D | 1 |
| Harney, JH | 1 |
| Serrano, AC | 1 |
| Shalif, I | 1 |
| Lerner, Y | 2 |
| Dasberg, H | 1 |
| Denijs, EL | 1 |
| Heikkilä, L | 2 |
| Laitinen, J | 1 |
| Vartiainen, H | 2 |
| Salzman, C | 3 |
| Hoffman, SA | 1 |
| Vroulis, G | 2 |
| Shvartsburd, A | 2 |
| Lewis, N | 1 |
| Schoolar, JC | 1 |
| Chojnacki, M | 1 |
| Johnson, R | 1 |
| Castellani, S | 1 |
| Ziegler, MG | 1 |
| van Kammen, DP | 2 |
| Alexander, PE | 1 |
| Siris, SG | 1 |
| Lake, CR | 2 |
| Fishbain, DA | 2 |
| Kissling, W | 1 |
| Lang, C | 1 |
| Doerr, P | 1 |
| Pirke, KM | 1 |
| von Zerssen, D | 1 |
| Neborsky, R | 1 |
| Perel, J | 1 |
| Kuehnle, JC | 3 |
| Petty, LK | 1 |
| Spar, CJ | 1 |
| Bianchetti, G | 2 |
| Zarifian, E | 3 |
| Poirier-Littre, MF | 1 |
| Morselli, PL | 4 |
| Deniker, P | 3 |
| Deberdt, R | 1 |
| Elens, P | 1 |
| Berghmans, W | 1 |
| Heykants, J | 1 |
| Woestenborghs, R | 1 |
| Driesens, F | 1 |
| Reyntjens, A | 1 |
| van Wijngaarden, I | 1 |
| Meisner, M | 3 |
| Freudenreich, O | 1 |
| Stone, CK | 1 |
| Garve, DL | 1 |
| Griffith, J | 1 |
| Bennett, J | 1 |
| Knott, P | 1 |
| Stern, RG | 1 |
| Apter, S | 1 |
| Davis, KL | 2 |
| Keks, NA | 3 |
| Copolov, DL | 3 |
| McKenzie, DP | 1 |
| Kulkarni, J | 3 |
| Hill, C | 2 |
| Hope, JD | 1 |
| Singh, BS | 3 |
| Ibrahim, ZY | 1 |
| Carney, MM | 1 |
| Mauri, MC | 1 |
| Bravin, S | 1 |
| Mantero, M | 1 |
| Invernizzi, G | 1 |
| Pearlson, GD | 1 |
| Wong, DF | 2 |
| Tune, LE | 1 |
| Ross, CA | 1 |
| Chase, GA | 1 |
| Links, JM | 1 |
| Dannals, RF | 1 |
| Wilson, AA | 1 |
| Ravert, HT | 1 |
| Wagner, HN | 1 |
| Olbrich, HM | 1 |
| Martin, P | 1 |
| Pai, BN | 1 |
| Janakiramaiah, N | 1 |
| Gangadhar, BN | 1 |
| Ravindranath, V | 1 |
| Assion, HJ | 1 |
| Heinemann, F | 1 |
| Sarkar, P | 1 |
| Andrade, C | 1 |
| Kapur, B | 1 |
| Das, P | 1 |
| Sivaramakrishna, Y | 1 |
| Harihar, C | 1 |
| Pandey, A | 1 |
| Anand, A | 1 |
| Dharmendra, MS | 1 |
| Calore, EE | 1 |
| Cavaliere, MJ | 1 |
| Perez, NM | 1 |
| Russo, DH | 1 |
| Wakamatsu, A | 1 |
| Razzouk, D | 1 |
| Toney, G | 1 |
| Anderson, C | 1 |
| Seidel, D | 1 |
| Raja, M | 1 |
| Altavista, MC | 1 |
| Cavallari, S | 1 |
| Lubich, L | 1 |
| Newcomer, JW | 1 |
| Miller, LS | 1 |
| Faustman, WO | 2 |
| Wetzel, MW | 1 |
| Vogler, GP | 1 |
| Csernansky, JG | 2 |
| Aguilar, EJ | 1 |
| Martínez-Quiles, MD | 1 |
| Hernández, J | 1 |
| Gómez-Beneyto, M | 1 |
| Schooler, NR | 2 |
| Benazzi, F | 1 |
| Mazzoli, M | 1 |
| Johnson, TW | 1 |
| Polger, S | 1 |
| Emerich, DF | 2 |
| Freeman, TB | 1 |
| Cahill, DW | 1 |
| Sanberg, PR | 2 |
| Baastrup, PC | 1 |
| Alhfors, UG | 1 |
| Bjerkenstedt, L | 1 |
| Dencker, SJ | 1 |
| Fensbo, C | 1 |
| Gravem, A | 1 |
| Pedersen, V | 3 |
| Elgen, K | 1 |
| Brekke, B | 1 |
| Fredslund-Andersen, K | 1 |
| Blair, DT | 1 |
| Dauner, A | 1 |
| Kunz, M | 2 |
| Marneros, A | 1 |
| Jäger, A | 1 |
| Convit, A | 1 |
| de Asis, J | 1 |
| Evangelista, C | 1 |
| Chouinard, G | 1 |
| Annable, L | 1 |
| Turnier, L | 1 |
| Holobow, N | 1 |
| Szkrumelak, N | 1 |
| Gex-Fabry, M | 1 |
| Balant-Gorgia, AE | 2 |
| Balant, LP | 1 |
| Alam, MY | 1 |
| Boshes, RA | 1 |
| Waternaux, C | 1 |
| Pappalardo, KM | 1 |
| Fitzgibbon, ME | 1 |
| Tsuang, MT | 1 |
| Schildkraut, JJ | 1 |
| Shibasaki, M | 2 |
| Someya, T | 2 |
| Takahashi, S | 2 |
| Remington, G | 1 |
| Pollock, B | 1 |
| Voineskos, G | 1 |
| Reed, K | 1 |
| Coulter, K | 1 |
| Lane, HY | 2 |
| Lin, HN | 1 |
| Jann, M | 1 |
| Hu, WH | 1 |
| Chang, WH | 2 |
| Adinamis, A | 1 |
| Petti, TA | 1 |
| Small, J | 1 |
| Nurnberger, J | 1 |
| Dunn, D | 1 |
| Patrick, V | 1 |
| Kronenberger, W | 1 |
| Pitkälä, K | 1 |
| Amore, M | 3 |
| Giordani, L | 2 |
| Giorgetti, G | 1 |
| Zazzeri, N | 1 |
| Sunderland, T | 1 |
| Javaid, JI | 2 |
| Sharma, RP | 3 |
| Leach, AM | 1 |
| Davis, JM | 3 |
| Wang, Z | 1 |
| Odou, P | 1 |
| Vaiva, G | 1 |
| Luyckx, M | 1 |
| Brunet, C | 1 |
| Dine, T | 1 |
| Gressier, B | 1 |
| Cazin, M | 1 |
| Cazin, JC | 1 |
| Schwartz, JC | 1 |
| Griffon, N | 1 |
| Diaz, J | 1 |
| Levesque, D | 1 |
| Sautel, F | 1 |
| Sokoloff, P | 1 |
| Simon, P | 1 |
| Costentin, J | 1 |
| Garrido, F | 1 |
| Mann, A | 1 |
| Gerlach, J | 3 |
| Peacock, L | 1 |
| Jauss, M | 1 |
| Krack, P | 1 |
| Franz, M | 1 |
| Klett, R | 1 |
| Bauer, R | 1 |
| Gallhofer, B | 2 |
| Dorndorf, W | 1 |
| Bondolfi, G | 1 |
| Musella, V | 1 |
| Passannanti, G | 1 |
| Pellicano, M | 1 |
| Cirillo, D | 1 |
| Tanzillo, M | 1 |
| Busiello, G | 1 |
| Vitelli, R | 1 |
| Martius, P | 1 |
| Hüther, R | 1 |
| Zilker, T | 1 |
| Küfferle, B | 3 |
| Brücke, T | 2 |
| Topitz-Schratzberger, A | 1 |
| Tauscher, J | 2 |
| Gössler, R | 1 |
| Vesely, C | 2 |
| Asenbaum, S | 2 |
| Podreka, I | 2 |
| Kasper, S | 2 |
| Aschheim, E | 1 |
| Aschheim, L | 1 |
| Inayama, Y | 1 |
| Yoneda, H | 1 |
| Fukushima, K | 1 |
| Sakai, J | 1 |
| Asaba, H | 1 |
| Sakai, T | 1 |
| Beasley, CM | 5 |
| Tran, PV | 5 |
| Street, JS | 1 |
| Krueger, JA | 1 |
| Tamura, RN | 2 |
| Graffeo, KA | 1 |
| Thieme, ME | 1 |
| Steinberg, JL | 1 |
| McDermott, BE | 1 |
| Yao, JK | 3 |
| Ramberg, JE | 1 |
| Lewis, S | 1 |
| Kingsbury, SJ | 1 |
| Leach, A | 1 |
| Dowd, S | 1 |
| Jeffries, JJ | 1 |
| Manor, I | 1 |
| Hermesh, H | 2 |
| Munitz, H | 2 |
| Weizman, A | 5 |
| Bunker, MT | 1 |
| Marken, PA | 1 |
| Schneiderhan, ME | 1 |
| Ruehter, VL | 1 |
| Battaglia, J | 1 |
| Moss, S | 1 |
| Rush, J | 1 |
| Kang, J | 1 |
| Mendoza, R | 1 |
| Leedom, L | 1 |
| Dubin, W | 1 |
| McGlynn, C | 1 |
| Goodman, L | 1 |
| Zimnitzky, BM | 1 |
| DeMaso, DR | 1 |
| Steingard, RJ | 1 |
| Dryden-Edwards, RC | 1 |
| Reiss, AL | 1 |
| Foster, S | 1 |
| Kessel, J | 1 |
| Berman, ME | 1 |
| Simpson, GM | 6 |
| Podschus, J | 1 |
| Kirsch, J | 1 |
| van Heys, R | 1 |
| Winzer, B | 1 |
| Potvin, JH | 1 |
| Brown, AS | 1 |
| Gewirtz, G | 1 |
| Harkavy-Friedman, J | 1 |
| Cooper, T | 2 |
| Brébion, G | 1 |
| Amador, XF | 1 |
| Malaspina, D | 1 |
| Gorman, JM | 1 |
| Fogelson, DL | 1 |
| Sternbach, H | 1 |
| Payne, D | 1 |
| Kutz, I | 1 |
| David, D | 1 |
| Hillard, JR | 1 |
| Yoshida, K | 1 |
| Smith, B | 1 |
| Craggs, M | 1 |
| Kumar, R | 1 |
| al Jeshi, A | 1 |
| al Kaisi, HH | 1 |
| Iancu, I | 1 |
| Spivak, B | 2 |
| Mester, R | 1 |
| Zhang-Wong, J | 2 |
| Lambe, EK | 1 |
| Bean, G | 2 |
| Beiser, M | 2 |
| Müller-Siecheneder, F | 1 |
| Müller, MJ | 1 |
| Hillert, A | 1 |
| Szegedi, A | 1 |
| Wetzel, H | 1 |
| Benkert, O | 1 |
| Yamaguchi, S | 1 |
| Mishio, M | 1 |
| Okuda, Y | 1 |
| Kitajima, T | 1 |
| Savedia, SM | 1 |
| Bobba, RS | 1 |
| Garside, S | 1 |
| Goff, DC | 4 |
| Posever, T | 1 |
| Herz, L | 1 |
| Simmons, J | 1 |
| Kletti, N | 1 |
| Lapierre, K | 1 |
| Wilner, KD | 1 |
| Law, CG | 1 |
| Ko, GN | 1 |
| Reclusa Poyo, FJ | 1 |
| Hortells Aznar, JL | 1 |
| Millán Sáez, L | 1 |
| Broto Civera, E | 1 |
| Velilla Marco, J | 1 |
| Black, KJ | 1 |
| Racette, B | 1 |
| Perlmutter, JS | 1 |
| Dellva, MA | 1 |
| Wentley, AL | 1 |
| Chou, JC | 3 |
| Douyon, R | 1 |
| Neuhof, S | 1 |
| Braun, V | 1 |
| Meyer, FP | 1 |
| Feifel, D | 2 |
| Reza, T | 1 |
| Robeck, S | 1 |
| Grundy, S | 1 |
| Beasley, C | 1 |
| Dorevitch, A | 1 |
| Katz, N | 1 |
| Zemishlany, Z | 1 |
| Aizenberg, D | 1 |
| Bardgett, M | 1 |
| Faull, KF | 1 |
| Pfefferbaum, A | 1 |
| Lu, Y | 1 |
| Berg, PH | 1 |
| Nisijima, K | 1 |
| Ishiguro, T | 1 |
| Hesslinger, B | 1 |
| Normann, C | 1 |
| Klose, P | 1 |
| Berger, M | 1 |
| Walden, J | 1 |
| Prendergast, J | 1 |
| Spira, P | 1 |
| Schnieden, V | 1 |
| Gaulin, BD | 1 |
| Markowitz, JS | 1 |
| Caley, CF | 1 |
| Nesbitt, LA | 1 |
| Dufresne, RL | 1 |
| Yamashita, H | 1 |
| Horiguchi, J | 1 |
| Mizuno, S | 1 |
| Kuramoto, Y | 1 |
| Yamawaki, S | 2 |
| Inami, Y | 1 |
| Hughes, DH | 1 |
| Hess-Röver, J | 1 |
| Crichton, J | 1 |
| Byrne, K | 1 |
| Holland, AJ | 1 |
| Stanilla, JK | 1 |
| Nair, C | 1 |
| Abraham, G | 1 |
| Odom-White, A | 1 |
| Turner, RM | 1 |
| Bozikas, V | 1 |
| Vartzopoulos, D | 1 |
| Phocas, C | 1 |
| Karavatos, A | 1 |
| Kaprinis, G | 1 |
| Ryan, CJ | 1 |
| Coley, KC | 1 |
| Carter, CS | 1 |
| DaPos, SV | 1 |
| Maxwell, R | 1 |
| Wilson, JW | 1 |
| Branch, RA | 1 |
| Mishory, A | 1 |
| Yaroslavsky, Y | 1 |
| Bersudsky, Y | 1 |
| Belmaker, RH | 3 |
| Wahlbeck, K | 1 |
| Nikkilä, H | 1 |
| Rimón, R | 1 |
| Ahokas, A | 1 |
| Casey, DE | 1 |
| Citrome, LL | 1 |
| Mohr, P | 1 |
| Woods, SW | 1 |
| Kornreich, C | 1 |
| Dan, B | 1 |
| Verbanck, P | 1 |
| Pelc, I | 1 |
| Green, B | 1 |
| Mohan, MS | 1 |
| Patole, SK | 1 |
| Whitehall, JS | 1 |
| George, S | 1 |
| Chin, CN | 1 |
| Fitzgerald, PB | 1 |
| Kennedy, NB | 1 |
| Procyshyn, RM | 1 |
| Lare, SB | 1 |
| Labbate, LA | 1 |
| Heck, AH | 1 |
| Haffmans, PM | 1 |
| de Groot, IW | 1 |
| Hoencamp, E | 2 |
| Fukuda, R | 1 |
| Reddy, R | 1 |
| Kohler, CG | 1 |
| Pickholtz, J | 1 |
| Ballas, C | 1 |
| Lucey, JV | 1 |
| Gunn, KP | 1 |
| Seeman, P | 1 |
| Novakovic, M | 1 |
| Fischer, R | 1 |
| Eich, P | 1 |
| Basson, BR | 1 |
| Gilmore, JA | 1 |
| Ty, EB | 1 |
| Rothner, AD | 1 |
| Guntermann, A | 1 |
| Erfurth, A | 1 |
| Bondy, B | 1 |
| Poyurovsky, M | 1 |
| Al-Sughayir, MA | 1 |
| Vukosavic, S | 1 |
| Ruzdijic, S | 1 |
| Veskov, R | 1 |
| Rakic, L | 1 |
| Kanazir, S | 1 |
| Raju, GV | 1 |
| Kumar, TC | 1 |
| Khanna, S | 1 |
| Keck, PE | 2 |
| Kasckow, JW | 1 |
| Tugrul, K | 1 |
| Dowd, SM | 1 |
| Strong, J | 1 |
| Dacpano, G | 1 |
| Richardson, N | 1 |
| Tuma, I | 1 |
| Trujillo, M | 1 |
| Gjedde, A | 1 |
| Umbricht, D | 1 |
| Baker, RW | 1 |
| Safferman, A | 1 |
| Ganguli, R | 1 |
| McMeniman, M | 1 |
| Borenstein, M | 1 |
| Turner, J | 1 |
| Kafantaris, V | 1 |
| Dicker, R | 1 |
| Coletti, DJ | 1 |
| Zhang, F | 1 |
| Feldman, PD | 1 |
| Risser, RC | 1 |
| Sultzer, DL | 1 |
| Gray, KF | 1 |
| Gunay, I | 1 |
| Wheatley, MV | 1 |
| Mahler, ME | 1 |
| Potkin, SG | 2 |
| Thyrum, PT | 1 |
| Alva, G | 1 |
| Bera, R | 1 |
| Yeh, C | 1 |
| Arvanitis, LA | 1 |
| Zwanzger, P | 1 |
| Ella, R | 1 |
| Keck, ME | 1 |
| Rupprecht, R | 1 |
| Padberg, F | 1 |
| Bilder, RM | 1 |
| Goldman, RS | 1 |
| Hoptman, M | 1 |
| Horowitz, TL | 1 |
| McAllister-Williams, RH | 1 |
| Ferrier, IN | 1 |
| Val'dman, AV | 1 |
| Kozlovskaia, MM | 1 |
| Mason, AS | 1 |
| Granacher, RP | 1 |
| Firling, RJ | 1 |
| Colpaert, FC | 1 |
| Niemegeers, CJ | 2 |
| Janssen, PA | 2 |
| Pary, RJ | 1 |
| Bures, E | 2 |
| Pöldinger, W | 2 |
| Heath, A | 1 |
| Garfinkel, PE | 2 |
| Calil, HM | 1 |
| Avery, DH | 1 |
| Hollister, LE | 3 |
| Creese, I | 1 |
| Snyder, SH | 1 |
| Chalmers, RA | 1 |
| Watts, RW | 1 |
| Lawson, AM | 1 |
| Simmelsgaard, H | 2 |
| Gold, MS | 1 |
| Pottash, AL | 1 |
| Extein, I | 1 |
| Redmond, DE | 1 |
| Kleber, HD | 1 |
| Van Praag, HM | 3 |
| Korf, J | 2 |
| Young, LD | 1 |
| Carter, RG | 2 |
| Ingall, MA | 1 |
| Farber, BL | 1 |
| Kuppe, JV | 1 |
| Silveira, AP | 1 |
| Gerstenzang, ML | 1 |
| Krulisky, TV | 1 |
| Haage, H | 1 |
| Fruensgaard, K | 1 |
| Korsgaard, S | 1 |
| Jorgensen, H | 1 |
| Jensen, K | 1 |
| Stotsky, BA | 1 |
| Suleman, DE | 1 |
| Lwow, E | 1 |
| Levitin, A | 1 |
| Berger, SH | 1 |
| Moore, DP | 1 |
| Eldore, A | 1 |
| Zylber-Katz, E | 1 |
| de-Nour, AK | 1 |
| Cottereau, MJ | 1 |
| Cuche, H | 1 |
| Lôo, H | 1 |
| Hornbeck, CL | 1 |
| Griffiths, JC | 1 |
| Faulkner, MA | 1 |
| Maerz, JC | 2 |
| Durand, G | 1 |
| Le Heuzey, MF | 1 |
| Dugas, M | 2 |
| Rosenstock, HA | 1 |
| Vincent, KR | 1 |
| Cameron, OG | 1 |
| Ayd, FJ | 1 |
| Ketai, R | 2 |
| Matthews, J | 1 |
| Mozdzen, JJ | 1 |
| Caroli, F | 1 |
| Littre-Poirier, MF | 1 |
| Ginestet, D | 1 |
| Cohen, DJ | 1 |
| Johnson, WT | 1 |
| Caparulo, BK | 1 |
| Rossner, M | 1 |
| König, L | 1 |
| Carpenter, WT | 2 |
| Anderson, WH | 2 |
| Catanzano, DM | 1 |
| Robak, OH | 1 |
| Waldmeier, PC | 1 |
| Maître, L | 1 |
| Lavagna, J | 1 |
| Lafont, A | 1 |
| Darcourt, G | 1 |
| Abe, K | 1 |
| de Francisco, CP | 1 |
| Thornton, WE | 1 |
| Swett, C | 1 |
| Hoell, NL | 1 |
| Ombrato, M | 1 |
| Capone, D | 1 |
| Hanson, JW | 1 |
| Oakley, GP | 1 |
| McCullar, FW | 1 |
| Heggeness, L | 1 |
| Archer, JD | 1 |
| Quenstedt, M | 1 |
| Ramsay, R | 1 |
| Bernadt, M | 1 |
| Haffmans, PJ | 1 |
| Jansen, GS | 1 |
| De Beaurepaire, R | 1 |
| Zonda, T | 1 |
| Kövári, E | 1 |
| Stárková, L | 2 |
| Mrna, B | 1 |
| Woodbury, MM | 1 |
| Woodbury, MA | 1 |
| Egorov, AY | 1 |
| Nikolaenko, NN | 1 |
| Lee, K | 1 |
| Romero, JA | 1 |
| Tsuang, M | 1 |
| O'Connor, M | 1 |
| Rooney, MD | 1 |
| Nienaber, CP | 1 |
| Warkentin, S | 1 |
| Nilsson, A | 1 |
| Karlson, S | 1 |
| Risberg, J | 1 |
| Franze'n, G | 1 |
| Gustafson, L | 1 |
| Dysken, MW | 1 |
| Kim, SW | 1 |
| Vatassery, G | 1 |
| Johnson, SB | 1 |
| Skare, S | 1 |
| Holden, L | 1 |
| Thomsyck, L | 1 |
| Mazure, CM | 2 |
| Nelson, JC | 2 |
| Eliander, H | 1 |
| Turunen, M | 1 |
| Boyd, RD | 1 |
| Laska, E | 1 |
| Gastanaga, P | 1 |
| Krakowski, M | 1 |
| Crowner, M | 1 |
| Solomon, D | 1 |
| Miyawaki, E | 1 |
| Glassman, R | 1 |
| Rood, L | 1 |
| Flowers, E | 1 |
| Thayer, S | 1 |
| Wiedermann, J | 1 |
| Plotnick, EK | 1 |
| Brown, GR | 1 |
| Lublin, H | 1 |
| Hagert, U | 1 |
| Meidahl, B | 1 |
| Mølbjerg, C | 1 |
| Rendtorff, C | 1 |
| Tolvanen, E | 1 |
| Kato, T | 1 |
| Noguchi, T | 1 |
| Ishida, N | 1 |
| Montanari, M | 1 |
| Cerisoli, M | 1 |
| Hogarty, GE | 1 |
| Steingard, S | 1 |
| Sethna, R | 1 |
| Notkin, R | 1 |
| Bandelow, B | 1 |
| Müller, P | 1 |
| Rüther, E | 1 |
| Robinson, S | 1 |
| Rosca, P | 1 |
| Durst, R | 1 |
| Shai, U | 1 |
| Ghinea, C | 1 |
| Schmidt, U | 1 |
| Nir, I | 1 |
| Brotman, AW | 2 |
| McCormick, S | 1 |
| Wolovick, L | 1 |
| Tyano, S | 1 |
| den Boer, JA | 1 |
| Ravelli, DP | 1 |
| Huisman, J | 1 |
| Ohrvik, J | 1 |
| Verhoeven, WM | 1 |
| Westenberg, HG | 1 |
| Laux, G | 1 |
| Klieser, E | 2 |
| Schröder, HG | 1 |
| Dittmann, V | 1 |
| Unterweger, B | 1 |
| Schubert, H | 1 |
| Schöny, HW | 1 |
| Bunse, J | 2 |
| Beckmann, H | 1 |
| Lindström, LH | 1 |
| Wieselgren, IM | 1 |
| Struwe, G | 1 |
| Kristjansson, E | 1 |
| Akselson, S | 1 |
| Arthur, H | 1 |
| Andersen, T | 1 |
| Lindgren, S | 1 |
| Norman, O | 1 |
| Naimell, L | 1 |
| Mendlewicz, J | 1 |
| de Bleeker, E | 1 |
| Cosyns, P | 1 |
| Deleu, G | 1 |
| Lotstra, F | 1 |
| Masson, A | 1 |
| Mertens, C | 1 |
| Peuskens, J | 1 |
| Suy, E | 1 |
| Pflug, B | 1 |
| Bartels, M | 2 |
| Bauer, H | 1 |
| Haas, S | 1 |
| Kanzow, WT | 1 |
| Stein, D | 1 |
| Lewander, T | 1 |
| Westerbergh, SE | 1 |
| Morrison, D | 1 |
| Bissette, G | 1 |
| Midha, KK | 1 |
| Waites, M | 1 |
| Arana, GW | 2 |
| Dupont, R | 1 |
| Ornsteen, M | 2 |
| Harmatz, JS | 1 |
| Shader, RI | 2 |
| Roca, RP | 1 |
| Blackman, MR | 1 |
| Ackerley, MB | 1 |
| Harman, SM | 1 |
| Gregerman, RI | 1 |
| Kemperman, CJ | 1 |
| van den Hoofdakker, RH | 1 |
| Raptis, C | 1 |
| Garcia-Borreguero, D | 1 |
| Weber, MM | 1 |
| Dose, M | 1 |
| Bremer, D | 1 |
| Emrich, HM | 1 |
| McKenzie, D | 1 |
| McGorry, P | 1 |
| Stuart, G | 1 |
| Mackie, B | 1 |
| Minas, IH | 1 |
| Kontaxakis, VP | 1 |
| Vaidakis, NM | 1 |
| Christodoulou, GN | 1 |
| Valergaki, HC | 1 |
| Yadalam, KG | 1 |
| Levinson, DF | 1 |
| Stephanos, MJ | 1 |
| Lo, ES | 1 |
| Truong, DD | 1 |
| Hermanowicz, N | 1 |
| Rontal, M | 1 |
| Kaplan, MJ | 1 |
| Lazoff, M | 1 |
| Kelly, K | 1 |
| Lukin, R | 1 |
| Jaeger, J | 2 |
| Maeda, K | 1 |
| Jauch, D | 1 |
| Tamminga, CA | 1 |
| Wysowski, DK | 1 |
| Baum, C | 1 |
| Solano, OA | 1 |
| Sadow, T | 1 |
| Ananth, J | 1 |
| Price, DK | 1 |
| Turnbull, GJ | 1 |
| Gregory, RP | 1 |
| Stevens, DG | 1 |
| Zbytovský, J | 1 |
| Zapletálek, M | 1 |
| Garza-Treviño, ES | 1 |
| Overall, JE | 1 |
| Alexander, WF | 1 |
| Quinn, DE | 1 |
| Goodman, MA | 1 |
| Eisele, R | 1 |
| Garrone, G | 1 |
| Wagemaker, H | 1 |
| Lippmann, S | 1 |
| Cade, JR | 1 |
| Glazer, WM | 1 |
| Hafez, HM | 1 |
| Benarroche, CL | 1 |
| Baumgartner, R | 2 |
| Ravichandran, GK | 2 |
| Mauldin, M | 2 |
| Marchant, N | 1 |
| Caruso, S | 1 |
| Cuervo, L | 1 |
| Brizuela, A | 1 |
| Dubin, WR | 1 |
| Waxman, HM | 1 |
| Weiss, KJ | 1 |
| Ramchandani, D | 1 |
| Tavani-Petrone, C | 1 |
| Sramek, JJ | 1 |
| Morrison, RL | 1 |
| Heiser, JF | 1 |
| De Cuyper, H | 1 |
| Bollen, J | 1 |
| Verstraeten, D | 1 |
| Largen, J | 1 |
| Calderon, M | 1 |
| Burd, A | 1 |
| Alvarez, JV | 1 |
| Li Gambi, M | 1 |
| Turns, DM | 1 |
| Pary, R | 1 |
| Tobias, CR | 1 |
| James, WA | 1 |
| Mann, K | 1 |
| Gärtner, HJ | 1 |
| Schied, HW | 1 |
| Wagner, W | 1 |
| Heimann, H | 1 |
| Hoffman, FJ | 2 |
| Bulens, C | 1 |
| Meerwaldt, JD | 1 |
| van der Wildt, GJ | 1 |
| Keemink, CJ | 1 |
| Goyot, C | 2 |
| Debray, Q | 2 |
| Guay, C | 1 |
| Giraud, J | 1 |
| Grenier, J | 2 |
| Benfield, P | 1 |
| Ward, A | 2 |
| Clark, BG | 1 |
| Jue, SG | 1 |
| Bellomo, LE | 1 |
| Rosset, N | 1 |
| Tellarini, L | 1 |
| Forconesi, N | 1 |
| Addy, RO | 1 |
| Foliart, RH | 1 |
| Saran, AS | 1 |
| Schubert, DS | 1 |
| Pakalnis, A | 1 |
| John, K | 1 |
| Kellum, JB | 1 |
| Magnusson, M | 1 |
| Gerada, C | 1 |
| Reveley, A | 1 |
| Birnie, WA | 1 |
| Matsuno, K | 1 |
| Aschauer, HN | 1 |
| Hatzinger, R | 1 |
| Chaudry, HR | 1 |
| Sieghart, W | 1 |
| Ellerman, LA | 1 |
| Shostak, M | 1 |
| Stiller, RL | 1 |
| Wyman, W | 1 |
| Curran, S | 1 |
| Harris, M | 1 |
| Nora, L | 1 |
| Tanner, CM | 1 |
| Rampertaap, MP | 1 |
| Beresford, R | 1 |
| Boyer, WF | 1 |
| Bakalar, NH | 1 |
| Hooper, JF | 1 |
| Nemes, ZC | 1 |
| O'Donnell, J | 1 |
| Carter, JG | 1 |
| Zohar, J | 1 |
| Shemesh, Z | 1 |
| Walevski, A | 1 |
| Radwan, M | 1 |
| Yanagawa, K | 1 |
| Morio, M | 1 |
| Mori, K | 1 |
| Schiffman, J | 1 |
| Giraud-Serio, J | 1 |
| Plaisant, O | 1 |
| Pélicier, Y | 1 |
| Kuniyoshi, M | 1 |
| Inanaga, K | 1 |
| Kendler, KS | 1 |
| Davis, BM | 1 |
| Horvath, TB | 1 |
| Mohs, RC | 1 |
| Gonçalves, N | 1 |
| Stoll, KD | 1 |
| Amen, DG | 1 |
| Moleman, P | 1 |
| Janzen, G | 1 |
| von Bargen, BA | 1 |
| Kappers, EJ | 1 |
| Pepplinkhuizen, L | 1 |
| Schmitz, PI | 1 |
| Campbell, R | 1 |
| Andrews, E | 1 |
| Bellard, J | 1 |
| Walter-Ryan, WG | 1 |
| Friedman, H | 1 |
| Black, B | 1 |
| Montanari, A | 1 |
| Berlinzani, L | 1 |
| Gentili, C | 1 |
| Shen, YC | 1 |
| Zhou, DF | 1 |
| Pardes, H | 1 |
| Shu, L | 1 |
| Phelps, B | 1 |
| Poland, R | 1 |
| Mavroidis, ML | 1 |
| Kanter, DR | 1 |
| Ellison, JM | 1 |
| Gomez, EA | 1 |
| Ostergaard, PK | 1 |
| Pelonero, AL | 1 |
| Levenson, JL | 1 |
| Silverman, JJ | 1 |
| Schellekens, KH | 1 |
| Dresse, A | 1 |
| Lenaerts, FM | 1 |
| Schaper, WK | 1 |
| van Nueten, JM | 1 |
| Verbruggen, FJ | 1 |
| Stepanian, K | 1 |
| Flügel, KA | 2 |
| Mattsson, B | 1 |
| Perris, C | 1 |
| Ritter, RM | 1 |
| Davidson, DE | 1 |
| Robinson, TA | 1 |
| Lewis, PJ | 1 |
| James, NM | 1 |
| Eggers, C | 1 |
| Guz, I | 1 |
| Moraes, R | 1 |
| Sartoretto, JN | 1 |
| Claghorn, JL | 1 |
| Leonard, RB | 1 |
| Sangiovanni, F | 1 |
| Taylor, MA | 1 |
| Abrams, R | 1 |
| Gaztanaga, P | 1 |
| Jacobson, G | 1 |
| Manschreck, T | 1 |
| Winslow, WW | 1 |
| Stone, WN | 1 |
| Hofling, CK | 1 |
| Vangtorp, A | 1 |
| Mellegaard, M | 1 |
| Tobin, JM | 1 |
| Brousseau, ER | 1 |
| Lorenz, AA | 1 |
| Melon, J | 1 |
| Mormont, C | 1 |
| Dufrasne, M | 1 |
| Rubin, R | 1 |
| Dom, R | 1 |
| Van Lommel, R | 1 |
| Baro, F | 1 |
| Goldstein, BJ | 2 |
| Clyde, DJ | 1 |
| Feldman, PE | 1 |
| Bay, AP | 1 |
| Baser, AN | 1 |
| Bhasker, KN | 1 |
| Kennedy, LL | 1 |
| Shopsin, B | 1 |
| Hekimian, LJ | 1 |
| Gershon, S | 1 |
| Floyd, A | 1 |
| Olivennes, M | 1 |
| Nash, LR | 1 |
| Radzuweit, H | 1 |
| Knorr, W | 1 |
| Gurovich, IIa | 1 |
| Fleĭs, EP | 1 |
| Marc, V | 1 |
| Garattini, S | 2 |
| Zaccala, M | 2 |
| Faretra, G | 1 |
| Dooher, L | 1 |
| Dowling, J | 1 |
| Rizzo, M | 1 |
| Kulenkampff, C | 1 |
| Angyal, L | 1 |
| Tissot, R | 1 |
| Bovet, J | 1 |
| Pfeiffer, WM | 1 |
| Greger, J | 1 |
| Glitschka, A | 1 |
| Müller, K | 1 |
| Glatzel, J | 1 |
| Renard, P | 1 |
| Larroutis-Bicheron, C | 1 |
| Morin, Y | 1 |
| Marino, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Reducing the Burden of Chronic Psychotic Disorders in Tanzania[NCT04327843] | Phase 3 | 22 participants (Actual) | Interventional | 2019-11-05 | Completed | ||
| Phase IV Study of Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II): a 3-year Follow-up[NCT02526030] | Phase 4 | 203 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| A Prospective Trial of Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic (CAE-L) in Individuals With Schizophrenia or Schizoaffective Disorder at Risk for Treatment Non-adherence and for Homelessness[NCT01152697] | 30 participants (Actual) | Interventional | 2010-06-30 | Completed | |||
| An Open-label, Randomized Trial of Intramuscular (IM) Olanzapine Versus Intramuscular Combination of Haloperidol and Lorazepam in the Treatment of Acute Agitation in Schizophrenia[NCT00797277] | Phase 3 | 67 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| A Comparison of Long-Acting Injectable Medications for Schizophrenia[NCT01136772] | Phase 4 | 311 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Study Evaluating Effectiveness of Ziprasidone Using the Overlapped Switching Strategy in Patients With Schizophrenia or Schizoaffective Disorder[NCT01198353] | Phase 4 | 67 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Blood Lactate Levels in Patients Treated With Typical or Atypical Antipsychotics[NCT01139463] | 60 participants (Actual) | Observational | 2008-06-30 | Completed | |||
| Treatment of Behavioral Symptoms in Alzheimer's Disease[NCT00009217] | Phase 4 | 44 participants (Actual) | Interventional | 1999-01-31 | Completed | ||
| Clozapine and Olanzapine in the Treatment of Violence in Schizophrenic Patients[NCT01123408] | 110 participants (Actual) | Interventional | 1999-06-30 | Completed | |||
| Effectiveness of the RemedRugby Program, a Program of Ecological Cognitive Remediation of Social Cognition Disorders in Schizophrenia[NCT03775564] | 60 participants (Actual) | Interventional | 2014-11-30 | Completed | |||
| Aripiprazole, Abilify Maintena Collaborative Clinical Protocol[NCT02717130] | 9 participants (Actual) | Interventional | 2016-06-08 | Terminated (stopped due to The study was terminated due to lack of enrollment.) | |||
| Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308] | Phase 2 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Aripiprazole for Clozapine Associated Medical Morbidity[NCT00345033] | Phase 4 | 38 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness[NCT00661869] | 295 participants (Actual) | Interventional | 2006-09-30 | Completed | |||
| Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study[NCT00837707] | Phase 4 | 25 participants (Anticipated) | Interventional | 2008-06-30 | Recruiting | ||
| CSP #451 - The Clinical and Economic Impact of Olanzapine in the Treatment of Schizophrenia[NCT00007774] | Phase 4 | 600 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| The Cognitive Effects of Risperidone and Olanzapine[NCT00108368] | Phase 4 | 0 participants | Interventional | 2003-10-31 | Completed | ||
| Clozapine Response and Biogenic Amines in Schizophrenia[NCT00169039] | Phase 4 | 66 participants | Interventional | 1994-12-31 | Terminated | ||
| Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia[NCT00156715] | Phase 4 | 23 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone[NCT00096863] | Phase 2 | 102 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| [NCT01615185] | Phase 4 | 96 participants (Actual) | Interventional | 2008-01-31 | Terminated | ||
| A Prospective, Double Blind, Randomized, Sham-Controlled, Clinical Trial to Evaluate The Safety And Efficacy Of Biometrics-Guided Magnetic EEG Resonance Therapy (MeRT) Treatment Of Post-Traumatic Stress Disorder With And Without Persistent Post-Concussive[NCT02990793] | 152 participants (Anticipated) | Interventional | 2022-04-04 | Recruiting | |||
| A Randomized, Double-Blind, Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Combined With Low Dose of Haloperidol in the Treatment of Schizophrenic Disorder[NCT00998608] | Phase 4 | 88 participants (Actual) | Interventional | 2007-08-31 | Terminated (stopped due to terminated) | ||
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia[NCT03075657] | Phase 4 | 120 participants (Actual) | Interventional | 2017-05-01 | Completed | ||
| Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)[NCT00130923] | Phase 4 | 95 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
LAI injection adherence will be determined as a count of participants who received LAI injections at the appropriate time (within 7 days of scheduled time). (NCT04327843)
Timeframe: Baseline to 6 month visit
| Intervention | Participants (Count of Participants) |
|---|---|
| CAE + LAI Treatment | 18 |
Body Mass Index kg/m^2 of participants (NCT04327843)
Timeframe: Baseline to Month 6(week 25)
| Intervention | kg/m^2 (Mean) | |
|---|---|---|
| Baseline | 25 Weeks | |
| CAE + LAI Treatment | 22.79 | 22.92 |
The BPRS measures levels of mania. There are 24 items, scored on a 7-point scale ranging from 0 to 6. Total scores range from 0 to 42, with higher scores indicating higher levels of mania. (NCT04327843)
Timeframe: Baseline to 6 month visit
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | 25-Weeks | |
| CAE + LAI Treatment | 27.00 | 25.06 |
The minimum possible score is 1 and the maximum score is 7. A higher score implies a worse condition. (NCT04327843)
Timeframe: Baseline to 6 month visit
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 25 Weeks | |
| CAE + LAI Treatment | 2.88 | 2.24 |
DAI-10 scoring ranges from -10 to +10 with a total score >0 indicating a positive attitude toward psychiatric medications and a total score of <0 indicating a negative attitude toward psychiatric medications. (NCT04327843)
Timeframe: Baseline to 6 month visit
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | 25 Weeks | |
| CAE + LAI Treatment | 7.89 | 9.83 |
Extrapyramidal Symptoms Scale-Abbreviated version for akathisia- drug-induced akathisia consists of inner restlessness and urge to move. Items are measured on a 4 value scale: 0=absent, 3=severe, and higher values indicate more severe akathisia and worse outcomes. (NCT04327843)
Timeframe: Baseline to 6 months(25 weeks)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Week 25 | |
| CAE + LAI Treatment | 0.28 | 0.00 |
Extrapyramidal Symptoms Scale-Abbreviated version for Dyskinesia- drug-induced dyskinesia which is repetitive and involuntary movements. Each item is rated on a 4 point scale: 0=absent, 3=severe and higher values indicate greater severity of dyskinesia and worse outcomes. (NCT04327843)
Timeframe: Baseline to 6 months(25 weeks)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Week 25 | |
| CAE + LAI Treatment | 0.17 | 0.11 |
Extrapyramidal Symptoms Scale-Abbreviated version for dystonia- drug-induced dystonia is a muscle disorder in which movements are jerky or twisting. Due to the 0.00 values at baseline and 25 weeks, unable to perform t-test and get a p value so no statistical analysis section is reported for this Outcome Measure. Each item is rated on a 4 point scale: 0=absent, 3=severe with the higher numbers indicating worse dystonia and worse outcomes. (NCT04327843)
Timeframe: Baseline to 6 months(25 weeks)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Week 25 | |
| CAE + LAI Treatment | 0.00 | 0.00 |
Extrapyramidal Symptoms Scale-Abbreviated version for Parkinsonism. It looks at drug-induced Parkinsonism which is made up of motor disturbances. Rigidity, tremor, reduced facial expression/speech, impaired gait/posture, postural instability, and bradykinesia. Each item is rated on a 4 point scale: 0=absent, 3=severe. The higher the value the more severe the Parkinsonism and worst outcomes. (NCT04327843)
Timeframe: Baseline to 6 months(25 weeks)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | 25 Weeks | |
| CAE + LAI Treatment | 0.06 | 0.06 |
The SOFAS measures social and occupational functioning independent of the overall severity of the individual's psychological symptoms. The minimum score is 0 and the maximum score is 100. A higher rating implies a higher level of functioning. (NCT04327843)
Timeframe: Baseline to 6 month visit
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | 25 Weeks | |
| CAE + LAI Treatment | 62.17 | 68.39 |
The TRQ evaluates adherence to medications via a brief self-report instrument that has been validated in populations with bipolar disorder medication adherence. The TRQ identifies nonadherent individuals, defined as those who miss 20-30% or more of their medication in the last week or month. Total scores are represented as a percentage and range from 0 to 100, with higher scores indicating a greater level of nonadherence (higher scores indicate worse adherence to medications). (NCT04327843)
Timeframe: Change from Baseline to 6 month visit
| Intervention | percentage of change in adherence (Mean) | |
|---|---|---|
| TRQ Week adherence | TRQ Month adherence | |
| CAE + LAI Treatment | -57 | -23 |
Nineteen item inventory taken by the participant with Scale Range:0-19. Lower scores indicate improved outcomes. (NCT01152697)
Timeframe: 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Patient Noncompliance | 2.43 |
Ten item inventory taken by the participant with a Scale Range: 0-10. Higher scores indicate improved outcomes. (NCT01152697)
Timeframe: 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Patient Noncompliance | 7.00 |
Subjects will be asked how many days they have been homeless (NCT01152697)
Timeframe: 12 months
| Intervention | days (Mean) |
|---|---|
| Patient Noncompliance | 35 |
The frequency of health resource use will be measured through interview of the participant. (NCT01152697)
Timeframe: 25 weeks
| Intervention | days (Mean) |
|---|---|
| Patient Noncompliance | 20.18 |
Four item inventory taken by participant with Scale Range: 0-4. Lower scores indicate better outcomes. (NCT01152697)
Timeframe: 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Patient Noncompliance | 1.33 |
"Satisfaction will be measured by a seven item inventory taken by the participant.~Scale ranges from 1 (Strongly Agree) to 5 (Strongly Disagree). Lower scores indicate better outcomes, while higher scores indicate worse outcomes. The highest possible score is 35." (NCT01152697)
Timeframe: 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Patient Noncompliance | 12.33 |
"Satisfaction will be measured by a seven item inventory taken by the participant.~Scale ranges from 1 (Strongly Agree) to 5 (Strongly Disagree). Lower scores indicate better outcomes, while higher scores indicate worse outcomes. The highest possible score is 35." (NCT01152697)
Timeframe: 25 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Patient Noncompliance | 12.12 |
Nineteen item inventory taken by the participant with Scale Range:0-19. Lower scores indicate improved outcomes. (NCT01152697)
Timeframe: Baseline-25 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 25 | |
| Patient Noncompliance | 6.63 | 4.47 |
Ten item inventory taken by the participant with a Scale Range: 0-10. Higher scores indicate improved outcomes. (NCT01152697)
Timeframe: Baseline-25 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 25 | |
| Patient Noncompliance | 7.47 | 8.07 |
Subjects will be asked how many days they have been homeless (NCT01152697)
Timeframe: Baseline-25 weeks
| Intervention | days (Mean) | |
|---|---|---|
| Baseline | 25 Weeks | |
| Patient Noncompliance | 6.50 | 9.85 |
Four item inventory taken by participant with Scale Range: 0-4. Lower scores indicate improved outcomes. (NCT01152697)
Timeframe: Baseline-25 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 25 | |
| Patient Noncompliance | 2.31 | 1.19 |
A total treatment adherence score will calculated as a proportion of medications taken as reported from the participant, and evidenced by pill counts and documented medication injections. (NCT01152697)
Timeframe: Baseline-25 weeks
| Intervention | Percentage of doses (Mean) | |
|---|---|---|
| Past week | Past month | |
| Patient Noncompliance | 30.91 | 10.10 |
"Global psychopathology will be measured with the Clinical Global Impressions (CGI) (Guy 1976) a widely used scale which evaluates illness severity on a 1 to 7 point continuum. Severity of illness ratings on the CGI have reported reliability scores ranging from 0.41-0.66 (Guy 1976) Lower scores indicate improved outcomes. Higher scores indicate worse outcomes.~Illness scale: 1 - 7 (1 = Normal/not at all ill ; 7 = Among the most extremely ill patients) Global improvement scale: 1 - 7 (1 = Very much improved ; 7 = Very much worse)" (NCT01152697)
Timeframe: Baseline-25 weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline - Severity | Week 25 - Severity | Baseline - Global Improvement | Week 25 - Global Improvement | |
| Patient Noncompliance | 4.76 | 3.24 | 3.43 | 2.14 |
"The PANSS (Kay, Fiszbein, & Opler 1987) was created to assess both the positive and negative symptoms of schizophrenia such as hallucinations and emotional withdrawal, respectively. The scale rates 30 symptoms on a scale from 1 (absent) to 7 (extreme) and has been shown to limit bias between the assessment of positive and negative symptoms, providing a broad but balanced spectrum of the illness.~There are three subscales: positive symptoms, negative symptoms, general psychopathology. Potential responses to Items on all subscales range from 1 (absent) to 7 (extreme). Lower scores indicate lower symptoms and, therefore, better outcomes. Higher scores indicate more presence of symptoms and, therefore, worse outcomes.~Subscales are combined to produce a total score, which is summed from all of the subscales. Lower total scores indicate lower symptoms and, therefore, better outcomes. Higher total scores indicate more presence of symptoms and, therefore, worse outcomes." (NCT01152697)
Timeframe: Baseline-25 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 25 | |
| Patient Noncompliance | 46.37 | 32.84 |
"The BPRS, developed by Overall and Gorham (1962), is a widely used, relatively brief scale that measures major psychotic and non-psychotic symptoms in individuals with SMI. The 18-item BPRS is well-validated and is perhaps the most researched instrument in psychiatry. Reliability coefficients are reported to be in the range of 0.56-0.87.~Scale Range: 18-126 Lower scores represent improved outcomes." (NCT01152697)
Timeframe: Baseline-25 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 25 | |
| Patient Noncompliance | 46.37 | 32.84 |
Life and Work Functional status will be evaluated using the Social and Occupational Functioning Scale (SOFAS), which is derived from the GAF. The GAF is a 100-point single-item scale which measures global functioning of psychiatric patients and is widely utilized in clinical studies involving Seriously Mentally Ill patients (Jones 1995). The reliability of the GAF ranges from 0.62-0.82. Higher scores indicate improved outcomes. (NCT01152697)
Timeframe: Baseline-12 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Patient Noncompliance | 45.33 | 63.83 |
Life and Work Functional status will be evaluated using the Social and Occupational Functioning Scale (SOFAS), which is derived from the GAF (Global Assessment of Functioning). The GAF is a 100-point single-item scale which measures global functioning of psychiatric patients and is widely utilized in clinical studies involving Seriously Mentally Ill patients (Jones 1995). The reliability of the GAF ranges from 0.62-0.82. Higher scores indicate improved outcomes. (NCT01152697)
Timeframe: Baseline-25 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 25 | |
| Patient Noncompliance | 47.35 | 58.65 |
The frequency of health resource use will be measured through interview of the participant. (NCT01152697)
Timeframe: Month 1-3, Month 10-12
| Intervention | days (Mean) | |
|---|---|---|
| 3 Month | 12 Month | |
| Patient Noncompliance | 19.33 | 15.50 |
"Global psychopathology will be measured with the Clinical Global Impressions (CGI) (Guy 1976) a widely used scale which evaluates illness severity on a 1 to 7 point continuum. Severity of illness ratings on the CGI have reported reliability scores ranging from 0.41-0.66 (Guy 1976) Lower scores indicate improved outcomes. Higher scores indicate worse outcomes.~Illness scale: 1 - 7 (1 = Normal/not at all ill ; 7 = Among the most extremely ill patients) Global improvement scale: 1 - 7 (1 = Very much improved ; 7 = Very much worse)" (NCT01152697)
Timeframe: 12 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Severity | Global Improvement | |
| Patient Noncompliance | 3.17 | 2.42 |
A total treatment adherence score will calculated as a proportion of medications taken as reported from the participant, and evidenced by pill counts and documented medication injections. (NCT01152697)
Timeframe: 12 months
| Intervention | Percentage of doses (Mean) | |
|---|---|---|
| Past Week | Past Month | |
| Patient Noncompliance | 28.65 | 6 |
Agitation was further assessed by the Agitation Calmness Evaluation Scale (ACES) (Copyright 1998, Eli Lilly and Company), a single-item scale developed by Eli Lilly and Company on which 1 indicates marked agitation; 2, moderate agitation; 3, mild agitation; 4, normal; 5, mild calmness; 6, moderate calmness; 7, marked calmness; 8, deep sleep; and 9, unable to be aroused. (NCT00797277)
Timeframe: from baseline to 120 minutes after first injection
| Intervention | units on a scale (Mean) |
|---|---|
| 1. IM Olanzapine | 2.14 |
| 2. IM Haloperidol Pus Lorazepam | 2.23 |
The primary efficacy measure was PANSS-EC, which was derived from the PANSS by its originators using a principal-components factor analysis, and includes the items of tension, uncooperativeness, hostility, poor impulse control and excitement.22 The score of each item ranges from 1 (normal) to 7 (most severe), with a total sum score ranging from 5 to 35. The changes in PANSS-EC from baseline to 2 hours after the first injection were compared. (NCT00797277)
Timeframe: from baseline to 120 minutes after first injection
| Intervention | units on a scale (Mean) |
|---|---|
| 1. IM Olanzapine | -10.2 |
| 2. IM Haloperidol Plus Lorazepam | -9.9 |
The Positive and Negative Syndrome Scale measures the core symptoms associated with schizophrenia. The measure includes 30 items rated from 1=absent to 7=extremely severe. Full range of scores is 30-210 with higher scores representing more severe illness. Reductions in symptoms over time represent improvement. (NCT01136772)
Timeframe: Baseline to 6 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Paliperidone Palmitate | -6.87 |
| Haloperidol Decanoate | -6.40 |
Efficacy failure as indicated by psychiatric hospitalization, need for crisis intervention, clinical decision that oral antipsychotic medication cannot be discontinued in less than eight weeks, a clinical decision to discontinue the medication due to inadequate benefit, or the ongoing or repeated need for adjunctive antipsychotic medication. (NCT01136772)
Timeframe: 24 months
| Intervention | participants (Number) |
|---|---|
| Paliperidone Palmitate | 49 |
| Haloperidol Decanoate | 47 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 2 |
| Sham | 8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 1 |
| Sham | 0 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56.5 |
| Sham | 63.8 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56 |
| Sham | 59.8 |
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 29.5 |
| Sham | 31.5 |
A comparison between aripiprazole group and placebo group of change in Body Mass Index (BMI) measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.52 |
| Placebo | 0.03 |
A comparison between the aripiprazole group and placebo group in change in glucose metabolism measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Aripiprazole | 0.003 |
| Placebo | -0.005 |
A comparison between aripiprazole group and placebo group of change in insulin resistance measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Aripiprazole | 0.6 |
| Placebo | 0.65 |
A comparison of aripiprazole group and placebo group in change in total cholesterol measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -15.3 |
| Placebo | 5.6 |
(NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -5.9 |
| Placebo | -7.3 |
A comparison between aripiprazole group and placebo group in change in weight measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg (Mean) |
|---|---|
| Aripiprazole | -1.5 |
| Placebo | 0.3 |
The main outcome measure of clinical symptoms was the Positive and Negative Symptoms Scale. This is a 30 item scale for assessing patients diagnosed with schizophrenia. Each item is rated on a 1 (absent) to 7 (extreme) scale. The minimum total score is 30 and the maximum is 210. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| QUET | 65.5 |
Timeline Follow-back (TLFB) procedure was used at screening and baseline to establish current substance use, and it was also used weekly during the course of the study to assess continued alcohol and other substance use. TLFB cosisted of using a calendar and sasking participants to report alcohol and other drug use since last visit. At the screening visit, the TLFB was done for the four weeks prior to the visit. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Drinking Days per Week (Mean) |
|---|---|
| QUET | 2.7 |
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
Frequency of drinking days is obtained each week retrospectively as the number of drinking days during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 2.84 |
| Oral Risperidone Aka Risperdal | 3.46 |
A rater assesses social, occupational and psychological functioning on a hypothetical continuum of mental health - illness (using Global Assessment of Functioning); scores range from 100 to 1, where higher values represent a better outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of impairment (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 50.8 |
| Oral Risperidone Aka Risperdal | 49.9 |
A rater assesses positive and negative symptoms of schizophrenia using a 30-item scale (Positive and Negative Symptom Score) Scores range from 30 to 210, where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of symptoms (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 78.2 |
| Oral Risperidone Aka Risperdal | 75.5 |
A rater assesses the severity of illness and global impression using a scale from 1 to 7 (Clinical Global Impression), where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal unit of severity (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 4.02 |
| Oral Risperidone Aka Risperal | 3.96 |
Frequency of heavy drinking days is obtained each week retrospectively as the number of heavy drinking days during the prior week (assessed by the Timeline Followback Scale). A heavy drinking day is defined as 4 or more drinks per day for a female and 5 or more drinks per day for a male. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | heavy drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | -.11 |
| Oral Risperidone Aka Risperal | .68 |
Number of participants with medication adherence (defined as taking medication at least 75% of the days in the treatment period). (NCT00130923)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 43 |
| Oral Risperidone Aka Risperdal | 28 |
70 reviews available for haloperidol and Psychotic Disorders
| Article | Year |
|---|---|
Psychopharmacology of agitation in acute psychotic and manic episodes.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Haloperidol; Humans; Lorazepam; Ma | 2022 |
Psychopharmacology of agitation in acute psychotic and manic episodes.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Haloperidol; Humans; Lorazepam; Ma | 2022 |
The Use of Rapid Tranquilization in Aggressive Behavior.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Psychomotor Agitation; Psych | 2019 |
The Use of Rapid Tranquilization in Aggressive Behavior.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Psychomotor Agitation; Psych | 2019 |
Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Methamphetamine; Network M | 2021 |
Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Methamphetamine; Network M | 2021 |
Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.
Topics: Antipsychotic Agents; Aripiprazole; Clopenthixol; Delayed-Action Preparations; Flupenthixol; Fluphen | 2021 |
Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.
Topics: Antipsychotic Agents; Aripiprazole; Clopenthixol; Delayed-Action Preparations; Flupenthixol; Fluphen | 2021 |
Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Clozapine; Diabetic Ketoaci | 2017 |
Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Clozapine; Diabetic Ketoaci | 2017 |
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).
Topics: Aggression; Antipsychotic Agents; Dystonia; Haloperidol; Humans; Hypnotics and Sedatives; Placebos; | 2017 |
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).
Topics: Aggression; Antipsychotic Agents; Dystonia; Haloperidol; Humans; Hypnotics and Sedatives; Placebos; | 2017 |
Evidence-Based Review Of Pharmacotherapy For Acute Agitation. Part 2: Safety.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Emergency Service, Hospital; Evidence | 2018 |
Evidence-Based Review Of Pharmacotherapy For Acute Agitation. Part 2: Safety.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Emergency Service, Hospital; Evidence | 2018 |
The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis.
Topics: Aggression; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; H | 2019 |
The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis.
Topics: Aggression; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; H | 2019 |
Benzodiazepines for psychosis-induced aggression or agitation.
Topics: Acute Disease; Aggression; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Drug Thera | 2013 |
Benzodiazepines for psychosis-induced aggression or agitation.
Topics: Acute Disease; Aggression; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Drug Thera | 2013 |
Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.
Topics: Administration, Oral; Antipsychotic Agents; Haloperidol; Humans; Loxapine; Psychotic Disorders; Rand | 2015 |
Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.
Topics: Administration, Oral; Antipsychotic Agents; Haloperidol; Humans; Loxapine; Psychotic Disorders; Rand | 2015 |
Possible biomarkers modulating haloperidol efficacy and/or tolerability.
Topics: Antipsychotic Agents; Biomarkers; Epigenesis, Genetic; Gene Expression Profiling; Genetic Markers; G | 2016 |
Possible biomarkers modulating haloperidol efficacy and/or tolerability.
Topics: Antipsychotic Agents; Biomarkers; Epigenesis, Genetic; Gene Expression Profiling; Genetic Markers; G | 2016 |
Haloperidol plus promethazine for psychosis-induced aggression.
Topics: Aggression; Benzodiazepines; Drug Therapy, Combination; Haloperidol; Humans; Lorazepam; Midazolam; P | 2016 |
Haloperidol plus promethazine for psychosis-induced aggression.
Topics: Aggression; Benzodiazepines; Drug Therapy, Combination; Haloperidol; Humans; Lorazepam; Midazolam; P | 2016 |
Haloperidol for long-term aggression in psychosis.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; H | 2016 |
Haloperidol for long-term aggression in psychosis.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; H | 2016 |
Droperidol for psychosis-induced aggression or agitation.
Topics: Acute Disease; Aggression; Antipsychotic Agents; Benzodiazepines; Droperidol; Haloperidol; Humans; M | 2016 |
Droperidol for psychosis-induced aggression or agitation.
Topics: Acute Disease; Aggression; Antipsychotic Agents; Benzodiazepines; Droperidol; Haloperidol; Humans; M | 2016 |
Interventions for psychotic symptoms concomitant with epilepsy.
Topics: Antipsychotic Agents; Benzodiazepines; Epilepsy; Haloperidol; Humans; Olanzapine; Psychotic Disorder | 2008 |
Interventions for psychotic symptoms concomitant with epilepsy.
Topics: Antipsychotic Agents; Benzodiazepines; Epilepsy; Haloperidol; Humans; Olanzapine; Psychotic Disorder | 2008 |
The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Evi | 2009 |
The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Evi | 2009 |
Haloperidol plus promethazine for psychosis-induced aggression.
Topics: Aggression; Benzodiazepines; Drug Therapy, Combination; Haloperidol; Humans; Lorazepam; Midazolam; O | 2009 |
Haloperidol plus promethazine for psychosis-induced aggression.
Topics: Aggression; Benzodiazepines; Drug Therapy, Combination; Haloperidol; Humans; Lorazepam; Midazolam; O | 2009 |
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Haloperi | 2010 |
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Haloperi | 2010 |
Chlorpromazine for psychosis induced aggression or agitation.
Topics: Administration, Oral; Aggression; Antipsychotic Agents; Chlorpromazine; Haloperidol; Humans; Injecti | 2010 |
Chlorpromazine for psychosis induced aggression or agitation.
Topics: Administration, Oral; Aggression; Antipsychotic Agents; Chlorpromazine; Haloperidol; Humans; Injecti | 2010 |
CNS drug development. Part I: The early period of CNS drugs.
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Anxiety Disorders; Bipolar Disorder; Central | 2010 |
CNS drug development. Part I: The early period of CNS drugs.
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Anxiety Disorders; Bipolar Disorder; Central | 2010 |
[Rapid tranquillisation; review of the literature and recommendations].
Topics: Aggression; Benzodiazepines; Conscious Sedation; Drug Therapy, Combination; Haloperidol; Humans; Hyp | 2011 |
[Rapid tranquillisation; review of the literature and recommendations].
Topics: Aggression; Benzodiazepines; Conscious Sedation; Drug Therapy, Combination; Haloperidol; Humans; Hyp | 2011 |
Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses.
Topics: Acute Disease; Aggression; Antipsychotic Agents; Benzodiazepines; Clopenthixol; Dibenzothiazepines; | 2012 |
Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses.
Topics: Acute Disease; Aggression; Antipsychotic Agents; Benzodiazepines; Clopenthixol; Dibenzothiazepines; | 2012 |
Antipsychotic medications, psychological side effects and treatment engagement.
Topics: Activities of Daily Living; Affect; Antipsychotic Agents; Awareness; Emotions; Haloperidol; Humans; | 2012 |
Antipsychotic medications, psychological side effects and treatment engagement.
Topics: Activities of Daily Living; Affect; Antipsychotic Agents; Awareness; Emotions; Haloperidol; Humans; | 2012 |
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).
Topics: Aggression; Antipsychotic Agents; Aripiprazole; Clopenthixol; Dystonia; Haloperidol; Humans; Lorazep | 2012 |
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).
Topics: Aggression; Antipsychotic Agents; Aripiprazole; Clopenthixol; Dystonia; Haloperidol; Humans; Lorazep | 2012 |
Recent developments in pharmacotherapy for the acutely psychotic patient.
Topics: Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Injections, Intr | 2002 |
Recent developments in pharmacotherapy for the acutely psychotic patient.
Topics: Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Injections, Intr | 2002 |
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; | 2003 |
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; | 2003 |
[Life threatening neuroleptic malignant syndrome due to olanzapine].
Topics: Antipsychotic Agents; Benzodiazepines; Critical Care; Electroconvulsive Therapy; Female; Haloperidol | 2003 |
[Life threatening neuroleptic malignant syndrome due to olanzapine].
Topics: Antipsychotic Agents; Benzodiazepines; Critical Care; Electroconvulsive Therapy; Female; Haloperidol | 2003 |
[COMPLICATIONS DURING CLINICAL THERAPY WITH PSYCHOPHARMACA].
Topics: Agranulocytosis; Autonomic Nervous System Diseases; Chemical and Drug Induced Liver Injury; Chlorpro | 1964 |
[COMPLICATIONS DURING CLINICAL THERAPY WITH PSYCHOPHARMACA].
Topics: Agranulocytosis; Autonomic Nervous System Diseases; Chemical and Drug Induced Liver Injury; Chlorpro | 1964 |
[Acute psychoses caused by infection].
Topics: Acute Disease; Antipsychotic Agents; Communicable Diseases; Diagnosis, Differential; Haloperidol; Hu | 2003 |
[Acute psychoses caused by infection].
Topics: Acute Disease; Antipsychotic Agents; Communicable Diseases; Diagnosis, Differential; Haloperidol; Hu | 2003 |
Haloperidol plus promethazine for psychosis induced aggression.
Topics: Aggression; Drug Therapy, Combination; Haloperidol; Humans; Lorazepam; Midazolam; Promethazine; Psyc | 2005 |
Haloperidol plus promethazine for psychosis induced aggression.
Topics: Aggression; Drug Therapy, Combination; Haloperidol; Humans; Lorazepam; Midazolam; Promethazine; Psyc | 2005 |
Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Injections, Intramuscular; L | 2005 |
Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Injections, Intramuscular; L | 2005 |
Antipsychotic drug-induced acute laryngeal dystonia: two case reports and a mini review.
Topics: Adult; Antipsychotic Agents; Diagnosis, Differential; Dystonia; Female; Haloperidol; Humans; Larynge | 2005 |
Antipsychotic drug-induced acute laryngeal dystonia: two case reports and a mini review.
Topics: Adult; Antipsychotic Agents; Diagnosis, Differential; Dystonia; Female; Haloperidol; Humans; Larynge | 2005 |
Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Double- | 2005 |
Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Double- | 2005 |
[Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review].
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Dementia; Haloperidol; Humans; Olanzapine; Psycho | 2006 |
[Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review].
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Dementia; Haloperidol; Humans; Olanzapine; Psycho | 2006 |
The management of psychosis in movement disorder patients.
Topics: Antipsychotic Agents; Clozapine; Haloperidol; Humans; Huntington Disease; Lewy Body Disease; Parkins | 2007 |
The management of psychosis in movement disorder patients.
Topics: Antipsychotic Agents; Clozapine; Haloperidol; Humans; Huntington Disease; Lewy Body Disease; Parkins | 2007 |
Forty years of antipsychotic Drug research--from haloperidol to paliperidone--with Dr. Paul Janssen.
Topics: Antipsychotic Agents; Haloperidol; History, 20th Century; History, 21st Century; Humans; Isoxazoles; | 2007 |
Forty years of antipsychotic Drug research--from haloperidol to paliperidone--with Dr. Paul Janssen.
Topics: Antipsychotic Agents; Haloperidol; History, 20th Century; History, 21st Century; Humans; Isoxazoles; | 2007 |
[Neuroleptics in 1979 (author's transl)].
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Halope | 1980 |
[Neuroleptics in 1979 (author's transl)].
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Halope | 1980 |
Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches.
Topics: Adult; Antipsychotic Agents; Biological Availability; Chromatography; Delayed-Action Preparations; F | 1984 |
Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches.
Topics: Adult; Antipsychotic Agents; Biological Availability; Chromatography; Delayed-Action Preparations; F | 1984 |
Lithium.
Topics: Aggression; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, C | 1984 |
Lithium.
Topics: Aggression; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, C | 1984 |
[Confusional states in the elderly--an underdiagnosed syndrome with a poor prognosis].
Topics: Aged; Comorbidity; Confusion; Delirium; Dementia; Diagnosis, Differential; Haloperidol; Humans; Neur | 1996 |
[Confusional states in the elderly--an underdiagnosed syndrome with a poor prognosis].
Topics: Aged; Comorbidity; Confusion; Delirium; Dementia; Diagnosis, Differential; Haloperidol; Humans; Neur | 1996 |
[Pharmacological treatment of delusional depression].
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Delusions; Depressive Disorde | 1996 |
[Pharmacological treatment of delusional depression].
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Delusions; Depressive Disorde | 1996 |
Treatment of the elderly suffering from psychosis and dementia.
Topics: Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Buspirone; Clinical Trials as Topic; Dem | 1996 |
Treatment of the elderly suffering from psychosis and dementia.
Topics: Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Buspirone; Clinical Trials as Topic; Dem | 1996 |
The D3 receptor and its relevance in psychiatry.
Topics: Antipsychotic Agents; Binding, Competitive; Haloperidol; Humans; Psychotic Disorders; Receptors, Dop | 1995 |
The D3 receptor and its relevance in psychiatry.
Topics: Antipsychotic Agents; Binding, Competitive; Haloperidol; Humans; Psychotic Disorders; Receptors, Dop | 1995 |
New antipsychotics: the present status.
Topics: Antipsychotic Agents; Binding, Competitive; Clozapine; Dopamine Antagonists; Haloperidol; Humans; Ps | 1995 |
New antipsychotics: the present status.
Topics: Antipsychotic Agents; Binding, Competitive; Clozapine; Dopamine Antagonists; Haloperidol; Humans; Ps | 1995 |
[Neuroleptic malignant syndrome].
Topics: Adolescent; Adult; Antipsychotic Agents; Diagnosis, Differential; Dibenzothiazepines; Female; Halope | 1996 |
[Neuroleptic malignant syndrome].
Topics: Adolescent; Adult; Antipsychotic Agents; Diagnosis, Differential; Dibenzothiazepines; Female; Halope | 1996 |
Emergency treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Decision Trees; Drug Administration | 1998 |
Emergency treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Decision Trees; Drug Administration | 1998 |
Acute psychopharmacological management of the aggressive psychotic patient.
Topics: Acute Disease; Aggression; Antipsychotic Agents; Dose-Response Relationship, Drug; Haloperidol; Huma | 1999 |
Acute psychopharmacological management of the aggressive psychotic patient.
Topics: Acute Disease; Aggression; Antipsychotic Agents; Dose-Response Relationship, Drug; Haloperidol; Huma | 1999 |
Diagnosis and treatment of a severe psychotic illness in a man with dual severe sensory impairments caused by the presence of Usher syndrome.
Topics: Animals; Antipsychotic Agents; Blindness; Cricetinae; Diagnosis, Differential; Genetic Predispositio | 1999 |
Diagnosis and treatment of a severe psychotic illness in a man with dual severe sensory impairments caused by the presence of Usher syndrome.
Topics: Animals; Antipsychotic Agents; Blindness; Cricetinae; Diagnosis, Differential; Genetic Predispositio | 1999 |
Tardive dyskinesia: pathophysiology and animal models.
Topics: Age Factors; Animals; Antipsychotic Agents; Basal Ganglia; Behavior, Animal; Disease Models, Animal; | 2000 |
Tardive dyskinesia: pathophysiology and animal models.
Topics: Age Factors; Animals; Antipsychotic Agents; Basal Ganglia; Behavior, Animal; Disease Models, Animal; | 2000 |
Focus on risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Haloperidol; Humans; Psychotic Disorders; Risperidone | 2000 |
Focus on risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Haloperidol; Humans; Psychotic Disorders; Risperidone | 2000 |
Rational antipsychotic polypharmacy.
Topics: Antipsychotic Agents; Clozapine; Cytochrome P-450 Enzyme System; Drug Interactions; Haloperidol; Hum | 2000 |
Rational antipsychotic polypharmacy.
Topics: Antipsychotic Agents; Clozapine; Cytochrome P-450 Enzyme System; Drug Interactions; Haloperidol; Hum | 2000 |
Atypical antipsychotic medications in the psychiatric emergency service.
Topics: Administration, Oral; Aggression; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedul | 2000 |
Atypical antipsychotic medications in the psychiatric emergency service.
Topics: Administration, Oral; Aggression; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedul | 2000 |
Rationale and guidelines for the inpatient treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; Drug | 2000 |
Rationale and guidelines for the inpatient treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; Drug | 2000 |
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
Topics: Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Dopamine D2 Receptor Antagonists; Haloperid | 2001 |
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
Topics: Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Dopamine D2 Receptor Antagonists; Haloperid | 2001 |
Neuroleptic malignant syndrome in children and adolescents.
Topics: Adolescent; Adult; Antipsychotic Agents; Child; Depressive Disorder, Major; Female; Haloperidol; Hum | 2001 |
Neuroleptic malignant syndrome in children and adolescents.
Topics: Adolescent; Adult; Antipsychotic Agents; Child; Depressive Disorder, Major; Female; Haloperidol; Hum | 2001 |
Rapid tranquillisation: time for a reappraisal of options for parenteral therapy.
Topics: Acute Disease; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Clopenthixol; Death, Sudd | 2002 |
Rapid tranquillisation: time for a reappraisal of options for parenteral therapy.
Topics: Acute Disease; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Clopenthixol; Death, Sudd | 2002 |
Psychiatric drug treatment in children.
Topics: Adolescent; Amphetamines; Antipsychotic Agents; Anxiety; Autistic Disorder; Behavior Therapy; Child; | 1979 |
Psychiatric drug treatment in children.
Topics: Adolescent; Amphetamines; Antipsychotic Agents; Anxiety; Autistic Disorder; Behavior Therapy; Child; | 1979 |
Clinical evidence for multiple dopamine receptors in man.
Topics: Adenylyl Cyclases; Antipsychotic Agents; Brain; Brain Chemistry; Butyrophenones; Dopamine Antagonist | 1979 |
Clinical evidence for multiple dopamine receptors in man.
Topics: Adenylyl Cyclases; Antipsychotic Agents; Brain; Brain Chemistry; Butyrophenones; Dopamine Antagonist | 1979 |
Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome.
Topics: Adolescent; Catatonia; Drug Therapy, Combination; Haloperidol; Humans; Lorazepam; Male; Neuroleptic | 1992 |
Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome.
Topics: Adolescent; Catatonia; Drug Therapy, Combination; Haloperidol; Humans; Lorazepam; Male; Neuroleptic | 1992 |
[30 years experience with haloperidol].
Topics: Brain; Dopamine Antagonists; Dyskinesia, Drug-Induced; Haloperidol; Humans; Psychotic Disorders | 1991 |
[30 years experience with haloperidol].
Topics: Brain; Dopamine Antagonists; Dyskinesia, Drug-Induced; Haloperidol; Humans; Psychotic Disorders | 1991 |
A systematic approach to pharmacotherapy in patients with neuroleptic-resistant psychoses.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Human | 1989 |
A systematic approach to pharmacotherapy in patients with neuroleptic-resistant psychoses.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Human | 1989 |
Rapid tranquilization: a reevaluation.
Topics: Antipsychotic Agents; Chlorpromazine; Dose-Response Relationship, Drug; Drug Administration Schedule | 1989 |
Rapid tranquilization: a reevaluation.
Topics: Antipsychotic Agents; Chlorpromazine; Dose-Response Relationship, Drug; Drug Administration Schedule | 1989 |
The psychoses of epilepsy and their treatment.
Topics: Anticonvulsants; Antipsychotic Agents; Diethylcarbamazine; Electroencephalography; Epilepsy; Haloper | 1985 |
The psychoses of epilepsy and their treatment.
Topics: Anticonvulsants; Antipsychotic Agents; Diethylcarbamazine; Electroencephalography; Epilepsy; Haloper | 1985 |
Low-dose treatment strategies.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, | 1986 |
Low-dose treatment strategies.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, | 1986 |
Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses.
Topics: Clinical Trials as Topic; Haloperidol; Humans; Psychotic Disorders | 1988 |
Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses.
Topics: Clinical Trials as Topic; Haloperidol; Humans; Psychotic Disorders | 1988 |
Use of benzodiazepines to control disruptive behavior in inpatients.
Topics: Aggression; Benzodiazepines; Haloperidol; Hospitalization; Humans; Injections, Intramuscular; Loraze | 1988 |
Use of benzodiazepines to control disruptive behavior in inpatients.
Topics: Aggression; Benzodiazepines; Haloperidol; Hospitalization; Humans; Injections, Intramuscular; Loraze | 1988 |
Neuroleptic malignant syndrome.
Topics: Adolescent; Adult; Benztropine; Bromocriptine; Catatonia; Child; Child, Preschool; Diagnosis, Differ | 1986 |
Neuroleptic malignant syndrome.
Topics: Adolescent; Adult; Benztropine; Bromocriptine; Catatonia; Child; Child, Preschool; Diagnosis, Differ | 1986 |
Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis.
Topics: Haloperidol; Humans; Psychotic Disorders | 1987 |
Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis.
Topics: Haloperidol; Humans; Psychotic Disorders | 1987 |
[Prepsychotic states in infancy (author's transl)].
Topics: Affective Symptoms; Age Factors; Child; Child Behavior Disorders; Child Development; Child, Preschoo | 1974 |
[Prepsychotic states in infancy (author's transl)].
Topics: Affective Symptoms; Age Factors; Child; Child Behavior Disorders; Child Development; Child, Preschoo | 1974 |
Drug therapy.
Topics: Amphetamine; Antidepressive Agents; Chlorpromazine; Chlorprothixene; Clinical Trials as Topic; Hallu | 1967 |
Drug therapy.
Topics: Amphetamine; Antidepressive Agents; Chlorpromazine; Chlorprothixene; Clinical Trials as Topic; Hallu | 1967 |
197 trials available for haloperidol and Psychotic Disorders
| Article | Year |
|---|---|
Pharmacokinetics of haloperidol in psychotic patients.
Topics: Administration, Oral; Adult; Biological Availability; Haloperidol; Humans; Injections, Intravenous; | 1987 |
Pharmacokinetics of haloperidol in psychotic patients.
Topics: Administration, Oral; Adult; Biological Availability; Haloperidol; Humans; Injections, Intravenous; | 1987 |
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Haloperidol; Human | 2020 |
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Haloperidol; Human | 2020 |
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Haloper | 2017 |
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Haloper | 2017 |
Potential diagnostic markers of olanzapine efficiency for acute psychosis: a focus on peripheral biogenic amines.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers; Dopamine; Dyskinesia, Drug-Ind | 2017 |
Potential diagnostic markers of olanzapine efficiency for acute psychosis: a focus on peripheral biogenic amines.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers; Dopamine; Dyskinesia, Drug-Ind | 2017 |
Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Female; Follow-Up St | 2013 |
Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Female; Follow-Up St | 2013 |
Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Female; Haloperidol; Humans | 2014 |
Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Female; Haloperidol; Humans | 2014 |
Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Male; Metabolic Disea | 2014 |
Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Male; Metabolic Disea | 2014 |
Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; | 2014 |
Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; | 2014 |
Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Delayed-Action Preparations; Female; Haloperid | 2013 |
Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Delayed-Action Preparations; Female; Haloperid | 2013 |
Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Female; Halo | 2015 |
Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Female; Halo | 2015 |
Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Haloperidol; Humans | 2015 |
Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Haloperidol; Humans | 2015 |
Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cost-Benefit Analysis; Delayed-Action Preparations; D | 2016 |
Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cost-Benefit Analysis; Delayed-Action Preparations; D | 2016 |
Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach.
Topics: Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Double-Blind Method; Drug-Related Side Effects | 2009 |
Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach.
Topics: Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Double-Blind Method; Drug-Related Side Effects | 2009 |
Trajectories and antecedents of treatment response over time in early-episode psychosis.
Topics: Adult; Age of Onset; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Early Diagnosis | 2010 |
Trajectories and antecedents of treatment response over time in early-episode psychosis.
Topics: Adult; Age of Onset; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Early Diagnosis | 2010 |
Lack of association between clinical and cognitive change in first-episode psychosis: the first 6 weeks of treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Haloperidol; Humans; Male | 2008 |
Lack of association between clinical and cognitive change in first-episode psychosis: the first 6 weeks of treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Haloperidol; Humans; Male | 2008 |
Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Haloperidol; Humans; Male; Middle Aged; Piperazin | 2009 |
Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Haloperidol; Humans; Male; Middle Aged; Piperazin | 2009 |
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cognition Disorders; Fe | 2009 |
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cognition Disorders; Fe | 2009 |
Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female; Haloperido | 2009 |
Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female; Haloperido | 2009 |
Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Black People; Double-Blind Method; Dyskinesia, Drug-I | 2009 |
Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Black People; Double-Blind Method; Dyskinesia, Drug-I | 2009 |
Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Electrocardiogr | 2010 |
Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Electrocardiogr | 2010 |
Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Aged; Antipsychotic Agents; Blood Pressure; Dose-Response Relationship, Drug; Electrocardiogr | 2010 |
Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Aged; Antipsychotic Agents; Blood Pressure; Dose-Response Relationship, Drug; Electrocardiogr | 2010 |
Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan.
Topics: Acute Disease; Administration, Oral; Adult; Benzodiazepines; Disease Management; Female; Haloperidol | 2010 |
Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan.
Topics: Acute Disease; Administration, Oral; Adult; Benzodiazepines; Disease Management; Female; Haloperidol | 2010 |
Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Ha | 2010 |
Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Ha | 2010 |
Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Diagnostic and Statistical Manual of Menta | 2011 |
Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Diagnostic and Statistical Manual of Menta | 2011 |
Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; | 2011 |
Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; | 2011 |
Blood lactate levels in patients receiving first- or second- generation antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dopamine Antagonists; Drug Monitoring; Haloperidol; Hu | 2011 |
Blood lactate levels in patients receiving first- or second- generation antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dopamine Antagonists; Drug Monitoring; Haloperidol; Hu | 2011 |
Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Dru | 2011 |
Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Dru | 2011 |
Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis.
Topics: Adult; Benzodiazepines; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; | 2012 |
Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis.
Topics: Adult; Benzodiazepines; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; | 2012 |
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Haloperid | 2011 |
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Haloperid | 2011 |
A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; Female; Halop | 2011 |
A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; Female; Halop | 2011 |
First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Substitution; F | 2011 |
First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Substitution; F | 2011 |
Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Executive Function; Female; Hal | 2012 |
Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Executive Function; Female; Hal | 2012 |
Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Dru | 2012 |
Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Dru | 2012 |
Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Awareness; Benzodiazepines; Case-Control Studies; C | 2012 |
Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Awareness; Benzodiazepines; Case-Control Studies; C | 2012 |
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dibenzot | 2013 |
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dibenzot | 2013 |
Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers; Female; Follow-Up Studies; Haloperidol; Hu | 2012 |
Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers; Female; Follow-Up Studies; Haloperidol; Hu | 2012 |
Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Educational Status; Female; Haloperidol; Humans; Logis | 2013 |
Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Educational Status; Female; Haloperidol; Humans; Logis | 2013 |
QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Debrisoquin; Female; Gas Chromatography-Mas | 2002 |
QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Debrisoquin; Female; Gas Chromatography-Mas | 2002 |
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Doubl | 2002 |
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Doubl | 2002 |
The effects of neuroleptic medications on basal ganglia blood flow in schizophreniform disorders: a comparison between the neuroleptic-naïve and medicated states.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Cerebrovascular Circulation; Female; Follow-Up Studies; | 2002 |
The effects of neuroleptic medications on basal ganglia blood flow in schizophreniform disorders: a comparison between the neuroleptic-naïve and medicated states.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Cerebrovascular Circulation; Female; Follow-Up Studies; | 2002 |
Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment.
Topics: Adrenergic beta-Antagonists; Adult; Analysis of Variance; Antipsychotic Agents; Atenolol; Blood Gluc | 2003 |
Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment.
Topics: Adrenergic beta-Antagonists; Adult; Analysis of Variance; Antipsychotic Agents; Atenolol; Blood Gluc | 2003 |
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Clozapine; Double-Bl | 2003 |
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Clozapine; Double-Bl | 2003 |
Age-related alteration of haloperidol-serum protein binding.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Female; Haloperido | 2003 |
Age-related alteration of haloperidol-serum protein binding.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Female; Haloperido | 2003 |
Comparative study of the effectiveness of zuclopenthixol acetate and haloperidol in acutely disturbed psychotic patients.
Topics: Acute Disease; Adult; Brief Psychiatric Rating Scale; Clopenthixol; Dose-Response Relationship, Drug | 2002 |
Comparative study of the effectiveness of zuclopenthixol acetate and haloperidol in acutely disturbed psychotic patients.
Topics: Acute Disease; Adult; Brief Psychiatric Rating Scale; Clopenthixol; Dose-Response Relationship, Drug | 2002 |
Are patients enrolled in first episode psychosis drug trials representative of patients treated in routine clinical practice?
Topics: Adolescent; Adult; Antipsychotic Agents; Cohort Studies; Cross-Cultural Comparison; Female; Haloperi | 2003 |
Are patients enrolled in first episode psychosis drug trials representative of patients treated in routine clinical practice?
Topics: Adolescent; Adult; Antipsychotic Agents; Cohort Studies; Cross-Cultural Comparison; Female; Haloperi | 2003 |
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Metho | 2003 |
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Metho | 2003 |
A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Dose-Response Relationship, Drug; Double-B | 2004 |
A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Dose-Response Relationship, Drug; Double-B | 2004 |
Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Dose-Response Rel | 2003 |
Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Dose-Response Rel | 2003 |
A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Drug Interactions; Dyskinesia, Drug-In | 2004 |
A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Drug Interactions; Dyskinesia, Drug-In | 2004 |
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.
Topics: Adolescent; Adult; Benzodiazepines; Comorbidity; Diagnostic and Statistical Manual of Mental Disorde | 2004 |
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.
Topics: Adolescent; Adult; Benzodiazepines; Comorbidity; Diagnostic and Statistical Manual of Mental Disorde | 2004 |
A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Dibenzothiazepines; Drug Administration Schedule; Dyskinesia, Drug-Indu | 2004 |
A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Dibenzothiazepines; Drug Administration Schedule; Dyskinesia, Drug-Indu | 2004 |
Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cannabinoids; Double-Blind Method; Drugs, Investigati | 2004 |
Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cannabinoids; Double-Blind Method; Drugs, Investigati | 2004 |
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cognition Disorder | 2004 |
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cognition Disorder | 2004 |
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Huma | 2004 |
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Huma | 2004 |
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; | 2004 |
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; | 2004 |
Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzamides; Drug Resistance; Dyskinesia, Drug-Induced; Female; Haloperi | 2005 |
Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzamides; Drug Resistance; Dyskinesia, Drug-Induced; Female; Haloperi | 2005 |
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Ind | 2005 |
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Ind | 2005 |
Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Double-Bli | 2005 |
Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Double-Bli | 2005 |
Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dibenzothiazepines; Femal | 2005 |
Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dibenzothiazepines; Femal | 2005 |
Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; Nursing | 2005 |
Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; Nursing | 2005 |
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Disease Progression; Double-Blind Method; Female; Foll | 2005 |
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Disease Progression; Double-Blind Method; Female; Foll | 2005 |
Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Corpus Striatum; Dose-Respo | 2005 |
Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Corpus Striatum; Dose-Respo | 2005 |
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dose-Response Relationship, Drug; | 2006 |
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dose-Response Relationship, Drug; | 2006 |
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
Topics: Adult; Age of Onset; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Drug Administra | 2005 |
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
Topics: Adult; Age of Onset; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Drug Administra | 2005 |
[Therapy of mental states at high risk for psychosis: preliminary results from Hungary].
Topics: Adult; Antipsychotic Agents; Female; Follow-Up Studies; Haloperidol; Humans; Hungary; Male; Psychoth | 2006 |
[Therapy of mental states at high risk for psychosis: preliminary results from Hungary].
Topics: Adult; Antipsychotic Agents; Female; Follow-Up Studies; Haloperidol; Humans; Hungary; Male; Psychoth | 2006 |
Time course for antipsychotic treatment response in first-episode schizophrenia.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Sch | 2006 |
Time course for antipsychotic treatment response in first-episode schizophrenia.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Sch | 2006 |
Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Female; Haloperidol; Hospitaliz | 2006 |
Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Female; Haloperidol; Hospitaliz | 2006 |
Insight in first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Attitude to Health; Benzodiazepines; Brain; Cognition Disor | 2006 |
Insight in first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Attitude to Health; Benzodiazepines; Brain; Cognition Disor | 2006 |
Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Female; Ha | 2006 |
Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Female; Ha | 2006 |
Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Comorbidity; F | 2007 |
Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Comorbidity; F | 2007 |
Olanzapine and haloperidol in first episode psychosis: two-year data.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Follow-Up Studies; Halope | 2006 |
Olanzapine and haloperidol in first episode psychosis: two-year data.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Follow-Up Studies; Halope | 2006 |
Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Bri | 2006 |
Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Bri | 2006 |
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Dyskinesia Agents; Antipsychotic Agents | 2006 |
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Dyskinesia Agents; Antipsychotic Agents | 2006 |
A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Sc | 2006 |
A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Sc | 2006 |
Remission in first-episode psychosis: predictor variables and symptom improvement patterns.
Topics: Adult; Antipsychotic Agents; Female; Follow-Up Studies; Haloperidol; Humans; Male; Predictive Value | 2006 |
Remission in first-episode psychosis: predictor variables and symptom improvement patterns.
Topics: Adult; Antipsychotic Agents; Female; Follow-Up Studies; Haloperidol; Humans; Male; Predictive Value | 2006 |
Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Do | 2007 |
Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Do | 2007 |
Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial.
Topics: Acoustic Stimulation; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Electromyography; | 2007 |
Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial.
Topics: Acoustic Stimulation; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Electromyography; | 2007 |
Association of symptomatology and cognitive deficits to functional capacity in schizophrenia.
Topics: Activities of Daily Living; Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Cogn | 2008 |
Association of symptomatology and cognitive deficits to functional capacity in schizophrenia.
Topics: Activities of Daily Living; Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Cogn | 2008 |
Haloperidol for chronically hospitalized psychotics: a double-blind comparison with thiothixene and placebo; a follow-up open evaluation.
Topics: Adult; Aged; Antipsychotic Agents; Attitude of Health Personnel; Double-Blind Method; Female; Follow | 1974 |
Haloperidol for chronically hospitalized psychotics: a double-blind comparison with thiothixene and placebo; a follow-up open evaluation.
Topics: Adult; Aged; Antipsychotic Agents; Attitude of Health Personnel; Double-Blind Method; Female; Follow | 1974 |
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Basal Ganglia Disea | 2008 |
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Basal Ganglia Disea | 2008 |
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
Topics: Adolescent; Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass In | 2007 |
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
Topics: Adolescent; Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass In | 2007 |
Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: effects of antipsychotic drugs.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Demography; Diagnostic and Statistical Manual of Menta | 2008 |
Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: effects of antipsychotic drugs.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Demography; Diagnostic and Statistical Manual of Menta | 2008 |
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.
Topics: Adiponectin; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Mass I | 2008 |
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.
Topics: Adiponectin; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Mass I | 2008 |
Lithium response and psychoses: a double-blind, placebo-controlled study.
Topics: Affective Disorders, Psychotic; Chlorides; Clinical Trials as Topic; Double-Blind Method; Drug Thera | 1984 |
Lithium response and psychoses: a double-blind, placebo-controlled study.
Topics: Affective Disorders, Psychotic; Chlorides; Clinical Trials as Topic; Double-Blind Method; Drug Thera | 1984 |
Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Clinical Trials as Topic; Double-Blind Metho | 1984 |
Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Clinical Trials as Topic; Double-Blind Metho | 1984 |
Droperidol vs. haloperidol in the initial management of acutely agitated patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Clinical Trials as Topic; Commitment of Mentally Ill; Danger | 1984 |
Droperidol vs. haloperidol in the initial management of acutely agitated patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Clinical Trials as Topic; Commitment of Mentally Ill; Danger | 1984 |
Comparison of bupropion alone and with haloperidol in schizo-affective disorder, depressed type.
Topics: Adolescent; Adult; Bupropion; Depressive Disorder; Drug Therapy, Combination; Female; Haloperidol; H | 1983 |
Comparison of bupropion alone and with haloperidol in schizo-affective disorder, depressed type.
Topics: Adolescent; Adult; Bupropion; Depressive Disorder; Drug Therapy, Combination; Female; Haloperidol; H | 1983 |
Akathisia with haloperidol and thiothixene.
Topics: Adult; Akathisia, Drug-Induced; Anxiety Disorders; Depressive Disorder; Dose-Response Relationship, | 1984 |
Akathisia with haloperidol and thiothixene.
Topics: Adult; Akathisia, Drug-Induced; Anxiety Disorders; Depressive Disorder; Dose-Response Relationship, | 1984 |
Serum haloperidol concentrations and clinical response in acute psychosis.
Topics: Adolescent; Adult; Chromatography, Gas; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric | 1984 |
Serum haloperidol concentrations and clinical response in acute psychosis.
Topics: Adolescent; Adult; Chromatography, Gas; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric | 1984 |
[Controlled comparison of nalorphine with haloperidol in acute psychoses of the schizophrenic group ].
Topics: Adult; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Middle Aged; Nalorphine; Psychot | 1982 |
[Controlled comparison of nalorphine with haloperidol in acute psychoses of the schizophrenic group ].
Topics: Adult; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Middle Aged; Nalorphine; Psychot | 1982 |
Flupenthixol versus haloperidol in acute psychosis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anxiety Disorders; Bipolar Disorder; Female; Flupenthixol; H | 1983 |
Flupenthixol versus haloperidol in acute psychosis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anxiety Disorders; Bipolar Disorder; Female; Flupenthixol; H | 1983 |
A symptom profile analysis of antipsychotic drug treatment: nonparametric multidimensional technique.
Topics: Drug Combinations; Drug Evaluation; Haloperidol; Humans; Lithium; Psychiatric Status Rating Scales; | 1981 |
A symptom profile analysis of antipsychotic drug treatment: nonparametric multidimensional technique.
Topics: Drug Combinations; Drug Evaluation; Haloperidol; Humans; Lithium; Psychiatric Status Rating Scales; | 1981 |
Clinical evaluation of bromperidol versus haloperidol in psychotic patients.
Topics: Adult; Aged; Akathisia, Drug-Induced; Clinical Trials as Topic; Double-Blind Method; Drug Tolerance; | 1980 |
Clinical evaluation of bromperidol versus haloperidol in psychotic patients.
Topics: Adult; Aged; Akathisia, Drug-Induced; Clinical Trials as Topic; Double-Blind Method; Drug Tolerance; | 1980 |
Cis(Z)-clopenthixol and haloperidol in chronic schizophrenic patients--a double-blind clinical multicentre investigation.
Topics: Adult; Clinical Trials as Topic; Clopenthixol; Double-Blind Method; Female; Haloperidol; Humans; Mal | 1981 |
Cis(Z)-clopenthixol and haloperidol in chronic schizophrenic patients--a double-blind clinical multicentre investigation.
Topics: Adult; Clinical Trials as Topic; Clopenthixol; Double-Blind Method; Female; Haloperidol; Humans; Mal | 1981 |
Efficacy and side effects of haloperidol in psychotic patients: oral versus intravenous administration.
Topics: Administration, Oral; Adult; Female; Haloperidol; Humans; Injections, Intravenous; Male; Prolactin; | 1982 |
Efficacy and side effects of haloperidol in psychotic patients: oral versus intravenous administration.
Topics: Administration, Oral; Adult; Female; Haloperidol; Humans; Injections, Intravenous; Male; Prolactin; | 1982 |
[Flupenthixol versus haloperidol in acute psychotic episodes].
Topics: Acute Disease; Adolescent; Adult; Aged; Bipolar Disorder; Double-Blind Method; Flupenthixol; Haloper | 1982 |
[Flupenthixol versus haloperidol in acute psychotic episodes].
Topics: Acute Disease; Adolescent; Adult; Aged; Bipolar Disorder; Double-Blind Method; Flupenthixol; Haloper | 1982 |
Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; | 1995 |
Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; | 1995 |
Further evidence of a dose-response threshold for haloperidol in psychosis.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; | 1995 |
Further evidence of a dose-response threshold for haloperidol in psychosis.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; | 1995 |
Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Fema | 1993 |
Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Fema | 1993 |
An exploratory evaluation of ECT in haloperidol-treated DSM-IIIR schizophreniform disorder.
Topics: Adolescent; Adult; Double-Blind Method; Electroconvulsive Therapy; Haloperidol; Humans; Male; Middle | 1994 |
An exploratory evaluation of ECT in haloperidol-treated DSM-IIIR schizophreniform disorder.
Topics: Adolescent; Adult; Double-Blind Method; Electroconvulsive Therapy; Haloperidol; Humans; Male; Middle | 1994 |
Predictors of acute dystonia in first-episode psychotic patients.
Topics: Adolescent; Adult; Age Factors; Biperiden; Delusions; Double-Blind Method; Dystonia; Female; Haloper | 1994 |
Predictors of acute dystonia in first-episode psychotic patients.
Topics: Adolescent; Adult; Age Factors; Biperiden; Delusions; Double-Blind Method; Dystonia; Female; Haloper | 1994 |
Rapid tranquilization with intramuscular clonazepam.
Topics: Adult; Bipolar Disorder; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Method; Drug Adm | 1994 |
Rapid tranquilization with intramuscular clonazepam.
Topics: Adult; Bipolar Disorder; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Method; Drug Adm | 1994 |
A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis.
Topics: Acute Disease; Adult; Analysis of Variance; Antipsychotic Agents; Clopenthixol; Delayed-Action Prepa | 1993 |
A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis.
Topics: Acute Disease; Adult; Analysis of Variance; Antipsychotic Agents; Clopenthixol; Delayed-Action Prepa | 1993 |
Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia.
Topics: Adult; Cohort Studies; Comorbidity; Confounding Factors, Epidemiologic; Double-Blind Method; Female; | 1994 |
Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia.
Topics: Adult; Cohort Studies; Comorbidity; Confounding Factors, Epidemiologic; Double-Blind Method; Female; | 1994 |
A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms.
Topics: Adolescent; Adult; Arousal; Bipolar Disorder; Clonazepam; Double-Blind Method; Drug Therapy, Combina | 1993 |
A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms.
Topics: Adolescent; Adult; Arousal; Bipolar Disorder; Clonazepam; Double-Blind Method; Drug Therapy, Combina | 1993 |
Prediction of haloperidol steady-state levels in plasma after a single test dose.
Topics: Adult; Antipsychotic Agents; Biotransformation; Chromatography, Gas; Double-Blind Method; Female; Ha | 1996 |
Prediction of haloperidol steady-state levels in plasma after a single test dose.
Topics: Adult; Antipsychotic Agents; Biotransformation; Chromatography, Gas; Double-Blind Method; Female; Ha | 1996 |
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depre | 1997 |
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depre | 1997 |
Etiologic heterogeneity of the psychoses: is there a dopamine psychosis?
Topics: Adolescent; Adult; Antipsychotic Agents; Family; Female; Haloperidol; Homovanillic Acid; Humans; Mal | 1997 |
Etiologic heterogeneity of the psychoses: is there a dopamine psychosis?
Topics: Adolescent; Adult; Antipsychotic Agents; Family; Female; Haloperidol; Homovanillic Acid; Humans; Mal | 1997 |
A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; D | 1997 |
A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; D | 1997 |
Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Brief Psychiatric Rating Scale; Demogr | 1997 |
Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Brief Psychiatric Rating Scale; Demogr | 1997 |
Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting.
Topics: Administration, Oral; Adolescent; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Double-Blind Met | 1997 |
Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting.
Topics: Administration, Oral; Adolescent; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Double-Blind Met | 1997 |
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration | 1997 |
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration | 1997 |
Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol.
Topics: Aged; Analysis of Variance; Antipsychotic Agents; Clozapine; Haloperidol; Homovanillic Acid; Humans; | 1997 |
Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol.
Topics: Aged; Analysis of Variance; Antipsychotic Agents; Clozapine; Haloperidol; Homovanillic Acid; Humans; | 1997 |
IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzamides; Clozapine; Dibenzothiazepines; Dopamine Antagonists; Female | 1997 |
IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzamides; Clozapine; Dibenzothiazepines; Dopamine Antagonists; Female | 1997 |
Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Depr | 1998 |
Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Depr | 1998 |
An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug | 1998 |
An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug | 1998 |
Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder.
Topics: Adult; Brief Psychiatric Rating Scale; Dopamine; Dopamine Antagonists; Female; Haloperidol; Humans; | 1998 |
Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder.
Topics: Adult; Brief Psychiatric Rating Scale; Dopamine; Dopamine Antagonists; Female; Haloperidol; Humans; | 1998 |
Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Drug Monitoring; Female; Haloperidol; Humans; Male; Middle Aged; Patien | 1998 |
Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Drug Monitoring; Female; Haloperidol; Humans; Male; Middle Aged; Patien | 1998 |
Olanzapine versus haloperidol treatment in first-episode psychosis.
Topics: Age of Onset; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Ratin | 1999 |
Olanzapine versus haloperidol treatment in first-episode psychosis.
Topics: Age of Onset; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Ratin | 1999 |
Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior.
Topics: Acute Disease; Adult; Aggression; Antipsychotic Agents; Brief Psychiatric Rating Scale; Double-Blind | 1999 |
Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior.
Topics: Acute Disease; Adult; Aggression; Antipsychotic Agents; Brief Psychiatric Rating Scale; Double-Blind | 1999 |
Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients.
Topics: Adult; Antipsychotic Agents; Glutamic Acid; Haloperidol; Humans; Male; Middle Aged; Psychiatric Stat | 1999 |
Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients.
Topics: Adult; Antipsychotic Agents; Glutamic Acid; Haloperidol; Humans; Male; Middle Aged; Psychiatric Stat | 1999 |
Optimal haloperidol dosage in first-episode psychosis.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administra | 1999 |
Optimal haloperidol dosage in first-episode psychosis.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administra | 1999 |
Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperido | 1999 |
Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperido | 1999 |
Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Drug Interactions; Drug Therapy, Combi | 1999 |
Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Drug Interactions; Drug Therapy, Combi | 1999 |
Double-blind study of clozapine dose response in chronic schizophrenia.
Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Cross-Sectional Studies; Dose-Respo | 1999 |
Double-blind study of clozapine dose response in chronic schizophrenia.
Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Cross-Sectional Studies; Dose-Respo | 1999 |
Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Child; Cholinergic Antagonist | 1999 |
Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Child; Cholinergic Antagonist | 1999 |
Phenytoin as an antimanic anticonvulsant: a controlled study.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Brief Psychiatric Rating Scale; Double-Blind Me | 2000 |
Phenytoin as an antimanic anticonvulsant: a controlled study.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Brief Psychiatric Rating Scale; Double-Blind Me | 2000 |
High-dose treatment with haloperidol: the effect of dose reduction.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administrat | 2000 |
High-dose treatment with haloperidol: the effect of dose reduction.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administrat | 2000 |
Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Brief Psychiatric Rating Scale; Dose-Response Relation | 2000 |
Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Brief Psychiatric Rating Scale; Dose-Response Relation | 2000 |
Factors affecting serum haloperidol level assessed by longitudinal therapeutic monitoring.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Interac | 2000 |
Factors affecting serum haloperidol level assessed by longitudinal therapeutic monitoring.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Interac | 2000 |
Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group.
Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Drug Administratio | 2000 |
Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group.
Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Drug Administratio | 2000 |
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Blood Pressure; Body Mass Index; Body W | 2001 |
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Blood Pressure; Body Mass Index; Body W | 2001 |
A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Female; Hal | 2001 |
A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Female; Hal | 2001 |
Haloperidol blood levels in acute mania with psychosis.
Topics: Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Female; Haloperidol; Humans; Male; Middle Aged; | 2001 |
Haloperidol blood levels in acute mania with psychosis.
Topics: Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Female; Haloperidol; Humans; Male; Middle Aged; | 2001 |
Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison.
Topics: Adult; Anorexia; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Dizziness; Dose-Re | 2001 |
Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison.
Topics: Adult; Anorexia; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Dizziness; Dose-Re | 2001 |
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Bl | 2001 |
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Bl | 2001 |
Determining the optimal dose of haloperidol in first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Female; Haloperidol; Humans; Male; | 2001 |
Determining the optimal dose of haloperidol in first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Female; Haloperidol; Humans; Male; | 2001 |
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Double-Blind M | 2002 |
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Double-Blind M | 2002 |
Adjunctive antipsychotic treatment is necessary for adolescents with psychotic mania.
Topics: Acute Disease; Adolescent; Age Factors; Bipolar Disorder; Child; Double-Blind Method; Drug Therapy, | 2001 |
Adjunctive antipsychotic treatment is necessary for adolescents with psychotic mania.
Topics: Acute Disease; Adolescent; Age Factors; Bipolar Disorder; Child; Double-Blind Method; Drug Therapy, | 2001 |
Olanzapine versus haloperidol in schizoaffective disorder, bipolar type.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind M | 2001 |
Olanzapine versus haloperidol in schizoaffective disorder, bipolar type.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind M | 2001 |
Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia?
Topics: Aged; Alzheimer Disease; Analysis of Variance; Antidepressive Agents, Second-Generation; Antipsychot | 2001 |
Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia?
Topics: Aged; Alzheimer Disease; Analysis of Variance; Antidepressive Agents, Second-Generation; Antipsychot | 2001 |
The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Dose-Response Relatio | 2002 |
The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Dose-Response Relatio | 2002 |
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Double-Blind Method; Female; Hal | 2002 |
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Double-Blind Method; Female; Hal | 2002 |
[Introductory words to the exchange of results on the clinical effects of bromperidol. Results of open and double blind research].
Topics: Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; Humans; Ma | 1978 |
[Introductory words to the exchange of results on the clinical effects of bromperidol. Results of open and double blind research].
Topics: Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; Humans; Ma | 1978 |
Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine.
Topics: Aged; Biperiden; Clinical Trials as Topic; Clozapine; Dibenzazepines; Drug Therapy, Combination; Dys | 1978 |
Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine.
Topics: Aged; Biperiden; Clinical Trials as Topic; Clozapine; Dibenzazepines; Drug Therapy, Combination; Dys | 1978 |
Parenteral haloperidol in psychiatric emergencies. Double-blind comparison with chlorpromazine.
Topics: Adolescent; Adult; Aged; Chlorpromazine; Clinical Trials as Topic; Drug Evaluation; Emergencies; Fem | 1977 |
Parenteral haloperidol in psychiatric emergencies. Double-blind comparison with chlorpromazine.
Topics: Adolescent; Adult; Aged; Chlorpromazine; Clinical Trials as Topic; Drug Evaluation; Emergencies; Fem | 1977 |
Double-blind study with two butyrophenone derivatives: bromperidol vs. haloperidol.
Topics: Butyrophenones; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Haloperidol; | 1977 |
Double-blind study with two butyrophenone derivatives: bromperidol vs. haloperidol.
Topics: Butyrophenones; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Haloperidol; | 1977 |
Loxapine versus haloperidol parenterally in acute psychosis with agitation. A double-blind study.
Topics: Acute Disease; Adult; Aged; Aggression; Biperiden; Clinical Trials as Topic; Dibenzoxazepines; Doubl | 1977 |
Loxapine versus haloperidol parenterally in acute psychosis with agitation. A double-blind study.
Topics: Acute Disease; Adult; Aged; Aggression; Biperiden; Clinical Trials as Topic; Dibenzoxazepines; Doubl | 1977 |
Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients.
Topics: Acute Disease; Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation | 1977 |
Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients.
Topics: Acute Disease; Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation | 1977 |
A comparison of the efficacy and acceptability of two formulations of injectable serenace in the treatment of states of excitement.
Topics: Acute Disease; Adult; Chemistry, Pharmaceutical; Clinical Trials as Topic; Double-Blind Method; Fema | 1978 |
A comparison of the efficacy and acceptability of two formulations of injectable serenace in the treatment of states of excitement.
Topics: Acute Disease; Adult; Chemistry, Pharmaceutical; Clinical Trials as Topic; Double-Blind Method; Fema | 1978 |
Acute high-dose parenteral haloperidol treatment of psychosis.
Topics: Acute Disease; Adult; Bipolar Disorder; Blood Pressure; Clinical Trials as Topic; Diazepam; Dose-Res | 1979 |
Acute high-dose parenteral haloperidol treatment of psychosis.
Topics: Acute Disease; Adult; Bipolar Disorder; Blood Pressure; Clinical Trials as Topic; Diazepam; Dose-Res | 1979 |
[Trial of interruption of antiparkinson drugs in long term treatments with neuroleptics].
Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as Topic; Fluph | 1975 |
[Trial of interruption of antiparkinson drugs in long term treatments with neuroleptics].
Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as Topic; Fluph | 1975 |
Haloperidol in psychiatry.
Topics: Anxiety Disorders; Basal Ganglia Diseases; Clinical Trials as Topic; Dopamine Antagonists; Fluphenaz | 1975 |
Haloperidol in psychiatry.
Topics: Anxiety Disorders; Basal Ganglia Diseases; Clinical Trials as Topic; Dopamine Antagonists; Fluphenaz | 1975 |
Use of haloperidol decanoate in psychiatric diseases.
Topics: Adult; Drug Utilization; Female; Haloperidol; Hospitals, General; Humans; Hungary; Male; Middle Aged | 1992 |
Use of haloperidol decanoate in psychiatric diseases.
Topics: Adult; Drug Utilization; Female; Haloperidol; Hospitals, General; Humans; Hungary; Male; Middle Aged | 1992 |
Zuclopenthixol and haloperidol in patients with acute psychotic states. A double-blind, multi-centre study.
Topics: Adult; Aged; Biperiden; Clopenthixol; Double-Blind Method; Drug Administration Schedule; Drug Therap | 1992 |
Zuclopenthixol and haloperidol in patients with acute psychotic states. A double-blind, multi-centre study.
Topics: Adult; Aged; Biperiden; Clopenthixol; Double-Blind Method; Drug Administration Schedule; Drug Therap | 1992 |
Haloperidol blood levels and clinical effects.
Topics: Acute Disease; Double-Blind Method; Drug Administration Schedule; Haloperidol; Humans; Placebos; Psy | 1992 |
Haloperidol blood levels and clinical effects.
Topics: Acute Disease; Double-Blind Method; Drug Administration Schedule; Haloperidol; Humans; Placebos; Psy | 1992 |
Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior.
Topics: Acute Disease; Adult; Aggression; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combinati | 1991 |
Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior.
Topics: Acute Disease; Adult; Aggression; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combinati | 1991 |
Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia.
Topics: Adult; Aged; Clopenthixol; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Human | 1991 |
Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia.
Topics: Adult; Aged; Clopenthixol; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Human | 1991 |
Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.
Topics: Acute Disease; Adolescent; Adult; Basal Ganglia Diseases; Double-Blind Method; Drug Administration S | 1991 |
Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.
Topics: Acute Disease; Adolescent; Adult; Basal Ganglia Diseases; Double-Blind Method; Drug Administration S | 1991 |
A double-blind comparative study of remoxipride and haloperidol in acute schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzamides; Double-Blind Method; Female; Hal | 1990 |
A double-blind comparative study of remoxipride and haloperidol in acute schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzamides; Double-Blind Method; Female; Hal | 1990 |
A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzamides; Dose-Response Relationship | 1990 |
A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzamides; Dose-Response Relationship | 1990 |
A double-blind comparative multicentre study of remoxipride and haloperidol in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzamides; Dose-Response Relationship, Drug | 1990 |
A double-blind comparative multicentre study of remoxipride and haloperidol in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzamides; Dose-Response Relationship, Drug | 1990 |
A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Double-Blind Method; Female; | 1990 |
A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Double-Blind Method; Female; | 1990 |
A double-blind multicentre study comparing remoxipride, controlled release formulation, with haloperidol in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; De | 1990 |
A double-blind multicentre study comparing remoxipride, controlled release formulation, with haloperidol in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; De | 1990 |
Clinical profile of remoxipride--a combined analysis of a comparative double-blind multicentre trial programme.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzamides; Double-Blind Method; Female; Haloperidol; | 1990 |
Clinical profile of remoxipride--a combined analysis of a comparative double-blind multicentre trial programme.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzamides; Double-Blind Method; Female; Haloperidol; | 1990 |
The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial.
Topics: Adult; Benztropine; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Halope | 1991 |
The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial.
Topics: Adult; Benztropine; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Halope | 1991 |
Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide.
Topics: Anticonvulsants; Chlorprothixene; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therap | 1990 |
Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide.
Topics: Anticonvulsants; Chlorprothixene; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therap | 1990 |
Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
Topics: Adult; Female; Haloperidol; Humans; Male; Psychiatric Status Rating Scales; Psychotic Disorders; Sch | 1990 |
Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
Topics: Adult; Female; Haloperidol; Humans; Male; Psychiatric Status Rating Scales; Psychotic Disorders; Sch | 1990 |
Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation.
Topics: Adolescent; Adult; Drug Combinations; Drug Therapy, Combination; Female; Haloperidol; Humans; Inject | 1989 |
Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation.
Topics: Adolescent; Adult; Drug Combinations; Drug Therapy, Combination; Female; Haloperidol; Humans; Inject | 1989 |
Molindone and haloperidol in tardive dyskinesia.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Dose-Response Relationship, Drug; Dy | 1985 |
Molindone and haloperidol in tardive dyskinesia.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Dose-Response Relationship, Drug; Dy | 1985 |
Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia.
Topics: Adult; Brief Psychiatric Rating Scale; Erythrocytes; Haloperidol; Humans; Psychiatric Status Rating | 1985 |
Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia.
Topics: Adult; Brief Psychiatric Rating Scale; Erythrocytes; Haloperidol; Humans; Psychiatric Status Rating | 1985 |
Rapid tranquilization: the efficacy of oral concentrate.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Drug Administrat | 1985 |
Rapid tranquilization: the efficacy of oral concentrate.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Drug Administrat | 1985 |
Low-dose treatment strategies.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, | 1986 |
Low-dose treatment strategies.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, | 1986 |
Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Biperiden; Chlorprothixene; Dyskinesia, Drug-I | 1986 |
Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Biperiden; Chlorprothixene; Dyskinesia, Drug-I | 1986 |
[Evaluation of the efficacy of haloperidol decanoate].
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Female; Haloperidol; Humans; Injections, Intr | 1986 |
[Evaluation of the efficacy of haloperidol decanoate].
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Female; Haloperidol; Humans; Injections, Intr | 1986 |
Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol. Results of an open and crossover study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Depression; Dibenzazepines; F | 1987 |
Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol. Results of an open and crossover study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Depression; Dibenzazepines; F | 1987 |
Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses.
Topics: Clinical Trials as Topic; Haloperidol; Humans; Psychotic Disorders | 1988 |
Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses.
Topics: Clinical Trials as Topic; Haloperidol; Humans; Psychotic Disorders | 1988 |
[Clinical experience with bromperidol in chronic psychoses].
Topics: Adolescent; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Female; Haloperidol; Humans; Inp | 1988 |
[Clinical experience with bromperidol in chronic psychoses].
Topics: Adolescent; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Female; Haloperidol; Humans; Inp | 1988 |
[Open clinical trial with haloperidol decanoate in patients with psychotic disorders].
Topics: Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Psychotic Disorders | 1987 |
[Open clinical trial with haloperidol decanoate in patients with psychotic disorders].
Topics: Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Psychotic Disorders | 1987 |
Utility of neuroleptic blood levels in the treatment of acute psychosis.
Topics: Acute Disease; Adult; Female; Haloperidol; Humans; Male; Outcome and Process Assessment, Health Care | 1986 |
Utility of neuroleptic blood levels in the treatment of acute psychosis.
Topics: Acute Disease; Adult; Female; Haloperidol; Humans; Male; Outcome and Process Assessment, Health Care | 1986 |
[Carbamazepine in manic syndromes. A controlled double-blind study].
Topics: Adult; Aged; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Double-Blind Method; Drug Th | 1985 |
[Carbamazepine in manic syndromes. A controlled double-blind study].
Topics: Adult; Aged; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Double-Blind Method; Drug Th | 1985 |
Does a therapeutic window for plasma haloperidol exist?: Preliminary Chinese data.
Topics: Adolescent; Adult; China; Haloperidol; Humans; Middle Aged; Psychotic Disorders; Schizophrenia | 1985 |
Does a therapeutic window for plasma haloperidol exist?: Preliminary Chinese data.
Topics: Adolescent; Adult; China; Haloperidol; Humans; Middle Aged; Psychotic Disorders; Schizophrenia | 1985 |
Plasma haloperidol levels and clinical response: confounding variables.
Topics: Haloperidol; Humans; Psychotic Disorders; Schizophrenia | 1985 |
Plasma haloperidol levels and clinical response: confounding variables.
Topics: Haloperidol; Humans; Psychotic Disorders; Schizophrenia | 1985 |
Efficacy of haloperidol in drug refractory patients.
Topics: Adult; Antidepressive Agents; Clinical Trials as Topic; Female; Fluphenazine; Haloperidol; Humans; M | 1967 |
Efficacy of haloperidol in drug refractory patients.
Topics: Adult; Antidepressive Agents; Clinical Trials as Topic; Female; Fluphenazine; Haloperidol; Humans; M | 1967 |
Comparison of injectable haloperidol and chlorpromazine.
Topics: Acute Disease; Adult; Age Factors; Aged; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as | 1972 |
Comparison of injectable haloperidol and chlorpromazine.
Topics: Acute Disease; Adult; Age Factors; Aged; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as | 1972 |
Haloperidol and chlorpromazine: a double-blind cross-over trial and clinical study in children and adolescents.
Topics: Adjustment Disorders; Adolescent; Analysis of Variance; Child; Child Behavior Disorders; Chlorpromaz | 1973 |
Haloperidol and chlorpromazine: a double-blind cross-over trial and clinical study in children and adolescents.
Topics: Adjustment Disorders; Adolescent; Analysis of Variance; Child; Child Behavior Disorders; Chlorpromaz | 1973 |
The therapeutic effects of lorazepam in psychotic patients treated with haloperidol: a double-blind study.
Topics: Adult; Anxiety; Behavior; Benzazepines; Clinical Trials as Topic; Drug Interactions; Haloperidol; Hu | 1972 |
The therapeutic effects of lorazepam in psychotic patients treated with haloperidol: a double-blind study.
Topics: Adult; Anxiety; Behavior; Benzazepines; Clinical Trials as Topic; Drug Interactions; Haloperidol; Hu | 1972 |
A double-blind comparison of haloperidol (Haldol) and thioridazine (Mellaril) in outpatient children.
Topics: Behavior; Child; Child, Preschool; Clinical Trials as Topic; Female; Haloperidol; Humans; Intellectu | 1972 |
A double-blind comparison of haloperidol (Haldol) and thioridazine (Mellaril) in outpatient children.
Topics: Behavior; Child; Child, Preschool; Clinical Trials as Topic; Female; Haloperidol; Humans; Intellectu | 1972 |
Drug therapy.
Topics: Amphetamine; Antidepressive Agents; Chlorpromazine; Chlorprothixene; Clinical Trials as Topic; Hallu | 1967 |
Drug therapy.
Topics: Amphetamine; Antidepressive Agents; Chlorpromazine; Chlorprothixene; Clinical Trials as Topic; Hallu | 1967 |
Experience with a new butyrophenone derivative (Buronil).
Topics: Aged; Butyrophenones; Clinical Trials as Topic; Dementia; Female; Haloperidol; Humans; Male; Promazi | 1968 |
Experience with a new butyrophenone derivative (Buronil).
Topics: Aged; Butyrophenones; Clinical Trials as Topic; Dementia; Female; Haloperidol; Humans; Male; Promazi | 1968 |
Clinical evaluation of haloperidol in geriatric patients.
Topics: Aged; Clinical Trials as Topic; Dementia; Haloperidol; Humans; Psychomotor Disorders; Psychopharmaco | 1970 |
Clinical evaluation of haloperidol in geriatric patients.
Topics: Aged; Clinical Trials as Topic; Dementia; Haloperidol; Humans; Psychomotor Disorders; Psychopharmaco | 1970 |
[A long-acting neuroleptic. 3. Pilot study of penfluridol (R 16341)].
Topics: Adult; Aged; Clinical Trials as Topic; Delayed-Action Preparations; Electroencephalography; Female; | 1970 |
[A long-acting neuroleptic. 3. Pilot study of penfluridol (R 16341)].
Topics: Adult; Aged; Clinical Trials as Topic; Delayed-Action Preparations; Electroencephalography; Female; | 1970 |
A double-blind comparison of the onset of activity of haloperidol and trifluoperazine.
Topics: Adult; Clinical Trials as Topic; Haloperidol; Humans; Male; Middle Aged; Psychotic Disorders; Time F | 1971 |
A double-blind comparison of the onset of activity of haloperidol and trifluoperazine.
Topics: Adult; Clinical Trials as Topic; Haloperidol; Humans; Male; Middle Aged; Psychotic Disorders; Time F | 1971 |
A quantitative study of neuroleptic-induced extrapyramidal symptoms and their response to dexetimide, a potent and long-acting antiparkinsonian agent.
Topics: Administration, Oral; Adult; Antiparkinson Agents; Basal Ganglia Diseases; Benztropine; Benzyl Compo | 1971 |
A quantitative study of neuroleptic-induced extrapyramidal symptoms and their response to dexetimide, a potent and long-acting antiparkinsonian agent.
Topics: Administration, Oral; Adult; Antiparkinson Agents; Basal Ganglia Diseases; Benztropine; Benzyl Compo | 1971 |
Haloperidol in controlling the symptoms of acute psychoses. II. A double-blind evaluation of haloperidol and trifluoperazine.
Topics: Adult; Clinical Trials as Topic; Haloperidol; Humans; Middle Aged; Psychological Tests; Psychotic Di | 1966 |
Haloperidol in controlling the symptoms of acute psychoses. II. A double-blind evaluation of haloperidol and trifluoperazine.
Topics: Adult; Clinical Trials as Topic; Haloperidol; Humans; Middle Aged; Psychological Tests; Psychotic Di | 1966 |
A controlled evaluation of haloperidol, chlorpromazine, and sodium amobarbital: intramuscular short-term use in acute psychotic patients.
Topics: Acute Disease; Adult; Amobarbital; Chlorpromazine; Clinical Trials as Topic; Female; Haloperidol; Hu | 1969 |
A controlled evaluation of haloperidol, chlorpromazine, and sodium amobarbital: intramuscular short-term use in acute psychotic patients.
Topics: Acute Disease; Adult; Amobarbital; Chlorpromazine; Clinical Trials as Topic; Female; Haloperidol; Hu | 1969 |
A butyrophenone (haloperidol) for the treatment of institutionalized patients.
Topics: Adolescent; Adult; Aged; Antisocial Personality Disorder; Brain Damage, Chronic; Child; Clinical Tri | 1966 |
A butyrophenone (haloperidol) for the treatment of institutionalized patients.
Topics: Adolescent; Adult; Aged; Antisocial Personality Disorder; Brain Damage, Chronic; Child; Clinical Tri | 1966 |
464 other studies available for haloperidol and Psychotic Disorders
| Article | Year |
|---|---|
Pharmacological evaluation of a diarylmethylene-piperidine derivative: a new potent atypical antipsychotic?
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evalua | 2001 |
Pharmacological evaluation of a diarylmethylene-piperidine derivative: a new potent atypical antipsychotic?
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evalua | 2001 |
Upregulation of heat-shock protein HSP-70 and glutamate transporter-1/glutamine synthetase in the striatum and hippocampus in haloperidol-induced dopamine-supersensitivity-state rats.
Topics: Animals; Antipsychotic Agents; Brain; Corpus Striatum; Dopamine; Excitatory Amino Acid Transporter 2 | 2021 |
Upregulation of heat-shock protein HSP-70 and glutamate transporter-1/glutamine synthetase in the striatum and hippocampus in haloperidol-induced dopamine-supersensitivity-state rats.
Topics: Animals; Antipsychotic Agents; Brain; Corpus Striatum; Dopamine; Excitatory Amino Acid Transporter 2 | 2021 |
Olanzapine intramuscular shows better efficacy than zuclopenthixol acetate intramuscular in reducing the need for restraint, but not in comparison to haloperidol intramuscular.
Topics: Antipsychotic Agents; Benzodiazepines; Clopenthixol; Haloperidol; Humans; Injections, Intramuscular; | 2022 |
Olanzapine intramuscular shows better efficacy than zuclopenthixol acetate intramuscular in reducing the need for restraint, but not in comparison to haloperidol intramuscular.
Topics: Antipsychotic Agents; Benzodiazepines; Clopenthixol; Haloperidol; Humans; Injections, Intramuscular; | 2022 |
Atypical, but Not Typical, Antipsychotic Drugs Reduce Hypersynchronized Prefrontal-Hippocampal Circuits during Psychosis-Like States in Mice: Contribution of 5-HT2A and 5-HT1A Receptors.
Topics: Animals; Antipsychotic Agents; Clozapine; Haloperidol; Hippocampus; Mice; Phencyclidine; Prefrontal | 2022 |
Atypical, but Not Typical, Antipsychotic Drugs Reduce Hypersynchronized Prefrontal-Hippocampal Circuits during Psychosis-Like States in Mice: Contribution of 5-HT2A and 5-HT1A Receptors.
Topics: Animals; Antipsychotic Agents; Clozapine; Haloperidol; Hippocampus; Mice; Phencyclidine; Prefrontal | 2022 |
Influence of haloperidol and clozapine on the cognitive performance in patients with psychotic disorders: possible attributes.
Topics: Antipsychotic Agents; Clozapine; Cognition; Haloperidol; Humans; Psychotic Disorders | 2023 |
Influence of haloperidol and clozapine on the cognitive performance in patients with psychotic disorders: possible attributes.
Topics: Antipsychotic Agents; Clozapine; Cognition; Haloperidol; Humans; Psychotic Disorders | 2023 |
An interventional pilot of customized adherence enhancement combined with long-acting injectable antipsychotic medication (CAE-L) for poorly adherent patients with chronic psychotic disorder in Tanzania.
Topics: Adolescent; Adult; Antipsychotic Agents; Delayed-Action Preparations; Haloperidol; Humans; Medicatio | 2022 |
An interventional pilot of customized adherence enhancement combined with long-acting injectable antipsychotic medication (CAE-L) for poorly adherent patients with chronic psychotic disorder in Tanzania.
Topics: Adolescent; Adult; Antipsychotic Agents; Delayed-Action Preparations; Haloperidol; Humans; Medicatio | 2022 |
Acute Onset Psychosis With Mystical Delusions in a Young Male Patient Following Discontinuation of Corticosteroid Therapy: A Case Report.
Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Delusions; Haloperidol; Humans; Male; Psychotic D | 2022 |
Acute Onset Psychosis With Mystical Delusions in a Young Male Patient Following Discontinuation of Corticosteroid Therapy: A Case Report.
Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Delusions; Haloperidol; Humans; Male; Psychotic D | 2022 |
Association of
Topics: Adult; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Genotype; Haloperidol; Humans; Male; Middle Ag | 2022 |
Association of
Topics: Adult; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Genotype; Haloperidol; Humans; Male; Middle Ag | 2022 |
Cariprazine for treating coprophagia and organic psychosis in a young woman with acquired brain injury.
Topics: Antipsychotic Agents; Brain Injuries; Coprophagia; Female; Haloperidol; Humans; Psychotic Disorders | 2023 |
Cariprazine for treating coprophagia and organic psychosis in a young woman with acquired brain injury.
Topics: Antipsychotic Agents; Brain Injuries; Coprophagia; Female; Haloperidol; Humans; Psychotic Disorders | 2023 |
Disclosing common biological signatures and predicting new therapeutic targets in schizophrenia and obsessive-compulsive disorder by integrated bioinformatics analysis.
Topics: Haloperidol; Humans; MicroRNAs; Obsessive-Compulsive Disorder; Psychotic Disorders; Schizophrenia; S | 2023 |
Disclosing common biological signatures and predicting new therapeutic targets in schizophrenia and obsessive-compulsive disorder by integrated bioinformatics analysis.
Topics: Haloperidol; Humans; MicroRNAs; Obsessive-Compulsive Disorder; Psychotic Disorders; Schizophrenia; S | 2023 |
Second International Consensus Study of Antipsychotic Dosing (ICSAD-2).
Topics: Antipsychotic Agents; Delayed-Action Preparations; Haloperidol; Humans; Olanzapine; Psychotic Disord | 2023 |
Second International Consensus Study of Antipsychotic Dosing (ICSAD-2).
Topics: Antipsychotic Agents; Delayed-Action Preparations; Haloperidol; Humans; Olanzapine; Psychotic Disord | 2023 |
Improved Treatment Outcome with Haloperidol Decanoate and Amantadine in an Adolescent with Schizoaffective Disorder.
Topics: Adolescent; Amantadine; Antipsychotic Agents; Haloperidol; Humans; Psychotic Disorders; Treatment Ou | 2023 |
Improved Treatment Outcome with Haloperidol Decanoate and Amantadine in an Adolescent with Schizoaffective Disorder.
Topics: Adolescent; Amantadine; Antipsychotic Agents; Haloperidol; Humans; Psychotic Disorders; Treatment Ou | 2023 |
Severe movement disorder and psychosis from haloperidol withdrawal in a 7-year-old girl with autism.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Female; Haloperidol; Humans; Movement Disorders; Psy | 2021 |
Severe movement disorder and psychosis from haloperidol withdrawal in a 7-year-old girl with autism.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Female; Haloperidol; Humans; Movement Disorders; Psy | 2021 |
Cycloid psychosis and its longitudinal diagnosis: case report.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Female; Haloperidol; Humans; Hypnotics and Sedat | 2020 |
Cycloid psychosis and its longitudinal diagnosis: case report.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Female; Haloperidol; Humans; Hypnotics and Sedat | 2020 |
Situational analysis of prevailing practices in the management of first-episode psychosis in Chennai, India.
Topics: Haloperidol; Humans; India; Olanzapine; Psychotic Disorders; Risperidone | 2021 |
Situational analysis of prevailing practices in the management of first-episode psychosis in Chennai, India.
Topics: Haloperidol; Humans; India; Olanzapine; Psychotic Disorders; Risperidone | 2021 |
Overcoming Complications in Management of a Difficult-to-Treat Adolescent with Schizoaffective Disorder.
Topics: Adolescent; Adolescent Psychiatry; Antidepressive Agents; Antipsychotic Agents; Diphenhydramine; Fem | 2020 |
Overcoming Complications in Management of a Difficult-to-Treat Adolescent with Schizoaffective Disorder.
Topics: Adolescent; Adolescent Psychiatry; Antidepressive Agents; Antipsychotic Agents; Diphenhydramine; Fem | 2020 |
Three Cases of COVID-19-related First Onset Brief Reactive Psychosis.
Topics: Adult; Antipsychotic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Delusions; Haloperid | 2020 |
Three Cases of COVID-19-related First Onset Brief Reactive Psychosis.
Topics: Adult; Antipsychotic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Delusions; Haloperid | 2020 |
Evaluation of NDEL1 oligopeptidase activity in blood and brain in an animal model of schizophrenia: effects of psychostimulants and antipsychotics.
Topics: Animals; Antipsychotic Agents; Brain; Central Nervous System Stimulants; Clozapine; Cysteine Endopep | 2020 |
Evaluation of NDEL1 oligopeptidase activity in blood and brain in an animal model of schizophrenia: effects of psychostimulants and antipsychotics.
Topics: Animals; Antipsychotic Agents; Brain; Central Nervous System Stimulants; Clozapine; Cysteine Endopep | 2020 |
Postpartum psychosis in mothers with SARS-CoV-2 infection: A case series from India.
Topics: Antipsychotic Agents; Asymptomatic Infections; COVID-19; Delusions; Female; Hallucinations; Haloperi | 2020 |
Postpartum psychosis in mothers with SARS-CoV-2 infection: A case series from India.
Topics: Antipsychotic Agents; Asymptomatic Infections; COVID-19; Delusions; Female; Hallucinations; Haloperi | 2020 |
Presynaptic vesicular accumulation is required for antipsychotic efficacy in psychotic-like rats.
Topics: Animals; Antipsychotic Agents; Cells, Cultured; Dopamine D2 Receptor Antagonists; Drug Delivery Syst | 2021 |
Presynaptic vesicular accumulation is required for antipsychotic efficacy in psychotic-like rats.
Topics: Animals; Antipsychotic Agents; Cells, Cultured; Dopamine D2 Receptor Antagonists; Drug Delivery Syst | 2021 |
Effects of repeated electroconvulsive shocks on dopamine supersensitivity psychosis model rats.
Topics: Animals; Antipsychotic Agents; Dopamine; Electroshock; Haloperidol; Humans; Psychotic Disorders; Rat | 2021 |
Effects of repeated electroconvulsive shocks on dopamine supersensitivity psychosis model rats.
Topics: Animals; Antipsychotic Agents; Dopamine; Electroshock; Haloperidol; Humans; Psychotic Disorders; Rat | 2021 |
Risk and Prevention of Aggression in Patients With Psychotic Disorders.
Topics: Aggression; Clozapine; Conduct Disorder; Haloperidol; Humans; Olanzapine; Psychotic Disorders; Schiz | 2021 |
Risk and Prevention of Aggression in Patients With Psychotic Disorders.
Topics: Aggression; Clozapine; Conduct Disorder; Haloperidol; Humans; Olanzapine; Psychotic Disorders; Schiz | 2021 |
Striatal dopamine mediates hallucination-like perception in mice.
Topics: Animals; Auditory Perception; Corpus Striatum; Dopamine; Female; Hallucinations; Haloperidol; Humans | 2021 |
Striatal dopamine mediates hallucination-like perception in mice.
Topics: Animals; Auditory Perception; Corpus Striatum; Dopamine; Female; Hallucinations; Haloperidol; Humans | 2021 |
Pseudodelirium: Psychiatric Conditions to Consider on the Differential for Delirium.
Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Catatonia; Delirium; Diagnosis, Differential; | 2021 |
Pseudodelirium: Psychiatric Conditions to Consider on the Differential for Delirium.
Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Catatonia; Delirium; Diagnosis, Differential; | 2021 |
[Haloperidol and promethazine in psychotic aggression].
Topics: Aggression; Antipsychotic Agents; Drug Therapy, Combination; Haloperidol; Humans; Promethazine; Psyc | 2017 |
[Haloperidol and promethazine in psychotic aggression].
Topics: Aggression; Antipsychotic Agents; Drug Therapy, Combination; Haloperidol; Humans; Promethazine; Psyc | 2017 |
Narcolepsy-cataplexy and psychosis: a case study.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compound | 2017 |
Narcolepsy-cataplexy and psychosis: a case study.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compound | 2017 |
Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats.
Topics: Animals; Antipsychotic Agents; Brain; Dopamine; Glutamate Decarboxylase; Glutamic Acid; Glutamine; H | 2017 |
Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats.
Topics: Animals; Antipsychotic Agents; Brain; Dopamine; Glutamate Decarboxylase; Glutamic Acid; Glutamine; H | 2017 |
Extract of Synedrella nodiflora (L) Gaertn exhibits antipsychotic properties in murine models of psychosis.
Topics: Animals; Antipsychotic Agents; Apomorphine; Asteraceae; Behavior, Animal; Catalepsy; Chlorpromazine; | 2017 |
Extract of Synedrella nodiflora (L) Gaertn exhibits antipsychotic properties in murine models of psychosis.
Topics: Animals; Antipsychotic Agents; Apomorphine; Asteraceae; Behavior, Animal; Catalepsy; Chlorpromazine; | 2017 |
Meditation induced psychosis: Case report.
Topics: Adult; Antipsychotic Agents; GABA Modulators; Haloperidol; Humans; Lorazepam; Male; Meditation; Prom | 2018 |
Meditation induced psychosis: Case report.
Topics: Adult; Antipsychotic Agents; GABA Modulators; Haloperidol; Humans; Lorazepam; Male; Meditation; Prom | 2018 |
Nicotine and caffeine modulate haloperidol-induced changes in postsynaptic density transcripts expression: Translational insights in psychosis therapy and treatment resistance.
Topics: Animals; Brain; Caffeine; Central Nervous System Agents; Cytoskeletal Proteins; Drug Interactions; D | 2018 |
Nicotine and caffeine modulate haloperidol-induced changes in postsynaptic density transcripts expression: Translational insights in psychosis therapy and treatment resistance.
Topics: Animals; Brain; Caffeine; Central Nervous System Agents; Cytoskeletal Proteins; Drug Interactions; D | 2018 |
Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study.
Topics: Administration, Oral; Adult; Algorithms; Antipsychotic Agents; Clozapine; Commitment of Mentally Ill | 2019 |
Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study.
Topics: Administration, Oral; Adult; Algorithms; Antipsychotic Agents; Clozapine; Commitment of Mentally Ill | 2019 |
[In process].
Topics: Antipsychotic Agents; Atrophy; Brain; Cerebral Cortex; Dopamine; Dose-Response Relationship, Drug; G | 2016 |
[In process].
Topics: Antipsychotic Agents; Atrophy; Brain; Cerebral Cortex; Dopamine; Dose-Response Relationship, Drug; G | 2016 |
Schizophrenia dimension-specific antipsychotic drug action and failure in amphetamine-sensitized psychotic-like rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Disease Models, Animal; Dose-Re | 2018 |
Schizophrenia dimension-specific antipsychotic drug action and failure in amphetamine-sensitized psychotic-like rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Disease Models, Animal; Dose-Re | 2018 |
Effects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: a responder analysis.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Dopamine | 2019 |
Effects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: a responder analysis.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Dopamine | 2019 |
Role of D3 dopamine receptors in modulating neuroanatomical changes in response to antipsychotic administration.
Topics: Animals; Antipsychotic Agents; Cell Count; Clozapine; Corpus Striatum; Female; Gyrus Cinguli; Halope | 2019 |
Role of D3 dopamine receptors in modulating neuroanatomical changes in response to antipsychotic administration.
Topics: Animals; Antipsychotic Agents; Cell Count; Clozapine; Corpus Striatum; Female; Gyrus Cinguli; Halope | 2019 |
Adverse drug reactions experienced by out-patients taking chlorpromazine or haloperidol at Zomba Mental Hospital, Malawi.
Topics: Adolescent; Adult; Antipsychotic Agents; Chlorpromazine; Cross-Sectional Studies; Erectile Dysfuncti | 2019 |
Adverse drug reactions experienced by out-patients taking chlorpromazine or haloperidol at Zomba Mental Hospital, Malawi.
Topics: Adolescent; Adult; Antipsychotic Agents; Chlorpromazine; Cross-Sectional Studies; Erectile Dysfuncti | 2019 |
First generation antipsychotic-induced severe hypothermia: A case report and review of the literature.
Topics: Antipsychotic Agents; Chlorpromazine; Diagnosis, Differential; Drug Administration Schedule; Female; | 2019 |
First generation antipsychotic-induced severe hypothermia: A case report and review of the literature.
Topics: Antipsychotic Agents; Chlorpromazine; Diagnosis, Differential; Drug Administration Schedule; Female; | 2019 |
Prevalence and clinical presentation of HIV positive female psychiatric inpatients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Cross-Sectional Studie | 2013 |
Prevalence and clinical presentation of HIV positive female psychiatric inpatients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Cross-Sectional Studie | 2013 |
Psychotic disorder after contact with a potentially rabid animal and post-exposure prophylactic anti-rabies treatment.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Clonazepam; Diag | 2014 |
Psychotic disorder after contact with a potentially rabid animal and post-exposure prophylactic anti-rabies treatment.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Clonazepam; Diag | 2014 |
Thyrotoxic psychosis in an elderly woman and haloperidol use: a case report.
Topics: Antipsychotic Agents; Antithyroid Agents; Apathy; Diagnosis, Differential; Female; Hallucinations; H | 2013 |
Thyrotoxic psychosis in an elderly woman and haloperidol use: a case report.
Topics: Antipsychotic Agents; Antithyroid Agents; Apathy; Diagnosis, Differential; Female; Hallucinations; H | 2013 |
Cobalamin deficiency manifested with seizures, mood oscillations, psychotic features and reversible dementia in the absence of typical neurologic and hematologic signs and symptoms: a case report.
Topics: Carbamazepine; Dementia; Diazepam; Electroencephalography; Haloperidol; Hematology; Humans; Hydroxoc | 2013 |
Cobalamin deficiency manifested with seizures, mood oscillations, psychotic features and reversible dementia in the absence of typical neurologic and hematologic signs and symptoms: a case report.
Topics: Carbamazepine; Dementia; Diazepam; Electroencephalography; Haloperidol; Hematology; Humans; Hydroxoc | 2013 |
What about temperature? Haloperidol-induced hypotermia.
Topics: Antipsychotic Agents; Body Temperature; Female; Follow-Up Studies; Haloperidol; Humans; Hypothermia; | 2013 |
What about temperature? Haloperidol-induced hypotermia.
Topics: Antipsychotic Agents; Body Temperature; Female; Follow-Up Studies; Haloperidol; Humans; Hypothermia; | 2013 |
Is the use of haloperidol a safe and effective method of tranquilization for patients with psychosis-induced aggression or agitation?
Topics: Aggression; Antipsychotic Agents; Haloperidol; Humans; Psychomotor Agitation; Psychotic Disorders | 2014 |
Is the use of haloperidol a safe and effective method of tranquilization for patients with psychosis-induced aggression or agitation?
Topics: Aggression; Antipsychotic Agents; Haloperidol; Humans; Psychomotor Agitation; Psychotic Disorders | 2014 |
[QTc prolongation induced by intravenous sedation with Haloperidol, Prothipendyl and Lorazepam].
Topics: Adult; Age Factors; Aged; Comorbidity; Conscious Sedation; Drug Synergism; Drug Therapy, Combination | 2014 |
[QTc prolongation induced by intravenous sedation with Haloperidol, Prothipendyl and Lorazepam].
Topics: Adult; Age Factors; Aged; Comorbidity; Conscious Sedation; Drug Synergism; Drug Therapy, Combination | 2014 |
[Emergency psychopharmacotherapy in Hungary -- preliminary data].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clopenthixol; Droperidol; Drug Prescript | 2014 |
[Emergency psychopharmacotherapy in Hungary -- preliminary data].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clopenthixol; Droperidol; Drug Prescript | 2014 |
Effects of antipsychotic drugs on insight in schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Awareness; Benzodiazepines; Female; Haloperidol; Humans; | 2014 |
Effects of antipsychotic drugs on insight in schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Awareness; Benzodiazepines; Female; Haloperidol; Humans; | 2014 |
Koro presenting as acute and transient psychosis: implications for classification.
Topics: Adult; Antipsychotic Agents; Diagnosis, Differential; Haloperidol; Humans; Koro; Male; Promethazine; | 2014 |
Koro presenting as acute and transient psychosis: implications for classification.
Topics: Adult; Antipsychotic Agents; Diagnosis, Differential; Haloperidol; Humans; Koro; Male; Promethazine; | 2014 |
[Psychiatric problems in a motor disorder: psychosis in Huntington's disease].
Topics: Antipsychotic Agents; Haloperidol; Humans; Huntington Disease; Male; Middle Aged; Psychotic Disorder | 2015 |
[Psychiatric problems in a motor disorder: psychosis in Huntington's disease].
Topics: Antipsychotic Agents; Haloperidol; Humans; Huntington Disease; Male; Middle Aged; Psychotic Disorder | 2015 |
[First Episode Psychosis: Relationship of Symptoms, Initial Treatment and Clinical Response].
Topics: Adolescent; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; Female; Hal | 2015 |
[First Episode Psychosis: Relationship of Symptoms, Initial Treatment and Clinical Response].
Topics: Adolescent; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; Female; Hal | 2015 |
G protein-coupled receptor kinase 6/β-arrestin 2 system in a rat model of dopamine supersensitivity psychosis.
Topics: Animals; Antipsychotic Agents; Arrestins; beta-Arrestin 2; beta-Arrestins; Dopamine; G-Protein-Coupl | 2015 |
G protein-coupled receptor kinase 6/β-arrestin 2 system in a rat model of dopamine supersensitivity psychosis.
Topics: Animals; Antipsychotic Agents; Arrestins; beta-Arrestin 2; beta-Arrestins; Dopamine; G-Protein-Coupl | 2015 |
Comparative effectiveness of long-acting antipsychotics: issues and challenges from a pragmatic randomised study.
Topics: Antipsychotic Agents; Haloperidol; Humans; Paliperidone Palmitate; Psychotic Disorders; Randomized C | 2016 |
Comparative effectiveness of long-acting antipsychotics: issues and challenges from a pragmatic randomised study.
Topics: Antipsychotic Agents; Haloperidol; Humans; Paliperidone Palmitate; Psychotic Disorders; Randomized C | 2016 |
Drug-induced parkinsonism following chronic methamphetamine use by a patient on haloperidol decanoate.
Topics: Adult; Amphetamine-Related Disorders; Diphenhydramine; Dose-Response Relationship, Drug; Drug Intera | 2015 |
Drug-induced parkinsonism following chronic methamphetamine use by a patient on haloperidol decanoate.
Topics: Adult; Amphetamine-Related Disorders; Diphenhydramine; Dose-Response Relationship, Drug; Drug Intera | 2015 |
Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics.
Topics: Adult; Amino Acids; Antipsychotic Agents; Chromatography, Ion Exchange; Clopenthixol; Clozapine; Coh | 2015 |
Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics.
Topics: Adult; Amino Acids; Antipsychotic Agents; Chromatography, Ion Exchange; Clopenthixol; Clozapine; Coh | 2015 |
Managing Care of an Intrapartum Patient with Agitation and Psychosis: Ethical and Legal Implications.
Topics: Adult; Antipsychotic Agents; Cesarean Section; Decision Making; Ethical Analysis; Ethics Consultatio | 2016 |
Managing Care of an Intrapartum Patient with Agitation and Psychosis: Ethical and Legal Implications.
Topics: Adult; Antipsychotic Agents; Cesarean Section; Decision Making; Ethical Analysis; Ethics Consultatio | 2016 |
The predictive value of early treatment response in antipsychotic-naive patients with first-episode psychosis: Haloperidol versus olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; Haloperidol; Humans; Male; O | 2016 |
The predictive value of early treatment response in antipsychotic-naive patients with first-episode psychosis: Haloperidol versus olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; Haloperidol; Humans; Male; O | 2016 |
Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia.
Topics: Animals; Antipsychotic Agents; Cerebral Cortex; Drug Resistance; Gene Expression; Haloperidol; Homer | 2017 |
Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia.
Topics: Animals; Antipsychotic Agents; Cerebral Cortex; Drug Resistance; Gene Expression; Haloperidol; Homer | 2017 |
Revisiting an old foe: The face of psychosis in neurosyphilis.
Topics: Anti-Bacterial Agents; Antipsychotic Agents; Haloperidol; Humans; Male; Middle Aged; Neurosyphilis; | 2016 |
Revisiting an old foe: The face of psychosis in neurosyphilis.
Topics: Anti-Bacterial Agents; Antipsychotic Agents; Haloperidol; Humans; Male; Middle Aged; Neurosyphilis; | 2016 |
The Relationship Between Early Haloperidol Response and Associated Extrapyramidal Side Effects.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Brief Psychiatric Rating Scale; Dyskinesia, Dr | 2017 |
The Relationship Between Early Haloperidol Response and Associated Extrapyramidal Side Effects.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Brief Psychiatric Rating Scale; Dyskinesia, Dr | 2017 |
Attitudes of patients and family members towards implantable psychiatric medication.
Topics: Adult; Attitude to Health; Clozapine; Cross-Cultural Comparison; Data Collection; Drug Implants; Fam | 2008 |
Attitudes of patients and family members towards implantable psychiatric medication.
Topics: Adult; Attitude to Health; Clozapine; Cross-Cultural Comparison; Data Collection; Drug Implants; Fam | 2008 |
Haloperidol versus chlorpromazine for treatment of schizophrenia.
Topics: Antipsychotic Agents; Chlorpromazine; Haloperidol; Humans; Psychotic Disorders; Randomized Controlle | 2008 |
Haloperidol versus chlorpromazine for treatment of schizophrenia.
Topics: Antipsychotic Agents; Chlorpromazine; Haloperidol; Humans; Psychotic Disorders; Randomized Controlle | 2008 |
Acute disseminated encephalomyelitis presenting as acute psychotic disorder.
Topics: Acute Disease; Anti-Inflammatory Agents; Antipsychotic Agents; Child; Child, Preschool; Diagnosis, D | 2008 |
Acute disseminated encephalomyelitis presenting as acute psychotic disorder.
Topics: Acute Disease; Anti-Inflammatory Agents; Antipsychotic Agents; Child; Child, Preschool; Diagnosis, D | 2008 |
Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-B | 2008 |
Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-B | 2008 |
The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice.
Topics: Analgesics, Opioid; Animals; Antipsychotic Agents; Belgium; Butyrophenones; Drug Industry; Haloperid | 2009 |
The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice.
Topics: Analgesics, Opioid; Animals; Antipsychotic Agents; Belgium; Butyrophenones; Drug Industry; Haloperid | 2009 |
New-onset psychosis after temporal lobectomy.
Topics: Antipsychotic Agents; Electroencephalography; Epilepsy, Temporal Lobe; Haloperidol; Humans; Magnetic | 2008 |
New-onset psychosis after temporal lobectomy.
Topics: Antipsychotic Agents; Electroencephalography; Epilepsy, Temporal Lobe; Haloperidol; Humans; Magnetic | 2008 |
The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; | 2009 |
The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; | 2009 |
Neuroleptic malignant syndrome with use of quetiapine in mental retardation.
Topics: Antipsychotic Agents; Dibenzothiazepines; Drug Therapy, Combination; Haloperidol; Humans; Intellectu | 2009 |
Neuroleptic malignant syndrome with use of quetiapine in mental retardation.
Topics: Antipsychotic Agents; Dibenzothiazepines; Drug Therapy, Combination; Haloperidol; Humans; Intellectu | 2009 |
Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Sch | 2009 |
Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Sch | 2009 |
Acute altered mental status in a psychiatric patient.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benztropine; Consciousness Disorders; Diagnosis, Differe | 2009 |
Acute altered mental status in a psychiatric patient.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benztropine; Consciousness Disorders; Diagnosis, Differe | 2009 |
[Catatonia in a 14 year-old girl: treatment with clorazepam and carbamazepine, a 10-year follow-up].
Topics: Acute Disease; Adolescent; Adult; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Cataplexy; C | 2010 |
[Catatonia in a 14 year-old girl: treatment with clorazepam and carbamazepine, a 10-year follow-up].
Topics: Acute Disease; Adolescent; Adult; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Cataplexy; C | 2010 |
Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis?
Topics: Amphetamine; Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dopamine; Dopamine Up | 2010 |
Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis?
Topics: Amphetamine; Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dopamine; Dopamine Up | 2010 |
The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
Topics: Adult; Alleles; Antipsychotic Agents; Bipolar Disorder; Clozapine; Cytochrome P-450 CYP2D6; Dibenzot | 2010 |
The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
Topics: Adult; Alleles; Antipsychotic Agents; Bipolar Disorder; Clozapine; Cytochrome P-450 CYP2D6; Dibenzot | 2010 |
Acute psychosis associated with dissociated sleep-wakefulness state after mirtazapine treatment.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Depressive Disorder, Major; Dreams; Ha | 2010 |
Acute psychosis associated with dissociated sleep-wakefulness state after mirtazapine treatment.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Depressive Disorder, Major; Dreams; Ha | 2010 |
Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relati | 2010 |
Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relati | 2010 |
The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics.
Topics: Aged; Antipsychotic Agents; Cinnarizine; Cohort Studies; Diagnosis, Differential; Female; Flunarizin | 2010 |
The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics.
Topics: Aged; Antipsychotic Agents; Cinnarizine; Cohort Studies; Diagnosis, Differential; Female; Flunarizin | 2010 |
An early improvement threshold to predict response and remission in first-episode schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Germany; Ha | 2010 |
An early improvement threshold to predict response and remission in first-episode schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Germany; Ha | 2010 |
Opposite roles of dopamine and orexin in quinpirole-induced excessive drinking: a rat model of psychotic polydipsia.
Topics: Animals; Benzoxazoles; Cerebral Cortex; Conditioning, Operant; Corticosterone; Disease Models, Anima | 2010 |
Opposite roles of dopamine and orexin in quinpirole-induced excessive drinking: a rat model of psychotic polydipsia.
Topics: Animals; Benzoxazoles; Cerebral Cortex; Conditioning, Operant; Corticosterone; Disease Models, Anima | 2010 |
Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Clozapine | 2011 |
Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Clozapine | 2011 |
Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Fe | 2011 |
Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Fe | 2011 |
Folie à deux: double case-report of shared delusions with a fatal outcome.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Clozapine; Combined Modality Therapy; | 2011 |
Folie à deux: double case-report of shared delusions with a fatal outcome.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Clozapine; Combined Modality Therapy; | 2011 |
[The effect of serotonin on the cytotoxic activity of natural killer lymphocytes in patients with the first episode of endogenous psychosis].
Topics: Adolescent; Adult; Antipsychotic Agents; Clozapine; Cytotoxicity, Immunologic; Haloperidol; Humans; | 2011 |
[The effect of serotonin on the cytotoxic activity of natural killer lymphocytes in patients with the first episode of endogenous psychosis].
Topics: Adolescent; Adult; Antipsychotic Agents; Clozapine; Cytotoxicity, Immunologic; Haloperidol; Humans; | 2011 |
B vitamins attenuate haloperidol-induced orofacial dyskinesia in rats: possible involvement of antioxidant mechanisms.
Topics: Animals; Antioxidants; Antipsychotic Agents; Behavior, Animal; Drug Therapy, Combination; Dyskinesia | 2011 |
B vitamins attenuate haloperidol-induced orofacial dyskinesia in rats: possible involvement of antioxidant mechanisms.
Topics: Animals; Antioxidants; Antipsychotic Agents; Behavior, Animal; Drug Therapy, Combination; Dyskinesia | 2011 |
Cerebral blood flow changes in very-late-onset schizophrenia-like psychosis with catatonia before and after successful treatment.
Topics: Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Catatonia; Cerebrovascular Circulation; Fe | 2011 |
Cerebral blood flow changes in very-late-onset schizophrenia-like psychosis with catatonia before and after successful treatment.
Topics: Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Catatonia; Cerebrovascular Circulation; Fe | 2011 |
Neuroleptic-induced catatonia in two hospitalized patients.
Topics: Adult; Antipsychotic Agents; Dopamine D2 Receptor Antagonists; Female; Haloperidol; Hospitalization; | 2012 |
Neuroleptic-induced catatonia in two hospitalized patients.
Topics: Adult; Antipsychotic Agents; Dopamine D2 Receptor Antagonists; Female; Haloperidol; Hospitalization; | 2012 |
Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Female; Haloperido | 2011 |
Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Female; Haloperido | 2011 |
Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Combinations; Drug Interactions; Female; Haloperidol | 2012 |
Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Combinations; Drug Interactions; Female; Haloperidol | 2012 |
Effects of sertraline on experimental mouse models of psychosis.
Topics: Animals; Antidepressive Agents; Apomorphine; Catalepsy; Dextroamphetamine; Disease Models, Animal; D | 2012 |
Effects of sertraline on experimental mouse models of psychosis.
Topics: Animals; Antidepressive Agents; Apomorphine; Catalepsy; Dextroamphetamine; Disease Models, Animal; D | 2012 |
Antipsychotics leading to neuroleptic malignant syndrome in pregnancy.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Neuroleptic Malignant Syndrome; Pregnancy; | 2012 |
Antipsychotics leading to neuroleptic malignant syndrome in pregnancy.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Neuroleptic Malignant Syndrome; Pregnancy; | 2012 |
Effect of zinc in animal models of anxiety, depression and psychosis.
Topics: Animals; Anxiety; Behavior, Animal; Central Nervous System Agents; Chlorides; Depression; Disease Mo | 2012 |
Effect of zinc in animal models of anxiety, depression and psychosis.
Topics: Animals; Anxiety; Behavior, Animal; Central Nervous System Agents; Chlorides; Depression; Disease Mo | 2012 |
Reduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidol.
Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Ratin | 2012 |
Reduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidol.
Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Ratin | 2012 |
Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Disease Models, Animal; Down-Regulation; | 2013 |
Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Disease Models, Animal; Down-Regulation; | 2013 |
AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment.
Topics: A Kinase Anchor Proteins; Adult; Antipsychotic Agents; Bipolar Disorder; Calcium Channels; Drug Resi | 2013 |
AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment.
Topics: A Kinase Anchor Proteins; Adult; Antipsychotic Agents; Bipolar Disorder; Calcium Channels; Drug Resi | 2013 |
No association of a set of candidate genes on haloperidol side effects.
Topics: Analysis of Variance; Antipsychotic Agents; Cytochrome P-450 CYP3A; Haloperidol; Humans; Psychotic D | 2012 |
No association of a set of candidate genes on haloperidol side effects.
Topics: Analysis of Variance; Antipsychotic Agents; Cytochrome P-450 CYP3A; Haloperidol; Humans; Psychotic D | 2012 |
Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Child; Clozapine; Double-Blind Method; Fem | 2002 |
Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Child; Clozapine; Double-Blind Method; Fem | 2002 |
The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Delayed-Action Preparations; Dose | 2002 |
The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Delayed-Action Preparations; Dose | 2002 |
[Deterioration of schizoaffective disorder due to an interaction between haloperidol and carbamazepine].
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Drug Interactions; Female; Haloperidol | 2002 |
[Deterioration of schizoaffective disorder due to an interaction between haloperidol and carbamazepine].
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Drug Interactions; Female; Haloperidol | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Clozapine; | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Clozapine; | 2003 |
[Deterioration of schizoaffective disorder due to an interaction between haloperidol and carbamazepine].
Topics: Antipsychotic Agents; Carbamazepine; Drug Interactions; Haloperidol; Psychotic Disorders | 2003 |
[Deterioration of schizoaffective disorder due to an interaction between haloperidol and carbamazepine].
Topics: Antipsychotic Agents; Carbamazepine; Drug Interactions; Haloperidol; Psychotic Disorders | 2003 |
Fire-settng behavior associated with Klinefelter syndrome.
Topics: Adult; Antipsychotic Agents; Firesetting Behavior; Haloperidol; Humans; Klinefelter Syndrome; Male; | 2002 |
Fire-settng behavior associated with Klinefelter syndrome.
Topics: Adult; Antipsychotic Agents; Firesetting Behavior; Haloperidol; Humans; Klinefelter Syndrome; Male; | 2002 |
Urethral masturbation and sexual disinhibition in dementia: a case report.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Foreign Bodies; Haloperidol; Human | 2003 |
Urethral masturbation and sexual disinhibition in dementia: a case report.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Foreign Bodies; Haloperidol; Human | 2003 |
[Deterioration of schizoaffective disorder due to an interaction between haloperidol and carbamazepine].
Topics: Antipsychotic Agents; Carbamazepine; Drug Interactions; Haloperidol; Humans; Psychotic Disorders | 2003 |
[Deterioration of schizoaffective disorder due to an interaction between haloperidol and carbamazepine].
Topics: Antipsychotic Agents; Carbamazepine; Drug Interactions; Haloperidol; Humans; Psychotic Disorders | 2003 |
[Study & clinical trial of R 1625 or haloperidol, a new neuroleptic & so-called neurodysleptic agent].
Topics: Antipsychotic Agents; Electroconvulsive Therapy; Haloperidol; Humans; Hypnotics and Sedatives; Menta | 1959 |
[Study & clinical trial of R 1625 or haloperidol, a new neuroleptic & so-called neurodysleptic agent].
Topics: Antipsychotic Agents; Electroconvulsive Therapy; Haloperidol; Humans; Hypnotics and Sedatives; Menta | 1959 |
[Contribution to the study of R-1625 or haloperidol in chronic psychoses or behavior disorders of certain mentally degenerated patients].
Topics: Anesthesia; Chronic Disease; Haloperidol; Hypnotics and Sedatives; Mental Disorders; Psychopharmacol | 1960 |
[Contribution to the study of R-1625 or haloperidol in chronic psychoses or behavior disorders of certain mentally degenerated patients].
Topics: Anesthesia; Chronic Disease; Haloperidol; Hypnotics and Sedatives; Mental Disorders; Psychopharmacol | 1960 |
[Haloperidol in the treatment of delirium tremens].
Topics: Alcohol Withdrawal Delirium; Anesthesia; Haloperidol; Humans; Hypnotics and Sedatives; Mental Disord | 1961 |
[Haloperidol in the treatment of delirium tremens].
Topics: Alcohol Withdrawal Delirium; Anesthesia; Haloperidol; Humans; Hypnotics and Sedatives; Mental Disord | 1961 |
[Haloperidol in states of manic excitation (apropos of 10 cases)].
Topics: Anesthesia; Bipolar Disorder; Haloperidol; Humans; Hypnotics and Sedatives; Mental Disorders; Psycho | 1961 |
[Haloperidol in states of manic excitation (apropos of 10 cases)].
Topics: Anesthesia; Bipolar Disorder; Haloperidol; Humans; Hypnotics and Sedatives; Mental Disorders; Psycho | 1961 |
[Clinical experience with Haloperidol, a chemically and clinically specific neuroplegic].
Topics: Electroconvulsive Therapy; Haloperidol; Hypnotics and Sedatives; Psychosurgery; Psychotherapy; Psych | 1961 |
[Clinical experience with Haloperidol, a chemically and clinically specific neuroplegic].
Topics: Electroconvulsive Therapy; Haloperidol; Hypnotics and Sedatives; Psychosurgery; Psychotherapy; Psych | 1961 |
[On the therapy of various acute psychoses with "R 1625" and on a rare extra neurological complication (parotitis)].
Topics: Electroconvulsive Therapy; Haloperidol; Hypnotics and Sedatives; Parotitis; Psychosurgery; Psychotic | 1960 |
[On the therapy of various acute psychoses with "R 1625" and on a rare extra neurological complication (parotitis)].
Topics: Electroconvulsive Therapy; Haloperidol; Hypnotics and Sedatives; Parotitis; Psychosurgery; Psychotic | 1960 |
[Our experience with haloperidol (R-1625) in psychiatric treatment].
Topics: Electroconvulsive Therapy; Haloperidol; Hypnotics and Sedatives; Psychosurgery; Psychotherapy; Psych | 1960 |
[Our experience with haloperidol (R-1625) in psychiatric treatment].
Topics: Electroconvulsive Therapy; Haloperidol; Hypnotics and Sedatives; Psychosurgery; Psychotherapy; Psych | 1960 |
[Haloperidol (R-1625) in psychiatric practice (its therapeutic results obtained in 42 cases of mental diseases)].
Topics: Haloperidol; Humans; Mental Disorders; Psychopharmacology; Psychotic Disorders | 1960 |
[Haloperidol (R-1625) in psychiatric practice (its therapeutic results obtained in 42 cases of mental diseases)].
Topics: Haloperidol; Humans; Mental Disorders; Psychopharmacology; Psychotic Disorders | 1960 |
[The therapy of psychoses with haloperidol].
Topics: Electroconvulsive Therapy; Haloperidol; Hypnotics and Sedatives; Mental Disorders; Psychosurgery; Ps | 1960 |
[The therapy of psychoses with haloperidol].
Topics: Electroconvulsive Therapy; Haloperidol; Hypnotics and Sedatives; Mental Disorders; Psychosurgery; Ps | 1960 |
[Clinical tests of haldol].
Topics: Electroconvulsive Therapy; Haloperidol; Hypnotics and Sedatives; Psychosurgery; Psychotherapy; Psych | 1961 |
[Clinical tests of haldol].
Topics: Electroconvulsive Therapy; Haloperidol; Hypnotics and Sedatives; Psychosurgery; Psychotherapy; Psych | 1961 |
[Clinical experience with Haloperidol].
Topics: Electroconvulsive Therapy; Haloperidol; Hypnotics and Sedatives; Psychosurgery; Psychotherapy; Psych | 1961 |
[Clinical experience with Haloperidol].
Topics: Electroconvulsive Therapy; Haloperidol; Hypnotics and Sedatives; Psychosurgery; Psychotherapy; Psych | 1961 |
[Clinical tests with haldol in long-term schizophrenia and acute manic states].
Topics: Anesthesia; Bipolar Disorder; Haloperidol; Humans; Hypnotics and Sedatives; Mental Disorders; Psycho | 1961 |
[Clinical tests with haldol in long-term schizophrenia and acute manic states].
Topics: Anesthesia; Bipolar Disorder; Haloperidol; Humans; Hypnotics and Sedatives; Mental Disorders; Psycho | 1961 |
[A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses].
Topics: Antipsychotic Agents; Haloperidol; Mental Disorders; Phenothiazines; Psychosurgery; Psychotic Disord | 1960 |
[A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses].
Topics: Antipsychotic Agents; Haloperidol; Mental Disorders; Phenothiazines; Psychosurgery; Psychotic Disord | 1960 |
[Haloperidol and chemotherapy of psychoses].
Topics: Electroconvulsive Therapy; Haloperidol; Humans; Mental Disorders; Psychopharmacology; Psychotherapy; | 1960 |
[Haloperidol and chemotherapy of psychoses].
Topics: Electroconvulsive Therapy; Haloperidol; Humans; Mental Disorders; Psychopharmacology; Psychotherapy; | 1960 |
[The action of haloperidol in psychoses].
Topics: Anesthesia; Haloperidol; Hypnotics and Sedatives; Mental Disorders; Psychotic Disorders | 1960 |
[The action of haloperidol in psychoses].
Topics: Anesthesia; Haloperidol; Hypnotics and Sedatives; Mental Disorders; Psychotic Disorders | 1960 |
Problems in evaluation of R-1625.
Topics: Electroconvulsive Therapy; Haloperidol; Piperidines; Psychotherapy; Psychotic Disorders | 1959 |
Problems in evaluation of R-1625.
Topics: Electroconvulsive Therapy; Haloperidol; Piperidines; Psychotherapy; Psychotic Disorders | 1959 |
[Clinical observations on the treatment of psychoses with haloperidol].
Topics: Electroconvulsive Therapy; Haloperidol; Hypnotics and Sedatives; Mental Disorders; Psychosurgery; Ps | 1961 |
[Clinical observations on the treatment of psychoses with haloperidol].
Topics: Electroconvulsive Therapy; Haloperidol; Hypnotics and Sedatives; Mental Disorders; Psychosurgery; Ps | 1961 |
The treatment of mania with Haloperidol ('Serenace').
Topics: Anesthesia; Bipolar Disorder; Haloperidol; Humans; Hypnotics and Sedatives; Mental Disorders; Psycho | 1962 |
The treatment of mania with Haloperidol ('Serenace').
Topics: Anesthesia; Bipolar Disorder; Haloperidol; Humans; Hypnotics and Sedatives; Mental Disorders; Psycho | 1962 |
[Study of the therapeutic effects of a butyrophenone (R-1625--Haloperidin--haloperidol) in psychoses].
Topics: Butyrophenones; Haloperidol; Humans; Mental Disorders; Psychotic Disorders | 1963 |
[Study of the therapeutic effects of a butyrophenone (R-1625--Haloperidin--haloperidol) in psychoses].
Topics: Butyrophenones; Haloperidol; Humans; Mental Disorders; Psychotic Disorders | 1963 |
[Clinical experience with Haloperidol treatment of long-term patients].
Topics: Haloperidol; Humans; Mental Disorders; Psychotic Disorders | 1963 |
[Clinical experience with Haloperidol treatment of long-term patients].
Topics: Haloperidol; Humans; Mental Disorders; Psychotic Disorders | 1963 |
[Acute alcoholic psychoses. Treatmetn by haloperidol].
Topics: Haloperidol; Humans; Mental Disorders; Psychoses, Alcoholic; Psychotic Disorders | 1962 |
[Acute alcoholic psychoses. Treatmetn by haloperidol].
Topics: Haloperidol; Humans; Mental Disorders; Psychoses, Alcoholic; Psychotic Disorders | 1962 |
[Differences in biological reactivity to haloperiodol in 2 groups of psychotics, American and European].
Topics: Ethnicity; Haloperidol; Humans; Mental Disorders; Psychotic Disorders; United States | 1962 |
[Differences in biological reactivity to haloperiodol in 2 groups of psychotics, American and European].
Topics: Ethnicity; Haloperidol; Humans; Mental Disorders; Psychotic Disorders; United States | 1962 |
PSYCHOMOTOR ASSESSMENT OF THE EFFECTS OF HALOPERIDOL.
Topics: Bipolar Disorder; Haloperidol; Kinesthesis; Motor Skills; Parkinsonian Disorders; Psychotic Disorder | 1963 |
PSYCHOMOTOR ASSESSMENT OF THE EFFECTS OF HALOPERIDOL.
Topics: Bipolar Disorder; Haloperidol; Kinesthesis; Motor Skills; Parkinsonian Disorders; Psychotic Disorder | 1963 |
HALOPERIDOL IN THE TREATMENT OF 120 PSYCHOTIC PATIENTS.
Topics: Haloperidol; Humans; Psychotic Disorders | 1963 |
HALOPERIDOL IN THE TREATMENT OF 120 PSYCHOTIC PATIENTS.
Topics: Haloperidol; Humans; Psychotic Disorders | 1963 |
THE USE OF HALOPERIDOL (SERENASE (R)) IN CHLORPROTIXEN RESISTANT PATIENTS.
Topics: Accommodation, Ocular; Adolescent; Antisocial Personality Disorder; Bipolar Disorder; Chlorprothixen | 1963 |
THE USE OF HALOPERIDOL (SERENASE (R)) IN CHLORPROTIXEN RESISTANT PATIENTS.
Topics: Accommodation, Ocular; Adolescent; Antisocial Personality Disorder; Bipolar Disorder; Chlorprothixen | 1963 |
OBSERVATIONS ON USE OF HALOPERIDOL FOLLOWING 3 YEARS' EXPERIENCE.
Topics: Haloperidol; Humans; Mental Disorders; Psychotic Disorders | 1963 |
OBSERVATIONS ON USE OF HALOPERIDOL FOLLOWING 3 YEARS' EXPERIENCE.
Topics: Haloperidol; Humans; Mental Disorders; Psychotic Disorders | 1963 |
[OUR EXPERIENCES WITH A NEW MAJOR NEUROLEPTIC: HALOPERIDOL].
Topics: Antipsychotic Agents; Bipolar Disorder; Epilepsy; Haloperidol; Humans; Mental Disorders; Psychoses, | 1963 |
[OUR EXPERIENCES WITH A NEW MAJOR NEUROLEPTIC: HALOPERIDOL].
Topics: Antipsychotic Agents; Bipolar Disorder; Epilepsy; Haloperidol; Humans; Mental Disorders; Psychoses, | 1963 |
[TREATMENT OF ACUTE COMPLICATIONS OF CHRONIC ALCOHOLISM WITH R-1625 (HALOPERIDOL)].
Topics: Alcoholism; Haloperidol; Humans; Mental Disorders; Psychoses, Alcoholic; Psychotic Disorders | 1963 |
[TREATMENT OF ACUTE COMPLICATIONS OF CHRONIC ALCOHOLISM WITH R-1625 (HALOPERIDOL)].
Topics: Alcoholism; Haloperidol; Humans; Mental Disorders; Psychoses, Alcoholic; Psychotic Disorders | 1963 |
[URINARY STEROIDS AND PSYCHOTROPIC CHEMOTHERAPY].
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Chlorpromazine; Haloperidol; Imipramine; Iproniazid; Menta | 1963 |
[URINARY STEROIDS AND PSYCHOTROPIC CHEMOTHERAPY].
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Chlorpromazine; Haloperidol; Imipramine; Iproniazid; Menta | 1963 |
HALOPERIDOL: A CONTROLLED CLINICAL TRIAL IN CHRONIC DISTURBED PSYCHOTIC PATIENTS.
Topics: Haloperidol; Humans; Mental Disorders; Placebos; Psychotic Disorders; Toxicology | 1964 |
HALOPERIDOL: A CONTROLLED CLINICAL TRIAL IN CHRONIC DISTURBED PSYCHOTIC PATIENTS.
Topics: Haloperidol; Humans; Mental Disorders; Placebos; Psychotic Disorders; Toxicology | 1964 |
POTENTIATION OF PHARMACOLOGICAL AND THERAPEUTIC ACTION OF PHENOTHIAZINES BY NYLIDRIN (ARLIDIN).
Topics: Bipolar Disorder; Brain; Brain Damage, Chronic; Chlorprothixene; Depressive Disorder, Major; Dextran | 1964 |
POTENTIATION OF PHARMACOLOGICAL AND THERAPEUTIC ACTION OF PHENOTHIAZINES BY NYLIDRIN (ARLIDIN).
Topics: Bipolar Disorder; Brain; Brain Damage, Chronic; Chlorprothixene; Depressive Disorder, Major; Dextran | 1964 |
[ON PSYCHOSES INDUCED BY CARDIAC DECOMPENSATION. THERAPEUTIC FINDINGS AND NOTES].
Topics: Haloperidol; Heart Failure; Humans; Mental Disorders; Psychotic Disorders | 1963 |
[ON PSYCHOSES INDUCED BY CARDIAC DECOMPENSATION. THERAPEUTIC FINDINGS AND NOTES].
Topics: Haloperidol; Heart Failure; Humans; Mental Disorders; Psychotic Disorders | 1963 |
[THE TREATMENT OF MANIAS AND MANIC STATES WITH HALOPERIDOL].
Topics: Bipolar Disorder; Haloperidol; Humans; Mental Disorders; Psychotic Disorders | 1964 |
[THE TREATMENT OF MANIAS AND MANIC STATES WITH HALOPERIDOL].
Topics: Bipolar Disorder; Haloperidol; Humans; Mental Disorders; Psychotic Disorders | 1964 |
[CLINICAL ASPECTS OF HALOPERIDOL].
Topics: Dementia; Geriatrics; Haloperidol; Injections, Intramuscular; Mental Disorders; Neurotic Disorders; | 1964 |
[CLINICAL ASPECTS OF HALOPERIDOL].
Topics: Dementia; Geriatrics; Haloperidol; Injections, Intramuscular; Mental Disorders; Neurotic Disorders; | 1964 |
[CLINICAL EXPERIENCES WITH HALOPERIDOL (SERENASE)].
Topics: Bipolar Disorder; Chlorpromazine; Chorea; Dementia; Depressive Disorder, Major; Epilepsy; Haloperido | 1964 |
[CLINICAL EXPERIENCES WITH HALOPERIDOL (SERENASE)].
Topics: Bipolar Disorder; Chlorpromazine; Chorea; Dementia; Depressive Disorder, Major; Epilepsy; Haloperido | 1964 |
DEPRESSIVE AND MANIC PSYCHOSES AND ALLIED DISORDERS.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Barbiturates; Bipolar Disorder; Depression; Electr | 1964 |
DEPRESSIVE AND MANIC PSYCHOSES AND ALLIED DISORDERS.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Barbiturates; Bipolar Disorder; Depression; Electr | 1964 |
DIFFERENTIAL INTER-DRUG ANALYSIS: A PRELIMINARY STUDY.
Topics: Aggression; Biomedical Research; Chlorpromazine; Delusions; Haloperidol; Humans; Mental Disorders; P | 1964 |
DIFFERENTIAL INTER-DRUG ANALYSIS: A PRELIMINARY STUDY.
Topics: Aggression; Biomedical Research; Chlorpromazine; Delusions; Haloperidol; Humans; Mental Disorders; P | 1964 |
HALOPERIDOL IN THE PSYCHIATRIC DISORDERS OF OLD AGE.
Topics: Biomedical Research; Dementia; Geriatrics; Haloperidol; Intracranial Arteriosclerosis; Mental Disord | 1964 |
HALOPERIDOL IN THE PSYCHIATRIC DISORDERS OF OLD AGE.
Topics: Biomedical Research; Dementia; Geriatrics; Haloperidol; Intracranial Arteriosclerosis; Mental Disord | 1964 |
THE BUTYROPHENONES IN THE TREATMENT OF THE PSYCHOTIC PATIENT.
Topics: Biomedical Research; Butyrophenones; Catatonia; Haloperidol; Humans; Meperidine; Paranoid Disorders; | 1964 |
THE BUTYROPHENONES IN THE TREATMENT OF THE PSYCHOTIC PATIENT.
Topics: Biomedical Research; Butyrophenones; Catatonia; Haloperidol; Humans; Meperidine; Paranoid Disorders; | 1964 |
[HUNTINGTON'S CHOREA, HUMOR DISORDERS WITH MANIC MANIFESTATIONS, BENEFICIAL EFFECTS OF HALOPERIDOL (FLUOROPHENYLPIPERIDINOBUTYROPHENONE). ABSENCE OF THE THERAPEUTIC AKINETO-HYPERTONIC SYNDROME].
Topics: Bipolar Disorder; Chlorpromazine; Chorea; Electroencephalography; Electromyography; Haloperidol; Hum | 1964 |
[HUNTINGTON'S CHOREA, HUMOR DISORDERS WITH MANIC MANIFESTATIONS, BENEFICIAL EFFECTS OF HALOPERIDOL (FLUOROPHENYLPIPERIDINOBUTYROPHENONE). ABSENCE OF THE THERAPEUTIC AKINETO-HYPERTONIC SYNDROME].
Topics: Bipolar Disorder; Chlorpromazine; Chorea; Electroencephalography; Electromyography; Haloperidol; Hum | 1964 |
[COGENTINE (BTMS) IN THE TREATMENT OF NEUROLEPTIC SYNDROMES].
Topics: Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Delirium; Depression; Hallucinations; Halope | 1964 |
[COGENTINE (BTMS) IN THE TREATMENT OF NEUROLEPTIC SYNDROMES].
Topics: Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Delirium; Depression; Hallucinations; Halope | 1964 |
[CLINICO-THERAPEUTIC TRIALS WITH DIPIPERON, A NEW BUTYROPHENONE SERIES DERIVATIVE].
Topics: Butyrophenones; Depression; Haloperidol; Humans; Hypnotics and Sedatives; Mental Disorders; Psychoti | 1964 |
[CLINICO-THERAPEUTIC TRIALS WITH DIPIPERON, A NEW BUTYROPHENONE SERIES DERIVATIVE].
Topics: Butyrophenones; Depression; Haloperidol; Humans; Hypnotics and Sedatives; Mental Disorders; Psychoti | 1964 |
[EFFECT OF DRUG THERAPY ON REHOSPITALIZATIONS AT THE BEL AIR CLINIC OF PATIENTS WITH CHRONIC PSYCHOSES EXCEPT MANIC-DEPRESSIVE PSYCHOSES].
Topics: Bipolar Disorder; Chlorpromazine; Chlorprothixene; Convulsive Therapy; Drug Therapy; Haloperidol; Ho | 1964 |
[EFFECT OF DRUG THERAPY ON REHOSPITALIZATIONS AT THE BEL AIR CLINIC OF PATIENTS WITH CHRONIC PSYCHOSES EXCEPT MANIC-DEPRESSIVE PSYCHOSES].
Topics: Bipolar Disorder; Chlorpromazine; Chlorprothixene; Convulsive Therapy; Drug Therapy; Haloperidol; Ho | 1964 |
[TREATMENT OF CHRONIC PSYCHOSES WITH HALOPERIDOL (R 1625)].
Topics: Bipolar Disorder; Drug Therapy; Haloperidol; Humans; Mental Disorders; Movement Disorders; Psychotic | 1964 |
[TREATMENT OF CHRONIC PSYCHOSES WITH HALOPERIDOL (R 1625)].
Topics: Bipolar Disorder; Drug Therapy; Haloperidol; Humans; Mental Disorders; Movement Disorders; Psychotic | 1964 |
[HUNTINGTON'S CHOREA, TEMPERAMENT DISORDERS OF MANIAC EXPRESSION. BENEFICIAL EFFECTS OF HALOPERIDOL (FLUORO-PHENYL-PIPERIDINE BUTYROPHENONE). ABSENCE OF THE THERAPEUTIC AKINETO-HYPERTONIC SYNDROME].
Topics: Bipolar Disorder; Butyrophenones; Chorea; Drug Therapy; Electromyography; Haloperidol; Humans; Hunti | 1964 |
[HUNTINGTON'S CHOREA, TEMPERAMENT DISORDERS OF MANIAC EXPRESSION. BENEFICIAL EFFECTS OF HALOPERIDOL (FLUORO-PHENYL-PIPERIDINE BUTYROPHENONE). ABSENCE OF THE THERAPEUTIC AKINETO-HYPERTONIC SYNDROME].
Topics: Bipolar Disorder; Butyrophenones; Chorea; Drug Therapy; Electromyography; Haloperidol; Humans; Hunti | 1964 |
CHANGES IN SERUM PROTEINS AND CEREBROSPINAL FLUID PROTEINS DURING PHARMACOTHERAPY OF PSYCHOSES.
Topics: Alcoholism; Bipolar Disorder; Blood Proteins; Cerebrospinal Fluid Proteins; Chlorpromazine; Drug The | 1964 |
CHANGES IN SERUM PROTEINS AND CEREBROSPINAL FLUID PROTEINS DURING PHARMACOTHERAPY OF PSYCHOSES.
Topics: Alcoholism; Bipolar Disorder; Blood Proteins; Cerebrospinal Fluid Proteins; Chlorpromazine; Drug The | 1964 |
[SOMATOTHERAPY OF ENDOGENOUS PSYCHOSES AT MARBURG UNIVERSITY NEUROLOGIC CLINIC].
Topics: Bipolar Disorder; Chlordiazepoxide; Chlorpromazine; Chlorprothixene; Convulsive Therapy; Depression; | 1964 |
[SOMATOTHERAPY OF ENDOGENOUS PSYCHOSES AT MARBURG UNIVERSITY NEUROLOGIC CLINIC].
Topics: Bipolar Disorder; Chlordiazepoxide; Chlorpromazine; Chlorprothixene; Convulsive Therapy; Depression; | 1964 |
[HALOPERIDOL IN MENTAL DISEASES; CLINICAL CONTRIBUTION].
Topics: Drug Therapy; Haloperidol; Humans; Mental Disorders; Psychotic Disorders | 1965 |
[HALOPERIDOL IN MENTAL DISEASES; CLINICAL CONTRIBUTION].
Topics: Drug Therapy; Haloperidol; Humans; Mental Disorders; Psychotic Disorders | 1965 |
[The therapeutic use of a new non-phenothiazine drug. R 1625 or haloperiodol, in long-term mental patients].
Topics: Anesthesia; Haloperidol; Hypnotics and Sedatives; Mentally Ill Persons; Phenothiazines; Psychotic Di | 1960 |
[The therapeutic use of a new non-phenothiazine drug. R 1625 or haloperiodol, in long-term mental patients].
Topics: Anesthesia; Haloperidol; Hypnotics and Sedatives; Mentally Ill Persons; Phenothiazines; Psychotic Di | 1960 |
[Note on the use of R 1625 in a group of acute psychoses of alcoholic origin].
Topics: Haloperidol; Humans; Hypnotics and Sedatives; Mental Disorders; Psychoses, Alcoholic; Psychotic Diso | 1961 |
[Note on the use of R 1625 in a group of acute psychoses of alcoholic origin].
Topics: Haloperidol; Humans; Hypnotics and Sedatives; Mental Disorders; Psychoses, Alcoholic; Psychotic Diso | 1961 |
[Importance of R 1625 (Haloperidol) in the treatment of chronic hallucinatory psychoses].
Topics: Electroconvulsive Therapy; Hallucinations; Haloperidol; Hypnotics and Sedatives; Psychosurgery; Psyc | 1961 |
[Importance of R 1625 (Haloperidol) in the treatment of chronic hallucinatory psychoses].
Topics: Electroconvulsive Therapy; Hallucinations; Haloperidol; Hypnotics and Sedatives; Psychosurgery; Psyc | 1961 |
[Haloperidol treatment of psychotic mentally deficient patients].
Topics: Electroconvulsive Therapy; Haloperidol; Hypnotics and Sedatives; Intellectual Disability; Mental Dis | 1962 |
[Haloperidol treatment of psychotic mentally deficient patients].
Topics: Electroconvulsive Therapy; Haloperidol; Hypnotics and Sedatives; Intellectual Disability; Mental Dis | 1962 |
[Therapeutic notes on the association of a major neuroleptic, R-1625, with an antiparkinsonian agent, RP-2987, in newly admitted cases and in long-standing cases].
Topics: Antiparkinson Agents; Antipsychotic Agents; Haloperidol; Hypnotics and Sedatives; Psychosurgery; Psy | 1961 |
[Therapeutic notes on the association of a major neuroleptic, R-1625, with an antiparkinsonian agent, RP-2987, in newly admitted cases and in long-standing cases].
Topics: Antiparkinson Agents; Antipsychotic Agents; Haloperidol; Hypnotics and Sedatives; Psychosurgery; Psy | 1961 |
No recurrence of a neuroleptic malignant syndrome under quetiapine.
Topics: Anticonvulsants; Antipsychotic Agents; Diazepam; Dibenzothiazepines; Drug Therapy, Combination; Halo | 2003 |
No recurrence of a neuroleptic malignant syndrome under quetiapine.
Topics: Anticonvulsants; Antipsychotic Agents; Diazepam; Dibenzothiazepines; Drug Therapy, Combination; Halo | 2003 |
Maternal haloperidol therapy associated with dyskinesia in a newborn.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Clonazepam; Dyskinesia, Drug-Induced; Female; Haloperi | 2003 |
Maternal haloperidol therapy associated with dyskinesia in a newborn.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Clonazepam; Dyskinesia, Drug-Induced; Female; Haloperi | 2003 |
Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Sched | 2003 |
Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Sched | 2003 |
Olanzapine excretion into breast milk: a case report.
Topics: Adult; Benzodiazepines; Breast Feeding; Chromatography, Gas; Drug Therapy, Combination; Female; Halo | 2004 |
Olanzapine excretion into breast milk: a case report.
Topics: Adult; Benzodiazepines; Breast Feeding; Chromatography, Gas; Drug Therapy, Combination; Female; Halo | 2004 |
Enhancement of central dopaminergic activity in the kainate model of temporal lobe epilepsy: implication for the mechanism of epileptic psychosis.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain Chemistry; Chromatography, High Pressure Liqu | 2004 |
Enhancement of central dopaminergic activity in the kainate model of temporal lobe epilepsy: implication for the mechanism of epileptic psychosis.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain Chemistry; Chromatography, High Pressure Liqu | 2004 |
A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses.
Topics: Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Chromosomes, Human, Pair 12; Comorbidity; Ge | 2004 |
A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses.
Topics: Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Chromosomes, Human, Pair 12; Comorbidity; Ge | 2004 |
Chronic antidopaminergic medication might affect amygdala structure in patients with schizophrenia.
Topics: Amygdala; Antipsychotic Agents; Brain; Clopenthixol; Dose-Response Relationship, Drug; Epilepsy, Tem | 2004 |
Chronic antidopaminergic medication might affect amygdala structure in patients with schizophrenia.
Topics: Amygdala; Antipsychotic Agents; Brain; Clopenthixol; Dose-Response Relationship, Drug; Epilepsy, Tem | 2004 |
Potentiation of haloperidol neurotoxicity in acute hyperthyroidism: report of a case.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Catatonia; Haloperidol; Humans; Hyperthyroidism | 2004 |
Potentiation of haloperidol neurotoxicity in acute hyperthyroidism: report of a case.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Catatonia; Haloperidol; Humans; Hyperthyroidism | 2004 |
Persistent psychotic disorder in an adolescent with a past history of butane gas dependence.
Topics: Adolescent; Antipsychotic Agents; Butanes; Diagnostic and Statistical Manual of Mental Disorders; Ha | 2004 |
Persistent psychotic disorder in an adolescent with a past history of butane gas dependence.
Topics: Adolescent; Antipsychotic Agents; Butanes; Diagnostic and Statistical Manual of Mental Disorders; Ha | 2004 |
Duration of untreated psychosis and outcome in first-episode psychosis. Perspective from a developing country.
Topics: Adolescent; Adult; Antipsychotic Agents; Cohort Studies; Developing Countries; Diagnostic and Statis | 2005 |
Duration of untreated psychosis and outcome in first-episode psychosis. Perspective from a developing country.
Topics: Adolescent; Adult; Antipsychotic Agents; Cohort Studies; Developing Countries; Diagnostic and Statis | 2005 |
Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis.
Topics: Amphetamine; Amphetamines; Animals; Apomorphine; Behavior, Animal; Cues; Discrimination Learning; Do | 2005 |
Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis.
Topics: Amphetamine; Amphetamines; Animals; Apomorphine; Behavior, Animal; Cues; Discrimination Learning; Do | 2005 |
A case of delayed galactorrhoea as an adverse event of overlapping haloperidol and clozapine administration.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Interactions; Female; Galactorrhea; Haloperidol; Humans | 2005 |
A case of delayed galactorrhoea as an adverse event of overlapping haloperidol and clozapine administration.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Interactions; Female; Galactorrhea; Haloperidol; Humans | 2005 |
Infanticide.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Depression, Postpartum; Expert Testimony; Female; For | 2005 |
Infanticide.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Depression, Postpartum; Expert Testimony; Female; For | 2005 |
Cinnarizine has an atypical antipsychotic profile in animal models of psychosis.
Topics: Amphetamine; Animals; Antipsychotic Agents; Calcium Channel Blockers; Catalepsy; Central Nervous Sys | 2005 |
Cinnarizine has an atypical antipsychotic profile in animal models of psychosis.
Topics: Amphetamine; Animals; Antipsychotic Agents; Calcium Channel Blockers; Catalepsy; Central Nervous Sys | 2005 |
Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Chromatography, High Pressure Liquid; Cross | 2005 |
Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Chromatography, High Pressure Liquid; Cross | 2005 |
Clinical application of the concept of relative potency: an example involving chlorpromazine and haloperidol.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Dose-Response Relationship, Drug; Emergency Services, P | 2005 |
Clinical application of the concept of relative potency: an example involving chlorpromazine and haloperidol.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Dose-Response Relationship, Drug; Emergency Services, P | 2005 |
Reading and writing: psychoanalytical treatment in a case of paranoia.
Topics: Adult; Antipsychotic Agents; Art Therapy; Combined Modality Therapy; Delirium; Female; Haloperidol; | 2005 |
Reading and writing: psychoanalytical treatment in a case of paranoia.
Topics: Adult; Antipsychotic Agents; Art Therapy; Combined Modality Therapy; Delirium; Female; Haloperidol; | 2005 |
Neuroleptic malignant syndrome precipitated by haloperidol following clozapine discontinuation.
Topics: Adult; Anti-Anxiety Agents; Antiparkinson Agents; Antipsychotic Agents; Bromocriptine; Clozapine; Cr | 2005 |
Neuroleptic malignant syndrome precipitated by haloperidol following clozapine discontinuation.
Topics: Adult; Anti-Anxiety Agents; Antiparkinson Agents; Antipsychotic Agents; Bromocriptine; Clozapine; Cr | 2005 |
Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cerebrovascular Disorders; Cohort St | 2005 |
Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cerebrovascular Disorders; Cohort St | 2005 |
Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Delusions; Depressive Disorder, Major; Dyskinesia, Drug-Induced; | 2005 |
Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Delusions; Depressive Disorder, Major; Dyskinesia, Drug-Induced; | 2005 |
New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Haloperidol; Humans; Inciden | 2006 |
New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Haloperidol; Humans; Inciden | 2006 |
Methodological issues in a study of long-term maintenance therapy with quetiapine versus haloperidol decanoate.
Topics: Administration, Oral; Antipsychotic Agents; Dibenzothiazepines; Drug Administration Schedule; Halope | 2006 |
Methodological issues in a study of long-term maintenance therapy with quetiapine versus haloperidol decanoate.
Topics: Administration, Oral; Antipsychotic Agents; Dibenzothiazepines; Drug Administration Schedule; Halope | 2006 |
Linking animal models of psychosis to computational models of dopamine function.
Topics: Action Potentials; Amphetamine; Animals; Computer Simulation; Conditioning, Classical; Disease Model | 2007 |
Linking animal models of psychosis to computational models of dopamine function.
Topics: Action Potentials; Amphetamine; Animals; Computer Simulation; Conditioning, Classical; Disease Model | 2007 |
Psychosis and Wilson's disease: a case report.
Topics: Acute Disease; Adult; Antipsychotic Agents; Athetosis; Chelating Agents; Chorea; Diagnosis, Differen | 2006 |
Psychosis and Wilson's disease: a case report.
Topics: Acute Disease; Adult; Antipsychotic Agents; Athetosis; Chelating Agents; Chorea; Diagnosis, Differen | 2006 |
Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol; H | 2005 |
Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol; H | 2005 |
Association of serum iron and serum CPK in acute psychosis.
Topics: Aged; Antipsychotic Agents; Creatine Kinase; Female; Haloperidol; Humans; Iron; Psychotic Disorders | 2006 |
Association of serum iron and serum CPK in acute psychosis.
Topics: Aged; Antipsychotic Agents; Creatine Kinase; Female; Haloperidol; Humans; Iron; Psychotic Disorders | 2006 |
[Which antipsychotic as first choice in schizophrenia? The Dutch Multidisciplinary Guideline for Schizophrenia 2005 versus the Pharmacotherapy Compass 2005, the Dutch National Health Insurance System Formulary].
Topics: Antipsychotic Agents; Haloperidol; Health Policy; Humans; Netherlands; Practice Guidelines as Topic; | 2006 |
[Which antipsychotic as first choice in schizophrenia? The Dutch Multidisciplinary Guideline for Schizophrenia 2005 versus the Pharmacotherapy Compass 2005, the Dutch National Health Insurance System Formulary].
Topics: Antipsychotic Agents; Haloperidol; Health Policy; Humans; Netherlands; Practice Guidelines as Topic; | 2006 |
Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Biomarkers; Brain; Brain Chemistry; | 2007 |
Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Biomarkers; Brain; Brain Chemistry; | 2007 |
Undiagnosed progressive supranuclear palsy in a patient with neuroleptic malignant syndrome due to use of neuroleptics: the utility of autopsy in deaths due to known drug reactions.
Topics: Adult; Antipsychotic Agents; Brain; Female; Forensic Pathology; Haloperidol; Humans; Neuroleptic Mal | 2007 |
Undiagnosed progressive supranuclear palsy in a patient with neuroleptic malignant syndrome due to use of neuroleptics: the utility of autopsy in deaths due to known drug reactions.
Topics: Adult; Antipsychotic Agents; Brain; Female; Forensic Pathology; Haloperidol; Humans; Neuroleptic Mal | 2007 |
Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Atrophy; Benzodiazepines; Cerebral Cortex; Child; Cognition | 2007 |
Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Atrophy; Benzodiazepines; Cerebral Cortex; Child; Cognition | 2007 |
FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Brain; Cognition Disorders; Female; Fluoro | 2007 |
FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Brain; Cognition Disorders; Female; Fluoro | 2007 |
Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; gamma-Aminobutyric Acid; | 2007 |
Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; gamma-Aminobutyric Acid; | 2007 |
Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Olanzapine; Psychia | 2007 |
Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Olanzapine; Psychia | 2007 |
The evolution of antipsychotic drug therapy: reserpine, chlorpromazine, and haloperidol.
Topics: Antipsychotic Agents; Chlorpromazine; Dyskinesia, Drug-Induced; Europe; Haloperidol; History, 20th C | 2007 |
The evolution of antipsychotic drug therapy: reserpine, chlorpromazine, and haloperidol.
Topics: Antipsychotic Agents; Chlorpromazine; Dyskinesia, Drug-Induced; Europe; Haloperidol; History, 20th C | 2007 |
Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Fetal Blood; Haloperidol; | 2007 |
Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Fetal Blood; Haloperidol; | 2007 |
Functional consequences of iron overload in catecholaminergic interactions: the Youdim factor.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Brain Chemistry; Catecholamines; Clozapine; Denerva | 2007 |
Functional consequences of iron overload in catecholaminergic interactions: the Youdim factor.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Brain Chemistry; Catecholamines; Clozapine; Denerva | 2007 |
Effective electroconvulsive therapy in a 92-year-old dementia patient with psychotic feature.
Topics: Aged, 80 and over; Antipsychotic Agents; Combined Modality Therapy; Dementia, Multi-Infarct; Electro | 2007 |
Effective electroconvulsive therapy in a 92-year-old dementia patient with psychotic feature.
Topics: Aged, 80 and over; Antipsychotic Agents; Combined Modality Therapy; Dementia, Multi-Infarct; Electro | 2007 |
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Emotions; Fa | 2007 |
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Emotions; Fa | 2007 |
People in glass houses.
Topics: Antipsychotic Agents; Coercion; Commitment of Mentally Ill; Haloperidol; Humans; Patient Rights; Psy | 2007 |
People in glass houses.
Topics: Antipsychotic Agents; Coercion; Commitment of Mentally Ill; Haloperidol; Humans; Patient Rights; Psy | 2007 |
[Acute psychosis: in an emergency always still haloperidol?].
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Emergencies; Haloperidol; Humans; Injecti | 2008 |
[Acute psychosis: in an emergency always still haloperidol?].
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Emergencies; Haloperidol; Humans; Injecti | 2008 |
[Postictal paranoid-hallucinatory psychosis in cryptogenic epilepsy].
Topics: Acute Disease; Adult; Anticonvulsants; Cooperative Behavior; Delusions; Diazepam; Epilepsy; Epilepsy | 2007 |
[Postictal paranoid-hallucinatory psychosis in cryptogenic epilepsy].
Topics: Acute Disease; Adult; Anticonvulsants; Cooperative Behavior; Delusions; Diazepam; Epilepsy; Epilepsy | 2007 |
[The effect of treatment on interleukin-1beta production in patients with first episode of juvenile psychosis].
Topics: Adolescent; Adult; Antipsychotic Agents; Biomarkers; Clozapine; Drug Therapy, Combination; Enzyme-Li | 2007 |
[The effect of treatment on interleukin-1beta production in patients with first episode of juvenile psychosis].
Topics: Adolescent; Adult; Antipsychotic Agents; Biomarkers; Clozapine; Drug Therapy, Combination; Enzyme-Li | 2007 |
Did CATIE influence antipsychotic use?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy; Haloperidol; Hum | 2008 |
Did CATIE influence antipsychotic use?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy; Haloperidol; Hum | 2008 |
Reduced dendritic spine density in auditory cortex of subjects with schizophrenia.
Topics: Adult; Animals; Antipsychotic Agents; Auditory Cortex; Dendritic Spines; Female; Haloperidol; Humans | 2009 |
Reduced dendritic spine density in auditory cortex of subjects with schizophrenia.
Topics: Adult; Animals; Antipsychotic Agents; Auditory Cortex; Dendritic Spines; Female; Haloperidol; Humans | 2009 |
Sterol metabolism: biochemical differences among the butyrophenones.
Topics: Animals; Antidepressive Agents; Cholesterol; Haloperidol; Humans; Psychotic Disorders; Trifluperidol | 1967 |
Sterol metabolism: biochemical differences among the butyrophenones.
Topics: Animals; Antidepressive Agents; Cholesterol; Haloperidol; Humans; Psychotic Disorders; Trifluperidol | 1967 |
Clinical efficacy of haloperidol in chronic psychotic patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Chronic Disease; Female; Haloperidol; Humans; Male; Middle A | 1967 |
Clinical efficacy of haloperidol in chronic psychotic patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Chronic Disease; Female; Haloperidol; Humans; Male; Middle A | 1967 |
Hypothyroidism, psychotropic drugs and cardiotoxicity.
Topics: Acute Disease; Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Hypothyroidism; Phenothiazi | 1980 |
Hypothyroidism, psychotropic drugs and cardiotoxicity.
Topics: Acute Disease; Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Hypothyroidism; Phenothiazi | 1980 |
Increased serum prolactin levels during phenothiazine and butyrophenone treatment of six postpartum women.
Topics: Adolescent; Adult; Antipsychotic Agents; Chlorpromazine; Female; Haloperidol; Humans; Pregnancy; Pro | 1980 |
Increased serum prolactin levels during phenothiazine and butyrophenone treatment of six postpartum women.
Topics: Adolescent; Adult; Antipsychotic Agents; Chlorpromazine; Female; Haloperidol; Humans; Pregnancy; Pro | 1980 |
Cerebrospinal fluid homovanillic acid patterns during neuroleptic treatment.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Female; Haloperidol; Homovanillic Acid; Humans; Male; P | 1981 |
Cerebrospinal fluid homovanillic acid patterns during neuroleptic treatment.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Female; Haloperidol; Homovanillic Acid; Humans; Male; P | 1981 |
Observations on neuroleptic use in acutely psychotic patients.
Topics: Aged; Antipsychotic Agents; Chlorpromazine; Drug Utilization; Haloperidol; Humans; Psychotic Disorde | 1982 |
Observations on neuroleptic use in acutely psychotic patients.
Topics: Aged; Antipsychotic Agents; Chlorpromazine; Drug Utilization; Haloperidol; Humans; Psychotic Disorde | 1982 |
Sudden death.
Topics: Adolescent; Antipsychotic Agents; Chlorpromazine; Death, Sudden; Drug Therapy, Combination; Glycosam | 1982 |
Sudden death.
Topics: Adolescent; Antipsychotic Agents; Chlorpromazine; Death, Sudden; Drug Therapy, Combination; Glycosam | 1982 |
Effects of neuroleptics on platelet monoamine oxidase activity.
Topics: Adult; Antipsychotic Agents; Blood Platelets; Haloperidol; Humans; Monoamine Oxidase; Phenothiazines | 1982 |
Effects of neuroleptics on platelet monoamine oxidase activity.
Topics: Adult; Antipsychotic Agents; Blood Platelets; Haloperidol; Humans; Monoamine Oxidase; Phenothiazines | 1982 |
Mania: diagnosis and treatment.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Antiparkinson Agents; Antipsychotic Agents; Bipol | 1982 |
Mania: diagnosis and treatment.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Antiparkinson Agents; Antipsychotic Agents; Bipol | 1982 |
Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Benztropine; Female; Fluphenazine; Haloperidol; Humans; Mal | 1984 |
Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Benztropine; Female; Fluphenazine; Haloperidol; Humans; Mal | 1984 |
Reversible neurotoxicity with combined lithium-haloperidol administration.
Topics: Drug Therapy, Combination; Female; Haloperidol; Humans; Lithium; Lithium Carbonate; Middle Aged; Psy | 1984 |
Reversible neurotoxicity with combined lithium-haloperidol administration.
Topics: Drug Therapy, Combination; Female; Haloperidol; Humans; Lithium; Lithium Carbonate; Middle Aged; Psy | 1984 |
Gilles de la Tourette syndrome in mental handicap.
Topics: Adult; Drug Therapy, Combination; Epilepsy, Tonic-Clonic; Female; Haloperidol; Humans; Intellectual | 1984 |
Gilles de la Tourette syndrome in mental handicap.
Topics: Adult; Drug Therapy, Combination; Epilepsy, Tonic-Clonic; Female; Haloperidol; Humans; Intellectual | 1984 |
TSH-response patterns to TRH stimulation may indicate therapeutic mechanisms of antidepressant and neuroleptic drugs.
Topics: Adult; Clomipramine; Depressive Disorder; Female; Haloperidol; Humans; Prognosis; Psychiatric Status | 1984 |
TSH-response patterns to TRH stimulation may indicate therapeutic mechanisms of antidepressant and neuroleptic drugs.
Topics: Adult; Clomipramine; Depressive Disorder; Female; Haloperidol; Humans; Prognosis; Psychiatric Status | 1984 |
[Choreic syndrome following intramuscular exhibition of a contraceptive preparation (author's transl)].
Topics: Adult; Chorea; Electroencephalography; Evoked Potentials; Female; Haloperidol; Humans; Injections, I | 1981 |
[Choreic syndrome following intramuscular exhibition of a contraceptive preparation (author's transl)].
Topics: Adult; Chorea; Electroencephalography; Evoked Potentials; Female; Haloperidol; Humans; Injections, I | 1981 |
Ratio of serum prolactin to haloperidol and early clinical outcome in acute psychosis.
Topics: Acute Disease; Adolescent; Adult; Female; Haloperidol; Humans; Male; Middle Aged; Prolactin; Psychia | 1984 |
Ratio of serum prolactin to haloperidol and early clinical outcome in acute psychosis.
Topics: Acute Disease; Adolescent; Adult; Female; Haloperidol; Humans; Male; Middle Aged; Prolactin; Psychia | 1984 |
Haloperidol (Haldol) and possible association with fatal sickle cell disease (Hgb S-C)
Topics: Adult; Death, Sudden; Haloperidol; Hemoglobin SC Disease; Humans; Male; Psychotic Disorders | 1984 |
Haloperidol (Haldol) and possible association with fatal sickle cell disease (Hgb S-C)
Topics: Adult; Death, Sudden; Haloperidol; Hemoglobin SC Disease; Humans; Male; Psychotic Disorders | 1984 |
[Haloperidol decanoate. Results of an open-ended multicentric study in chronic psychotic states].
Topics: Adult; Delusions; Drug Therapy, Combination; Female; Haloperidol; Humans; Injections, Intramuscular; | 1984 |
[Haloperidol decanoate. Results of an open-ended multicentric study in chronic psychotic states].
Topics: Adult; Delusions; Drug Therapy, Combination; Female; Haloperidol; Humans; Injections, Intramuscular; | 1984 |
[Influence of nutritional status on intravenous pharmacokinetics of haloperidol in psychotic patients].
Topics: Adult; Body Height; Body Weight; Chronic Disease; Haloperidol; Humans; Injections, Intravenous; Iron | 1984 |
[Influence of nutritional status on intravenous pharmacokinetics of haloperidol in psychotic patients].
Topics: Adult; Body Height; Body Weight; Chronic Disease; Haloperidol; Humans; Injections, Intravenous; Iron | 1984 |
Effect of combined haloperidol-lithium treatment on vitro RBC lithium uptake in patients with affective disorders.
Topics: Bipolar Disorder; Drug Therapy, Combination; Erythrocytes; Haloperidol; Humans; Lithium; Psychotic D | 1983 |
Effect of combined haloperidol-lithium treatment on vitro RBC lithium uptake in patients with affective disorders.
Topics: Bipolar Disorder; Drug Therapy, Combination; Erythrocytes; Haloperidol; Humans; Lithium; Psychotic D | 1983 |
High-dose neuroleptics: uncontrolled clinical practice confirms controlled clinical trials.
Topics: Adolescent; Adult; Aged; Female; Haloperidol; Humans; Length of Stay; Male; Middle Aged; Prospective | 1984 |
High-dose neuroleptics: uncontrolled clinical practice confirms controlled clinical trials.
Topics: Adolescent; Adult; Aged; Female; Haloperidol; Humans; Length of Stay; Male; Middle Aged; Prospective | 1984 |
Assessment of SIADH in psychosis with a water-loading test: case report.
Topics: Adult; Drinking Behavior; Haloperidol; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Psych | 1984 |
Assessment of SIADH in psychosis with a water-loading test: case report.
Topics: Adult; Drinking Behavior; Haloperidol; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Psych | 1984 |
The use of depot neuroleptic haloperidol decanoate.
Topics: Bipolar Disorder; Depressive Disorder; Haloperidol; Humans; Prognosis; Psychotic Disorders; Schizoph | 1984 |
The use of depot neuroleptic haloperidol decanoate.
Topics: Bipolar Disorder; Depressive Disorder; Haloperidol; Humans; Prognosis; Psychotic Disorders; Schizoph | 1984 |
Plasma catecholamine metabolites and early response to haloperidol.
Topics: Acute Disease; Adolescent; Adult; Female; Glycols; Haloperidol; Homovanillic Acid; Hospitalization; | 1984 |
Plasma catecholamine metabolites and early response to haloperidol.
Topics: Acute Disease; Adolescent; Adult; Female; Glycols; Haloperidol; Homovanillic Acid; Hospitalization; | 1984 |
Plasma level and effect of low-dose haloperidol in acute psychosis.
Topics: Acute Disease; Administration, Oral; Adult; Female; Haloperidol; Humans; Male; Middle Aged; Psychoti | 1984 |
Plasma level and effect of low-dose haloperidol in acute psychosis.
Topics: Acute Disease; Administration, Oral; Adult; Female; Haloperidol; Humans; Male; Middle Aged; Psychoti | 1984 |
Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs.
Topics: Acute Disease; Adult; Dystonia; Haloperidol; Humans; Male; Muscles; Myoglobinuria; Psychotic Disorde | 1984 |
Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs.
Topics: Acute Disease; Adult; Dystonia; Haloperidol; Humans; Male; Muscles; Myoglobinuria; Psychotic Disorde | 1984 |
CSF GABA in psychotic disorders.
Topics: Adolescent; Adult; Female; gamma-Aminobutyric Acid; Haloperidol; Homovanillic Acid; Humans; Male; Mi | 1980 |
CSF GABA in psychotic disorders.
Topics: Adolescent; Adult; Female; gamma-Aminobutyric Acid; Haloperidol; Homovanillic Acid; Humans; Male; Mi | 1980 |
Haloperidol secreted in breast milk.
Topics: Breast Feeding; Child Development; Female; Haloperidol; Humans; Infant; Infant, Newborn; Milk, Human | 1981 |
Haloperidol secreted in breast milk.
Topics: Breast Feeding; Child Development; Female; Haloperidol; Humans; Infant; Infant, Newborn; Milk, Human | 1981 |
Sex differences in plasma homovanillic acid in acute psychosis.
Topics: Acute Disease; Adolescent; Adult; Female; Haloperidol; Homovanillic Acid; Humans; Male; Middle Aged; | 1983 |
Sex differences in plasma homovanillic acid in acute psychosis.
Topics: Acute Disease; Adolescent; Adult; Female; Haloperidol; Homovanillic Acid; Humans; Male; Middle Aged; | 1983 |
Neuroleptic malignant syndrome after haloperidol therapy.
Topics: Deglutition Disorders; Haloperidol; Heart Arrest; Humans; Male; Middle Aged; Myoclonus; Pneumonia, A | 1983 |
Neuroleptic malignant syndrome after haloperidol therapy.
Topics: Deglutition Disorders; Haloperidol; Heart Arrest; Humans; Male; Middle Aged; Myoclonus; Pneumonia, A | 1983 |
Haloperidol -- its use in children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Haloperidol; | 1981 |
Haloperidol -- its use in children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Haloperidol; | 1981 |
Red blood cell/plasma haloperidol ratios and antipsychotic efficacy.
Topics: Dose-Response Relationship, Drug; Erythrocytes; Haloperidol; Humans; Male; Psychotic Disorders | 1982 |
Red blood cell/plasma haloperidol ratios and antipsychotic efficacy.
Topics: Dose-Response Relationship, Drug; Erythrocytes; Haloperidol; Humans; Male; Psychotic Disorders | 1982 |
Clinical conferences: Management of depression in older people.
Topics: Aged; Antidepressive Agents; Dementia; Depressive Disorder; Desipramine; Diagnosis, Differential; Do | 1982 |
Clinical conferences: Management of depression in older people.
Topics: Aged; Antidepressive Agents; Dementia; Depressive Disorder; Desipramine; Diagnosis, Differential; Do | 1982 |
Rapid tranquilization.
Topics: Acute Disease; Dose-Response Relationship, Drug; Haloperidol; Humans; Psychotic Disorders | 1982 |
Rapid tranquilization.
Topics: Acute Disease; Dose-Response Relationship, Drug; Haloperidol; Humans; Psychotic Disorders | 1982 |
RBC and plasma levels of haloperidol and clinical response in schizophrenia.
Topics: Adolescent; Adult; Drug Administration Schedule; Erythrocytes; Haloperidol; Humans; Middle Aged; Psy | 1982 |
RBC and plasma levels of haloperidol and clinical response in schizophrenia.
Topics: Adolescent; Adult; Drug Administration Schedule; Erythrocytes; Haloperidol; Humans; Middle Aged; Psy | 1982 |
Plasma norepinephrine and dopamine-beta-hydroxylase activity in schizophrenia.
Topics: Adult; Blood Pressure; Chlorpromazine; Dopamine beta-Hydroxylase; Haloperidol; Humans; Hypotension, | 1982 |
Plasma norepinephrine and dopamine-beta-hydroxylase activity in schizophrenia.
Topics: Adult; Blood Pressure; Chlorpromazine; Dopamine beta-Hydroxylase; Haloperidol; Humans; Hypotension, | 1982 |
Pain insensitivity in psychosis.
Topics: Adult; Bipolar Disorder; Chlorpromazine; Diagnosis, Differential; Duodenal Ulcer; Female; Haloperido | 1982 |
Pain insensitivity in psychosis.
Topics: Adult; Bipolar Disorder; Chlorpromazine; Diagnosis, Differential; Duodenal Ulcer; Female; Haloperido | 1982 |
Haloperidol plasma/red blood cell ratios and clinical efficacy.
Topics: Erythrocytes; Haloperidol; Humans; Plasma; Psychotic Disorders | 1982 |
Haloperidol plasma/red blood cell ratios and clinical efficacy.
Topics: Erythrocytes; Haloperidol; Humans; Plasma; Psychotic Disorders | 1982 |
Titrated versus fixed-dose protocols.
Topics: Dose-Response Relationship, Drug; Haloperidol; Humans; Psychotic Disorders | 1980 |
Titrated versus fixed-dose protocols.
Topics: Dose-Response Relationship, Drug; Haloperidol; Humans; Psychotic Disorders | 1980 |
Haloperidol-induced tardive dyskinesia in a 10-year-old girl.
Topics: Child; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Psychotic Disorders | 1980 |
Haloperidol-induced tardive dyskinesia in a 10-year-old girl.
Topics: Child; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Psychotic Disorders | 1980 |
Influence of route of administration on haloperidol plasma levels in psychotic patients.
Topics: Administration, Oral; Adult; Biological Availability; Dose-Response Relationship, Drug; Half-Life; H | 1980 |
Influence of route of administration on haloperidol plasma levels in psychotic patients.
Topics: Administration, Oral; Adult; Biological Availability; Dose-Response Relationship, Drug; Half-Life; H | 1980 |
Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. An open multicenter study.
Topics: Adult; Aged; Chronic Disease; Drug Administration Schedule; Female; Haloperidol; Humans; Injections, | 1980 |
Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. An open multicenter study.
Topics: Adult; Aged; Chronic Disease; Drug Administration Schedule; Female; Haloperidol; Humans; Injections, | 1980 |
How much haldol D does Larry really need?
Topics: Administration, Oral; Adult; Antipsychotic Agents; Drug Administration Schedule; Female; Haloperidol | 1995 |
How much haldol D does Larry really need?
Topics: Administration, Oral; Adult; Antipsychotic Agents; Drug Administration Schedule; Female; Haloperidol | 1995 |
Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment.
Topics: Adult; Dopamine; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Psychiatric | 1993 |
Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment.
Topics: Adult; Dopamine; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Psychiatric | 1993 |
Basal and haloperidol-stimulated prolactin and symptoms of nonaffective and affective psychoses in neuroleptic-free men.
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Haloperidol; Humans; Male; Prolactin; P | 1995 |
Basal and haloperidol-stimulated prolactin and symptoms of nonaffective and affective psychoses in neuroleptic-free men.
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Haloperidol; Humans; Male; Prolactin; P | 1995 |
Safe use of haloperidol in acute intermittent porphyria.
Topics: Acute Disease; Adult; Confusion; Hallucinations; Haloperidol; Humans; Male; Porphyria, Acute Intermi | 1995 |
Safe use of haloperidol in acute intermittent porphyria.
Topics: Acute Disease; Adult; Confusion; Hallucinations; Haloperidol; Humans; Male; Porphyria, Acute Intermi | 1995 |
Depression in schizophrenia: clinical and pharmacological variables.
Topics: Adolescent; Adult; Age Factors; Aged; Depressive Disorder; Dexamethasone; Female; Fluphenazine; Halo | 1995 |
Depression in schizophrenia: clinical and pharmacological variables.
Topics: Adolescent; Adult; Age Factors; Aged; Depressive Disorder; Dexamethasone; Female; Fluphenazine; Halo | 1995 |
In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder.
Topics: Adult; Bipolar Disorder; Brain; Carbon Radioisotopes; Caudate Nucleus; Female; Haloperidol; Humans; | 1995 |
In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder.
Topics: Adult; Bipolar Disorder; Brain; Carbon Radioisotopes; Caudate Nucleus; Female; Haloperidol; Humans; | 1995 |
[Drug treatment of schizophrenic psychoses in puerperium].
Topics: Adult; Antipsychotic Agents; Bromocriptine; Chronic Disease; Clozapine; Dose-Response Relationship, | 1994 |
[Drug treatment of schizophrenic psychoses in puerperium].
Topics: Adult; Antipsychotic Agents; Bromocriptine; Chronic Disease; Clozapine; Dose-Response Relationship, | 1994 |
Depletion of glutathione and enhanced lipid peroxidation in the CSF of acute psychotics following haloperidol administration.
Topics: Administration, Oral; Adolescent; Adult; Female; Glutathione; Haloperidol; Humans; Lipid Peroxidatio | 1994 |
Depletion of glutathione and enhanced lipid peroxidation in the CSF of acute psychotics following haloperidol administration.
Topics: Administration, Oral; Adolescent; Adult; Female; Glutathione; Haloperidol; Humans; Lipid Peroxidatio | 1994 |
[Tardive dystonia. A rare neuroleptic-induced disease picture].
Topics: Basal Ganglia; Basal Ganglia Diseases; Drug Therapy, Combination; Dystonia; Electromyography; Female | 1994 |
[Tardive dystonia. A rare neuroleptic-induced disease picture].
Topics: Basal Ganglia; Basal Ganglia Diseases; Drug Therapy, Combination; Dystonia; Electromyography; Female | 1994 |
Hyperthermic reaction to haloperidol with rigidity, associated to central core disease.
Topics: Adult; Diagnosis, Differential; Female; Haloperidol; Humans; Malignant Hyperthermia; Muscles; Myopat | 1994 |
Hyperthermic reaction to haloperidol with rigidity, associated to central core disease.
Topics: Adult; Diagnosis, Differential; Female; Haloperidol; Humans; Malignant Hyperthermia; Muscles; Myopat | 1994 |
A loading-dose strategy for converting from oral to depot haloperidol.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Chronic Disease; Delayed-Action Preparations; Dos | 1993 |
A loading-dose strategy for converting from oral to depot haloperidol.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Chronic Disease; Delayed-Action Preparations; Dos | 1993 |
Neuroleptic malignant syndrome and catatonia. A report of three cases.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Catatonia; Depressive Disorder; Dibenzothiazepines; D | 1994 |
Neuroleptic malignant syndrome and catatonia. A report of three cases.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Catatonia; Depressive Disorder; Dibenzothiazepines; D | 1994 |
Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria.
Topics: Adult; Aged; Akathisia, Drug-Induced; Anxiety Disorders; Depressive Disorder; Dose-Response Relation | 1994 |
Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria.
Topics: Adult; Aged; Akathisia, Drug-Induced; Anxiety Disorders; Depressive Disorder; Dose-Response Relation | 1994 |
Does the change of psychopathology during the placebo period predict the response to subsequent treatment with active medication.
Topics: Adult; Haloperidol; Hospitalization; Hospitals, Psychiatric; Humans; Length of Stay; Placebo Effect; | 1994 |
Does the change of psychopathology during the placebo period predict the response to subsequent treatment with active medication.
Topics: Adult; Haloperidol; Hospitalization; Hospitals, Psychiatric; Humans; Length of Stay; Placebo Effect; | 1994 |
Neuroleptic dysphoria: in search of an animal model.
Topics: Brain; Depressive Disorder; Domperidone; Haloperidol; Humans; Psychotic Disorders | 1993 |
Neuroleptic dysphoria: in search of an animal model.
Topics: Brain; Depressive Disorder; Domperidone; Haloperidol; Humans; Psychotic Disorders | 1993 |
Neuroleptic malignant syndrome: liability in nursing practice.
Topics: Adult; Antipsychotic Agents; Brain Damage, Chronic; Dose-Response Relationship, Drug; Female; Halope | 1993 |
Neuroleptic malignant syndrome: liability in nursing practice.
Topics: Adult; Antipsychotic Agents; Brain Damage, Chronic; Dose-Response Relationship, Drug; Female; Halope | 1993 |
Long-term high-dose neuroleptic treatment: who gets it and why?
Topics: Affective Disorders, Psychotic; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Halo | 1993 |
Long-term high-dose neuroleptic treatment: who gets it and why?
Topics: Affective Disorders, Psychotic; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Halo | 1993 |
Treatment of catatonic stupor with oral lorazepam in 14-year-old psychotic boy.
Topics: Adolescent; Catatonia; Haloperidol; Humans; Lorazepam; Male; Psychotic Disorders | 1993 |
Treatment of catatonic stupor with oral lorazepam in 14-year-old psychotic boy.
Topics: Adolescent; Catatonia; Haloperidol; Humans; Lorazepam; Male; Psychotic Disorders | 1993 |
Analysis of 935 haloperidol concentration measurements obtained during routine drug monitoring of 134 patients.
Topics: Adult; Aged; Analysis of Variance; Drug Monitoring; Female; Haloperidol; Humans; Male; Middle Aged; | 1993 |
Analysis of 935 haloperidol concentration measurements obtained during routine drug monitoring of 134 patients.
Topics: Adult; Aged; Analysis of Variance; Drug Monitoring; Female; Haloperidol; Humans; Male; Middle Aged; | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Relation of plasma and red blood cells reduced haloperidol concentrations to haloperidol reductase activity assayed in red blood cells in psychiatric population.
Topics: Adolescent; Adult; Alcohol Oxidoreductases; Erythrocytes; Female; Haloperidol; Humans; Japan; Male; | 1993 |
Relation of plasma and red blood cells reduced haloperidol concentrations to haloperidol reductase activity assayed in red blood cells in psychiatric population.
Topics: Adolescent; Adult; Alcohol Oxidoreductases; Erythrocytes; Female; Haloperidol; Humans; Japan; Male; | 1993 |
Acutely psychotic patients receiving high-dose haloperidol therapy.
Topics: Acute Disease; Adolescent; Adult; Bipolar Disorder; Crisis Intervention; Dose-Response Relationship, | 1993 |
Acutely psychotic patients receiving high-dose haloperidol therapy.
Topics: Acute Disease; Adolescent; Adult; Bipolar Disorder; Crisis Intervention; Dose-Response Relationship, | 1993 |
Haloperidol plasma concentrations in Taiwanese psychiatric patients.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Haloperidol; Humans; Linear Models; Psychotic Dis | 1995 |
Haloperidol plasma concentrations in Taiwanese psychiatric patients.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Haloperidol; Humans; Linear Models; Psychotic Dis | 1995 |
The cyclic dilemma: organic, functional, and environmental interaction in a young teenager.
Topics: Adolescent; Antipsychotic Agents; Brain; Environment; Family; Female; Haloperidol; Humans; Interpers | 1995 |
The cyclic dilemma: organic, functional, and environmental interaction in a young teenager.
Topics: Adolescent; Antipsychotic Agents; Brain; Environment; Family; Female; Haloperidol; Humans; Interpers | 1995 |
Haloperidol dosing strategies.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Psychotic Disor | 1996 |
Haloperidol dosing strategies.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Psychotic Disor | 1996 |
Neuroleptic monitoring: relation between antipsychotic efficiency and radioreceptor assay of serum haloperidol.
Topics: Adult; Antipsychotic Agents; Binding, Competitive; Dopamine D2 Receptor Antagonists; Double-Blind Me | 1996 |
Neuroleptic monitoring: relation between antipsychotic efficiency and radioreceptor assay of serum haloperidol.
Topics: Adult; Antipsychotic Agents; Binding, Competitive; Dopamine D2 Receptor Antagonists; Double-Blind Me | 1996 |
Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benperidol; Benzamides; Dopamine Antagonists; Frontal Lo | 1996 |
Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benperidol; Benzamides; Dopamine Antagonists; Frontal Lo | 1996 |
[Postpartum psychoses. A case report].
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Cesarean Section; Diazepam; Female; Haloperidol; H | 1996 |
[Postpartum psychoses. A case report].
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Cesarean Section; Diazepam; Female; Haloperidol; H | 1996 |
[A case of malignant neuroleptic syndrome. Case report].
Topics: Adult; Antipsychotic Agents; Critical Care; Diagnosis, Differential; Dose-Response Relationship, Dru | 1996 |
[A case of malignant neuroleptic syndrome. Case report].
Topics: Adult; Antipsychotic Agents; Critical Care; Diagnosis, Differential; Dose-Response Relationship, Dru | 1996 |
Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzamides; Brain Mapping; Dopamin | 1996 |
Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzamides; Brain Mapping; Dopamin | 1996 |
Clozapine and dopamine.
Topics: Antipsychotic Agents; Clozapine; Dopamine; Drug Therapy, Combination; Haloperidol; Humans; Norepinep | 1997 |
Clozapine and dopamine.
Topics: Antipsychotic Agents; Clozapine; Dopamine; Drug Therapy, Combination; Haloperidol; Humans; Norepinep | 1997 |
Paracentric inversion of chromosome 9 with schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Chromosome Inversion; Chromosomes, Human, Pair 9; Haloperidol; Humans; | 1997 |
Paracentric inversion of chromosome 9 with schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Chromosome Inversion; Chromosomes, Human, Pair 9; Haloperidol; Humans; | 1997 |
Re: Rapid stabilization at home.
Topics: Antipsychotic Agents; Fluspirilene; Haloperidol; Home Care Services; Humans; Injections, Intramuscul | 1997 |
Re: Rapid stabilization at home.
Topics: Antipsychotic Agents; Fluspirilene; Haloperidol; Home Care Services; Humans; Injections, Intramuscul | 1997 |
Neuroleptic malignant syndrome with gangliosidosis type II.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Psyc | 1997 |
Neuroleptic malignant syndrome with gangliosidosis type II.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Psyc | 1997 |
Attenuation of antipsychotic-induced hyperprolactinemia with clozapine.
Topics: Adolescent; Amenorrhea; Antipsychotic Agents; Bromocriptine; Clozapine; Female; Fluphenazine; Galact | 1997 |
Attenuation of antipsychotic-induced hyperprolactinemia with clozapine.
Topics: Adolescent; Amenorrhea; Antipsychotic Agents; Bromocriptine; Clozapine; Female; Fluphenazine; Galact | 1997 |
Use of risperidone in psychotic disorder following ischemic brain damage.
Topics: Adult; Brain Ischemia; Haloperidol; Humans; Male; Perphenazine; Psychotic Disorders; Risperidone | 1996 |
Use of risperidone in psychotic disorder following ischemic brain damage.
Topics: Adult; Brain Ischemia; Haloperidol; Humans; Male; Perphenazine; Psychotic Disorders; Risperidone | 1996 |
Differential response of psychotic and obsessive symptoms to risperidone in an adolescent.
Topics: 1-Naphthylamine; Adolescent; Antidepressive Agents; Antipsychotic Agents; Clomipramine; Hallucinatio | 1996 |
Differential response of psychotic and obsessive symptoms to risperidone in an adolescent.
Topics: 1-Naphthylamine; Adolescent; Antidepressive Agents; Antipsychotic Agents; Clomipramine; Hallucinatio | 1996 |
[Acute delusional psychosis and neuroleptic malignant syndrome after emigration of a Russian German patient].
Topics: Adult; Antipsychotic Agents; Delusions; Drug Therapy, Combination; Emigration and Immigration; Ethni | 1997 |
[Acute delusional psychosis and neuroleptic malignant syndrome after emigration of a Russian German patient].
Topics: Adult; Antipsychotic Agents; Delusions; Drug Therapy, Combination; Emigration and Immigration; Ethni | 1997 |
A naturalistic pilot study comparing haloperidol, clozapine, sertindole, and risperidone in partially responsive chronic schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Haloperidol; Humans; Imidazoles; Indoles; Male; Psyc | 1997 |
A naturalistic pilot study comparing haloperidol, clozapine, sertindole, and risperidone in partially responsive chronic schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Haloperidol; Humans; Imidazoles; Indoles; Male; Psyc | 1997 |
Possible pitfalls in the diagnosis of acute myocardial infarction in acutely psychotic patients.
Topics: Acute Disease; Adult; Creatine Kinase; Diagnostic Errors; Electrocardiography; Emergency Service, Ho | 1997 |
Possible pitfalls in the diagnosis of acute myocardial infarction in acutely psychotic patients.
Topics: Acute Disease; Adult; Creatine Kinase; Diagnostic Errors; Electrocardiography; Emergency Service, Ho | 1997 |
Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants.
Topics: Adult; Antipsychotic Agents; Bottle Feeding; Breast Feeding; Child Development; Chlorpromazine; Chro | 1998 |
Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants.
Topics: Adult; Antipsychotic Agents; Bottle Feeding; Breast Feeding; Child Development; Chlorpromazine; Chro | 1998 |
Intravenous benzotropine mesylate challenge in acute neuroleptic-induced dystonia.
Topics: Adolescent; Antipsychotic Agents; Benztropine; Haloperidol; Humans; Injections, Intramuscular; Injec | 1998 |
Intravenous benzotropine mesylate challenge in acute neuroleptic-induced dystonia.
Topics: Adolescent; Antipsychotic Agents; Benztropine; Haloperidol; Humans; Injections, Intramuscular; Injec | 1998 |
Belief in transmigration of the soul and psychopathology in Israeli Druze. A culture-sensitive psychotherapeutic approach.
Topics: Adult; Bipolar Disorder; Combined Modality Therapy; Conversion Disorder; Culture; Haloperidol; Human | 1998 |
Belief in transmigration of the soul and psychopathology in Israeli Druze. A culture-sensitive psychotherapeutic approach.
Topics: Adult; Bipolar Disorder; Combined Modality Therapy; Conversion Disorder; Culture; Haloperidol; Human | 1998 |
MRI correlates of treatment response in first episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Cerebral Cortex; Cerebral Ventricles; Dose-Response Relatio | 1998 |
MRI correlates of treatment response in first episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Cerebral Cortex; Cerebral Ventricles; Dose-Response Relatio | 1998 |
[A patient with drug abuse who developed multiple psychotic symptoms during sedation with propofol].
Topics: Adult; Anesthesia, Spinal; Antipsychotic Agents; Haloperidol; Humans; Hypnotics and Sedatives; Intra | 1998 |
[A patient with drug abuse who developed multiple psychotic symptoms during sedation with propofol].
Topics: Adult; Anesthesia, Spinal; Antipsychotic Agents; Haloperidol; Humans; Hypnotics and Sedatives; Intra | 1998 |
Persistent loss of tyrosine hydroxylase immunoreactivity in the substantia nigra after neuroleptic withdrawal.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Dendrites; Female; Haloperidol; Humans; Male; P | 1998 |
Persistent loss of tyrosine hydroxylase immunoreactivity in the substantia nigra after neuroleptic withdrawal.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Dendrites; Female; Haloperidol; Humans; Male; P | 1998 |
[Systemic lupus erythematosus and psychosis].
Topics: Aged; Anti-Inflammatory Agents; Antipsychotic Agents; Female; Haloperidol; Humans; Lupus Erythematos | 1998 |
[Systemic lupus erythematosus and psychosis].
Topics: Aged; Anti-Inflammatory Agents; Antipsychotic Agents; Female; Haloperidol; Humans; Lupus Erythematos | 1998 |
Preventing contractures [correction of contractions] in neuroleptic malignant syndrome and dystonia.
Topics: Anti-Dyskinesia Agents; Botulinum Toxins; Combined Modality Therapy; Contracture; Dystonia; Female; | 1998 |
Preventing contractures [correction of contractions] in neuroleptic malignant syndrome and dystonia.
Topics: Anti-Dyskinesia Agents; Botulinum Toxins; Combined Modality Therapy; Contracture; Dystonia; Female; | 1998 |
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Hal | 1998 |
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Hal | 1998 |
Antipsychotic potential of CCK-based treatments: an assessment using the prepulse inhibition model of psychosis.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Ceruletide; Cholecystokinin; Gastrointestinal Agent | 1999 |
Antipsychotic potential of CCK-based treatments: an assessment using the prepulse inhibition model of psychosis.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Ceruletide; Cholecystokinin; Gastrointestinal Agent | 1999 |
Electroconvulsive therapy for the treatment of neuroleptic malignant syndrome with psychotic symptoms: a report of five cases.
Topics: Adult; Antipsychotic Agents; Depressive Disorder; Drug Therapy, Combination; Female; Haloperidol; Hu | 1999 |
Electroconvulsive therapy for the treatment of neuroleptic malignant syndrome with psychotic symptoms: a report of five cases.
Topics: Adult; Antipsychotic Agents; Depressive Disorder; Drug Therapy, Combination; Female; Haloperidol; Hu | 1999 |
Post-ictal psychosis: an unusual clinical entity.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Psychotic Disorders; Seizures | 1999 |
Post-ictal psychosis: an unusual clinical entity.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Psychotic Disorders; Seizures | 1999 |
Clozapine-associated elevation in serum triglycerides.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Clozapine; Female; Haloperidol; Hospital Records; | 1999 |
Clozapine-associated elevation in serum triglycerides.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Clozapine; Female; Haloperidol; Hospital Records; | 1999 |
A case of neuroleptic-induced unilateral akathisia with periodic limb movements in the opposite side during sleep.
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Dominance, Cerebral; Dose-Respo | 1999 |
A case of neuroleptic-induced unilateral akathisia with periodic limb movements in the opposite side during sleep.
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Dominance, Cerebral; Dose-Respo | 1999 |
Recommended haloperidol and risperidone doses in first-episode psychosis.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; H | 1999 |
Recommended haloperidol and risperidone doses in first-episode psychosis.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; H | 1999 |
Lamotrigine-induced rash after sun exposure.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Drug Eruptions; Drug Therapy, Combination; Female; Haloper | 1999 |
Lamotrigine-induced rash after sun exposure.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Drug Eruptions; Drug Therapy, Combination; Female; Haloper | 1999 |
Haloperidol, midazolam and intravenous sedation.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Conscious Sedation; Dose-Response Relationship, Drug; Eme | 1999 |
Haloperidol, midazolam and intravenous sedation.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Conscious Sedation; Dose-Response Relationship, Drug; Eme | 1999 |
Response to 'cardiotoxicity associated with use of intravenous haloperidol'.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Conscious Sedation; Emergency Services, | 1999 |
Response to 'cardiotoxicity associated with use of intravenous haloperidol'.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Conscious Sedation; Emergency Services, | 1999 |
Current antipsychotic dose correlates to mononuclear cell counts in the cerebrospinal fluid of psychotic patients.
Topics: Acute Disease; Adult; Angiotensin I; Antipsychotic Agents; Chlorpromazine; Cross-Sectional Studies; | 2000 |
Current antipsychotic dose correlates to mononuclear cell counts in the cerebrospinal fluid of psychotic patients.
Topics: Acute Disease; Adult; Angiotensin I; Antipsychotic Agents; Chlorpromazine; Cross-Sectional Studies; | 2000 |
Olanzapine and tardive dyskinesia.
Topics: Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Pi | 1999 |
Olanzapine and tardive dyskinesia.
Topics: Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Pi | 1999 |
Treating Charles Bonnet syndrome: understanding inconsistency.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Hallucinations; Haloperidol; Humans; Male; Psychotic | 2000 |
Treating Charles Bonnet syndrome: understanding inconsistency.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Hallucinations; Haloperidol; Humans; Male; Psychotic | 2000 |
Severe hypothermia in a neonate following antenatal exposure to haloperidol.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Hypothermia; Infant, Newborn; Male; Pregna | 2000 |
Severe hypothermia in a neonate following antenatal exposure to haloperidol.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Hypothermia; Infant, Newborn; Male; Pregna | 2000 |
A 3 year case study of alcohol related psychotic disorders at Hospital Seremban.
Topics: Adult; Alcoholism; Anti-Anxiety Agents; Antipsychotic Agents; Diazepam; Drug Therapy, Combination; F | 1998 |
A 3 year case study of alcohol related psychotic disorders at Hospital Seremban.
Topics: Adult; Alcoholism; Anti-Anxiety Agents; Antipsychotic Agents; Diazepam; Drug Therapy, Combination; F | 1998 |
Management of acute psychosis.
Topics: Acute Disease; Anti-Anxiety Agents; Antipsychotic Agents; Australia; Benzodiazepines; Contraindicati | 2000 |
Management of acute psychosis.
Topics: Acute Disease; Anti-Anxiety Agents; Antipsychotic Agents; Australia; Benzodiazepines; Contraindicati | 2000 |
Sildenafil and erectile dysfunction.
Topics: Antipsychotic Agents; Erectile Dysfunction; Haloperidol; Humans; Male; Middle Aged; Phosphodiesteras | 2000 |
Sildenafil and erectile dysfunction.
Topics: Antipsychotic Agents; Erectile Dysfunction; Haloperidol; Humans; Male; Middle Aged; Phosphodiesteras | 2000 |
Abnormal age-related changes of plasma antioxidant proteins in schizophrenia.
Topics: Adolescent; Adult; Age Factors; Aging; Albumins; Antipsychotic Agents; Anxiety; Bilirubin; Depressio | 2000 |
Abnormal age-related changes of plasma antioxidant proteins in schizophrenia.
Topics: Adolescent; Adult; Age Factors; Aging; Albumins; Antipsychotic Agents; Anxiety; Bilirubin; Depressio | 2000 |
Neurosyphilis presenting as schizophrenialike psychosis.
Topics: Acute Disease; Adult; Diagnosis, Differential; Female; Frontal Lobe; Haloperidol; Humans; Neurosyphi | 2000 |
Neurosyphilis presenting as schizophrenialike psychosis.
Topics: Acute Disease; Adult; Diagnosis, Differential; Female; Frontal Lobe; Haloperidol; Humans; Neurosyphi | 2000 |
[Carbamazepine-induced SIADH with clinical signs of delirium].
Topics: Adult; Carbamazepine; Delusions; Drug Therapy, Combination; Haloperidol; Humans; Inappropriate ADH S | 2001 |
[Carbamazepine-induced SIADH with clinical signs of delirium].
Topics: Adult; Carbamazepine; Delusions; Drug Therapy, Combination; Haloperidol; Humans; Inappropriate ADH S | 2001 |
Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Drug Therapy, Combination; Emergen | 2001 |
Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Drug Therapy, Combination; Emergen | 2001 |
Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Haloperidol; Humans; | 2001 |
Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Haloperidol; Humans; | 2001 |
Mirtazapine for neuroleptic-induced akathisia.
Topics: Adrenergic alpha-Antagonists; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Haloperidol; Hum | 2001 |
Mirtazapine for neuroleptic-induced akathisia.
Topics: Adrenergic alpha-Antagonists; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Haloperidol; Hum | 2001 |
Depot antipsychotics. Patient characteristics and prescribing pattern.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Clopenthixol; Delayed-Action Preparations; Drug Utiliz | 2000 |
Depot antipsychotics. Patient characteristics and prescribing pattern.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Clopenthixol; Delayed-Action Preparations; Drug Utiliz | 2000 |
Differential effects of amphetamine and phencyclidine on the expression of growth-associated protein GAP-43.
Topics: Amphetamine; Animals; Biomarkers; Brain; Disease Models, Animal; Dopamine Agents; Dopamine Antagonis | 2001 |
Differential effects of amphetamine and phencyclidine on the expression of growth-associated protein GAP-43.
Topics: Amphetamine; Animals; Biomarkers; Brain; Disease Models, Animal; Dopamine Agents; Dopamine Antagonis | 2001 |
Sudden death following neuroleptic administration due to hemoperitoneum resulting from physical restraint.
Topics: Adult; Death, Sudden; Fatal Outcome; Haloperidol; Hemoperitoneum; Humans; Injections, Intramuscular; | 2001 |
Sudden death following neuroleptic administration due to hemoperitoneum resulting from physical restraint.
Topics: Adult; Death, Sudden; Fatal Outcome; Haloperidol; Hemoperitoneum; Humans; Injections, Intramuscular; | 2001 |
Quantification of neuroreceptors in living human brain. v. endogenous neurotransmitter inhibition of haloperidol binding in psychosis.
Topics: Adult; Antipsychotic Agents; Brain; Female; Haloperidol; Humans; Male; Numerical Analysis, Computer- | 2001 |
Quantification of neuroreceptors in living human brain. v. endogenous neurotransmitter inhibition of haloperidol binding in psychosis.
Topics: Adult; Antipsychotic Agents; Brain; Female; Haloperidol; Humans; Male; Numerical Analysis, Computer- | 2001 |
Differences in haloperidol epidemiologic pharmacokinetic studies.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Cytochrome P-450 Enzyme System; Haloperidol; H | 2001 |
Differences in haloperidol epidemiologic pharmacokinetic studies.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Cytochrome P-450 Enzyme System; Haloperidol; H | 2001 |
Occurrence of delusions during repetitive transcranial magnetic stimulation (rTMS) in major depression.
Topics: Delusions; Depressive Disorder, Major; Dopamine; Electric Stimulation Therapy; Electromagnetic Field | 2002 |
Occurrence of delusions during repetitive transcranial magnetic stimulation (rTMS) in major depression.
Topics: Delusions; Depressive Disorder, Major; Dopamine; Electric Stimulation Therapy; Electromagnetic Field | 2002 |
[An experimental study of the spectrum of individual psychotropic activity of clozapine (Leponex)].
Topics: Animals; Antipsychotic Agents; Cats; Clozapine; Diazepam; Dibenzazepines; Disease Models, Animal; Ha | 1975 |
[An experimental study of the spectrum of individual psychotropic activity of clozapine (Leponex)].
Topics: Animals; Antipsychotic Agents; Cats; Clozapine; Diazepam; Dibenzazepines; Disease Models, Animal; Ha | 1975 |
Letter: Dosage for antipsychotic drugs (concl.).
Topics: Acute Disease; Antipsychotic Agents; Haloperidol; Humans; Psychotic Disorders | 1976 |
Letter: Dosage for antipsychotic drugs (concl.).
Topics: Acute Disease; Antipsychotic Agents; Haloperidol; Humans; Psychotic Disorders | 1976 |
Basic principles of rapid neuroleptization.
Topics: Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Fluphenazine; Ha | 1976 |
Basic principles of rapid neuroleptization.
Topics: Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Fluphenazine; Ha | 1976 |
Acutely disturbed psychotic patients treated with parenteral haloperidol.
Topics: Acute Disease; Adult; Aged; Female; Haloperidol; Humans; Infusions, Parenteral; Male; Middle Aged; P | 1978 |
Acutely disturbed psychotic patients treated with parenteral haloperidol.
Topics: Acute Disease; Adult; Aged; Female; Haloperidol; Humans; Infusions, Parenteral; Male; Middle Aged; P | 1978 |
Neuroleptic interference with the cocaine cue: internal stimulus control of behavior and psychosis.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior; Cocaine; Cues; Drug Interactions; Haloperidol; | 1978 |
Neuroleptic interference with the cocaine cue: internal stimulus control of behavior and psychosis.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior; Cocaine; Cues; Drug Interactions; Haloperidol; | 1978 |
The "psychotic" curse.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Psychoti | 1979 |
The "psychotic" curse.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Psychoti | 1979 |
[Effective management of the acute psychotic patient: stabilization and maintenance with haloperidol].
Topics: Acute Disease; Antipsychotic Agents; Drug Administration Schedule; Haloperidol; Hospitalization; Hum | 1978 |
[Effective management of the acute psychotic patient: stabilization and maintenance with haloperidol].
Topics: Acute Disease; Antipsychotic Agents; Drug Administration Schedule; Haloperidol; Hospitalization; Hum | 1978 |
Serum levels of neuroleptics measured by dopamine radioreceptor assay and some clinical observations.
Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Haloperidol; Humans; Psychotic Disorders; Radi | 1979 |
Serum levels of neuroleptics measured by dopamine radioreceptor assay and some clinical observations.
Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Haloperidol; Humans; Psychotic Disorders; Radi | 1979 |
Letter: Organic acidurias.
Topics: Bacteriuria; Benzoates; Haloperidol; Humans; Psychotic Disorders; Reserpine | 1975 |
Letter: Organic acidurias.
Topics: Bacteriuria; Benzoates; Haloperidol; Humans; Psychotic Disorders; Reserpine | 1975 |
Decrease in serum prolactin by naloxone: evidence against antidopamine and antipsychotic effects.
Topics: Animals; Haloperidol; Haplorhini; Humans; Macaca; Male; Methadone; Morphine; Naloxone; Opioid-Relate | 1979 |
Decrease in serum prolactin by naloxone: evidence against antidopamine and antipsychotic effects.
Topics: Animals; Haloperidol; Haplorhini; Humans; Macaca; Male; Methadone; Morphine; Naloxone; Opioid-Relate | 1979 |
Neuroleptics, catecholamines, and psychoses: a study of their interrelations.
Topics: Adolescent; Adult; Brain; Brain Chemistry; Catecholamines; Chlorpromazine; Depression, Chemical; Dop | 1975 |
Neuroleptics, catecholamines, and psychoses: a study of their interrelations.
Topics: Adolescent; Adult; Brain; Brain Chemistry; Catecholamines; Chlorpromazine; Depression, Chemical; Dop | 1975 |
Biochemical research into psychosis.
Topics: Brain; Catecholamines; Chlorpromazine; Depression, Chemical; Dopamine; Drug Evaluation; Haloperidol; | 1975 |
Biochemical research into psychosis.
Topics: Brain; Catecholamines; Chlorpromazine; Depression, Chemical; Dopamine; Drug Evaluation; Haloperidol; | 1975 |
The medical-pharmacological management of acute psychoses.
Topics: Antipsychotic Agents; Chlorpromazine; Haloperidol; Humans; Psychotic Disorders | 1975 |
The medical-pharmacological management of acute psychoses.
Topics: Antipsychotic Agents; Chlorpromazine; Haloperidol; Humans; Psychotic Disorders | 1975 |
Use of oral haloperidol following rapid tranquilization of acutely disturbed patients.
Topics: Acute Disease; Administration, Oral; Haloperidol; Humans; Psychotic Disorders | 1978 |
Use of oral haloperidol following rapid tranquilization of acutely disturbed patients.
Topics: Acute Disease; Administration, Oral; Haloperidol; Humans; Psychotic Disorders | 1978 |
Outpatient titration with intramuscular haloperidol as an alternative to psychiatric hospitalization.
Topics: Adult; Ambulatory Care; Drug Evaluation; Haloperidol; Humans; Injections, Intramuscular; Male; Middl | 1979 |
Outpatient titration with intramuscular haloperidol as an alternative to psychiatric hospitalization.
Topics: Adult; Ambulatory Care; Drug Evaluation; Haloperidol; Humans; Injections, Intramuscular; Male; Middl | 1979 |
Trifluoperazine and haloperidol: sources of ejaculatory pain?
Topics: Adult; Ejaculation; Haloperidol; Humans; Male; Molindone; Pain; Psychotic Disorders; Trifluoperazine | 1979 |
Trifluoperazine and haloperidol: sources of ejaculatory pain?
Topics: Adult; Ejaculation; Haloperidol; Humans; Male; Molindone; Pain; Psychotic Disorders; Trifluoperazine | 1979 |
Rapid treatment of psychosis with haloperidol.
Topics: Haloperidol; Humans; Infusions, Parenteral; Psychotic Disorders; Time Factors | 1979 |
Rapid treatment of psychosis with haloperidol.
Topics: Haloperidol; Humans; Infusions, Parenteral; Psychotic Disorders; Time Factors | 1979 |
Anticoagulant abuse: a psychotic syndrome?
Topics: Adult; Denial, Psychological; Diagnosis, Differential; Female; Haloperidol; Hemorrhage; Humans; Psyc | 1979 |
Anticoagulant abuse: a psychotic syndrome?
Topics: Adult; Denial, Psychological; Diagnosis, Differential; Female; Haloperidol; Hemorrhage; Humans; Psyc | 1979 |
[Value of pharmacokinetic data during the treatment of psychoses with haloperidol].
Topics: Haloperidol; Humans; Intestinal Absorption; Kinetics; Psychotic Disorders; Psychotropic Drugs; Tissu | 1979 |
[Value of pharmacokinetic data during the treatment of psychoses with haloperidol].
Topics: Haloperidol; Humans; Intestinal Absorption; Kinetics; Psychotic Disorders; Psychotropic Drugs; Tissu | 1979 |
A gas chromatographic mass spectrometric chemical ionization assay for haloperidol with selected ion monitoring.
Topics: Adolescent; Adult; Ammonia; Gas Chromatography-Mass Spectrometry; Haloperidol; Humans; Male; Methane | 1979 |
A gas chromatographic mass spectrometric chemical ionization assay for haloperidol with selected ion monitoring.
Topics: Adolescent; Adult; Ammonia; Gas Chromatography-Mass Spectrometry; Haloperidol; Humans; Male; Methane | 1979 |
[Perspectives of adequate individual doses].
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Psychotic Disor | 1979 |
[Perspectives of adequate individual doses].
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Psychotic Disor | 1979 |
Haloperidol plasma level monitoring in pediatric patients.
Topics: Adolescent; Adult; Aging; Child; Female; Haloperidol; Humans; Male; Movement Disorders; Psychotic Di | 1979 |
Haloperidol plasma level monitoring in pediatric patients.
Topics: Adolescent; Adult; Aging; Child; Female; Haloperidol; Humans; Male; Movement Disorders; Psychotic Di | 1979 |
Capgras syndrome: case report of an adolescent and review of literature.
Topics: Adolescent; Body Image; Delusions; Female; Haloperidol; Humans; Object Attachment; Psychotic Disorde | 1978 |
Capgras syndrome: case report of an adolescent and review of literature.
Topics: Adolescent; Body Image; Delusions; Female; Haloperidol; Humans; Object Attachment; Psychotic Disorde | 1978 |
Safe use of haloperidol in a patient with cardiac dysrhythmia.
Topics: Adolescent; Arrhythmias, Cardiac; Haloperidol; Humans; Male; Psychotic Disorders | 1978 |
Safe use of haloperidol in a patient with cardiac dysrhythmia.
Topics: Adolescent; Arrhythmias, Cardiac; Haloperidol; Humans; Male; Psychotic Disorders | 1978 |
Haloperidol: twenty years' clinical experience.
Topics: Antiparkinson Agents; Biotransformation; Blood Pressure; Dose-Response Relationship, Drug; Drug Inte | 1978 |
Haloperidol: twenty years' clinical experience.
Topics: Antiparkinson Agents; Biotransformation; Blood Pressure; Dose-Response Relationship, Drug; Drug Inte | 1978 |
Sudden death in a patient taking haloperidol.
Topics: Adult; Death, Sudden; Drug Administration Schedule; Female; Haloperidol; Humans; Psychotic Disorders | 1979 |
Sudden death in a patient taking haloperidol.
Topics: Adult; Death, Sudden; Drug Administration Schedule; Female; Haloperidol; Humans; Psychotic Disorders | 1979 |
Pica and elevated blood lead level in autistic and atypical children.
Topics: Adolescent; Autistic Disorder; Cerebrospinal Fluid Proteins; Child; Child, Preschool; Dimercaprol; E | 1976 |
Pica and elevated blood lead level in autistic and atypical children.
Topics: Adolescent; Autistic Disorder; Cerebrospinal Fluid Proteins; Child; Child, Preschool; Dimercaprol; E | 1976 |
[Neuroleptic long term care with extremely low doses in psychotic syndromes of paranoid-hallucination type].
Topics: Dose-Response Relationship, Drug; Hallucinations; Haloperidol; Humans; Long-Term Care; Paranoid Diso | 1975 |
[Neuroleptic long term care with extremely low doses in psychotic syndromes of paranoid-hallucination type].
Topics: Dose-Response Relationship, Drug; Hallucinations; Haloperidol; Humans; Long-Term Care; Paranoid Diso | 1975 |
Questions about rapid treatment.
Topics: Acute Disease; Bipolar Disorder; Emergency Service, Hospital; Female; Haloperidol; Humans; Psychotic | 1977 |
Questions about rapid treatment.
Topics: Acute Disease; Bipolar Disorder; Emergency Service, Hospital; Female; Haloperidol; Humans; Psychotic | 1977 |
Psychotolysis with haloperidol. Rapid control of the acutely disturbed psychotic patient.
Topics: Acute Disease; Adolescent; Adult; Basal Ganglia Diseases; Conflict, Psychological; Female; Hallucina | 1977 |
Psychotolysis with haloperidol. Rapid control of the acutely disturbed psychotic patient.
Topics: Acute Disease; Adolescent; Adult; Basal Ganglia Diseases; Conflict, Psychological; Female; Hallucina | 1977 |
Rapid treatment of acute psychosis.
Topics: Acute Disease; Dose-Response Relationship, Drug; Haloperidol; Humans; Psychotic Disorders; Time Fact | 1976 |
Rapid treatment of acute psychosis.
Topics: Acute Disease; Dose-Response Relationship, Drug; Haloperidol; Humans; Psychotic Disorders; Time Fact | 1976 |
[Ambulatory treatment of psychoses. Report from a discussion meeting].
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Depression; Haloperidol; Humans; Injections, I | 1976 |
[Ambulatory treatment of psychoses. Report from a discussion meeting].
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Depression; Haloperidol; Humans; Injections, I | 1976 |
On the relevance of preferential increases of mesolimbic versus striatal dopamine turnover for the prediction of antipsychotic activity of psychotropic drugs.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anthracenes; Clozapine; Corpus Striatum; Dopamine; Dose-Res | 1976 |
On the relevance of preferential increases of mesolimbic versus striatal dopamine turnover for the prediction of antipsychotic activity of psychotropic drugs.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anthracenes; Clozapine; Corpus Striatum; Dopamine; Dose-Res | 1976 |
[Use of haloperidol at very high doses].
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Middle Aged; | 1976 |
[Use of haloperidol at very high doses].
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Middle Aged; | 1976 |
Efficient management of the acute psychotic patient: stabilization and maintenance with haloperidol.
Topics: Acute Disease; Half-Life; Haloperidol; Humans; Psychotic Disorders | 1976 |
Efficient management of the acute psychotic patient: stabilization and maintenance with haloperidol.
Topics: Acute Disease; Half-Life; Haloperidol; Humans; Psychotic Disorders | 1976 |
Adequate individualized dosages (AID) in perspective.
Topics: Europe; Extrapyramidal Tracts; Haloperidol; Humans; Psychotic Disorders; United States | 1976 |
Adequate individualized dosages (AID) in perspective.
Topics: Europe; Extrapyramidal Tracts; Haloperidol; Humans; Psychotic Disorders; United States | 1976 |
Therapeutic spectrum of sulpiride, haloperidol and lithium: a graphic representation by clinical observation.
Topics: Haloperidol; Humans; Lithium; Models, Theoretical; Psychotic Disorders; Sulpiride | 1976 |
Therapeutic spectrum of sulpiride, haloperidol and lithium: a graphic representation by clinical observation.
Topics: Haloperidol; Humans; Lithium; Models, Theoretical; Psychotic Disorders; Sulpiride | 1976 |
Letter: Combining antipsychotic agents.
Topics: Amobarbital; Drug Therapy, Combination; Haloperidol; Humans; Injections, Intramuscular; Psychotic Di | 1975 |
Letter: Combining antipsychotic agents.
Topics: Amobarbital; Drug Therapy, Combination; Haloperidol; Humans; Injections, Intramuscular; Psychotic Di | 1975 |
Drug-induced dystonia.
Topics: Adjustment Disorders; Adult; Basal Ganglia Diseases; Chlorpromazine; Chlorprothixene; Female; Fluphe | 1975 |
Drug-induced dystonia.
Topics: Adjustment Disorders; Adult; Basal Ganglia Diseases; Chlorpromazine; Chlorprothixene; Female; Fluphe | 1975 |
Technique of rapid tranquilization.
Topics: Chlorpromazine; Haloperidol; Humans; Methods; Psychotic Disorders; Tranquilizing Agents | 1975 |
Technique of rapid tranquilization.
Topics: Chlorpromazine; Haloperidol; Humans; Methods; Psychotic Disorders; Tranquilizing Agents | 1975 |
Psychotropic drugs in the management of psychiatric emergencies.
Topics: Administration, Oral; Amphetamine; Chlorpromazine; Hallucinogens; Haloperidol; Humans; Hypotension; | 1975 |
Psychotropic drugs in the management of psychiatric emergencies.
Topics: Administration, Oral; Amphetamine; Chlorpromazine; Hallucinogens; Haloperidol; Humans; Hypotension; | 1975 |
[Treatment of Parkinson's disease associated with psychosis].
Topics: Aged; Female; Haloperidol; Humans; Levodopa; Parkinson Disease; Psychotic Disorders | 1975 |
[Treatment of Parkinson's disease associated with psychosis].
Topics: Aged; Female; Haloperidol; Humans; Levodopa; Parkinson Disease; Psychotic Disorders | 1975 |
Letter: Haloperidol and limb deformity.
Topics: Abnormalities, Drug-Induced; Female; Haloperidol; Humans; Infant, Newborn; Limb Deformities, Congeni | 1975 |
Letter: Haloperidol and limb deformity.
Topics: Abnormalities, Drug-Induced; Female; Haloperidol; Humans; Infant, Newborn; Limb Deformities, Congeni | 1975 |
Limb malformations following maternal use of haloperidol.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Drug Therapy, Combination; Female; Fetus; Halo | 1975 |
Limb malformations following maternal use of haloperidol.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Drug Therapy, Combination; Female; Fetus; Halo | 1975 |
Editorial: Another possible teratogen?
Topics: Abnormalities, Drug-Induced; Female; Haloperidol; Humans; Infant, Newborn; Limb Deformities, Congeni | 1975 |
Editorial: Another possible teratogen?
Topics: Abnormalities, Drug-Induced; Female; Haloperidol; Humans; Infant, Newborn; Limb Deformities, Congeni | 1975 |
Rapid tranquillisation.
Topics: Adult; Arousal; Chlorpromazine; Coma; Diazepam; Dose-Response Relationship, Drug; Drug Therapy, Comb | 1992 |
Rapid tranquillisation.
Topics: Adult; Arousal; Chlorpromazine; Coma; Diazepam; Dose-Response Relationship, Drug; Drug Therapy, Comb | 1992 |
Lowest effective dose of depot neuroleptics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationsh | 1992 |
Lowest effective dose of depot neuroleptics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationsh | 1992 |
Treatment of neuroleptic-resistant mania and schizoaffective disorders.
Topics: Antipsychotic Agents; Bipolar Disorder; Drug Synergism; Drug Therapy, Combination; Haloperidol; Huma | 1992 |
Treatment of neuroleptic-resistant mania and schizoaffective disorders.
Topics: Antipsychotic Agents; Bipolar Disorder; Drug Synergism; Drug Therapy, Combination; Haloperidol; Huma | 1992 |
Prescription of psychopharmaca in common psychiatric diagnoses (discussion on the results of an anonymous survey).
Topics: Antipsychotic Agents; Czechoslovakia; Depressive Disorder; Drug Prescriptions; Haloperidol; Humans; | 1992 |
Prescription of psychopharmaca in common psychiatric diagnoses (discussion on the results of an anonymous survey).
Topics: Antipsychotic Agents; Czechoslovakia; Depressive Disorder; Drug Prescriptions; Haloperidol; Humans; | 1992 |
Functional brain asymmetry and visuospatial perception in mania, depression, and psychotropic medication.
Topics: Adult; Bipolar Disorder; Brain; Chlorpromazine; Depressive Disorder; Female; Functional Laterality; | 1992 |
Functional brain asymmetry and visuospatial perception in mania, depression, and psychotropic medication.
Topics: Adult; Bipolar Disorder; Brain; Chlorpromazine; Depressive Disorder; Female; Functional Laterality; | 1992 |
Late-onset atypical psychosis: a case involving neuroleptic drug toxicity and autoimmune serological abnormalities.
Topics: Autoimmune Diseases; Diagnosis, Differential; Haloperidol; Humans; Male; Middle Aged; Neurocognitive | 1992 |
Late-onset atypical psychosis: a case involving neuroleptic drug toxicity and autoimmune serological abnormalities.
Topics: Autoimmune Diseases; Diagnosis, Differential; Haloperidol; Humans; Male; Middle Aged; Neurocognitive | 1992 |
Neuroleptic-induced dislocation of the jaw.
Topics: Adult; Clonazepam; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Humans; Joint D | 1992 |
Neuroleptic-induced dislocation of the jaw.
Topics: Adult; Clonazepam; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Humans; Joint D | 1992 |
Cycloid psychosis: regional cerebral blood flow correlates of a psychotic episode.
Topics: Adult; Aged; Bipolar Disorder; Blood Flow Velocity; Cerebral Cortex; Chlorpromazine; Dominance, Cere | 1992 |
Cycloid psychosis: regional cerebral blood flow correlates of a psychotic episode.
Topics: Adult; Aged; Bipolar Disorder; Blood Flow Velocity; Cerebral Cortex; Chlorpromazine; Dominance, Cere | 1992 |
Haloperidol decanoate pharmacokinetics in red blood cells and plasma.
Topics: Adult; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Erythrocytes; Female; | 1992 |
Haloperidol decanoate pharmacokinetics in red blood cells and plasma.
Topics: Adult; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Erythrocytes; Female; | 1992 |
Drug-responsive symptoms during early neuroleptic treatment.
Topics: Adult; Benztropine; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Drug Th | 1992 |
Drug-responsive symptoms during early neuroleptic treatment.
Topics: Adult; Benztropine; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Drug Th | 1992 |
Recurrence of neuroleptic malignant syndrome via an inadvertent rechallenge in a woman with mental retardation.
Topics: Adult; Depressive Disorder; Female; Haloperidol; Humans; Intellectual Disability; Neuroleptic Malign | 1992 |
Recurrence of neuroleptic malignant syndrome via an inadvertent rechallenge in a woman with mental retardation.
Topics: Adult; Depressive Disorder; Female; Haloperidol; Humans; Intellectual Disability; Neuroleptic Malign | 1992 |
Neuroleptic dysphoria.
Topics: Affective Symptoms; Animals; Antipsychotic Agents; Arousal; Dyskinesia, Drug-Induced; Haloperidol; H | 1991 |
Neuroleptic dysphoria.
Topics: Affective Symptoms; Animals; Antipsychotic Agents; Arousal; Dyskinesia, Drug-Induced; Haloperidol; H | 1991 |
Our experience with incisive neuroleptic drugs in child psychiatry.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Haloperidol; Humans; Mental Disorders; Obsessive-Com | 1991 |
Our experience with incisive neuroleptic drugs in child psychiatry.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Haloperidol; Humans; Mental Disorders; Obsessive-Com | 1991 |
Intravenous haloperidol treatment of severely regressed, nonviolent psychiatric inpatients.
Topics: Adult; Haloperidol; Hospitals, Psychiatric; Humans; Injections, Intravenous; Male; Middle Aged; Psyc | 1991 |
Intravenous haloperidol treatment of severely regressed, nonviolent psychiatric inpatients.
Topics: Adult; Haloperidol; Hospitals, Psychiatric; Humans; Injections, Intravenous; Male; Middle Aged; Psyc | 1991 |
Haloperidol reductase activity in red blood cells from oriental patients on haloperidol.
Topics: Adolescent; Adult; Alcohol Oxidoreductases; Erythrocytes; Female; Haloperidol; Humans; Male; Middle | 1991 |
Haloperidol reductase activity in red blood cells from oriental patients on haloperidol.
Topics: Adolescent; Adult; Alcohol Oxidoreductases; Erythrocytes; Female; Haloperidol; Humans; Male; Middle | 1991 |
Severe immune thrombocytopenia induced by neuroleptics.
Topics: Adult; Azathioprine; Female; Haloperidol; Humans; Methotrimeprazine; Platelet Count; Psychotic Disor | 1991 |
Severe immune thrombocytopenia induced by neuroleptics.
Topics: Adult; Azathioprine; Female; Haloperidol; Humans; Methotrimeprazine; Platelet Count; Psychotic Disor | 1991 |
Haloperidol-induced bronchospasm.
Topics: Administration, Oral; Adult; Bronchial Spasm; Female; Haloperidol; Hospitalization; Humans; Psychoti | 1991 |
Haloperidol-induced bronchospasm.
Topics: Administration, Oral; Adult; Bronchial Spasm; Female; Haloperidol; Hospitalization; Humans; Psychoti | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
A role for high-dose antipsychotics.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration | 1990 |
A role for high-dose antipsychotics.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration | 1990 |
Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment.
Topics: Adolescent; Antipsychotic Agents; Chlorpromazine; Dose-Response Relationship, Drug; Drug Therapy, Co | 1990 |
Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment.
Topics: Adolescent; Antipsychotic Agents; Chlorpromazine; Dose-Response Relationship, Drug; Drug Therapy, Co | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients.
Topics: Adult; Female; Haloperidol; Homovanillic Acid; Humans; Lithium; Male; Middle Aged; Neurotensin; Psyc | 1991 |
Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients.
Topics: Adult; Female; Haloperidol; Homovanillic Acid; Humans; Lithium; Male; Middle Aged; Neurotensin; Psyc | 1991 |
Elevation of plasma concentrations of haloperidol after the addition of fluoxetine.
Topics: Adult; Aged; Basal Ganglia Diseases; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetin | 1991 |
Elevation of plasma concentrations of haloperidol after the addition of fluoxetine.
Topics: Adult; Aged; Basal Ganglia Diseases; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetin | 1991 |
Thyroid hormone elevations during acute psychiatric illness: relationship to severity and distinction from hyperthyroidism.
Topics: Adult; Bipolar Disorder; Blood Pressure; Depressive Disorder; Down-Regulation; Feedback; Female; Hal | 1990 |
Thyroid hormone elevations during acute psychiatric illness: relationship to severity and distinction from hyperthyroidism.
Topics: Adult; Bipolar Disorder; Blood Pressure; Depressive Disorder; Down-Regulation; Feedback; Female; Hal | 1990 |
Neuroleptic malignant syndrome (NMS): challenge with zuclopenthixol and follow-up--a case report.
Topics: Adult; Clopenthixol; Dyskinesia, Drug-Induced; Electroencephalography; Female; Haloperidol; Humans; | 1990 |
Neuroleptic malignant syndrome (NMS): challenge with zuclopenthixol and follow-up--a case report.
Topics: Adult; Clopenthixol; Dyskinesia, Drug-Induced; Electroencephalography; Female; Haloperidol; Humans; | 1990 |
Prolactin response to low-dose haloperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects.
Topics: Adult; Affective Disorders, Psychotic; Female; Haloperidol; Humans; Prolactin; Psychiatric Status Ra | 1990 |
Prolactin response to low-dose haloperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects.
Topics: Adult; Affective Disorders, Psychotic; Female; Haloperidol; Humans; Prolactin; Psychiatric Status Ra | 1990 |
Relationship of psychotic symptoms to haloperidol-stimulated prolactin release.
Topics: Adult; Bipolar Disorder; Haloperidol; Humans; Male; Prolactin; Psychiatric Status Rating Scales; Psy | 1990 |
Relationship of psychotic symptoms to haloperidol-stimulated prolactin release.
Topics: Adult; Bipolar Disorder; Haloperidol; Humans; Male; Prolactin; Psychiatric Status Rating Scales; Psy | 1990 |
Neuroleptic-induced catatonia or a mild form of neuroleptic malignant syndrome?
Topics: Adult; Catatonia; Diagnosis, Differential; Haloperidol; Humans; Injections, Intramuscular; Male; Neu | 1990 |
Neuroleptic-induced catatonia or a mild form of neuroleptic malignant syndrome?
Topics: Adult; Catatonia; Diagnosis, Differential; Haloperidol; Humans; Injections, Intramuscular; Male; Neu | 1990 |
Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration.
Topics: Adult; Chronic Disease; Drug Therapy, Combination; Fluphenazine; Haloperidol; Humans; Injections, In | 1990 |
Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration.
Topics: Adult; Chronic Disease; Drug Therapy, Combination; Fluphenazine; Haloperidol; Humans; Injections, In | 1990 |
Botulinum toxin in treatment of tardive dyskinetic syndrome.
Topics: Aged; Botulinum Toxins; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Injections, Intramusc | 1990 |
Botulinum toxin in treatment of tardive dyskinetic syndrome.
Topics: Aged; Botulinum Toxins; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Injections, Intramusc | 1990 |
Enlargement of cerebral third ventricle in psychotic patients with delayed response to neuroleptics.
Topics: Adult; Affective Disorders, Psychotic; Age Factors; Cerebral Ventricles; Cerebral Ventriculography; | 1990 |
Enlargement of cerebral third ventricle in psychotic patients with delayed response to neuroleptics.
Topics: Adult; Affective Disorders, Psychotic; Age Factors; Cerebral Ventricles; Cerebral Ventriculography; | 1990 |
Effect of neuroleptic withdrawal on plasma prolactin: a possible marker of receptor adaptation.
Topics: Adult; Antipsychotic Agents; Brain; Female; Fluphenazine; Haloperidol; Humans; Male; Prolactin; Psyc | 1989 |
Effect of neuroleptic withdrawal on plasma prolactin: a possible marker of receptor adaptation.
Topics: Adult; Antipsychotic Agents; Brain; Female; Fluphenazine; Haloperidol; Humans; Male; Prolactin; Psyc | 1989 |
Antipsychotic drug use in the United States, 1976-1985.
Topics: Age Factors; Ambulatory Care; Antipsychotic Agents; Chlorpromazine; Drug Prescriptions; Drug Utiliza | 1989 |
Antipsychotic drug use in the United States, 1976-1985.
Topics: Age Factors; Ambulatory Care; Antipsychotic Agents; Chlorpromazine; Drug Prescriptions; Drug Utiliza | 1989 |
Neuroleptic malignant syndrome in a case of post-partum psychosis.
Topics: Adult; Chlorpromazine; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Therapy, Comb | 1989 |
Neuroleptic malignant syndrome in a case of post-partum psychosis.
Topics: Adult; Chlorpromazine; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Therapy, Comb | 1989 |
Longitudinal study of the effect, tolerance and undesired side effects of injection haloperidol decanoate applied in different psychiatric indications.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Longitudinal Studi | 1989 |
Longitudinal study of the effect, tolerance and undesired side effects of injection haloperidol decanoate applied in different psychiatric indications.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Longitudinal Studi | 1989 |
Neuroleptic malignant syndrome in the multiple trauma patient.
Topics: Adult; Creatine Kinase; Diagnosis, Differential; Haloperidol; Humans; Male; Multiple Trauma; Neurole | 1989 |
Neuroleptic malignant syndrome in the multiple trauma patient.
Topics: Adult; Creatine Kinase; Diagnosis, Differential; Haloperidol; Humans; Male; Multiple Trauma; Neurole | 1989 |
[Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring].
Topics: Adult; Antipsychotic Agents; Drug Interactions; Female; Flupenthixol; Haloperidol; Humans; Kinetics; | 1985 |
[Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring].
Topics: Adult; Antipsychotic Agents; Drug Interactions; Female; Flupenthixol; Haloperidol; Humans; Kinetics; | 1985 |
Acutely psychotic patients: a treatment approach.
Topics: Acute Disease; Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Combined Modality Therapy; Do | 1985 |
Acutely psychotic patients: a treatment approach.
Topics: Acute Disease; Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Combined Modality Therapy; Do | 1985 |
[Evaluation of the efficacy of haloperidol decanoate in the treatment of chronic psychotic hospital patients].
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Drug Evaluation; Female; Haloperidol; Humans; In | 1985 |
[Evaluation of the efficacy of haloperidol decanoate in the treatment of chronic psychotic hospital patients].
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Drug Evaluation; Female; Haloperidol; Humans; In | 1985 |
Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study.
Topics: Adolescent; Adult; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Child; Chlorp | 1986 |
Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study.
Topics: Adolescent; Adult; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Child; Chlorp | 1986 |
Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration.
Topics: Adult; Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Kinetics; | 1986 |
Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration.
Topics: Adult; Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Kinetics; | 1986 |
Cortical atrophy and white matter density in the brains of schizophrenics and clinical response to neuroleptics.
Topics: Adult; Antipsychotic Agents; Atrophy; Cerebral Cortex; Female; Haloperidol; Humans; Male; Middle Age | 1987 |
Cortical atrophy and white matter density in the brains of schizophrenics and clinical response to neuroleptics.
Topics: Adult; Antipsychotic Agents; Atrophy; Cerebral Cortex; Female; Haloperidol; Humans; Male; Middle Age | 1987 |
Depot neuroleptics for acutely psychotic patients.
Topics: Acute Disease; Antipsychotic Agents; Fluphenazine; Haloperidol; Humans; Psychotic Disorders | 1987 |
Depot neuroleptics for acutely psychotic patients.
Topics: Acute Disease; Antipsychotic Agents; Fluphenazine; Haloperidol; Humans; Psychotic Disorders | 1987 |
Psychotic patients who become worse on neuroleptics.
Topics: Adolescent; Adult; Antipsychotic Agents; Benztropine; Chlorpromazine; Dyskinesia, Drug-Induced; Fema | 1988 |
Psychotic patients who become worse on neuroleptics.
Topics: Adolescent; Adult; Antipsychotic Agents; Benztropine; Chlorpromazine; Dyskinesia, Drug-Induced; Fema | 1988 |
Plasma catecholamine metabolites and treatment response at neuroleptic steady state.
Topics: Adolescent; Adult; Aged; Female; Glycols; Haloperidol; Homovanillic Acid; Humans; Male; Methoxyhydro | 1989 |
Plasma catecholamine metabolites and treatment response at neuroleptic steady state.
Topics: Adolescent; Adult; Aged; Female; Glycols; Haloperidol; Homovanillic Acid; Humans; Male; Methoxyhydro | 1989 |
Visual contrast sensitivity in drug-induced Parkinsonism.
Topics: Adolescent; Adult; Bipolar Disorder; Depressive Disorder; Drug Therapy, Combination; Female; Fluspir | 1989 |
Visual contrast sensitivity in drug-induced Parkinsonism.
Topics: Adolescent; Adult; Bipolar Disorder; Depressive Disorder; Drug Therapy, Combination; Female; Fluspir | 1989 |
[Haloperidol. Plasma monitoring and hormonal effects of treatment].
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; beta-Endorphin; Child; Delayed-Action Pr | 1985 |
[Haloperidol. Plasma monitoring and hormonal effects of treatment].
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; beta-Endorphin; Child; Delayed-Action Pr | 1985 |
EEG observations during combined haloperidol-lithium treatment.
Topics: Adult; Drug Therapy, Combination; Electroencephalography; Epilepsies, Myoclonic; Epilepsies, Partial | 1986 |
EEG observations during combined haloperidol-lithium treatment.
Topics: Adult; Drug Therapy, Combination; Electroencephalography; Epilepsies, Myoclonic; Epilepsies, Partial | 1986 |
Forced normalization. Acute psychosis after seizure control in seven patients.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Haloperidol; Humans; Male; Psychotic Disord | 1987 |
Forced normalization. Acute psychosis after seizure control in seven patients.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Haloperidol; Humans; Male; Psychotic Disord | 1987 |
TSH response to TRH and haloperidol response latency in psychoses.
Topics: Adult; Female; Haloperidol; Humans; Lithium; Lithium Carbonate; Male; Psychiatric Status Rating Scal | 1988 |
TSH response to TRH and haloperidol response latency in psychoses.
Topics: Adult; Female; Haloperidol; Humans; Lithium; Lithium Carbonate; Male; Psychiatric Status Rating Scal | 1988 |
Schizophreniform psychosis associated with the menstrual cycle.
Topics: Adult; Dydrogesterone; Female; Haloperidol; Humans; Menstrual Cycle; Menstruation; Psychotic Disorde | 1988 |
Schizophreniform psychosis associated with the menstrual cycle.
Topics: Adult; Dydrogesterone; Female; Haloperidol; Humans; Menstrual Cycle; Menstruation; Psychotic Disorde | 1988 |
The psychiatric acute observation unit in a general hospital.
Topics: Adolescent; Adult; Aged; Chlorpromazine; Combined Modality Therapy; Emergency Services, Psychiatric; | 1988 |
The psychiatric acute observation unit in a general hospital.
Topics: Adolescent; Adult; Aged; Chlorpromazine; Combined Modality Therapy; Emergency Services, Psychiatric; | 1988 |
Plasma concentrations of haloperidol and prolactin and clinical outcome in acutely psychotic patients.
Topics: Acute Disease; Adolescent; Adult; Female; Haloperidol; Humans; Male; Middle Aged; Prolactin; Psychot | 1988 |
Plasma concentrations of haloperidol and prolactin and clinical outcome in acutely psychotic patients.
Topics: Acute Disease; Adolescent; Adult; Female; Haloperidol; Humans; Male; Middle Aged; Prolactin; Psychot | 1988 |
Plasma haloperidol and clinical response: a role for reduced haloperidol in antipsychotic activity?
Topics: Adult; Basal Ganglia Diseases; Benztropine; Female; Haloperidol; Humans; Male; Middle Aged; Psychiat | 1987 |
Plasma haloperidol and clinical response: a role for reduced haloperidol in antipsychotic activity?
Topics: Adult; Basal Ganglia Diseases; Benztropine; Female; Haloperidol; Humans; Male; Middle Aged; Psychiat | 1987 |
Neuroleptic malignant syndrome responsive to carbidopa/levodopa: support for a dopaminergic pathogenesis.
Topics: Adult; Carbidopa; Drug Combinations; Haloperidol; Humans; Levodopa; Male; Neuroleptic Malignant Synd | 1987 |
Neuroleptic malignant syndrome responsive to carbidopa/levodopa: support for a dopaminergic pathogenesis.
Topics: Adult; Carbidopa; Drug Combinations; Haloperidol; Humans; Levodopa; Male; Neuroleptic Malignant Synd | 1987 |
Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions.
Topics: Acute Disease; Adult; Benztropine; Drug Therapy, Combination; Dystonia; Female; Haloperidol; Humans; | 1987 |
Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions.
Topics: Acute Disease; Adult; Benztropine; Drug Therapy, Combination; Dystonia; Female; Haloperidol; Humans; | 1987 |
Droperidol and acute psychosis.
Topics: Acute Disease; Droperidol; Haloperidol; Humans; Psychotic Disorders | 1987 |
Droperidol and acute psychosis.
Topics: Acute Disease; Droperidol; Haloperidol; Humans; Psychotic Disorders | 1987 |
Correlates of early neuroleptic response using a uniform haloperidol dose.
Topics: Adult; Aged; Female; Haloperidol; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Middl | 1987 |
Correlates of early neuroleptic response using a uniform haloperidol dose.
Topics: Adult; Aged; Female; Haloperidol; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Middl | 1987 |
Lithium and haloperidol.
Topics: Adult; Drug Therapy, Combination; Erythrocytes; Haloperidol; Humans; Lithium; Psychotic Disorders; S | 1986 |
Lithium and haloperidol.
Topics: Adult; Drug Therapy, Combination; Erythrocytes; Haloperidol; Humans; Lithium; Psychotic Disorders; S | 1986 |
Intravenous haloperidol in the treatment of acute psychosis.
Topics: Acute Disease; Adult; Haloperidol; Humans; Injections, Intravenous; Middle Aged; Psychotic Disorders | 1986 |
Intravenous haloperidol in the treatment of acute psychosis.
Topics: Acute Disease; Adult; Haloperidol; Humans; Injections, Intravenous; Middle Aged; Psychotic Disorders | 1986 |
Choreoathetosis as toxic effect of lithium treatment.
Topics: Aged; Athetosis; Chorea; Drug Therapy, Combination; Female; Haloperidol; Humans; Indomethacin; Lithi | 1986 |
Choreoathetosis as toxic effect of lithium treatment.
Topics: Aged; Athetosis; Chorea; Drug Therapy, Combination; Female; Haloperidol; Humans; Indomethacin; Lithi | 1986 |
Possible central effect of dantrolene sodium in neuroleptic malignant syndrome.
Topics: Brain; Dantrolene; Female; Haloperidol; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Psychot | 1986 |
Possible central effect of dantrolene sodium in neuroleptic malignant syndrome.
Topics: Brain; Dantrolene; Female; Haloperidol; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Psychot | 1986 |
The daughter as the principal "double" in a Capgras' syndrome: psychodynamic correlates.
Topics: Adolescent; Adult; Aggression; Capgras Syndrome; Combined Modality Therapy; Female; Haloperidol; Hum | 1986 |
The daughter as the principal "double" in a Capgras' syndrome: psychodynamic correlates.
Topics: Adolescent; Adult; Aggression; Capgras Syndrome; Combined Modality Therapy; Female; Haloperidol; Hum | 1986 |
[Plasma monitoring of haloperidol. Correlation with clinical efficacy and plasma prolactin levels].
Topics: Adolescent; Adult; Female; Haloperidol; Humans; Male; Middle Aged; Prolactin; Psychotic Disorders | 1985 |
[Plasma monitoring of haloperidol. Correlation with clinical efficacy and plasma prolactin levels].
Topics: Adolescent; Adult; Female; Haloperidol; Humans; Male; Middle Aged; Prolactin; Psychotic Disorders | 1985 |
Haloperidol and biperiden plasma levels in a pregnant atypical psychotic woman and a neonate--a case report.
Topics: Adult; Biperiden; Female; Haloperidol; Humans; Infant, Newborn; Male; Maternal-Fetal Exchange; Milk, | 1985 |
Haloperidol and biperiden plasma levels in a pregnant atypical psychotic woman and a neonate--a case report.
Topics: Adult; Biperiden; Female; Haloperidol; Humans; Infant, Newborn; Male; Maternal-Fetal Exchange; Milk, | 1985 |
Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients.
Topics: Adult; Apomorphine; Haloperidol; Homovanillic Acid; Humans; Male; Middle Aged; Psychotic Disorders; | 1985 |
Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients.
Topics: Adult; Apomorphine; Haloperidol; Homovanillic Acid; Humans; Male; Middle Aged; Psychotic Disorders; | 1985 |
Use of hypnosis in EPS-associated anxiety.
Topics: Adult; Anxiety Disorders; Basal Ganglia Diseases; Haloperidol; Humans; Hypnosis; Male; Psychotic Dis | 1986 |
Use of hypnosis in EPS-associated anxiety.
Topics: Adult; Anxiety Disorders; Basal Ganglia Diseases; Haloperidol; Humans; Hypnosis; Male; Psychotic Dis | 1986 |
Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol.
Topics: Adolescent; Adult; Age Factors; Aged; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle A | 1986 |
Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol.
Topics: Adolescent; Adult; Age Factors; Aged; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle A | 1986 |
New pharmacologic approaches in the treatment of psychosis. Proceedings of a symposium. Philadelphia, June 29, 1985.
Topics: Haloperidol; Humans; Lorazepam; Psychotic Disorders | 1986 |
New pharmacologic approaches in the treatment of psychosis. Proceedings of a symposium. Philadelphia, June 29, 1985.
Topics: Haloperidol; Humans; Lorazepam; Psychotic Disorders | 1986 |
Alternative approaches in the treatment of psychotic agitation.
Topics: Combined Modality Therapy; Haloperidol; Humans; Injections, Intramuscular; Lorazepam; Psychomotor Ag | 1986 |
Alternative approaches in the treatment of psychotic agitation.
Topics: Combined Modality Therapy; Haloperidol; Humans; Injections, Intramuscular; Lorazepam; Psychomotor Ag | 1986 |
Monosymptomatic hypochondriacal psychosis manifesting as delusions of infestation: case studies of treatment with haloperidol.
Topics: Aged; Delusions; Female; Haloperidol; Humans; Hypochondriasis; Male; Middle Aged; Parasites; Pimozid | 1986 |
Monosymptomatic hypochondriacal psychosis manifesting as delusions of infestation: case studies of treatment with haloperidol.
Topics: Aged; Delusions; Female; Haloperidol; Humans; Hypochondriasis; Male; Middle Aged; Parasites; Pimozid | 1986 |
Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms?
Topics: Acute Disease; Adult; Aged; Carbamazepine; Chromatography, Gas; Depression, Chemical; Drug Therapy, | 1986 |
Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms?
Topics: Acute Disease; Adult; Aged; Carbamazepine; Chromatography, Gas; Depression, Chemical; Drug Therapy, | 1986 |
Pridinolum mesylate and neuroleptic malignant syndrome.
Topics: Adult; Basal Ganglia Diseases; Delusions; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; | 1985 |
Pridinolum mesylate and neuroleptic malignant syndrome.
Topics: Adult; Basal Ganglia Diseases; Delusions; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; | 1985 |
Emergency treatment of acute psychosis, agitation, and anxiety.
Topics: Anxiety Disorders; Diazepam; Droperidol; Emergencies; Haloperidol; Humans; Lorazepam; Panic; Propran | 1985 |
Emergency treatment of acute psychosis, agitation, and anxiety.
Topics: Anxiety Disorders; Diazepam; Droperidol; Emergencies; Haloperidol; Humans; Lorazepam; Panic; Propran | 1985 |
Neuroleptic-induced priapism.
Topics: Adult; Haloperidol; Humans; Indoles; Male; Molindone; Priapism; Psychotic Disorders; Schizophrenia, | 1985 |
Neuroleptic-induced priapism.
Topics: Adult; Haloperidol; Humans; Indoles; Male; Molindone; Priapism; Psychotic Disorders; Schizophrenia, | 1985 |
Capgras syndrome in senile dementia of the Alzheimer type.
Topics: Aged; Alzheimer Disease; Capgras Syndrome; Clomipramine; Female; Haloperidol; Humans; Psychotic Diso | 1985 |
Capgras syndrome in senile dementia of the Alzheimer type.
Topics: Aged; Alzheimer Disease; Capgras Syndrome; Clomipramine; Female; Haloperidol; Humans; Psychotic Diso | 1985 |
Neuroleptic therapy following neuroleptic malignant syndrome.
Topics: Adult; Drug Therapy, Combination; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Perphen | 1985 |
Neuroleptic therapy following neuroleptic malignant syndrome.
Topics: Adult; Drug Therapy, Combination; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Perphen | 1985 |
Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug. I. The comparative pharmacology of pimozide, haloperidol, and chlorpromazine.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Benzimidazoles; Blepharoptosis; Body Temperatur | 1968 |
Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug. I. The comparative pharmacology of pimozide, haloperidol, and chlorpromazine.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Benzimidazoles; Blepharoptosis; Body Temperatur | 1968 |
[Therapy of endogenic psychoses using Dominal or Dominal forte respectively combined with potent effective neuroleptics].
Topics: Adult; Aged; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Haloperidol; Humans; Mi | 1974 |
[Therapy of endogenic psychoses using Dominal or Dominal forte respectively combined with potent effective neuroleptics].
Topics: Adult; Aged; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Haloperidol; Humans; Mi | 1974 |
[Treatment of acute emotional disturbances].
Topics: Alcohol Withdrawal Delirium; Chlormethiazole; Chlorpromazine; Chlorprothixene; Diazepam; Family Char | 1974 |
[Treatment of acute emotional disturbances].
Topics: Alcohol Withdrawal Delirium; Chlormethiazole; Chlorpromazine; Chlorprothixene; Diazepam; Family Char | 1974 |
Average evoked responses (AER) and homovanillic acid (HVA) in cerebrospinal fluid (CSF) in a psychotic patient with Addison's disease.
Topics: Addison Disease; Adult; Cortisone; Electroconvulsive Therapy; Evoked Potentials; Haloperidol; Homova | 1974 |
Average evoked responses (AER) and homovanillic acid (HVA) in cerebrospinal fluid (CSF) in a psychotic patient with Addison's disease.
Topics: Addison Disease; Adult; Cortisone; Electroconvulsive Therapy; Evoked Potentials; Haloperidol; Homova | 1974 |
Strategies for the treatment of acute psychosis.
Topics: Acute Disease; Alcohol Amnestic Disorder; Cooperative Behavior; Emergencies; Female; Fluphenazine; H | 1974 |
Strategies for the treatment of acute psychosis.
Topics: Acute Disease; Alcohol Amnestic Disorder; Cooperative Behavior; Emergencies; Female; Fluphenazine; H | 1974 |
Clinical utility of haloperidol in 51 state hospital admissions.
Topics: Adolescent; Adult; Affective Symptoms; Aged; Electroconvulsive Therapy; Haloperidol; Hospitalization | 1973 |
Clinical utility of haloperidol in 51 state hospital admissions.
Topics: Adolescent; Adult; Affective Symptoms; Aged; Electroconvulsive Therapy; Haloperidol; Hospitalization | 1973 |
Rapid control of psychotic excitement states with intramuscular haloperidol.
Topics: Acute Disease; Adult; Age Factors; Aged; Body Weight; Dose-Response Relationship, Drug; Female; Halo | 1973 |
Rapid control of psychotic excitement states with intramuscular haloperidol.
Topics: Acute Disease; Adult; Age Factors; Aged; Body Weight; Dose-Response Relationship, Drug; Female; Halo | 1973 |
Tardive and withdrawal dyskinesia associated with haloperidol.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Butyrophenones; Dose-Response Relationship, Drug; Female; | 1974 |
Tardive and withdrawal dyskinesia associated with haloperidol.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Butyrophenones; Dose-Response Relationship, Drug; Female; | 1974 |
Haloperidol in controlling the symptoms of acute psychoses. I. A preliminary investigation.
Topics: Haloperidol; Humans; Psychotic Disorders | 1966 |
Haloperidol in controlling the symptoms of acute psychoses. I. A preliminary investigation.
Topics: Haloperidol; Humans; Psychotic Disorders | 1966 |
Parenteral haloperidol in controlling patient behavior during acute psychotic episodes.
Topics: Behavior; Haloperidol; Humans; Psychotic Disorders; Social Behavior Disorders | 1969 |
Parenteral haloperidol in controlling patient behavior during acute psychotic episodes.
Topics: Behavior; Haloperidol; Humans; Psychotic Disorders; Social Behavior Disorders | 1969 |
[Tic disease].
Topics: Birth Injuries; Child; Chlorpromazine; Chorea; Diagnosis, Differential; Haloperidol; Humans; Intelle | 1970 |
[Tic disease].
Topics: Birth Injuries; Child; Chlorpromazine; Chorea; Diagnosis, Differential; Haloperidol; Humans; Intelle | 1970 |
[Influencing of biological and immunologic pregnancy reactions by psychotropic drugs].
Topics: Adolescent; Adult; Aged; Butyrophenones; Chlorpromazine; Dementia; Depressive Disorder, Major; Dysau | 1969 |
[Influencing of biological and immunologic pregnancy reactions by psychotropic drugs].
Topics: Adolescent; Adult; Aged; Butyrophenones; Chlorpromazine; Dementia; Depressive Disorder, Major; Dysau | 1969 |
[A chronic extrapyramidal syndrome as a complication of neuroleptic therapy].
Topics: Aged; Bipolar Disorder; Chlorpromazine; Chronic Disease; Extrapyramidal Tracts; Female; Haloperidol; | 1969 |
[A chronic extrapyramidal syndrome as a complication of neuroleptic therapy].
Topics: Aged; Bipolar Disorder; Chlorpromazine; Chronic Disease; Extrapyramidal Tracts; Female; Haloperidol; | 1969 |
Metabolism of exogenous cortisol in humans. Influence of phenobarbital treatment on plasma cortisol disappearance rate.
Topics: Aged; Chronic Disease; Female; Haloperidol; Humans; Hydrocortisone; Male; Microsomes, Liver; Middle | 1970 |
Metabolism of exogenous cortisol in humans. Influence of phenobarbital treatment on plasma cortisol disappearance rate.
Topics: Aged; Chronic Disease; Female; Haloperidol; Humans; Hydrocortisone; Male; Microsomes, Liver; Middle | 1970 |
Comparison of haloperidol and fluphenazine in disturbed children.
Topics: Aggression; Anxiety; Autistic Disorder; Child; Child, Preschool; Female; Fluphenazine; Haloperidol; | 1970 |
Comparison of haloperidol and fluphenazine in disturbed children.
Topics: Aggression; Anxiety; Autistic Disorder; Child; Child, Preschool; Female; Fluphenazine; Haloperidol; | 1970 |
Haloperidol-desipramine interaction in mice, rats and man.
Topics: Animals; Basal Ganglia Diseases; Benperidol; Butyrophenones; Chronic Disease; Desipramine; Drug Anta | 1970 |
Haloperidol-desipramine interaction in mice, rats and man.
Topics: Animals; Basal Ganglia Diseases; Benperidol; Butyrophenones; Chronic Disease; Desipramine; Drug Anta | 1970 |
Choice of antipsychotic drugs.
Topics: Butyrophenones; Drug Synergism; Drug Tolerance; Haloperidol; Humans; Phenothiazines; Piperazines; Pi | 1970 |
Choice of antipsychotic drugs.
Topics: Butyrophenones; Drug Synergism; Drug Tolerance; Haloperidol; Humans; Phenothiazines; Piperazines; Pi | 1970 |
[Acute psychotic conditions].
Topics: Acute Disease; Diazepam; Haloperidol; Humans; Psychotic Disorders; Tranquilizing Agents | 1971 |
[Acute psychotic conditions].
Topics: Acute Disease; Diazepam; Haloperidol; Humans; Psychotic Disorders; Tranquilizing Agents | 1971 |
Clinical experiences with the application of haloperidol to mental patients.
Topics: Adolescent; Adult; Aged; Female; Haloperidol; Humans; Injections, Intravenous; Mental Disorders; Mid | 1967 |
Clinical experiences with the application of haloperidol to mental patients.
Topics: Adolescent; Adult; Aged; Female; Haloperidol; Humans; Injections, Intravenous; Mental Disorders; Mid | 1967 |
[Changes in habituation of the alpha rhythm arrest reaction in humans under the effect of chlorpromazine and haloperidol].
Topics: Adaptation, Psychological; Adolescent; Adult; Aged; Alcoholism; Auditory Threshold; Cerebral Cortex; | 1967 |
[Changes in habituation of the alpha rhythm arrest reaction in humans under the effect of chlorpromazine and haloperidol].
Topics: Adaptation, Psychological; Adolescent; Adult; Aged; Alcoholism; Auditory Threshold; Cerebral Cortex; | 1967 |
[Clinical experiences with butyrophenone benperidol].
Topics: Benperidol; Bipolar Disorder; Electroencephalography; Epilepsy; Female; Haloperidol; Humans; Male; P | 1967 |
[Clinical experiences with butyrophenone benperidol].
Topics: Benperidol; Bipolar Disorder; Electroencephalography; Epilepsy; Female; Haloperidol; Humans; Male; P | 1967 |
Haloperidol and trifluperidol in psychiatry.
Topics: Antidepressive Agents; Butyrophenones; Fluorine; Haloperidol; Humans; Piperidines; Psychotic Disorde | 1968 |
Haloperidol and trifluperidol in psychiatry.
Topics: Antidepressive Agents; Butyrophenones; Fluorine; Haloperidol; Humans; Piperidines; Psychotic Disorde | 1968 |
[On the position of the butyrophenone derivative Haloperidol in psychiatric treatment].
Topics: Adult; Aged; Bipolar Disorder; Catatonia; Child; Depression; Depressive Disorder, Major; Extrapyrami | 1968 |
[On the position of the butyrophenone derivative Haloperidol in psychiatric treatment].
Topics: Adult; Aged; Bipolar Disorder; Catatonia; Child; Depression; Depressive Disorder, Major; Extrapyrami | 1968 |
[On the problem of the therapeutical axis symptom of neuroleptic medicaments].
Topics: Adult; Extrapyramidal Tracts; Fluphenazine; Haloperidol; Handwriting; Humans; Male; Movement Disorde | 1968 |
[On the problem of the therapeutical axis symptom of neuroleptic medicaments].
Topics: Adult; Extrapyramidal Tracts; Fluphenazine; Haloperidol; Handwriting; Humans; Male; Movement Disorde | 1968 |
[Results of the use of haloperidol in a service for adults].
Topics: Haloperidol; Humans; Psychotic Disorders | 1965 |
[Results of the use of haloperidol in a service for adults].
Topics: Haloperidol; Humans; Psychotic Disorders | 1965 |
[Parkinsonian and neurodysleptic syndromes during treatment with neuroleptic drugs].
Topics: Adolescent; Adult; Female; Haloperidol; Humans; Male; Middle Aged; Parkinson Disease; Psychotic Diso | 1965 |
[Parkinsonian and neurodysleptic syndromes during treatment with neuroleptic drugs].
Topics: Adolescent; Adult; Female; Haloperidol; Humans; Male; Middle Aged; Parkinson Disease; Psychotic Diso | 1965 |